{
  "filename": "ehac244.pdf",
  "title": null,
  "type": "heart_failure",
  "year": 2022,
  "chapters": [
    {
      "number": "1",
      "title": "2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)",
      "start_page": 0,
      "end_page": 6,
      "content": "2022 ESC Guidelines on cardio-oncology\ndeveloped in collaboration with the European\nHematology Association (EHA), the European\nSociety for Therapeutic Radiology and\nOncology (ESTRO) and the International\nCardio-Oncology Society (IC-OS)\nDeveloped by the task force on cardio-oncology of the European\nSociety of Cardiology (ESC)\nAuthors/Task Force Members: Alexander R. Lyon*† (Chairperson) (United\nKingdom), Teresa López-Fernández*† (Chairperson) (Spain), Liam S. Couch (Task\nForce Coordinator) (United Kingdom), Riccardo Asteggiano (Italy),\nMarianne C. Aznar1 (United Kingdom), Jutta Bergler-Klein (Austria),\nGiuseppe Boriani (Italy), Daniela Cardinale (Italy), Raul Cordoba2 (Spain),\nBernard Cosyns (Belgium), David J. Cutter (United Kingdom),\nEvandro de Azambuja (Belgium), Rudolf A. de Boer (Netherlands), Susan F. Dent3\n(United States of America), Dimitrios Farmakis (Cyprus), Soﬁe A. Gevaert\n(Belgium), Diana A. Gorog (United Kingdom), Joerg Herrmann3 (United States of\nAmerica), Daniel Lenihan3 (United States of America), Javid Moslehi (United\nStates of America), Brenda Moura (Portugal), Sonja S. Salinger (Serbia),\nRichard Stephens (United Kingdom), Thomas M. Suter (Switzerland),\nSebastian Szmit (Poland), Juan Tamargo (Spain), Paaladinesh Thavendiranathan\n(Canada), Carlo G. Tocchetti (Italy), Peter van der Meer (Netherlands),\nHelena J.H. van der Pal (Netherlands), and ESC Scientiﬁc Document Group\n*Corresponding authors: Alexander R. Lyon, National Heart and Lung Institute, Imperial College London and Cardio-Oncology Service, Royal Brompton Hospital, London, United\nKingdom. Tel: +44 207 352 8121, E-mail: a.lyon@imperial.ac.uk.\nTeresa López-Fernández, Cardiology Department, La Paz University Hospital, IdiPAZ Research Institute, Madrid, Spain. Tel: +34 619 227 076, E-mail: tlfernandez8@gmail.com.\n† The two chairpersons contributed equally to the document and are joint corresponding authors.\nAuthor/Task Force Member afﬁliations are listed in Author information.\n1Representing the European Society for Therapeutic Radiology and Oncology (ESTRO); 2representing the European Hematology Association (EHA); 3representing the International\nCardio-Oncology Society (IC-OS).\nESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.\nESC subspecialty communities having participated in the development of this document:\nAssociations: Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC),\nEuropean Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).\nCouncils: Council of Cardio-Oncology, Council on Hypertension, Council on Valvular Heart Disease.\nWorking Groups: Aorta and Peripheral Vascular Diseases, Cardiovascular Pharmacotherapy, e-Cardiology, Myocardial Function, Pulmonary Circulation and Right Ventricular Function,\nThrombosis.\nPatient Forum\nEuropean Heart Journal (2022) 43, 4229–4361\nhttps://doi.org/10.1093/eurheartj/ehac244\nESC GUIDELINES\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nDocument Reviewers: Patrizio Lancellotti (CPG Review Coordinator) (Belgium), Franck Thuny (CPG Review\nCoordinator) (France), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Berthe Aleman1 (Netherlands),\nJoachim Alexandre (France), Ana Barac3 (United States of America), Michael A. Borger (Germany),\nRuben Casado-Arroyo (Belgium), Jennifer Cautela (France), Jolanta Čelutkienė (Lithuania), Maja Cikes\n(Croatia), Alain Cohen-Solal (France), Kreena Dhiman (United Kingdom), Stéphane Ederhy (France),\nThor Edvardsen (Norway), Laurent Fauchier (France), Michael Fradley3 (United States of America), Julia Grapsa\n(United Kingdom), Sigrun Halvorsen (Norway), Michael Heuser2 (Germany), Marc Humbert (France),\nTiny Jaarsma (Sweden), Thomas Kahan (Sweden), Aleksandra Konradi (Russian Federation),\nKonstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Bonnie Ky3 (United States\nof America), Ulf Landmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech Republic), Gregory Y.H. Lip\n(United Kingdom), Maja-Lisa Løchen (Norway), Katarzyna Malaczynska-Rajpold (United Kingdom),\nMarco Metra (Italy), Richard Mindham (United Kingdom), Marie Moonen (Belgium), Tomas G. Neilan\n(United States of America), Jens Cosedis Nielsen (Denmark), Anna-Sonia Petronio (Italy), Eva Prescott\n(Denmark), Amina Rakisheva (Kazakhstan), Joe-Elie Salem (France), Gianluigi Savarese (Sweden), Marta Sitges\n(Spain), Jurrien ten Berg (Netherlands), Rhian M. Touyz (Canada/United Kingdom), Agnieszka Tycinska\n(Poland), Matthias Wilhelm (Switzerland), and Jose Luis Zamorano (Spain)\nAll experts involved in the development of these Guidelines have submitted declarations of interest. These have\nbeen compiled in a report and published in a supplementary document simultaneously to the Guidelines. The\nreport is also available on the ESC website www.escardio.org/Guidelines\nSee the European Heart Journal online for supplementary data that includes background information and\ndetailed discussion of the data that have provided the basis of the guidelines.\n- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -\nKeywords\nGuidelines • Androgen deprivation therapy • Anthracycline • Atrial ﬁbrillation • Arrhythmias • Biomarkers •\nCancer • Cancer survivors • Carcinoid syndrome • Amyloid light-chain cardiac amyloidosis • Cardiac magnetic\nresonance • Cardiac tumour • Cardio-oncology • Cardiotoxicity • Coronary artery disease • Chemotherapy •\nEchocardiography • Fluoropyrimidine • Heart failure • Haematopoietic stem cell transplantation • Hormone therapy\n• Hypertension • Immunotherapy • Ischaemic heart disease • Myocarditis • Pericardial disease • Pulmonary\nhypertension • Thrombosis • Risk stratiﬁcation • Trastuzumab • Valvular heart disease • Vascular endothelial\ngrowth factor inhibitors (VEGFi) • Venous thromboembolism • Pericardial disease • Proteasome inhibitors • QTc\nprolongation • Radiotherapy • Strain\nThe content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC\nGuidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University\nPress, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).\nDisclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the\ntime of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other ofﬁcial recommendations\nor guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the\nESC Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strat-\negies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consid-\neration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health\nprofessionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to\nmanage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to\nverify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.\nThis article has been co-published with permission in the European Heart Journal and the European Heart Journal – Cardiovascular Imaging. © The European Society of Cardiology 2022. All\nrights reserved. The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article. For\npermissions please e-mail: journals.permissions@oup.com.\n4230\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nTable of contents\n1. Preamble ........................................................................................................\n4236\n2. Introduction .................................................................................................\n4238\n2.1. Cancer and cardiovascular needs of patients with cancer\n4238\n2.2. Role of cardio-oncology services ............................................... 4238\n2.3. General principles of cardio-oncology ..................................... 4239\n3. Cancer therapy-related cardiovascular toxicity deﬁnitions .....\n4242\n4. Cardiovascular toxicity risk stratiﬁcation before anticancer\ntherapy .................................................................................................................\n4244\n4.1. General approach to cardiovascular toxicity risk in patients\nwith cancer ................................................................................................... 4244\n4.2. History and clinical examination ................................................. 4249\n4.3. Electrocardiogram ............................................................................. 4249\n4.4. Cardiac serum biomarkers ............................................................ 4251\n4.5. Cardiovascular imaging ................................................................... 4252\n4.6. Cardiopulmonary ﬁtness assessment ....................................... 4253\n4.7. Cardiovascular risk evaluation before cancer surgery ...... 4254\n4.8. Genetic testing ................................................................................... 4254\n5. Prevention and monitoring of cardiovascular complications\nduring cancer therapy ...................................................................................\n4254\n5.1. General principles ............................................................................. 4254\n5.2. Primary prevention strategies ...................................................... 4256\n5.2.1. Primary prevention of cancer therapy-related\ncardiovascular toxicity during anthracycline\nchemotherapy ..................................................................................\n4256\n5.2.2. Primary prevention of radiation-induced\ncardiovascular toxicity ..................................................................\n4256\n5.3. Secondary prevention strategies ................................................ 4257\n5.4. Cardiovascular surveillance during cancer therapies ......... 4257\n5.4.1. Cardiac serum biomarkers .............................................\n4257\n5.4.2. Cardiac imaging ....................................................................\n4257\n5.5. Cancer therapy-related cardiovascular toxicity monitoring\nprotocols ....................................................................................................... 4259\n5.5.1. Anthracycline chemotherapy .........................................\n4259\n5.5.2. HER2-targeted therapies .................................................\n4259\n5.5.3. Fluoropyrimidines ...............................................................\n4261\n5.5.4. Vascular endothelial growth factor inhibitors ........\n4261\n5.5.5. Multitargeted kinase inhibitors targeting BCR-ABL\n4264\n5.5.6. Bruton tyrosine kinase inhibitors .................................\n4267\n5.5.7. Multiple myeloma therapies ...........................................\n4268\n5.5.8. Rapidly accelerated ﬁbrosarcoma and mitogen-\nactivated extracellular signal-regulated kinase inhibitor\ntreatment ............................................................................................\n4271\n5.5.9. Immune checkpoint inhibitors ......................................\n4273\n5.5.10. Androgen deprivation therapies for prostate\ncancer ...................................................................................................\n4274\n5.5.11. Endocrine therapies for breast cancer ...................\n4276\n5.5.12. Cyclin-dependent kinase 4/6 inhibitors ..................\n4276\n5.5.13. Anaplastic lymphoma kinase inhibitors ...................\n4277\n5.5.14. Epidermal growth factor receptor inhibitors ......\n4277\n5.5.15. Chimeric antigen receptor\nT cell and tumour-inﬁltrating lymphocytes therapies .....\n4278\n5.5.16. Radiotherapy ......................................................................\n4279\n5.5.17. Haematopoietic stem cell transplantation ............\n4279\n5.5.18. Other cancer treatments .............................................\n4282\n6. Diagnosis and management of acute and subacute\ncardiovascular toxicity in patients receiving anticancer treatment\n4282\n6.1. Cancer therapy-related cardiac dysfunction .......................... 4282\n6.1.1. Anthracycline chemotherapy-related cardiac\ndysfunction .........................................................................................\n4282\n6.1.2. Human epidermal receptor 2-targeted therapy-\nrelated cardiac dysfunction .........................................................\n4284\n6.1.3. Immune checkpoint inhibitor-associated\nmyocarditis and non-inﬂammatory heart failure ...............\n4286\n6.1.4. Chimeric antigen receptor T cell and tumour-\ninﬁltrating lymphocytes therapies and heart dysfunction\n4290\n6.1.5. Heart failure during haematopoietic stem cell\ntransplantation .................................................................................\n4291\n6.1.6. Takotsubo syndrome and cancer ................................\n4291\n6.2. Coronary artery disease ................................................................. 4291\n6.2.1. Acute coronary syndromes ............................................\n4291\n6.2.2. Chronic coronary syndromes .......................................\n4293\n6.3. Valvular heart disease ...................................................................... 4293\n6.4. Cardiac arrhythmias ......................................................................... 4294\n6.4.1. Atrial ﬁbrillation ...................................................................\n4294\n6.4.2. Long corrected QT interval and ventricular\narrhythmias ........................................................................................\n4298\n6.4.3. Bradyarrhythmias ................................................................\n4300\n6.5. Arterial hypertension ....................................................................... 4300\n6.6. Thrombosis and thromboembolic events .............................. 4303\n6.6.1. Venous thromboembolism .............................................\n4303\n6.6.2. Arterial thromboembolism ............................................\n4304\n6.6.3. Intracardiac thrombosis ...................................................\n4304\n6.6.4. Anticoagulation therapy ...................................................\n4305\n6.7. Bleeding complications .................................................................... 4306\n6.7.1. High-risk patients ................................................................\n4306\n6.7.2. Antiplatelet therapy ...........................................................\n4306\n6.7.3. Management of bleeding ..................................................\n4306\n6.8. Peripheral artery disease ................................................................ 4307\n6.9. Pulmonary hypertension ................................................................ 4307\n6.10. Pericardial diseases ......................................................................... 4308\n6.10.1. Pericarditis ...........................................................................\n4308\n6.10.2. Pericardial effusion ...........................................................\n4308\n7. End-of-cancer therapy cardiovascular risk assessment .............\n4309\n7.1. Cardiovascular evaluation during the ﬁrst year after\ncardiotoxic anticancer therapy ............................................................ 4309\n7.2. Which cancer survivors require cardiovascular surveillance\nin the ﬁrst year after cancer treatment? .......................................... 4309\n7.3. Management of cancer therapy-related cardiac dysfunction\nat the end-of-therapy assessment ...................................................... 4310\n7.4. Cardiopulmonary exercise testing and ﬁtness during the\nend-of-therapy assessment .................................................................... 4310\n7.5. The role of cardiac rehabilitation ............................................... 4310\n8. Long-term follow-up and chronic cardiovascular complications\nin cancer survivors ..........................................................................................\n4312\n8.1. Cancer survivors ................................................................................ 4312\n8.1.1. Adult survivors of childhood and adolescent\ncancer ...................................................................................................\n4312\n8.1.2. Adult cancer survivors ......................................................\n4313\n8.2. Myocardial dysfunction and heart failure ................................ 4315\n8.3. Coronary artery disease ................................................................. 4316\n8.4. Valvular heart disease ...................................................................... 4317\n8.5. Peripheral artery disease and stroke ........................................ 4317\n8.6. Pericardial complications ................................................................ 4317\n8.7. Arrhythmias and autonomic disease ......................................... 4318\nESC Guidelines\n4231\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n8.8. Metabolic syndrome, lipid abnormalities, diabetes mellitus,\nand hypertension ........................................................................................ 4318\n8.9. Pregnancy in cancer survivors ..................................................... 4318\n8.10. Pulmonary hypertension .............................................................. 4319\n9. Special populations ....................................................................................\n4319\n9.1. Cardiac tumours ................................................................................ 4319\n9.2. Pregnant patients with cancer ..................................................... 4319\n9.2.1. Left ventricular dysfunction and heart failure ........\n4320\n9.2.2. Venous thromboembolism and pulmonary\nembolism ..................................................................................... 4320\n9.3. Carcinoid valvular heart disease ................................................. 4323\n9.4. Amyloid light-chain cardiac amyloidosis .................................. 4324\n9.5. Cardiac implantable electronic devices .................................... 4326\n10. Patient information, communication, and self-management\n4330\n11. The role of scientiﬁc societies in the promotion and\ndevelopment of cardio-oncology in modern medicine ..................\n4331\n12. Key messages ............................................................................................\n4331\n13. Future needs ..............................................................................................\n4332\n14. Gaps in evidence ......................................................................................\n4333\n15. ‘What to do’ and ‘what not to do’ messages from the\nGuidelines ...........................................................................................................\n4333\n16. Quality indicators for cardio-oncology ..........................................\n4342\n17. Supplementary data ................................................................................\n4342\n18. Data availability statement ...................................................................\n4342\n19. Author information ................................................................................\n4342\n20. Appendix .....................................................................................................\n4342\n21. References ..................................................................................................\n4343\nTables of Recommendations\nRecommendation Table 1 — Recommendations for a general\napproach to cardiovascular toxicity risk categorization .................\n4249\nRecommendation Table 2 — Recommendations for\nelectrocardiogram baseline assessment ................................................\n4251\nRecommendation Table 3 — Recommendation for cardiac\nbiomarker assessment prior to potentially cardiotoxic therapies .\n4252\nRecommendation Table 4 — Recommendations for cardiac\nimaging modalities in patients with cancer ..........................................\n4253\nRecommendation Table 5 — Recommendations for\nprimary prevention of cancer therapy-related cardiovascular\ntoxicity ......................................................................................................... 4256\nRecommendation Table 6 — Recommendation for secondary\nprevention of cancer therapy-related cardiovascular toxicity .....\n4257\nRecommendation Table 7 — Recommendations for baseline risk\nassessment and monitoring during anthracycline chemotherapy\nand in the ﬁrst 12 months after therapy ..............................................\n4259\nRecommendation Table 8 — Recommendations for baseline risk\nassessment and monitoring during human epidermal receptor\n2-targeted therapies and in the ﬁrst 12 months after therapy ...\n4260\nRecommendation Table 9 — Recommendations for baseline risk\nassessment and monitoring during ﬂuoropyrimidine therapy .....\n4261\nRecommendation Table 10 — Recommendations for baseline\nrisk assessment and monitoring during vascular endothelial\ngrowth factor inhibitors ...............................................................................\n4264\nRecommendation Table 11 — Recommendations for baseline\nrisk assessment and monitoring during second- and\nthird-generation breakpoint cluster region–Abelson oncogene\nlocus tyrosine kinase inhibitors .................................................................\n4267\nRecommendation Table 12 — Recommendations for baseline\nrisk assessment and monitoring during Bruton tyrosine kinase\ninhibitor therapy ..............................................................................................\n4267\nRecommendation Table 13 — Recommendations for baseline\nrisk assessment and monitoring during multiple myeloma\ntherapies ..................................................................................................... 4271\nRecommendation Table 14 — Recommendations for baseline\nrisk assessment and monitoring during combined rapidly\naccelerated ﬁbrosarcoma and mitogen-activated extracellular\nsignal-regulated kinase inhibitor therapy ...............................................\n4272\nRecommendation Table 15 — Recommendations for baseline\nrisk assessment and monitoring during immunotherapy ...............\n4274\nRecommendation Table 16 — Recommendations for baseline\nrisk assessment and monitoring during androgen deprivation\ntherapy for prostate cancer .......................................................................\n4276\nRecommendation Table 17 — Recommendations for baseline\nrisk assessment and monitoring during endocrine therapy for\nbreast cancer ....................................................................................................\n4276\nRecommendation Table 18 — Recommendations for baseline\nrisk assessment and monitoring during cyclin-dependent kinase\n4/6 inhibitor therapy ......................................................................................\n4277\nRecommendation Table 19 — Recommendations for baseline\nrisk assessment and monitoring during anaplastic lymphoma\nkinase and epidermal growth factor receptor inhibitors ...............\n4277\nRecommendation Table 20 — Recommendations for baseline\nrisk assessment and monitoring in patients receiving chimeric\nantigen receptor T cell and tumour-inﬁltrating lymphocytes\ntherapies .............................................................................................................\n4279\nRecommendation Table 21 — Recommendations for baseline\nrisk assessment of patients before radiotherapy to a volume\nincluding the heart ..........................................................................................\n4279\nRecommendation Table 22 — Recommendations for baseline\nrisk assessment in haematopoietic stem cell transplantation\npatients ................................................................................................................\n4281\nRecommendation Table 23 — Recommendation for the\nmanagement of cardiovascular disease and cancer\ntherapy-related cardiovascular toxicity in patients receiving\nanticancer treatment .....................................................................................\n4282\nRecommendation Table 24 — Recommendations for the\nmanagement of cancer treatment-related cardiac dysfunction\nduring anthracycline chemotherapy ........................................................\n4284\nRecommendation Table 25 — Recommendations for the\nmanagement of cancer treatment-related cardiac dysfunction\nduring human epidermal receptor 2-targeted therapies ...............\n4286\nRecommendation Table 26 — Recommendations for the\ndiagnosis and management of immune checkpoint\ninhibitor-associated myocarditis ...............................................................\n4289\nRecommendation Table 27 — Recommendations for the\ndiagnosis and management of Takotsubo syndrome in patients\nwith cancer ........................................................................................................\n4291\nRecommendation Table 28 — Recommendations for the\nmanagement of acute coronary syndromes in patients receiving\nanticancer treatment .....................................................................................\n4292\nRecommendation Table 29 — Recommendation for the\nmanagement of chronic coronary syndromes in patients receiving\nanticancer treatment .....................................................................................\n4293\nRecommendation Table 30 — Recommendations for the\nmanagement of valvular heart disease in patients receiving\nanticancer treatment .....................................................................................\n4293\n4232\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nRecommendation Table 31 — Recommendations for the\nmanagement of atrial ﬁbrillation in patients receiving anticancer\ntreatment ............................................................................................................\n4297\nRecommendation Table 32 — Recommendations for the\nmanagement of long corrected QT interval and ventricular\narrhythmias in patients receiving anticancer treatment .................\n4300\nRecommendation Table 33 — Recommendations for the\nmanagement of arterial hypertension in patients receiving\nanticancer treatment .....................................................................................\n4302\nRecommendation Table 34 — Recommendations for the\nmanagement of venous thromboembolism in patients receiving\nanticancer treatment .....................................................................................\n4305\nRecommendation Table 35 — Recommendations for venous\nthromboembolism prophylaxis during anticancer treatment ......\n4306\nRecommendation Table 36 — Recommendation for management\nof peripheral artery disease during anticancer treatment ..................\n4307\nRecommendation Table 37 — Recommendations for the\nmanagement of pulmonary hypertension during anticancer\ntreatment ............................................................................................................\n4308\nRecommendation Table 38 — Recommendations for the\nmanagement of pericardial diseases in patients receiving\nanticancer treatment .....................................................................................\n4309\nRecommendation Table 39 — Recommendations for\nend-of-cancer therapy cardiovascular risk assessment ...................\n4312\nRecommendation Table 40 — Recommendations for\ncardiovascular surveillance in asymptomatic adults who are\nchildhood and adolescent cancer survivors .........................................\n4313\nRecommendation Table 41 — Recommendations for\ncardiovascular surveillance in asymptomatic adult cancer survivors\n4314\nRecommendation Table 42 — Recommendations for adult\ncancer survivors who develop cancer therapy-related cardiac\ndysfunction late after cardiotoxic cancer therapy ............................\n4316\nRecommendation Table 43 — Recommendations for adult\ncancer survivors with coronary artery disease ..................................\n4316\nRecommendation Table 44 — Recommendations for adult\ncancer survivors with valvular heart disease .......................................\n4317\nRecommendation Table 45 — Recommendation for adult cancer\nsurvivors with pericardial complications ...............................................\n4318\nRecommendation Table 46 — Recommendations for\ncardiovascular monitoring in cancer survivors during pregnancy\n4319\nRecommendation Table 47 — Recommendations for cardiovascular\nassessment and monitoring of pregnant women with cancer .............\n4323\nRecommendation Table 48 — Recommendations for carcinoid\nvalvular heart diseases ...................................................................................\n4323\nRecommendation Table 49 — Recommendations for amyloid\nlight-chain cardiac amyloidosis diagnosis and monitoring ..............\n4326\nRecommendation Table 50 — Recommendations for risk\nstratiﬁcation and monitoring for patients with cardiac implantable\nelectronic devices undergoing radiotherapy ....................................................\n4330\nList of tables\nTable 1 Classes of recommendations ....................................................\n4237\nTable 2 Levels of evidence ..........................................................................\n4237\nTable 3 Cancer therapy-related cardiovascular toxicity deﬁnitions\n4243\nTable 4 Heart Failure Association–International Cardio-Oncology\nSociety baseline cardiovascular toxicity risk stratiﬁcation ............... 4246\nTable 5 Anthracycline equivalence dose ...............................................\n4247\nTable 6 Factors that could inﬂuence peri-operative risk during\ncancer surgery and preventive strategies .............................................\n4254\nTable 7 Cancer treatments that predispose to acute coronary\nsyndromes ..........................................................................................................\n4291\nTable 8 Risk factors for drug-induced QT prolongation and\ntorsade de pointes ..........................................................................................\n4298\nTable 9 Classiﬁcation of corrected QT interval prolongation\ninduced by cancer drug therapy ...............................................................\n4298\nTable 10 Risk factors for future cardiovascular disease at the\nend-of-cancer therapy cardiovascular risk assessment ...................\n4310\nTable 11 Risk categories for asymptomatic adults who are\nchildhood and adolescent cancer survivors .........................................\n4313\nTable 12 Risk categories for asymptomatic adult cancer survivors\n4314\nTable 13 Management strategies and surgery indications for\nsymptomatic and asymptomatic patients with benign and\nmalignant cardiac tumours ..........................................................................\n4321\nList of ﬁgures\nFigure 1 Video 1 Central Illustration: Dynamics of\ncardiovascular toxicity risk of patients with cancer over their\ntherapy continuum .................................................................................. 4239\nFigure 2 Cardio-oncology care pathways .............................................\n4240\nFigure 3 Baseline cardiovascular toxicity risk assessment checklist\n4241\nFigure 4 Dimensions of cancer therapy-related cardiovascular\ntoxicity risk and disease severity ..............................................................\n4242\nFigure 5 Baseline cardiovascular toxicity risk assessment before\nanticancer therapy ..........................................................................................\n4245\nFigure 6 General cardio-oncology approach after Heart Failure\nAssociation–International Cardio-Oncology Society\ncardiovascular toxicity risk assessment ................................................ 4248\nFigure 7 Baseline screening recommendations for patients with\ncancer treated with potentially cardiotoxic drugs ............................\n4250\nFigure 8 Recommended transthoracic echocardiography and\ncardiac magnetic resonance imaging parameters in the evaluation of\npatients with cancer ...............................................................................................\n4252\nFigure 9 Primary and secondary cancer therapy-related\ncardiovascular toxicity prevention ..................................................................\n4255\nFigure 10 Cardiovascular toxicity monitoring in patients receiving\nanthracycline chemotherapy ......................................................................\n4258\nFigure 11 Cardiovascular toxicity monitoring in patients receiving\nhuman epidermal receptor 2-targeted therapies ..............................\n4260\nFigure 12 Vascular endothelial growth factor inhibitors-related\ncardiovascular toxicities ...............................................................................\n4262\nFigure 13 Cardiovascular toxicity monitoring in patients receiving\nvascular endothelial growth factor inhibitors .....................................\n4263\nFigure 14 Breakpoint cluster region–Abelson oncogene locus\ntyrosine kinase inhibitor-related cardiovascular toxicities ............\n4265\nFigure 15 Second- and third-generation breakpoint cluster\nregion–Abelson oncogene locus tyrosine kinase inhibitors\nsurveillance protocol .....................................................................................\n4266\nFigure 16 Multiple myeloma drug-related cardiovascular toxicities\n4268\nFigure 17 Cardiovascular monitoring in patients with multiple\nmyeloma receiving proteasome inhibitors ...........................................\n4269\nFigure 18 Risk factors for venous thromboembolic events in\npatients with multiple myeloma ...............................................................\n4270\nFigure 19 Rapidly accelerated ﬁbrosarcoma and mitogen-activated\nextracellular signal-regulated kinase inhibitor-related cardiovascular\ntoxicities ........................................................................................................................\n4272\nESC Guidelines\n4233\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nFigure 20 Cardiovascular surveillance in patients treated with\nimmune checkpoint inhibitors ...................................................................\n4273\nFigure 21 Androgen deprivation therapy-related cardiovascular\ntoxicities ..............................................................................................................\n4275\nFigure 22 Anaplastic lymphoma kinase and epidermal growth\nfactor receptor inhibitor-related cardiovascular toxicities ...........\n4278\nFigure 23 Radiotherapy mean heart dose and associated\ncardiovascular toxicity risk ..........................................................................\n4280\nFigure 24 Risk factors and cardiovascular surveillance in patients\nreferred for haematopoietic stem cell transplantation ..................\n4281\nFigure 25 Management of anthracycline chemotherapy-related\ncardiac dysfunction .........................................................................................\n4283\nFigure 26 Management of human epidermal receptor 2-targeted\ntherapy-related cardiac dysfunction ........................................................\n4285\nFigure 27 Direct and indirect immune checkpoint\ninhibitor-related cardiovascular toxicity ................................................\n4287\nFigure 28 Diagnosis and management of immune checkpoint\ninhibitor-related myocarditis ......................................................................\n4288\nFigure 29 Diagnosis and management workup in cancer-related\nTakotsubo syndrome ....................................................................................\n4290\nFigure 30 Pathophysiology of atrial ﬁbrillation associated with\ncancer ...................................................................................................................\n4295\nFigure 31 Structured approach to anticoagulation for atrial\nﬁbrillation in patients with cancer ............................................................\n4296\nFigure 32 Corrected QT interval monitoring before and during\ntreatment with corrected QT interval-prolonging anticancer drugs\n4299\nFigure 33 Recommended threshold for asymptomatic\nhypertension treatment in different clinical scenarios ....................\n4301\nFigure 34 Treatment of arterial hypertension in patients with\ncancer ...................................................................................................................\n4302\nFigure 35 Risk factors for venous thromboembolism in patients\nwith cancer ........................................................................................................\n4303\nFigure 36 Structured approach to anticoagulation for venous\nthromboembolism in patients with active cancer ............................\n4304\nFigure 37 Management of cancer therapy-related cardiac\ndysfunction after cancer therapy .............................................................\n4311\nFigure 38 Long-term follow-up in cancer survivors .........................\n4315\nFigure 39 Location of primary and secondary cardiac tumours .\n4320\nFigure 40 Diagnostic algorithm for cardiac masses ..........................\n4321\nFigure 41 Cardiac monitoring protocol for pregnant women\nreceiving anthracycline-based chemotherapy .....................................\n4322\nFigure 42 Carcinoid heart disease: clinical features and diagnostic\ntests .......................................................................................................................\n4324\nFigure 43 Non-invasive diagnosis of amyloid light-chain cardiac\namyloidosis .........................................................................................................\n4325\nFigure 44 Risk stratiﬁcation in patients with a cardiac implantable\nelectronic device undergoing radiotherapy .........................................\n4327\nFigure 45 Management of patients with a cardiac implantable\nelectronic device located in the radiotherapy treatment beam .\n4328\nFigure 46 Management of patients with a cardiac implantable\nelectronic device located outside the radiotherapy treatment\nvolume .................................................................................................................\n4329\nFigure 47 Patient information, communication, and\nself-management ..............................................................................................\n4330\nFigure 48 The role of scientiﬁc societies in the promotion and\ndevelopment of cardio-oncology .............................................................\n4331\nAbbreviations and acronyms\n2D\nTwo-dimensional\n3D\nThree-dimensional\n5-FU\n5-ﬂuorouracil\n5HIAA\n5-hydroxyindoleacetic acid\na′\nLate diastolic velocity of mitral annulus\nobtained by tissue Doppler imaging\nABC\nAtrial ﬁbrillation Better Care\nABI\nAnkle–brachial index\nAC\nAnthracycline chemotherapy\nACE-I\nAngiotensin-converting enzyme inhibitors\nACS\nAcute coronary syndromes\nADT\nAndrogen deprivation therapy\nADVANCE\nAction in Diabetes and Vascular Disease:\nPreterax and Diamicron-MR Controlled\nEvaluation\nAF\nAtrial ﬁbrillation\nAI\nAromatase inhibitors\nAL-CA\nAmyloid light-chain cardiac amyloidosis\nALK\nAnaplastic lymphoma kinase\nANS\nAutonomic nervous system\nARB\nAngiotensin receptor blockers\nARISTOTLE\nApixaban for Reduction in Stroke and Other\nThromboembolic Events in Atrial Fibrillation\nASCVD\nAtheroSclerotic Cardiovascular Disease\nASPIRE\nCarﬁlzomib, Lenalidomide, and\nDexamethasone vs. Lenalidomide and\nDexamethasone for the Treatment of\nPatients with Relapsed Multiple Myeloma\nASTCT\nAmerican Society for Transplantation and\nCellular Therapy\nATAC\n‘Arimidex’ and Tamoxifen Alone or in\nCombination\nATE\nArterial thromboembolism\nAV\nAtrioventricular\nBB\nBeta-blockers\nBC\nBreast cancer\nBCR-ABL\nBreakpoint cluster region–Abelson oncogene\nlocus\nBIG\nBreast International Group\nBLEED\nIncreased bleeding risk\nBMI\nBody mass index\nBNP\nB-type natriuretic peptide\nBP\nBlood pressure\nBTK\nBruton tyrosine kinase\nC\nChemotherapy cycle\nCABG\nCoronary artery bypass graft\nCAD\nCoronary artery disease\nCARDIOTOX\nCARDIOvascular TOXicity induced by\ncancer-related therapies\nCAR-T\nChimeric antigen receptor T cell\nCCB\nCalcium channel blockers\nCCS\nChronic coronary syndromes\nCCTA\nCoronary computed tomography\nangiography\n4234\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "keywords": [
        "hypertension",
        "heart failure",
        "radiology",
        "blood pressure",
        "recommended",
        "echocardiography",
        "genetic",
        "angiography",
        "coronary artery",
        "developed",
        "hematology",
        "diabetes",
        "ascvd",
        "calcium channel",
        "bnp",
        "secondary prevention",
        "primary prevention",
        "anticoagulation",
        "atrial fibrillation",
        "bmi",
        "diastolic",
        "pulmonary hypertension",
        "peripheral artery",
        "arb",
        "cardio",
        "cardiovascular risk",
        "association",
        "exercise",
        "guidelines",
        "lipid"
      ],
      "tables": [
        {
          "title": "4230 ESC Guidelines",
          "page_number": 1,
          "content": " |  | rheartj/article/43/41/4229/6673995 by\n | - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -\nKeywords Guidelines • Androgen deprivation therapy • Anthracycline • Atrial fibrillation • Arrhythmias • Biomarkers •\nCancer • Cancer survivors • Carcinoid syndrome • Amyloid light-chain cardiac amyloidosis • Cardiac magnetic\nresonance • Cardiac tumour • Cardio-oncology • Cardiotoxicity • Coronary artery disease • Chemotherapy •\nEchocardiography • Fluoropyrimidine • Heart failure • Haematopoietic stem cell transplantation • Hormone therapy\n• Hypertension • Immunotherapy • Ischaemic heart disease • Myocarditis • Pericardial disease • Pulmonary\nhypertension • Thrombosis • Risk stratification • Trastuzumab • Valvular heart disease • Vascular endothelial\ngrowth factor inhibitors (VEGFi) • Venous thromboembolism • Pericardial disease • Proteasome inhibitors • QTc\nprolongation • Radiotherapy • Strain | \n |  | ",
          "bbox": [
            0.0,
            364.6339477539062,
            595.260009765625,
            499.9629821777344
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "2",
      "title": "Abbreviations and acronyms",
      "start_page": 5,
      "end_page": 10,
      "content": "Figure 20 Cardiovascular surveillance in patients treated with\nimmune checkpoint inhibitors ...................................................................\n4273\nFigure 21 Androgen deprivation therapy-related cardiovascular\ntoxicities ..............................................................................................................\n4275\nFigure 22 Anaplastic lymphoma kinase and epidermal growth\nfactor receptor inhibitor-related cardiovascular toxicities ...........\n4278\nFigure 23 Radiotherapy mean heart dose and associated\ncardiovascular toxicity risk ..........................................................................\n4280\nFigure 24 Risk factors and cardiovascular surveillance in patients\nreferred for haematopoietic stem cell transplantation ..................\n4281\nFigure 25 Management of anthracycline chemotherapy-related\ncardiac dysfunction .........................................................................................\n4283\nFigure 26 Management of human epidermal receptor 2-targeted\ntherapy-related cardiac dysfunction ........................................................\n4285\nFigure 27 Direct and indirect immune checkpoint\ninhibitor-related cardiovascular toxicity ................................................\n4287\nFigure 28 Diagnosis and management of immune checkpoint\ninhibitor-related myocarditis ......................................................................\n4288\nFigure 29 Diagnosis and management workup in cancer-related\nTakotsubo syndrome ....................................................................................\n4290\nFigure 30 Pathophysiology of atrial ﬁbrillation associated with\ncancer ...................................................................................................................\n4295\nFigure 31 Structured approach to anticoagulation for atrial\nﬁbrillation in patients with cancer ............................................................\n4296\nFigure 32 Corrected QT interval monitoring before and during\ntreatment with corrected QT interval-prolonging anticancer drugs\n4299\nFigure 33 Recommended threshold for asymptomatic\nhypertension treatment in different clinical scenarios ....................\n4301\nFigure 34 Treatment of arterial hypertension in patients with\ncancer ...................................................................................................................\n4302\nFigure 35 Risk factors for venous thromboembolism in patients\nwith cancer ........................................................................................................\n4303\nFigure 36 Structured approach to anticoagulation for venous\nthromboembolism in patients with active cancer ............................\n4304\nFigure 37 Management of cancer therapy-related cardiac\ndysfunction after cancer therapy .............................................................\n4311\nFigure 38 Long-term follow-up in cancer survivors .........................\n4315\nFigure 39 Location of primary and secondary cardiac tumours .\n4320\nFigure 40 Diagnostic algorithm for cardiac masses ..........................\n4321\nFigure 41 Cardiac monitoring protocol for pregnant women\nreceiving anthracycline-based chemotherapy .....................................\n4322\nFigure 42 Carcinoid heart disease: clinical features and diagnostic\ntests .......................................................................................................................\n4324\nFigure 43 Non-invasive diagnosis of amyloid light-chain cardiac\namyloidosis .........................................................................................................\n4325\nFigure 44 Risk stratiﬁcation in patients with a cardiac implantable\nelectronic device undergoing radiotherapy .........................................\n4327\nFigure 45 Management of patients with a cardiac implantable\nelectronic device located in the radiotherapy treatment beam .\n4328\nFigure 46 Management of patients with a cardiac implantable\nelectronic device located outside the radiotherapy treatment\nvolume .................................................................................................................\n4329\nFigure 47 Patient information, communication, and\nself-management ..............................................................................................\n4330\nFigure 48 The role of scientiﬁc societies in the promotion and\ndevelopment of cardio-oncology .............................................................\n4331\nAbbreviations and acronyms\n2D\nTwo-dimensional\n3D\nThree-dimensional\n5-FU\n5-ﬂuorouracil\n5HIAA\n5-hydroxyindoleacetic acid\na′\nLate diastolic velocity of mitral annulus\nobtained by tissue Doppler imaging\nABC\nAtrial ﬁbrillation Better Care\nABI\nAnkle–brachial index\nAC\nAnthracycline chemotherapy\nACE-I\nAngiotensin-converting enzyme inhibitors\nACS\nAcute coronary syndromes\nADT\nAndrogen deprivation therapy\nADVANCE\nAction in Diabetes and Vascular Disease:\nPreterax and Diamicron-MR Controlled\nEvaluation\nAF\nAtrial ﬁbrillation\nAI\nAromatase inhibitors\nAL-CA\nAmyloid light-chain cardiac amyloidosis\nALK\nAnaplastic lymphoma kinase\nANS\nAutonomic nervous system\nARB\nAngiotensin receptor blockers\nARISTOTLE\nApixaban for Reduction in Stroke and Other\nThromboembolic Events in Atrial Fibrillation\nASCVD\nAtheroSclerotic Cardiovascular Disease\nASPIRE\nCarﬁlzomib, Lenalidomide, and\nDexamethasone vs. Lenalidomide and\nDexamethasone for the Treatment of\nPatients with Relapsed Multiple Myeloma\nASTCT\nAmerican Society for Transplantation and\nCellular Therapy\nATAC\n‘Arimidex’ and Tamoxifen Alone or in\nCombination\nATE\nArterial thromboembolism\nAV\nAtrioventricular\nBB\nBeta-blockers\nBC\nBreast cancer\nBCR-ABL\nBreakpoint cluster region–Abelson oncogene\nlocus\nBIG\nBreast International Group\nBLEED\nIncreased bleeding risk\nBMI\nBody mass index\nBNP\nB-type natriuretic peptide\nBP\nBlood pressure\nBTK\nBruton tyrosine kinase\nC\nChemotherapy cycle\nCABG\nCoronary artery bypass graft\nCAD\nCoronary artery disease\nCARDIOTOX\nCARDIOvascular TOXicity induced by\ncancer-related therapies\nCAR-T\nChimeric antigen receptor T cell\nCCB\nCalcium channel blockers\nCCS\nChronic coronary syndromes\nCCTA\nCoronary computed tomography\nangiography\n4234\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nCCU\nCoronary care unit\nCDK\nCyclin-dependent kinase\nCHA2DS2-VASc\nCongestive heart failure, Hypertension, Age\n≥75 years (2 points), Diabetes mellitus,\nStroke (2 points)—Vascular disease, Age\n65–74 years, Sex category (female)\nCIED\nCardiac implantable electronic device\nCML\nChronic myeloid leukaemia\nCMR\nCardiac magnetic resonance\nCOMPASS-CAT\nProspective COmparison of Methods for\nthromboembolic risk assessment with clinical\nPerceptions and AwareneSS in real-life\npatients—Cancer Associated Thrombosis\nCPET\nCardiopulmonary exercise testing\nCrCl\nCreatinine clearance\nCRF\nCardiorespiratory ﬁtness\nCRS\nCytokine release syndrome\nCS\nCancer survivors\nCT\nComputed tomography\nCTLA-4\nCytotoxic T lymphocyte-associated\nantigen-4\ncTn\nCardiac troponin\nCTRCD\nCancer therapy-related cardiac\ndysfunction\nCTR-CVT\nCancer therapy-related cardiovascular\ntoxicity\nCV\nCardiovascular\nCVD\nCardiovascular disease\nCVRF\nCardiovascular risk factors\nDAPT\nDual antiplatelet therapy\nDASISION\nDASatinib vs. Imatinib Study In\ntreatment-Naïve chronic myeloid\nleukaemia patients\nDL\nDyslipidaemia\nDM\nDiabetes mellitus\nDNR\nDo not resuscitate\nDVT\nDeep vein thrombosis\nE\nMitral inﬂow early diastolic velocity\nobtained by pulsed wave\ne′\nEarly diastolic velocity of the mitral annulus\nobtained by tissue Doppler imaging\nEACTS\nEuropean Association for Cardio-Thoracic\nSurgery\nEBC\nEarly breast cancer\nECG\nElectrocardiogram\nEcho\nEchocardiography\nECV\nExtracellular volume fraction\neGFR\nEstimated glomerular ﬁltration rate\nEGFR\nEpidermal growth factor receptor\nEMA\nEuropean Medicines Agency\nEMB\nEndomyocardial biopsy\nENGAGE AF-TIMI 48\nEffective Anticoagulation with Factor\nXa Next Generation in Atrial Fibrillation-\nThrombolysis in Myocardial Infarction 48\nENOXACAN\nEnoxaparin and Cancer\nEoL\nEnd of life\nERS\nEuropean Respiratory Society\nESC\nEuropean Society of Cardiology\nESC-CCO\nEuropean Society of Cardiology Council of\nCardio-Oncology\nESH\nEuropean Society of Hypertension\nEuroSCORE\nEuropean System for Cardiac Operative\nRisk Evaluation\nFAC\nFractional area change\nFDA\nFood and Drug Administration\nFLT3\nFMS-like tyrosine kinase 3\nFWLS\nFree wall longitudinal strain\nGI\nGastrointestinal\nGLS\nGlobal longitudinal strain\nGnRH\nGonadotropin-releasing hormone\nGU\nGenitourinary\nGVHD\nGraft vs. host disease\nGy\nGray\nHAS-BLED\nHypertension, Abnormal renal and liver\nfunction, Stroke, Bleeding Labile\ninternational normalized ratio, Elderly,\nDrugs or alcohol\nHbA1c\nGlycated haemoglobin\nHDU\nHigh-dependency unit\nHER2\nHuman epidermal receptor 2\nHF\nHeart failure\nHFA\nHeart Failure Association\nHFmrEF\nHeart failure with mildly reduced ejection\nfraction\nHFpEF\nHeart failure with preserved ejection fraction\nHFrEF\nHeart failure with reduced ejection fraction\nHG\nHyperglycaemia\nHIIT\nHigh-intensity interval training\nHSCT\nHaematopoietic stem cell transplantation\nhs-cTn\nHigh-sensitivity cardiac troponin\nHTN\nHypertension\nICD\nImplantable cardioverter deﬁbrillator\nICI\nImmune checkpoint inhibitors\nICOS\nInternational Cardio-Oncology Society\nICU\nIntensive care unit\nIHD\nIschaemic heart disease\nIMiD\nImmunomodulatory drugs\ni.v.\nIntravenous\nIVC\nInferior vena cava\nIVS\nIntraventricular septum\nLA\nLeft atrial\nLAA\nLeft atrial appendage\nLGE\nLate gadolinium enhancement\nLIMA\nLeft internal mammary artery\nLMWH\nLow-molecular-weight heparins\nLQTS\nLong QT syndrome\nLS\nLongitudinal strain\nLV\nLeft ventricular\nLVD\nLeft ventricular dysfunction\nLVEDD\nLeft ventricular end diastolic diameter\nLVEF\nLeft ventricular ejection fraction\nLVV\nLeft ventricular volume\nM\nMonths\nMACE\nMajor adverse cardiovascular events\nMCS\nMechanical circulatory support\nMDT\nMultidisciplinary team\nESC Guidelines\n4235\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nMedDRA\nMedical dictionary for regulatory activities\nMEK\nMitogen-activated extracellular\nsignal-regulated kinase\nMHD\nMean heart dose\nMI\nMyocardial infarction\nMM\nMultiple myeloma\nMUGA\nMultigated acquisition nuclear imaging\nN\nNo\nNOAC\nNon-vitamin K antagonist oral\nanticoagulants\nNP\nNatriuretic peptides\nNSTE-ACS\nNon-ST-segment elevation acute coronary\nsyndromes\nNT-proBNP\nN-terminal pro-B-type natriuretic peptide\nPAD\nPeripheral artery disease\nPAH\nPulmonary arterial hypertension\nPAP\nPulmonary arterial pressure\nPCI\nPercutaneous coronary intervention\nPD-1\nProgrammed death-1\nPD-L1\nProgrammed death-ligand 1\nPE\nPulmonary embolism\nPeric-E\nPericardial effusion\nPET\nPositron emission tomography\nPH\nPulmonary hypertension\nPI\nProteasome inhibitors\nPleu-E\nPleural effusion\nPRECISE-DAPT\nPREdicting bleeding Complications In\npatients undergoing Stent implantation and\nsubsEquent Dual Anti Platelet Therapy\nPRONOUNCE\nA Trial Comparing Cardiovascular Safety\nof Degarelix Versus Leuprolide in Patients\nWith Advanced Prostate Cancer and\nCardiovascular Disease\nPW\nLeft ventricular posterior wall\nQI\nQuality indicator\n↑QTc\nCorrected QT interval prolongation\nQTc\nCorrected QT interval\nQTcF\nCorrected QT interval using Fridericia\ncorrection\nRA\nRight atrial\nRAF\nRapidly accelerated ﬁbrosarcoma\nRCT\nRandomized controlled trial\nRIMA\nRight internal mammary artery\nROCKET AF\nRivaroxaban Once Daily Oral Direct Factor\nXa Inhibition Compared with Vitamin K\nAntagonism for Prevention of Stroke and\nEmbolism Trial in Atrial Fibrillation\nRT\nRadiotherapy\nRV\nRight ventricular\nRVEF\nRight ventricular ejection fraction\nRVV\nRight ventricular volume\ns′\nSystolic velocity of tricuspid annulus\nobtained by doppler tissue imaging\nSBr\nSinus bradycardia\nSCORE2\nSystematic Coronary Risk Estimation 2\nSCORE2-OP\nSystematic Coronary Risk Estimation 2—\nOlder Persons\nSEER\nSurveillance, Epidemiology, and End Results\nSMART\nSecond manifestations of arterial disease\nsPAP\nSystolic pulmonary artery pressure\nSPEP\nSerum protein electrophoresis\nSTEMI\nST-segment elevation myocardial infarction\nSTIR\nShort tau inversion recovery\nSTS PROM\nSociety of Thoracic Surgeons – Predicted\nRisk of Mortality\nSVT\nSupraventricular tachycardia\nSYNTAX\nSYNergy between percutaneous coronary\nintervention with TAXus and cardiac surgery\nTAPSE\nTricuspid annular plane systolic excursion\nTAVI\nTranscatheter aortic valve implantation\nTBIP\nThromboembolic risk, Bleeding risk, drug–\ndrug Interactions, Patient preferences\nTdP\nTorsade de pointes\nTIL\nTumour-inﬁltrating lymphocytes\nTKI\nTyrosine kinase inhibitors\nTRV\nTricuspid regurgitation velocity\nTTE\nTransthoracic echocardiography\nTTS\nTakotsubo syndrome\ntx\nTreatment\nULN\nUpper limit of normal\nUPEP\nUrine protein electrophoresis\nVA\nVentricular arrhythmias\nVascTox\nVascular toxicity\nVEGF\nVascular endothelial growth factor\nVEGFi\nVascular endothelial growth factor inhibitors\nVH\nVery high risk\nVHD\nValvular heart disease\nVKA\nVitamin K antagonists\nVTE\nVenous thromboembolism\nY\nYes\n1. Preamble\nGuidelines summarize and evaluate available evidence with the aim of\nassisting health professionals in proposing the best management strat-\negies for an individual patient with a given condition. Guidelines and\ntheir recommendations should facilitate decision making of health pro-\nfessionals in their daily practice. However, guidelines are not a substi-\ntute for the patient’s relationship with their practitioner. The ﬁnal\ndecisions concerning an individual patient must be made by the re-\nsponsible health professional(s), based on what they consider to be\nthe most appropriate in the circumstances. These decisions are\nmade in consultation with the patient and caregiver as appropriate.\nGuidelines are intended for use by health professionals. To ensure\nthat all users have access to the most recent recommendations, the\nESC makes its Guidelines freely available. The ESC warns readers\nthat the technical language may be misinterpreted and declines any\nresponsibility in this respect.\nA great number of guidelines have been issued in recent years by the\nESC. Because of their impact on clinical practice, quality criteria for the\ndevelopment of guidelines have been established to make all decisions\ntransparent to the user. The recommendations for formulating and is-\nsuing ESC Guidelines can be found on the ESC website (https://www.\nescardio.org/Guidelines). The ESC Guidelines represent the ofﬁcial pos-\nition of the ESC on a given topic and are regularly updated.\n4236\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nIn addition to the publication of Clinical Practice Guidelines, the ESC\ncarries out the EURObservational Research Programme of internation-\nal registries of cardiovascular diseases and interventions, which are es-\nsential to assess diagnostic/therapeutic processes, use of resources\nand adherence to guidelines. These registries aim at providing a better\nunderstanding of medical practice in Europe and around the world,\nbased on high-quality data collected during routine clinical practice.\nFurthermore, the ESC develops sets of quality indicators (QIs),\nwhich are tools to evaluate the level of implementation of the guide-\nlines and may be used by the ESC, hospitals, healthcare providers and\nprofessionals to measure clinical practice, and in educational pro-\ngrammes, alongside the key messages from the guidelines, to im-\nprove quality of care and clinical outcomes.\nThe Members of this Task Force were selected by the ESC to re-\npresent professionals involved with the medical care of patients with\nthis pathology. The selection procedure aimed to ensure that there is\na representative mix of members predominantly from across the whole\nof the ESC region and from relevant ESC Subspecialty Communities.\nConsideration was given to diversity and inclusion, notably with respect\nto gender and country of origin. A critical evaluation of diagnostic and\ntherapeutic procedures was performed, including assessment of the\nrisk–beneﬁt ratio. The level of evidence and the strength of the recom-\nmendation of particular management options were weighed and scored\naccording to predeﬁned scales, as outlined below. The Task Force fol-\nlowed the ESC voting procedures. All recommendations subject to a\nvote achieved at least 75% among voting members.\nThe experts of the writing and reviewing panels provided declar-\nation of interest forms for all relationships that might be perceived as\nreal or potential sources of conﬂicts of interest. Their declarations of\ninterest were reviewed according to the ESC declaration of interest\nrules and can be found on the ESC website (http://www.escardio.org/\nGuidelines) and have been compiled in a report and published in a\nsupplementary document simultaneously to the guidelines.\nThis process ensures transparency and prevents potential biases in\nthe development and review processes. Any changes in declarations\nof interest that arise during the writing period were notiﬁed to the\nTable 1\nClasses of recommendations\n©ESC 2022\nClasses of recommendations\nClass I \nEvidence and/or general agreement\nthat a given treatment or procedure is\nbeneficial, useful, effective.\nefficacy of the given treatment or procedure.\nfavour of usefulness/efficacy.\nUsefulness/efficacy is less well\nuseful/effective, and in some cases\nConﬂicting evidence and/or a divergence of opinion about the usefulness/ \n \nIs recommended or is indicated\nWording to use\nDeﬁnition\nClass III \nEvidence or general agreement that the\ngiven treatment or procedure is not\nmay be harmful. \nIs not recommended\n     Class IIb\nestablished by evidence/opinion.\nMay be considered\n \n   Class IIa\nWeight of evidence/opinion is in\nShould be considered\nClass II \nTable 2\nLevels of evidence\nLevel of\nevidence A\nLevel of\nevidence B\nLevel of\nevidence C\nData derived from multiple randomized clinical trials\nor meta-analyses.\nData derived from a single randomized clinical trial\nor large non-randomized studies.\nConsensus of opinion of the experts and/or small studies,\nretrospective studies, registries.\n©ESC 2022\nESC Guidelines\n4237\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nESC and updated. The Task Force received its entire ﬁnancial support\nfrom the ESC without any involvement from the healthcare industry.\nThe ESC CPG supervises and coordinates the preparation of new\nguidelines. The Committee is also responsible for the approval pro-\ncess of these guidelines. The ESC Guidelines undergo extensive re-\nview by the CPG and external experts, including a mix of\nmembers from across the whole of the ESC region and from relevant\nESC Subspecialty Communities and National Cardiac Societies. After\nappropriate revisions, the guidelines are signed off by all the experts\ninvolved in the Task Force. The ﬁnalized document is signed off by\nthe CPG for publication in the European Heart Journal. The guidelines\nwere developed after careful consideration of the scientiﬁc and med-\nical knowledge and the evidence available at the time of their writing.\nThe task of developing ESC Guidelines also includes the creation of\neducational tools and implementation programmes for the recommen-\ndations, including condensed pocket guideline versions, summary slides,\nsummary cards for non-specialists and an electronic version for digital\napplications (smartphones, etc.). These versions are abridged and thus,\nfor more detailed information, the user should always access the full-\ntext version of the guidelines, which is freely available via the ESC web-\nsite and the European Heart Journal. The National Cardiac Societies of\nthe ESC are encouraged to endorse, adopt, translate and implement all\nESC Guidelines. Implementation programmes are needed because it\nhas been shown that the outcome of disease may be favourably inﬂu-\nenced by the thorough application of clinical recommendations.\nHealth professionals are encouraged to take the ESC Guidelines\nfully into account when exercising their clinical judgement, as well\nas in the determination and the implementation of preventive, diag-\nnostic or therapeutic medical strategies. However, the ESC\nGuidelines do not override in any way whatsoever the individual re-\nsponsibility of health professionals to make appropriate and accurate\ndecisions in consideration of each patient’s health condition and in\nconsultation with that patient or the patient’s caregiver where ap-\npropriate and/or necessary. It is also the health professional’s re-\nsponsibility to verify the rules and regulations applicable in each\ncountry to drugs and devices at the time of prescription and to re-\nspect the ethical rules of their profession.\nOff-label use of medication may be presented in this guideline if\nsufﬁcient level of evidence shows that it can be considered medically\nappropriate to a given condition and if patients could beneﬁt from\nthe recommended therapy. However, the ﬁnal decisions concerning\nan individual patient must be made by the responsible health profes-\nsional giving special consideration to:\n(1) the speciﬁc situation of the patient. In this respect, it is speciﬁed\nthat, unless otherwise provided for by national regulations, off-\nlabel use of medication should be limited to situations where it\nis in the patient’s interest to do so, with regard to the quality,\nsafety and efﬁcacy of care, and only after the patient has been in-\nformed and has provided consent;\n(2) country-speciﬁc health regulations, indications by governmental\ndrug regulatory agencies and the ethical rules to which health\nprofessionals are subject, where applicable.\n2. Introduction\nThis is the ﬁrst European Society of Cardiology (ESC) guideline on\ncardio-oncology. The aim of this guideline is to help all the healthcare\nprofessionals providing care to oncology patients before, during, and\nafter their cancer treatments with respect to their cardiovascular (CV)\nhealth and wellness. This guideline provides guidance on the deﬁnitions,\ndiagnosis, treatment, and prevention of cancer therapy-related CV\ntoxicity (CTR-CVT), and the management of CV disease (CVD)\ncaused directly or indirectly by cancer. This area of medicine has lim-\nited trials and evidence on which to base decision-making and,\nwhere evidence is limited, this guideline provides the consensus of\nexpert opinion to guide healthcare professionals.\nThis guideline includes the deﬁnitions of CTR-CVT (Section 3),1 and\nprovides a personalized approach to care based upon the baseline\nCV toxicity risk assessment (Section 4) and new protocols for CV sur-\nveillance during cancer treatment (Section 5). The management of acute\nCTR-CVT is addressed in Section 6, where patients with activecancer are\nthose receiving anticancer treatment. Throughout these sections,\ndecision-making depends upon the risk/beneﬁt balance of oncology\ntreatment efﬁcacy and the severity and impact of CTR-CVT. Guidance\nis provided for the ﬁrst 12 months after completion of cardiotoxic treat-\nments (Section 7), when subacute CVD can emerge, and when patients\nwho developed CTR-CVT during cancer treatment are reviewed.\nDiagnosis and management of the long-term CV complications of previ-\nous oncology treatments, beyond 12 months after completing the cardi-\notoxic treatments, and integration into the overall survivorship strategy\nfor cancer survivors (CS) is presented in Section 8 with new long-term\nsurveillance recommendations for high-risk patients.\nIn Section 9, we address special populations where CVDs are dir-\nectly caused by the cancer, or where special considerations are re-\nquired. Section 10 provides information for patients’ involvement in\ntheir own care. The ﬁnal section highlights the role of the ESC and\nthe ESC Council of Cardio-Oncology (ESC-CCO).\nCTR-CVT risk is a dynamic variable, and the risk changes through-\nout the pathway of care (Figure 1, Video 1). Absolute risk of\nCTR-CVT is important to understand and balance against the abso-\nlute beneﬁt of the cancer treatment before and during treatment.\nHowever, CTR-CVT risk can be inﬂuenced by several variables, in-\ncluding implementation of primary prevention treatments, optimiza-\ntion of pre-existing CVD, dose, frequency, and duration of oncology\ntreatment, emergence of CV complications during treatment and\ntheir severity, and in CS, the overall cumulative treatment received,\nthe time since treatment, and the interaction with other CVDs.\n2.1. Cancer and cardiovascular needs of\npatients with cancer\nSince the 1990s, there has been a steady decline in cancer-related\nmortality mirrored by a steady increase in CS.2,3 In this context,\ntreatment-related\nside\neffects\nhave\ngained\nmore\nsigniﬁcance.\nManagement of CTR-CVT has a tremendous impact on the type of\nanticancer therapies that patients can receive as well as the long-term\nmorbidity and mortality outcomes of patients with cancer. Effective\nmanagement of patients with both cancer and CVD requires the un-\nique interest and expertise of healthcare providers, which has led to\nthe formation of a new discipline: cardio-oncology.4,5 A recently pub-\nlished ESC-CCO document describes appropriate criteria for the or-\nganization and implementation of cardio-oncology services.5\n2.2. Role of cardio-oncology services\nThe overarching goal of the cardio-oncology discipline is to allow pa-\ntients with cancer to receive the best possible cancer treatments safely,\n4238\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "keywords": [
        "hypertension",
        "heart failure",
        "creatinine",
        "vte",
        "alcohol",
        "class ii",
        "guideline",
        "blood pressure",
        "age",
        "recommended",
        "risk estimation",
        "echocardiography",
        "angiography",
        "systolic",
        "coronary artery",
        "sex",
        "echo",
        "hba1c",
        "class i",
        "diabetes",
        "ascvd",
        "calcium channel",
        "bnp",
        "dvt",
        "abbreviations",
        "primary prevention",
        "nt-probnp",
        "atrial fibrillation",
        "anticoagulation",
        "tricuspid"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 4237",
          "page_number": 8,
          "content": "Class I | Evidence and/or general agreement\nthat a given treatment or procedure is\nbeneficial, useful, effective. | Is recommended or is indicated",
          "bbox": [
            137.13080444335938,
            101.58294677734375,
            466.15892283121747,
            147.4019775390625
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 4237",
          "page_number": 8,
          "content": "Class II | Conflicting evidence and/or a divergence of opinion about the usefulness/\nefficacy of the given treatment or procedure. |  |  | \n |  |  |  | \nClass IIa |  | Weight of evidence/opinion is in\nfavour of usefulness/efficacy. | Should be considered | \n |  |  |  | \nClass IIb |  | Usefulness/efficacy is less well\nestablished by evidence/opinion. | May be considered | ",
          "bbox": [
            137.13080444335938,
            152.68197631835938,
            466.15892283121747,
            240.07299296061197
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 4237",
          "page_number": 8,
          "content": "Class III | Evidence or general agreement that the\ngiven treatment or procedure is not\nuseful/effective, and in some cases\nmay be harmful. | Is not recommended",
          "bbox": [
            137.13080444335938,
            244.8599853515625,
            466.15892283121747,
            291.2985900878906
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 4239",
          "page_number": 10,
          "content": "Du ring | cardiot\n | er thera",
          "bbox": [
            253.93299865722656,
            114.24049894271359,
            301.38050345487375,
            129.40964111328125
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 4239",
          "page_number": 10,
          "content": "Long-term f |  | ollo | w-up after\n | cancer t | reatment | ",
          "bbox": [
            357.1525115966797,
            114.24049894271359,
            444.2279968261719,
            129.40964111328125
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "3. Cancer therapy-related cardiovascular toxicity definitions",
      "start_page": 13,
      "end_page": 16,
      "content": "3. Cancer therapy-related\ncardiovascular toxicity deﬁnitions\nSeveral terminologies and deﬁnitions have previously been proposed\nto describe the spectrum of CTR-CVT, leading to inconsistencies in\ndiagnosis and management. The need to harmonize these deﬁnitions\nhas frequently been stated and recognized, and resulted in the recent\ninternational deﬁnitions of CTR-CVT1 supported by this guideline\n(Table 3; Supplementary data, Table S1). This document will focus\non consensus deﬁnitions for cardiomyopathy and heart failure\n(HF), myocarditis, vascular toxicities, hypertension, cardiac arrhyth-\nmias, and corrected QT interval (QTc) prolongation. The deﬁnitions\nof other CTR-CVT, including pericardial and valvular heart diseases\n(VHDs), are the same as those used for the general cardiology popu-\nlation. For cardiac injury, cardiomyopathy, and HF, the descriptive\nterm cancer therapy-related cardiac dysfunction (CTRCD) is recom-\nmended as it captures the broad spectrum of possible presentations\nand the aetiological link with the broad scope of various cancer ther-\napies, including chemotherapy, targeted agents, immune therapies,\nand radiation therapy.\nHigh\nIntermediate\nLow\nSevere and\nvery severe\nModerate\nMild\nLikelihood of\nCTR-CVT\nClinical severity of CTR-CVT\nFigure 4 Dimensions of cancer therapy-related cardiovascular toxicity risk and disease severity. CTR-CVT, cancer therapy-related cardiovascular tox-\nicity; CV, cardiovascular. The ultimate risk is the combination of the likelihood (based on reported incidence) and degree (severity or grade) of the adverse\nevent. The most vulnerable patient groups are those at high likelihood of experiencing a severe adverse event. The level of attention that needs to be\ndevoted to these patients varies accordingly. The risk and type of CTR-CVT, as well as the potential for reversibility, depends on different factors, listed in\nFigure 3, that should be considered to deﬁne global CV and oncological prognosis and to individualize CTR-CVT surveillance. Additional factors that add to\nthe complexity of CTR-CVT risk assessment are the cancer type and prognosis, and type, duration, and intensity of cancer treatment.\n4242\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nTable 3\nCancer therapy-related cardiovascular toxicity deﬁnitions\nCTRCD\nSymptomatic CTRCD (HF)a,b\nVery severe\nHF requiring inotropic support, mechanical circulatory support, or\nconsideration of transplantation\nSevere\nHF hospitalization\nModerate\nNeed for outpatient intensiﬁcation of diuretic and HF therapy\nMild\nMild HF symptoms, no intensiﬁcation of therapy required\nAsymptomatic CTRCD\nSevere\nNew LVEF reduction to ,40%\nModerate\nNew LVEF reduction by ≥10 percentage points to an LVEF\nof 40–49%\nOR\nNew LVEF reduction by ,10 percentage points to an LVEF of 40–\n49% AND either new relative decline in GLS by .15% from baseline\nOR new rise in cardiac biomarkersc\nMild\nLVEF ≥50%\nAND new relative decline in GLS by .15% from baseline\nAND/OR new rise in cardiac biomarkersc\nICI myocarditis (either pathohistological diagnosis or clinical diagnosis)\nPathohistological diagnosis (EMB)\nMultifocal inﬂammatory cell inﬁltrates with overt cardiomyocyte loss by light microscopy\nClinical diagnosisd\ncTn elevation (new or signiﬁcant change from baseline)e with 1 major criterion or 2 minor criteria,\nafter exclusion of ACS and acute infectious myocarditis based on clinical suspicionf\nMajor criterion:\n• CMR diagnostic for acute myocarditis (modiﬁed Lake Louise criteria)g\nMinor criteria:\n• Clinical syndrome (including any one of the following: fatigue, myalgias, chest pain, diplopia, ptosis,\nshortness of breath, orthopnoea, lower-extremity oedema, palpitations, light-headedness/dizziness,\nsyncope, muscle weakness, cardiogenic shock)\n• Ventricular arrhythmia (including cardiac arrest) and/or new conduction system disease\n• Decline in LV systolic function, with or without regional wall motion abnormalities in a non-Takotsubo\npattern\n• Other immune-related adverse events, particularly myositis, myopathy, myasthenia gravis\n• Suggestive CMRh\nSeverity of myocarditis\n• Fulminant: Haemodynamic instability, HF requiring non-invasive or invasive ventilation, complete or\nhigh-grade heart block, and/or signiﬁcant ventricular arrhythmia\n• Non-fulminant: including symptomatic but haemodynamically and electrically stable patients and\nincidental cases diagnosed at the same time as other immuno-related adverse events. Patients may have\nreduced LVEF but no features of severe disease\n• Steroid refractory: non-resolving or worsening myocarditis (clinical worsening or persistent troponin\nelevation after exclusion of other aetiologies) despite high-dose methylprednisolone\nRecovery from myocarditis\n• Complete recovery: Patients with complete resolution of acute symptoms, normalization of\nbiomarkers, and recovery of LVEF after discontinuation of immunosuppression. CMR may still show LGE\nor elevated T1 due to ﬁbrosis, but any suggestion of acute oedema should be absent\n• Recovering: Ongoing improvement in patient clinical symptoms, signs, biomarkers, and imaging\nparameters, but not yet normalized, while on tapering doses of immunosuppression\nVascular toxicity (for general cardiology deﬁnitions, see Supplementary data, Table S1)\nAsymptomatic vascular toxicity\nCAD\nSymptomatic vascular\ntoxicity\nStroke\nPAD\nTransient ischaemic attack\nCarotid artery disease\nMI\nVenous thrombosis\nACS\nArterial thrombosis\nCCS\nPeripheral vasoreactivity\nPAD\nContinued\nESC Guidelines\n4243\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n4. Cardiovascular toxicity risk\nstratiﬁcation before anticancer\ntherapy\nThe optimal time to consider CVD prevention strategies in patients\nwith cancer is at the time of cancer diagnosis and prior to the initi-\nation of cancer treatment.4,5 This enables the oncology team to con-\nsider CV risk while making cancer treatment choices, educating\npatients regarding their CV risk, personalizing CV surveillance and\nfollow-up strategies, and making appropriate referrals of high-risk pa-\ntients to cardio-oncology services. These strategies are needed to\nmitigate CVD risk, and improve the adherence to effective cancer\ntreatments and the overall survival.\nCVD prevention strategies require a personalized approach. Risk\nassessment is a challenging task and it is vital that clinicians adopt a\nsystematic approach without delaying oncological treatment.12,21,22\nFigure 5 provides a comprehensive approach to risk assessment.\nThe choice of the cardiac tests (electrocardiogram [ECG], biomar-\nkers, and imaging) should be individualized based on CV risk and\nthe planned cancer treatments.\n4.1. General approach to cardiovascular\ntoxicity risk in patients with cancer\nPre-treatment CTR-CVT risk assessment should ideally be per-\nformed using a recognized risk stratiﬁcation method where multiple\nrisk factors are incorporated to determine patient-speciﬁc risk.23\nCoronary epicardial\nvasoreactivity\nVasospastic angina\nCoronary microvascular\nvasoreactivity\nMicrovascular angina\nRaynaud’s phenomenon\nArterial hypertension\nTreatment threshold for\nhypertension before, during, and\nafter therapy\nIn patients with high CV riski: ≥130 mmHg systolic and/or ≥80 mmHg diastolic\nOtherwise: ≥140 mmHg systolic and/or ≥90 mmHg diastolic\nCancer therapy holding threshold\n≥180 mmHg systolic and/or ≥110 mmHg diastolic\nHypertensive emergency\n(Very high) BP elevation associated with acute hypertension-mediated organ damage (heart, retina, brain,\nkidneys, and large arteries), requiring immediate BP reduction to limit extension or promote regression of\ntarget organ damage\nCardiac arrhythmias\nQT prolongation\nProlonged: QTcF . 500 msj\nBradycardia\nFor general cardiology deﬁnitions, see Supplementary data, Table S1\nSupraventricular tachycardia\nVentricular arrhythmias\nAF\n© ESC 2022\nACS, acute coronary syndromes; AF, atrial ﬁbrillation; BNP, B-type natriuretic peptide; BP, blood pressure; CAD, coronary artery disease; CCS, chronic coronary syndromes; CMR,\ncardiac magnetic resonance; cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; ECV, extracellular volume fraction; EMB,\nendomyocardial biopsy; ESC, European Society of Cardiology; GLS, global longitudinal strain; HF, heart failure; HFmrEF, HF with mildly reduced ejection fraction; HFpEF, heart\nfailure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICI, immune checkpoint inhibitors; LGE, late gadolinium enhancement; LV, left\nventricular; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAD, peripheral artery disease; QTcF,\ncorrected QT interval using Fridericia correction; SCORE2, Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic Coronary Risk Estimation 2—Older Persons.\nSee Supplementary data, Table S1 for expanded deﬁnitions.\naWith LVEF and supportive diagnostic biomarkers based on the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic HF.14\nbSymptomatic CTRCD represents HF, which is a clinical syndrome consisting of cardinal symptoms (e.g. breathlessness, ankle swelling, and fatigue) that may be accompanied by signs (e.g.\nelevated jugular venous pressure, pulmonary crackles, and peripheral oedema) and has traditionally been divided into distinct phenotypes based on the measurement of LVEF: ≤40% =\nHFrEF; 41–49% = HFmrEF; ≥50% = HFpEF.\nccTnI/cTnT . 99th percentile, BNP ≥35 pg/mL, NT-proBNP ≥125 pg/mL or new signiﬁcant rise from baseline beyond the biological and analytical variation of the assay used.\ndClinical diagnoses should be conﬁrmed with magnetic resonance imaging or EMB if possible and without causing treatment delays. Treatment with immunosuppression should be\npromptly initiated while awaiting further conﬁrmatory testing in symptomatic patients.\neBoth troponin I and troponin T can be used; however, clinical observations suggest that troponin T may be falsely elevated in patients with concomitant myositis and without myocarditis.15–17\nfAccording to local protocols.\ngDiagnostic CMR: Based on updated Lake Louise criteria18: T2-based criterion + T1-based criterion + supportive criteria (T2-based criteria: regional or global increase of native T2, or T2signal\nintensity; T1-based criteria: regional or global increase of native T1, or regional or global increase in the ECV, or presence of LGE; supportive criteria: pericarditis and/or regional or global LV\nsystolic dysfunction).\nhSuggestive CMR: meeting some but not all of the modiﬁed Lake Louise criteria. The presence of T2- or T1-based criteria may support a diagnosis of acute myocardial inﬂammation in the\nappropriate clinical scenario.\niSCORE2 (,70 years), SCORE2-OP (≥70 years) or equivalent.19 CV risk stratiﬁcation: ,50 years: low risk ,2.5%, moderate risk 2.5% to ,7.5%, high risk ≥7.5%; 50–69 years: low risk ,5%;\nmoderate risk 5% to ,10%; high risk ≥10%; ≥70 years: low risk ,7.5%, moderate risk 7.5% to ,15%, high risk ≥15%.\njQTcF 480–500 ms: correct reversible causes, minimize other QT prolonging medications, close QTcF monitoring. Fridericia correction is recommended (QTcF = QT/3√RR).20\n4244\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "keywords": [
        "hypertension",
        "heart failure",
        "systolic dysfunction",
        "guideline",
        "blood pressure",
        "recommended",
        "risk estimation",
        "cardiomyopathy",
        "systolic",
        "coronary artery",
        "cvd risk",
        "bnp",
        "carotid",
        "cardiovascular",
        "arrhythmia",
        "nt-probnp",
        "syncope",
        "diastolic",
        "lvef",
        "peripheral artery",
        "bradycardia",
        "related",
        "definitions",
        "older",
        "troponin",
        "ecg",
        "ejection fraction",
        "tachycardia",
        "toxicity",
        "electrocardiogram"
      ],
      "tables": [
        {
          "title": "4242 ESC Guidelines",
          "page_number": 13,
          "content": "Seve | r | e and",
          "bbox": [
            413.78150939941406,
            130.22838592529297,
            469.96649169921875,
            137.10506439208984
          ],
          "function_potential": "raw"
        },
        {
          "title": "4242 ESC Guidelines",
          "page_number": 13,
          "content": "very seve | r | e",
          "bbox": [
            413.78150939941406,
            145.3835906982422,
            469.96649169921875,
            152.22532399495444
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 4243",
          "page_number": 14,
          "content": "CTRCD |  |  |  |  | \nSymptomatic CTRCD (HF)a,b |  | Very severe | HF requiring inotropic support, mechanical circulatory support, or\nconsideration of transplantation |  | \n |  | Severe | HF hospitalization |  | \n |  | Moderate | Need for outpatient intensification of diuretic and HF therapy |  | \n |  | Mild | Mild HF symptoms, no intensification of therapy required |  | \nAsymptomatic CTRCD |  | Severe | New LVEF reduction to ,40% |  | \n |  | Moderate | New LVEF reduction by ≥10 percentage points to an LVEF\nof 40–49%\nOR\nNew LVEF reduction by ,10 percentage points to an LVEF of 40–\n49% AND either new relative decline in GLS by .15% from baseline\nOR new rise in cardiac biomarkersc |  | \n |  | Mild | LVEF ≥50%\nAND new relative decline in GLS by .15% from baseline\nAND/OR new rise in cardiac biomarkersc |  | \n | ICI myocarditis (either pathohistological diagnosis or clinical diagnosis) |  |  |  | \nPathohistological diagnosis (EMB) |  | Multifocal inflammatory cell infiltrates with overt cardiomyocyte loss by light microscopy |  |  | \nClinical diagnosisd |  | cTn elevation (new or significant change from baseline)e with 1 major criterion or 2 minor criteria,\nafter exclusion of ACS and acute infectious myocarditis based on clinical suspicionf |  |  | \n |  | Major criterion:\n• CMR diagnostic for acute myocarditis (modified Lake Louise criteria)g |  |  | \n |  | Minor criteria:\n• Clinical syndrome (including any one of the following: fatigue, myalgias, chest pain, diplopia, ptosis,\nshortness of breath, orthopnoea, lower-extremity oedema, palpitations, light-headedness/dizziness,\nsyncope, muscle weakness, cardiogenic shock)\n• Ventricular arrhythmia (including cardiac arrest) and/or new conduction system disease\n• Decline in LV systolic function, with or without regional wall motion abnormalities in a non-Takotsubo\npattern\n• Other immune-related adverse events, particularly myositis, myopathy, myasthenia gravis\n• Suggestive CMRh |  |  | \nSeverity of myocarditis |  | • Fulminant: Haemodynamic instability, HF requiring non-invasive or invasive ventilation, complete or\nhigh-grade heart block, and/or significant ventricular arrhythmia\n• Non-fulminant: including symptomatic but haemodynamically and electrically stable patients and\nincidental cases diagnosed at the same time as other immuno-related adverse events. Patients may have\nreduced LVEF but no features of severe disease\n• Steroid refractory: non-resolving or worsening myocarditis (clinical worsening or persistent troponin\nelevation after exclusion of other aetiologies) despite high-dose methylprednisolone |  |  | \nRecovery from myocarditis |  | • Complete recovery: Patients with complete resolution of acute symptoms, normalization of\nbiomarkers, and recovery of LVEF after discontinuation of immunosuppression. CMR may still show LGE\nor elevated T1 due to fibrosis, but any suggestion of acute oedema should be absent\n• Recovering: Ongoing improvement in patient clinical symptoms, signs, biomarkers, and imaging\nparameters, but not yet normalized, while on tapering doses of immunosuppression |  |  | \n | Vascular toxicity (for general cardiology definitions, see Supplementary data, Table S1) |  |  |  | \nAsymptomatic vascular toxicity |  | CAD | Symptomatic vascular\ntoxicity | Stroke | \n |  | PAD |  | Transient ischaemic attack | \n |  | Carotid artery disease |  | MI | \n |  | Venous thrombosis |  | ACS | \n |  | Arterial thrombosis |  | CCS | \n |  | Peripheral vasoreactivity |  | PAD | ",
          "bbox": [
            48.0,
            74.0009765625,
            551.364296875,
            711.7053426106771
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "4244 ESC Guidelines",
          "page_number": 15,
          "content": " |  | Coronary epicardial\nvasoreactivity |  | Vasospastic angina | \n |  | Coronary microvascular\nvasoreactivity |  | Microvascular angina | \n |  |  |  | Raynaud’s phenomenon | \n | Arterial hypertension |  |  |  | \nTreatment threshold for\nhypertension before, during, and\nafter therapy |  | In patients with high CV riski: ≥130 mmHg systolic and/or ≥80 mmHg diastolic |  |  | \n |  | Otherwise: ≥140 mmHg systolic and/or ≥90 mmHg diastolic |  |  | \nCancer therapy holding threshold |  | ≥180 mmHg systolic and/or ≥110 mmHg diastolic |  |  | \nHypertensive emergency |  | (Very high) BP elevation associated with acute hypertension-mediated organ damage (heart, retina, brain,\nkidneys, and large arteries), requiring immediate BP reduction to limit extension or promote regression of\ntarget organ damage |  |  | \n | Cardiac arrhythmias |  |  |  | \nQT prolongation |  | Prolonged: QTcF . 500 msj |  |  | \nBradycardia |  | For general cardiology definitions, see Supplementary data, Table S1 |  |  | \nSupraventricular tachycardia |  |  |  |  | \nVentricular arrhythmias |  |  |  |  | \nAF |  |  |  |  | ",
          "bbox": [
            42.99954681396484,
            68.5,
            546.591796875,
            305.3739814758301
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "4. Cardiovascular toxicity risk stratification before anticancer therapy",
      "start_page": 15,
      "end_page": 16,
      "content": "4. Cardiovascular toxicity risk\nstratiﬁcation before anticancer\ntherapy\nThe optimal time to consider CVD prevention strategies in patients\nwith cancer is at the time of cancer diagnosis and prior to the initi-\nation of cancer treatment.4,5 This enables the oncology team to con-\nsider CV risk while making cancer treatment choices, educating\npatients regarding their CV risk, personalizing CV surveillance and\nfollow-up strategies, and making appropriate referrals of high-risk pa-\ntients to cardio-oncology services. These strategies are needed to\nmitigate CVD risk, and improve the adherence to effective cancer\ntreatments and the overall survival.\nCVD prevention strategies require a personalized approach. Risk\nassessment is a challenging task and it is vital that clinicians adopt a\nsystematic approach without delaying oncological treatment.12,21,22\nFigure 5 provides a comprehensive approach to risk assessment.\nThe choice of the cardiac tests (electrocardiogram [ECG], biomar-\nkers, and imaging) should be individualized based on CV risk and\nthe planned cancer treatments.\n4.1. General approach to cardiovascular\ntoxicity risk in patients with cancer\nPre-treatment CTR-CVT risk assessment should ideally be per-\nformed using a recognized risk stratiﬁcation method where multiple\nrisk factors are incorporated to determine patient-speciﬁc risk.23\nCoronary epicardial\nvasoreactivity\nVasospastic angina\nCoronary microvascular\nvasoreactivity\nMicrovascular angina\nRaynaud’s phenomenon\nArterial hypertension\nTreatment threshold for\nhypertension before, during, and\nafter therapy\nIn patients with high CV riski: ≥130 mmHg systolic and/or ≥80 mmHg diastolic\nOtherwise: ≥140 mmHg systolic and/or ≥90 mmHg diastolic\nCancer therapy holding threshold\n≥180 mmHg systolic and/or ≥110 mmHg diastolic\nHypertensive emergency\n(Very high) BP elevation associated with acute hypertension-mediated organ damage (heart, retina, brain,\nkidneys, and large arteries), requiring immediate BP reduction to limit extension or promote regression of\ntarget organ damage\nCardiac arrhythmias\nQT prolongation\nProlonged: QTcF . 500 msj\nBradycardia\nFor general cardiology deﬁnitions, see Supplementary data, Table S1\nSupraventricular tachycardia\nVentricular arrhythmias\nAF\n© ESC 2022\nACS, acute coronary syndromes; AF, atrial ﬁbrillation; BNP, B-type natriuretic peptide; BP, blood pressure; CAD, coronary artery disease; CCS, chronic coronary syndromes; CMR,\ncardiac magnetic resonance; cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; CV, cardiovascular; ECV, extracellular volume fraction; EMB,\nendomyocardial biopsy; ESC, European Society of Cardiology; GLS, global longitudinal strain; HF, heart failure; HFmrEF, HF with mildly reduced ejection fraction; HFpEF, heart\nfailure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICI, immune checkpoint inhibitors; LGE, late gadolinium enhancement; LV, left\nventricular; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAD, peripheral artery disease; QTcF,\ncorrected QT interval using Fridericia correction; SCORE2, Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic Coronary Risk Estimation 2—Older Persons.\nSee Supplementary data, Table S1 for expanded deﬁnitions.\naWith LVEF and supportive diagnostic biomarkers based on the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic HF.14\nbSymptomatic CTRCD represents HF, which is a clinical syndrome consisting of cardinal symptoms (e.g. breathlessness, ankle swelling, and fatigue) that may be accompanied by signs (e.g.\nelevated jugular venous pressure, pulmonary crackles, and peripheral oedema) and has traditionally been divided into distinct phenotypes based on the measurement of LVEF: ≤40% =\nHFrEF; 41–49% = HFmrEF; ≥50% = HFpEF.\nccTnI/cTnT . 99th percentile, BNP ≥35 pg/mL, NT-proBNP ≥125 pg/mL or new signiﬁcant rise from baseline beyond the biological and analytical variation of the assay used.\ndClinical diagnoses should be conﬁrmed with magnetic resonance imaging or EMB if possible and without causing treatment delays. Treatment with immunosuppression should be\npromptly initiated while awaiting further conﬁrmatory testing in symptomatic patients.\neBoth troponin I and troponin T can be used; however, clinical observations suggest that troponin T may be falsely elevated in patients with concomitant myositis and without myocarditis.15–17\nfAccording to local protocols.\ngDiagnostic CMR: Based on updated Lake Louise criteria18: T2-based criterion + T1-based criterion + supportive criteria (T2-based criteria: regional or global increase of native T2, or T2signal\nintensity; T1-based criteria: regional or global increase of native T1, or regional or global increase in the ECV, or presence of LGE; supportive criteria: pericarditis and/or regional or global LV\nsystolic dysfunction).\nhSuggestive CMR: meeting some but not all of the modiﬁed Lake Louise criteria. The presence of T2- or T1-based criteria may support a diagnosis of acute myocardial inﬂammation in the\nappropriate clinical scenario.\niSCORE2 (,70 years), SCORE2-OP (≥70 years) or equivalent.19 CV risk stratiﬁcation: ,50 years: low risk ,2.5%, moderate risk 2.5% to ,7.5%, high risk ≥7.5%; 50–69 years: low risk ,5%;\nmoderate risk 5% to ,10%; high risk ≥10%; ≥70 years: low risk ,7.5%, moderate risk 7.5% to ,15%, high risk ≥15%.\njQTcF 480–500 ms: correct reversible causes, minimize other QT prolonging medications, close QTcF monitoring. Fridericia correction is recommended (QTcF = QT/3√RR).20\n4244\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "keywords": [
        "hypertension",
        "heart failure",
        "systolic dysfunction",
        "blood pressure",
        "recommended",
        "risk estimation",
        "systolic",
        "coronary artery",
        "cvd risk",
        "bnp",
        "risk",
        "cardiovascular",
        "nt-probnp",
        "diastolic",
        "lvef",
        "peripheral artery",
        "bradycardia",
        "older",
        "troponin",
        "ecg",
        "ejection fraction",
        "tachycardia",
        "toxicity",
        "before",
        "electrocardiogram",
        "score2",
        "anticancer",
        "score2-op",
        "hfpef",
        "therapy"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "5. Prevention and monitoring of cardiovascular complications during cancer therapy",
      "start_page": 25,
      "end_page": 26,
      "content": "CRF—typically measured as the peak rate of oxygen consump-\ntion110,111 or metabolic equivalents111,112 during exercise—is one\nof the most robust predictors of CV health and longevity,113,114\nand improves risk classiﬁcation.115–121 Evidence for CPET pre-\ntreatment is limited to pre-operative risk stratiﬁcation particularly\nfor patients with lung,122 colon,123 and rectal124 cancers. Whether\nCPET performed prior to cardiotoxic cancer therapies is prognostic\nof future CV events is unknown.\n4.7. Cardiovascular risk evaluation\nbefore cancer surgery\nCancer surgery remains the primary treatment modality for many\ncancers. Cardio-oncology teams should be involved in pre-operative\nCV risk stratiﬁcation to identify and provide appropriate manage-\nment and surveillance of the potential risk factors.5\nIn patients undergoing oncological surgery, peri-operative car-\ndiac complications are determined by patient-related risk factors,\nthe tumour type, concomitant cancer therapies, and the expected\nsurgical risk. To ensure safe cancer surgery, consultations should\nbe directed at: (1) patients with previous signiﬁcant or symptom-\natic CVD; (2) patients at high and very high CV toxicity risk, ac-\ncording to baseline HFA-ICOS risk assessment tools,12 when\nadjuvant (post-surgery) cancer treatment is planned; and (3) pa-\ntients who have received neoadjuvant (prior to surgery) cancer\ntherapy that is potentially cardiotoxic. Pre-operative clinical evalu-\nation should not delay surgery. Complementary tests required for\nthe patients included in groups 1 and 2 should be guided by general\nESC Guidelines.125 However, in group 3 patients, the pre-\noperative evaluation should be aimed at conﬁrming that no rele-\nvant events have occurred during CV monitoring (Section 5).\nTable 6 summarizes factors that could inﬂuence peri-operative\nrisk during cancer surgery.\n4.8. Genetic testing\nCandidate gene and genome-wide association studies have re-\nsulted in the identiﬁcation of 40 candidate genes and single nucleo-\ntide polymorphisms associated with anthracycline-related cardiac\ndysfunction.37,126–128 It should be noted that with the advent of\nimmunotherapies, germline genes may not be the only genetic pre-\ndispositions to CTR-CVT. A study of patients with ICI-associated\nmyocarditis identiﬁed that the selective clonal T-cell populations\ninﬁltrating the myocardium were identical to those present in tu-\nmours and skeletal muscle, with ribonucleic acid sequencing stud-\nies revealing expression of cardiac-speciﬁc genes in the tumour,129\nraising the intriguing possibility that somatic mutations in the tu-\nmour itself could contribute to CTR-CVT. A list of genetic variants\nassociated\nwith\nCVD\nduring\ncancer\ntherapy\nis\nprovided\n(Supplementary data, Table S9) and has recently been reviewed.38\nRoutine use of genetic testing for the assessment of CTR-CVT risk\nprior to initiation of cancer therapy is not currently recommended.\nIn the future, a personalized genetic approach may help deﬁne indi-\nvidual susceptibility to CVD in patients with cancer and more re-\nsearch is required.\n5. Prevention and monitoring of\ncardiovascular complications\nduring cancer therapy\n5.1. General principles\nCTR-CVT risk may vary according to cancer type and stage, antic-\nancer drugs, doses, and underlying comorbidities. Certain therapy\ncombinations (drug–drug or drug–radiation) may have a synergis-\ntically toxic effect on the heart, possibly depending on the timing\nof these therapies (sequential or concomitant) and previous co-\nmorbidities. The pathophysiology of CTR-CVT is out of the scope\nof this guideline and is extensively reviewed in the\nESC\nCardioMed textbook.130\nCVD and cancer share common modiﬁable and non-modiﬁable\nrisk factors (Figure 3).4,131,132 The ﬁrst step is to optimize lifestyle\nCVRF, smoking cessation, restricting alcohol consumption to a max-\nimum of 100 g per week, and maintaining adequate physical activ-\nity.30 Exercise prescription seems to be a promising treatment to\nTable 6\nFactors that could inﬂuence peri-operative risk during cancer surgery and preventive strategies\nFactors that could inﬂuence peri-operative risk during cancer surgery\nPreventive strategies\nPatient-related\nfactors\n• Lifestyle risk factors: smoking, obesity, sedentary lifestyle\n• Poorly controlled CVRF: hypertension, DM\n• Pre-existing CVD including CTR-CVT\n• Cardiac medications that increase peri-operative bleeding risk (e.g. antiplatelets and\nanticoagulants)\n• Historical primary malignancy\n• Current cancer type, stage and location\n• Optimal management of CVRF and\nCVD (Section 5)\n• Optimize VTE and ATE preventive\nstrategies (Section 6)\nNeoadjuvant cancer\ntherapy\n• Neoadjuvant cardiotoxic cancer treatments (see Section 5; especially anthracycline\nchemotherapy and/or trastuzumab, ICI, VEGFi, ﬂuoropyrimidine, and thoracic RT)\n• Cancer treatments that increase peri-operative bleeding risk (e.g. VEGFi, BTK\ninhibitors)\n• Thrombocytopaenia caused by cancer treatment\n• Ensure optimal CV monitoring of\nneoadjuvant therapy (Section 5)\n• Optimize VTE and ATE preventive\nstrategies (Section 6)\n© ESC 2022\nATE, arterial thromboembolism; BTK, Bruton tyrosine kinase; CTR-CVT, cancer therapy-related cardiovascular toxicity; CV, cardiovascular; CVD, cardiovascular disease; CVRF,\ncardiovascular risk factors; DM, diabetes mellitus; ICI, immune checkpoint inhibitors; RT, radiotherapy; VEGFi, vascular endothelial growth factor inhibitors; VTE, venous\nthromboembolism.\n4254\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "keywords": [
        "hypertension",
        "vte",
        "alcohol",
        "guideline",
        "recommended",
        "genetic",
        "monitoring",
        "diabetes",
        "cardiovascular",
        "complications",
        "cardiovascular risk",
        "exercise",
        "sedentary",
        "obesity",
        "smoking",
        "prevention",
        "during",
        "cancer",
        "therapy"
      ],
      "tables": [
        {
          "title": "4254 ESC Guidelines",
          "page_number": 25,
          "content": " | Factors that could influence peri-operative risk during cancer surgery | Preventive strategies\nPatient-related\nfactors | • Lifestyle risk factors: smoking, obesity, sedentary lifestyle\n• Poorly controlled CVRF: hypertension, DM\n• Pre-existing CVD including CTR-CVT\n• Cardiac medications that increase peri-operative bleeding risk (e.g. antiplatelets and\nanticoagulants)\n• Historical primary malignancy\n• Current cancer type, stage and location | • Optimal management of CVRF and\nCVD (Section 5)\n• Optimize VTE and ATE preventive\nstrategies (Section 6)\nNeoadjuvant cancer\ntherapy | • Neoadjuvant cardiotoxic cancer treatments (see Section 5; especially anthracycline\nchemotherapy and/or trastuzumab, ICI, VEGFi, fluoropyrimidine, and thoracic RT)\n• Cancer treatments that increase peri-operative bleeding risk (e.g. VEGFi, BTK\ninhibitors)\n• Thrombocytopaenia caused by cancer treatment | • Ensure optimal CV monitoring of\nneoadjuvant therapy (Section 5)\n• Optimize VTE and ATE preventive\nstrategies (Section 6)",
          "bbox": [
            43.0,
            538.552001953125,
            547.2750244140625,
            706.5506795247396
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "2",
      "title": "6. Diagnosis and management of acute and subacute cardiovascular toxicity in patients receiving anticancer treatment",
      "start_page": 53,
      "end_page": 54,
      "content": "5.5.18. Other cancer treatments\nSeveral other cancer therapies may also induce clinically relevant CV\nevents. Cyclophosphamide, cisplatin, ifosfamide, and taxanes (pacli-\ntaxel and docetaxel) can induce myocardial dysfunction and HF.4\nCyclophosphamide CV toxicity is primarily seen in patients receiving\nhigh doses (.140 mg/kg) before HSCT and typically occurs within\ndays of drug administration.410\nPlatinum-containing chemotherapy (cisplatin, carboplatin, oxali-\nplatin) may cause vascular disease (vasospasm, MI, and venous and\narterial thrombosis). These may occur during treatment and also\ncontribute to increased long-term risk of CAD in survivors.\nPatients with testicular cancer treated with cisplatin have a higher\nrisk for vascular disease at long-term follow-up.421 The risk of the in-\ndividual patient is still hard to predict, but lifestyle interventions, a\nhigh degree of clinical suspicion in patients who experience chest\npain, and close CVRF monitoring is recommended during and after\ntherapy.422 Cisplatin422 infrequently causes HF; however, because\nit requires the administration of a high i.v. volume to avoid renal tox-\nicity, patients with pre-existing CVD may develop symptomatic HF.\nArsenic trioxide is used to treat some leukaemias and myelomas.\nArsenic trioxide frequently prolongs the QT interval (26–93% of pa-\ntients), and life-threatening ventricular tachyarrhythmias have been\nreported.45,259 QTc prolongation was observed 1–5 weeks after ar-\nsenic trioxide infusion and then returned towards baseline by the end\nof 8 weeks. Patients receiving treatment with arsenic trioxide should\nbe monitored weekly with ECG during the ﬁrst 8 weeks of therapy.\nElectrolyte monitoring is also required as arsenic trioxide may induce\nhypokalaemia, hypomagnesaemia, and renal dysfunction. Risk factors\nfor QT prolongation should be controlled before, during, and after\ncancer treatment (Section 6.4.2).\nSeveral FMS-like tyrosine kinase 3 (FLT3) inhibitors (ﬁrst-generation:\nmidostaurin; second-generation: gilteritinib) have been tested for the\ntreatment of acute myeloid leukaemias. Gilterinib-induced differenti-\nation syndrome (fever, dyspnoea, pleuropericardial effusion, pulmon-\nary oedema, peripheral oedema, hypotension, renal dysfunction, and\nrash) requires early corticosteroid therapy and haemodynamic moni-\ntoring until resolution of symptoms. Midostaurin and gilterinib may\nprolong QTc interval and close electrolyte surveillance and minimizing\ndrug–drug interactions are required (see Section 6.4.2; Table 9;\nSupplementary data, Tables S15 and S16).423\n6. Diagnosis and management of\nacute and subacute cardiovascular\ntoxicity in patients receiving\nanticancer treatment\nA coordinated MDT is recommended to discuss patients with cancer\nwho develop acute CV complications of their cancer treatment.5\nReferral to a specialized cardio-oncology service is recommended\nfor patients with cancer who present with new CTR-CVT during\nand after cancer treatment.12 The prevention and management of\nCVD in patients with cancer should generally follow published ESC\nGuidelines for speciﬁc CVD. This chapter provides guidance on\nthe management of CTR-CVT that occur during cancer treatment,\nand highlights where management differs for patients with cancer\ncompared with those without. The decision to initiate CV treatment\n(medication, devices) needs to include consideration of a range of\nfactors including both cancer and CV symptom burden, cancer prog-\nnosis, ongoing cancer treatment requirements including alternative\noptions, possible adverse drug reactions, drug–drug interactions,\nand patient preferences. An extensive list of drug–drug interactions\nis provided in Supplementary data, Tables S15–S17.\n6.1. Cancer therapy-related cardiac\ndysfunction\n6.1.1. Anthracycline chemotherapy-related cardiac\ndysfunction\nCTRCD during anthracycline chemotherapy may present clinically or\nbe detected in asymptomatic patients during surveillance (Figure 10;\nTable 3).4 The diagnosis of anthracycline chemotherapy-related car-\ndiac dysfunction includes new CV symptoms, new abnormalities in\ncardiac function on CV imaging, and/or new increases in cardiac bio-\nmarkers (Table 3). A MDT discussion is recommended to consider\nthe risk/beneﬁt ratio of continuing anthracycline chemotherapy in\npatients who develop new CTRCD.\nDiscontinuation of anthracycline chemotherapy is recommended\nin patients with cancer who develop severe symptomatic CTRCD.22\nThere are rare exceptions where rechallenge with further anthracy-\ncline chemotherapy may be considered after a MDT discussion, using\nprevention strategies described below and under close monitoring\nwith each cycle of anthracycline chemotherapy. Temporary interrup-\ntion of anthracycline chemotherapy is recommended in patients who\ndevelop moderate symptomatic CTRCD, and in patients who de-\nvelop moderate or severe asymptomatic CTRCD. A MDT approach\nregarding interruption vs. continuation of anthracycline chemother-\napy is recommended in patients who develop mild symptomatic\nCTRCD.\nGuideline-based HF therapy is recommended in patients who de-\nvelop symptomatic CTRCD or asymptomatic moderate or severe\nCTRCD during anthracycline chemotherapy. The use of an ACE-I/\nARB or angiotensin receptor–neprilysin inhibitor, a beta-blocker, a\nsodium–glucose co-transporter 2 inhibitor, and a mineralocorticoid re-\nceptor antagonist is recommended unless the drugs are contraindi-\ncated or not tolerated. Up-titration to target doses as described in\nthe 2021 ESC Guidelines for the diagnosis and treatment of acute\nand chronic HF is recommended.14 ACE-I, ARB, and/or beta-blockers\nRecommendation Table 23 — Recommendation for\nthe management of cardiovascular disease and cancer\ntherapy-related cardiovascular toxicity in patients re-\nceiving anticancer treatment\nRecommendation\nClassa\nLevelb\nA specialist CV assessmentc is recommended for\noptimal diagnostic workup and management of\npatients with cancer who present with new CV\ntoxicity during and after cancer treatment.5\nI\nC\n© ESC 2022\nCV, cardiovascular; CVD, cardiovascular disease.\naClass of recommendation.\nbLevel of evidence.\ncCardio-oncology referral is recommended when available; alternatively, patients should\nbe referred to a specialized cardiologist with expertise in managing CVD in patients with\ncancer.\n4282\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "keywords": [
        "acute",
        "guideline",
        "treatment",
        "arb",
        "patients",
        "anticancer",
        "recommended",
        "receiving",
        "toxicity",
        "ecg",
        "cardiovascular",
        "management",
        "subacute",
        "glucose",
        "may be considered",
        "diagnosis"
      ],
      "tables": [
        {
          "title": "4282 ESC Guidelines",
          "page_number": 53,
          "content": "Recommendation | Classa | Levelb\nA specialist CV assessmentc is recommended for\noptimal diagnostic workup and management of\npatients with cancer who present with new CV\ntoxicity during and after cancer treatment.5 | I | C",
          "bbox": [
            307.2750015258789,
            198.87701416015625,
            547.2749633789062,
            269.8764953613281
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "7. End-of-cancer therapy cardiovascular risk assessment",
      "start_page": 80,
      "end_page": 81,
      "content": "7. End-of-cancer therapy\ncardiovascular risk assessment\n7.1. Cardiovascular evaluation during the\nﬁrst year after cardiotoxic anticancer\ntherapy\nEnd-of-cancer therapy CV risk assessment covers the ﬁrst 12\nmonths after the last cardiotoxic cancer treatment. These recom-\nmendations are where cardiotoxic cancer therapy has been success-\nfully\ncompleted\nwith\ngood\nlong-term\nprognosis.\nThese\nrecommendations are not indicated when cancer therapies are dis-\ncontinued due to cancer progression and prognosis is poor, or\nwhere end-of-life care is indicated. Selected patients with cancer\ncontinue on long-term oncology therapies, e.g. women with oestro-\ngen receptor-positive early invasive BC. In this example, the\nend-of-therapy risk assessment refers to the timepoint from the\nlast anthracycline or trastuzumab dose.\nHigh-risk patients can be identiﬁed at completion of their cardio-\ntoxic cancer therapies by their clinical characteristics, history of\nCTR-CVT during treatment, and by elevated cardiac biomarkers\nand/or abnormal CV imaging at follow up.53,54,92 Cardiac serum bio-\nmarkers (NP and cTn) are useful given their high negative predictive\nvalue for future CV events.197,631 In a prospective study of 2625 adult\npatients with cancer that assessed LVEF after anthracycline-based\nchemotherapy, the overall incidence of CTRCD was 9%; 98% of\ncases could be detected within 12 months after chemotherapy and\nthe median time from chemotherapy to CTRCD detection was\n3.5 months (interquartile range 3–6 months).208 The response to\nACE-I treatment declined when the interval between the end of\nchemotherapy and CTRCD detection lengthened; complete LVEF\nrecovery was not observed in patients where treatment was delayed\nby .6 months.425\nMeasurement of cTn after completion of anthracycline chemo-\ntherapy during the end-of-treatment assessment should be consid-\nered. Rises in cTnI after anthracycline chemotherapy identify\npatients at risk of future cardiac dysfunction who then beneﬁt\nfrom CV protection.4 Educating patients with cancer of their poten-\ntial increased CVD risk and supporting them to make appropriate\nhealthy lifestyle choices is recommended. CS should also be advised\nto promptly report early signs and symptoms of possible CVD and\ninform medical teams of their previous cardiotoxic cancer therapies.\nCVRF including hypertension, DM, and dyslipidaemia correlate with\nthe probability of future CV events in CS and should be well con-\ntrolled after completion of cancer therapy.31,632,633\n7.2. Which cancer survivors require\ncardiovascular surveillance in the ﬁrst\nyear after cancer treatment?\nThe end-of-treatment risk assessment ideally identiﬁes those high-risk\nCS, who require long-term CV surveillance, based on the following\ncriteria (Table 10):\n(1) Baseline high or very high risk based on HFA-ICOS risk assess-\nment tools12 (Section 4).\n(2) Cardiotoxic cancer therapy with a high risk of long-term CV\ncomplications7,21 (Section 8).\n(3) Moderate or severe CTR-CVT diagnosed during cancer treat-\nment (Table 3).68\n(4) New abnormalities in cardiac function detected by echocardiog-\nraphy, new elevated cardiac serum biomarkers, or newly CV\nsymptoms detected at the end-of-therapy assessment (3 or 12\nmonths after treatment).68,208\nThe timing of the ﬁrst CV assessment after cardiotoxic cancer\ntreatment depends on the risk deﬁned by baseline CV assessment,\nthe type of cancer therapy, and whether CTR-CVT was diagnosed\nduring treatment.\nIn asymptomatic high-risk patients (Table 10), echocardiography\nand cardiac serum biomarkers are recommended at 3 and 12 months\nafter\ncompletion\nof\ncancer\ntherapy.53,54,59,61,68,148,208,425\nIn\nRecommendation Table 38 — Recommendations for\nthe management of pericardial diseases in patients re-\nceiving anticancer treatment\nRecommendations\nClassa\nLevelb\nGeneral\nDiagnosis and management of acute pericarditis in\npatients with cancer based on the 2015 ESC\nGuidelines for the diagnosis and management of\npericardial diseases is recommended and a\nmultidisciplinary discussion is needed before\ninterrupting cancer therapy.444\nI\nC\nA surgical pericardial window should be\nconsidered if the percutaneous approach is not\nfeasible or in cases of recurrent malignant\npericardial effusions.\nIIa\nC\nIntrapericardial instillation of cytostatic or\nsclerosing agents may be considered for\nprevention of recurrence.\nIIb\nC\nDiagnosis and management of ICI-associated pericarditis\nMultimodality CV imaging (echocardiography,\nCMR + CT), ECG and measurement of cardiac\nbiomarkers are recommended to conﬁrm the\ndiagnosis, assess the haemodynamic\nconsequences of pericardial disease, and rule out\nassociated myocarditis.\nI\nC\nPrednisolone and colchicine are recommended\nfor patients with ICI-associated\npericarditis.326,624,625,630\nI\nC\nInterruption of ICI treatment in patients with\nconﬁrmed ICI-associated pericarditis with\nmoderate-to-severe pericardial effusion is\nrecommended.\nI\nC\nA multidisciplinary discussion is recommended\nbefore restarting ICI treatment.\nI\nC\n© ESC 2022\nCMR, cardiac magnetic resonance; CT, computed tomography; CV, cardiovascular;\nECG, electrocardiogram; ESC, European Society of Cardiology; ICI, immune\ncheckpoint inhibitors.\naClass of recommendation.\nbLevel of evidence.\nESC Guidelines\n4309\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "keywords": [
        "cvd risk",
        "hypertension",
        "lvef",
        "cardiovascular risk",
        "recommended",
        "echocardiography",
        "risk",
        "ecg",
        "cardiovascular",
        "cancer",
        "assessment",
        "therapy",
        "may be considered",
        "electrocardiogram"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 4309",
          "page_number": 80,
          "content": "Recommendations |  | Classa | Levelb | \n | General |  |  | \nDiagnosis and management of acute pericarditis in\npatients with cancer based on the 2015 ESC\nGuidelines for the diagnosis and management of\npericardial diseases is recommended and a\nmultidisciplinary discussion is needed before\ninterrupting cancer therapy.444 |  | I | C | \nA surgical pericardial window should be\nconsidered if the percutaneous approach is not\nfeasible or in cases of recurrent malignant\npericardial effusions. |  | IIa | C | \nIntrapericardial instillation of cytostatic or\nsclerosing agents may be considered for\nprevention of recurrence. |  | IIb | C | \n | Diagnosis and management of ICI-associated pericarditis |  |  | \nMultimodality CV imaging (echocardiography,\nCMR + CT), ECG and measurement of cardiac\nbiomarkers are recommended to confirm the\ndiagnosis, assess the haemodynamic\nconsequences of pericardial disease, and rule out\nassociated myocarditis. |  | I | C | \nPrednisolone and colchicine are recommended\nfor patients with ICI-associated\npericarditis.326,624,625,630 |  | I | C | \nInterruption of ICI treatment in patients with\nconfirmed ICI-associated pericarditis with\nmoderate-to-severe pericardial effusion is\nrecommended. |  | I | C | \nA multidisciplinary discussion is recommended\nbefore restarting ICI treatment. |  | I | C | ",
          "bbox": [
            48.0,
            94.0009765625,
            288.0000228881836,
            490.99798583984375
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "8. Long-term follow-up and chronic cardiovascular complications in cancer survivors",
      "start_page": 83,
      "end_page": 84,
      "content": "8. Long-term follow-up and\nchronic cardiovascular\ncomplications in cancer survivors\n8.1. Cancer survivors\n8.1.1. Adult survivors of childhood and adolescent\ncancer\nThe survival of children and adolescents with cancer has increased\nconsiderably in recent decades, with 5-year survival rates currently\nexceeding 80%.647 However, the long-term health effects in the\ngrowing population of childhood and adolescent CS are a major con-\ncern.648 CTR-CVT, as a consequence of treatment with anthracy-\nclines, mitoxantrone, and/or chest-directed RT can manifest as\nCTRCD but also as VHD, CAD, arrhythmias, autonomic dysfunc-\ntion, pericardial disease, and premature CV mortality, depending\non the type of cardiotoxic treatment.643,649\nCTRCD is one of the most frequent late effects in childhood CS\nwho received cardiotoxic cancer treatment and contributes to sig-\nniﬁcant morbidity and non-cancer-related mortality later in life.650\nThe cumulative incidence of CTRCD varies depending on the diag-\nnostic criteria applied and the population studied and ranges from\n4.8% to 10.6% at 40–45 years of age.651 RT to a ﬁeld involving the\nheart increases the risk of CTRCD and valvular and vascular\ncomplications.652\nFollow-up of paediatric CS according to the International Late\nEffects of Childhood Cancer Guideline Harmonization Group is re-\ncommended.653 This includes risk stratiﬁcation based upon the total\ncumulative dose of anthracycline chemotherapy and MHD delivered\n(Table 11). Annual review of CVRF and education to promote a\nhealthy lifestyle is recommended. The frequency of CV review\nwith TTE depends upon risk. A CV review should be considered\nevery 5 years for moderate-risk childhood and adolescent adult CS\nand every 2 years for high-risk childhood and adolescent adult CS.\nA recent retrospective analysis has shown that quantiﬁcation of\nLVEF .5 years after cancer diagnosis improves long-term childhood\nRecommendation Table 39 — Recommendations for\nend-of-cancer therapy cardiovascular risk assessment\nRecommendations\nClassa\nLevelb\nEducating and supporting patients with cancer to\nmake appropriate healthy lifestyle choices is\nrecommended.c\nI\nC\nEducation is recommended for patients with\ncancer regarding recognition for early signs and\nsymptoms of CVD.\nI\nC\nCVRF assessment is recommended during the\nﬁrst year after cancer therapyc,12,22,31,632,643 and\nthereafter according to the 2021 ESC Guidelines\non CVD prevention in clinical practice.19\nI\nB\nIn asymptomatic high-risk patients,d\nechocardiography and cardiac serum biomarkers\nare recommended at 3 and 12 months after\ncompletion of cancer\ntherapy.53,54,59,61,68,148,208,425\nI\nB\nIn asymptomatic moderate-risk patients,e\nechocardiography and cardiac serum biomarkers\nshould be considered within 12 months after\ncompletion of cancer therapy.53,54,59,61,68,148,208\nIIa\nB\nIn asymptomatic low-risk patients,e\nechocardiography and cardiac serum biomarkers\nmay be considered within 12 months after\ncompletion of cancer therapy.634\nIIb\nC\nCardiology referralf is recommended in patients\nwith cancer with new cardiac symptoms or new\nasymptomatic abnormalities in echocardiography\nand/or cardiac serum biomarkers at the end of\ntherapy assessment.11\nI\nC\nIn selected patients with exercise intolerance\npersisting at 12 months after cancer treatment\nand with normal resting echocardiogram and\ncardiac biomarkers, exercise stress\nechocardiography and/or CPET may be\nconsidered.\nIIb\nC\nTargeted cardiac rehabilitation should be\nconsidered in CS with high CV risk.638–640\nIIa\nB\nLong-term continuation of cardiac medication is\nrecommended in patients who develop severe\nCTRCD during cancer therapy.\nI\nC\nCV follow-up and treatment optimization is\nrecommended in patients who developed\nTKI-mediated hypertension during cancer\ntherapy.644,645\nI\nC\nCV follow-up and treatment optimization is\nrecommended in patients who developed vascular\ntoxicities during cancer therapy.10,237\nI\nC\nContinued\nECG follow-up is recommended in patients who\ndeveloped QT lengthening or LQTS during cancer\ntherapy.646\nI\nC\n© ESC 2022\nCPET, cardiopulmonary exercise testing; CS, cancer survivors; CTRCD, cancer\ntherapy-related cardiac dysfunction; CV, cardiovascular; CVD, cardiovascular disease;\nCVRF, cardiovascular risk factors; DM, diabetes mellitus; ECG, electrocardiogram;\nESC, European Society of Cardiology; LQTS, long QT syndrome; TKI, tyrosine kinase\ninhibitors.\naClass of recommendation.\nbLevel of evidence.\ncIncluding regulation of hypertension, DM, dyslipidaemia, smoking cessation, weight loss\nin case of obesity, and an adequate amount of exercise.\ndHigh-risk patients: see Table 10.\neModerate- or low-risk patients: according to CV toxicity baseline risk stratiﬁcation.\nfCardio-oncology referral is recommended when available; alternatively, the patient\nshould be referred to a cardiologist with expertise in managing CVD in patients with\ncancer.\n4312\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "keywords": [
        "hypertension",
        "guideline",
        "age",
        "recommended",
        "echocardiography",
        "long",
        "survivors",
        "diabetes",
        "cardiovascular",
        "complications",
        "chronic",
        "term",
        "lvef",
        "cardiovascular risk",
        "exercise",
        "ecg",
        "follow",
        "electrocardiogram",
        "obesity",
        "should be considered",
        "weight",
        "smoking",
        "cancer",
        "may be considered"
      ],
      "tables": [
        {
          "title": "4312 ESC Guidelines",
          "page_number": 83,
          "content": "ECG follow-up is recommended in patients who\ndeveloped QT lengthening or LQTS during cancer\ntherapy.646 | I | C",
          "bbox": [
            307.2749938964844,
            60.8280029296875,
            547.2749633789062,
            96.8280029296875
          ],
          "function_potential": "raw"
        },
        {
          "title": "4312 ESC Guidelines",
          "page_number": 83,
          "content": "Recommendations | Classa | Levelb\nEducating and supporting patients with cancer to\nmake appropriate healthy lifestyle choices is\nrecommended.c | I | C\nEducation is recommended for patients with\ncancer regarding recognition for early signs and\nsymptoms of CVD. | I | C\nCVRF assessment is recommended during the\nfirst year after cancer therapyc,12,22,31,632,643 and\nthereafter according to the 2021 ESC Guidelines\non CVD prevention in clinical practice.19 | I | B\nIn asymptomatic high-risk patients,d\nechocardiography and cardiac serum biomarkers\nare recommended at 3 and 12 months after\ncompletion of cancer\ntherapy.53,54,59,61,68,148,208,425 | I | B\nIn asymptomatic moderate-risk patients,e\nechocardiography and cardiac serum biomarkers\nshould be considered within 12 months after\ncompletion of cancer therapy.53,54,59,61,68,148,208 | IIa | B\nIn asymptomatic low-risk patients,e\nechocardiography and cardiac serum biomarkers\nmay be considered within 12 months after\ncompletion of cancer therapy.634 | IIb | C\nCardiology referralf is recommended in patients\nwith cancer with new cardiac symptoms or new\nasymptomatic abnormalities in echocardiography\nand/or cardiac serum biomarkers at the end of\ntherapy assessment.11 | I | C\nIn selected patients with exercise intolerance\npersisting at 12 months after cancer treatment\nand with normal resting echocardiogram and\ncardiac biomarkers, exercise stress\nechocardiography and/or CPET may be\nconsidered. | IIb | C\nTargeted cardiac rehabilitation should be\nconsidered in CS with high CV risk.638–640 | IIa | B\nLong-term continuation of cardiac medication is\nrecommended in patients who develop severe\nCTRCD during cancer therapy. | I | C\nCV follow-up and treatment optimization is\nrecommended in patients who developed\nTKI-mediated hypertension during cancer\ntherapy.644,645 | I | C\nCV follow-up and treatment optimization is\nrecommended in patients who developed vascular\ntoxicities during cancer therapy.10,237 | I | C",
          "bbox": [
            43.0,
            84.0009765625,
            283.0,
            670.719224717882
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 4313",
          "page_number": 84,
          "content": "Risk category | RT dosea (Gy MHD) | Total cumulative doxorubicinb\ndose (mg/m2) | Combination therapy | \n |  |  | RT dosea (Gy MHD) | Total cumulative doxorubicinb\ndose (mg/m2)\nVery high risk | .25c | ≥400 | .15c | ≥100\nHigh risk | .15 to 25c | 250–399 | 5–15d | ≥100\nModerate risk | 5–15d | 100–249 | ,5e | ≥100\nLow risk | ,5e | ,100 | – | ",
          "bbox": [
            48.0,
            74.0,
            552.2746785481771,
            186.0
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 4313",
          "page_number": 84,
          "content": "Recommendations | Classa | Levelb\nEducation of adults who are childhood and\nadolescent CS treated with anthracyclines,\nmitoxantrone, and/or RT to a volume including\nthe heart and their healthcare providers regarding\ntheir increased CV risk is recommended.655–657 | I | B\nAnnual screening for modifiable CVRFc is\nrecommended in adults who are childhood and\nadolescent CS treated with anthracyclines,\nmitoxantrone, and/or RT to a volume including\nthe heart. | I | C\nCV assessmentd is recommended in female\nchildhood and adolescent CS prior to pregnancy\nor in the first trimester. | I | C\nEchocardiography surveillance should be\nconsidered every 2 years in adults who are\nhigh-risk childhood and adolescente CS.7 | IIa | B\nEchocardiography surveillance should be\nconsidered every 5 years in adults who are\nmoderate-risk childhood and adolescente CS.7,654 | IIa | B",
          "bbox": [
            48.0,
            386.552001953125,
            288.0,
            641.551025390625
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "9. Special populations",
      "start_page": 90,
      "end_page": 91,
      "content": "Management by an expert MDT (the pregnancy heart team) is re-\ncommended for all CS with CTRCD who are considering preg-\nnancy.739,741,742 The risk of HF in CS without CTRCD is low,\nalthough vigilance remains important for potential maternal cardiac\ncomplications.\n8.10. Pulmonary hypertension\nLong-term clinical evaluation may be considered in patients who de-\nvelop PH during therapy (Section 6). In patients with new exertional\ndyspnoea, fatigue, or angina, a TTE is recommended to assess the\nprobability of PH. As TTE alone is not enough to conﬁrm the diagnosis\nof PH, CS diagnosed with high PH probability require a right-heart\ncatheterization to conﬁrm the diagnosis. PH should be treated accord-\ning to general guidelines with referral to a specialist PH service.620\n9. Special populations\n9.1. Cardiac tumours\nCardiac tumours are classiﬁed as either benign or malignant.743 Over\n90% of primary cardiac tumours are benign (myxomas are\npredominant in adults, rhabdomyomas in children).744 Malignant pri-\nmary tumours most commonly consist of sarcomas (approximately\n65%) or lymphomas (approximately 25%).745 Cardiac metastases\n(from melanoma, lymphoma, leukaemia, breast, lung, and oesopha-\ngeal cancers) are much more common than primary cardiac tumours\n(Figure 39).746 Presenting symptoms are paraneoplastic (fever, weak-\nness, fatigue), thromboembolic, haemodynamic (due to compression\nor obstruction from the tumour) or arrhythmic.747,748\nThe diagnostic pathway should be based on knowledge about\ntumour type epidemiology, imaging features, and usually the\nrequirement for a histopathological diagnosis. This topic has been\nextensively reviewed in\nESC CardioMed,749 and here we\nsummarize the main recommendations for differential diagnosis\nand management. Differential diagnosis should exclude cardiac\nthrombi or the presence of chemotherapy catheters. Imaging must\nassess the possibilities of cardiac surgery, and may include: (1) echo-\ncardiography (initial approach using TTE or transoesophageal\nechocardiography)748,750; (2) CMR (for cardiac tumour tissue char-\nacterization)751,752; and (3) CT and PET (to distinguish malignant\nfrom benign lesions and assess for non-cardiac metastatic disease\nor primary cancers) (Figure 40).753,754\nMyxomas are primarily treated with surgery with a good progno-\nsis. Malignant tumours are associated with a poor prognosis and evi-\ndence of the best treatment is lacking. Complete surgical resection is\noften impossible and adjuvant RT, systemic chemotherapy, and/or\ndebulking palliative surgery are needed.755 Cardiac aggressive B-cell\nlymphomas require histopathological diagnosis (often obtained via\nanalysis of pericardial effusion, EMB, or direct surgical biopsy) and\nare\ntreated\nwith\nchemotherapy,\npossibly\nfollowed\nby\nRT\n(Table 13).756\n9.2. Pregnant patients with cancer\nThe diagnosis of cancer during pregnancy is uncommon (1 in every\n1000 pregnant women is diagnosed with cancer), with BC, melan-\noma, and cervical cancer being the most frequent diagnoses.757\nChemotherapy is generally not applied during the ﬁrst trimester\ndue to the high risk of foetal congenital abnormalities (up to 20%)\nand cytotoxic chemotherapies have different risk proﬁles during\nthe second or third trimesters.758,759 Furthermore, chemotherapy\nadministration is usually not given beyond week 34 of gestation to\nprovide a 3-week window between the last cycle and delivery.757\nSupplementary data, Table S19 summarizes the chemotherapies\nfor pregnant patients with cancer.760,761\nCardiac assessment prior to chemotherapy in pregnant women\nwith cancer should consist of clinical history, physical examination,\nECG, cardiac biomarker assessment and TTE (Figure 41).741\nBaseline and follow-up TTE should be interpreted in the context\nof physiological haemodynamic alterations during pregnancy. In nor-\nmal pregnancy, increase in stroke volume, heart rate, and pre-load\nblood volume, and decrease in systemic vascular resistance, lead to\nan increase in cardiac output from the ﬁrst trimester to 80–85%\nabove baseline by the third trimester.762–764 An increase in LV\nmass and LV and RV volumes is observed in the third trimester.\nDuring normal pregnancy, LVEF is usually unchanged and can be\nused for CTRCD monitoring. Although NP and cTn may be slightly\nelevated during normal pregnancy (NT-proBNP , 300 ng/L, BNP ,\n100 pg/mL,14 and hs-cTnT765,766), serial evaluation may be useful for\nRecommendation Table 46 — Recommendations for\ncardiovascular monitoring in cancer survivors during\npregnancy\nRecommendations\nClassa\nLevelb\nIn high-risk female CS, pre-pregnancy counselling\nand management during pregnancy and around\ndelivery by a multidisciplinary pregnancy heart\nteam is recommended.\nI\nC\nA baseline CV evaluation including history,\nphysical examination, ECG, NP, and\nechocardiography is recommended in female CS\nwith a history of CTRCD who are considering\npregnancy.\nI\nC\nA baseline CV evaluation including history,\nphysical examination, ECG, and echocardiography\nshould be considered in all female CS who\nreceived potentially cardiotoxic cancer therapy\nand are considering pregnancy.\nIIa\nC\nA CV evaluation including echocardiography is\nrecommended at 12 weeks of pregnancy in female\nCS who are either high-risk or who received\npotentially cardiotoxic cancer therapy and did not\nhave a baseline CV assessment.\nI\nC\nA second CV evaluation including\nechocardiography should be considered at 20\nweeks of pregnancy in high-risk female CSc who\nreceived potentially cardiotoxic cancer therapy.\nIIa\nC\n© ESC 2022\nCS, cancer survivors; CTRCD, cancer therapy-related cardiac dysfunction; CV,\ncardiovascular; ECG, electrocardiogram, NP, natriuretic peptides.\naClass of recommendation.\nbLevel of evidence.\ncSee Tables 11 and 12.\nESC Guidelines\n4319\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "keywords": [
        "hypertension",
        "should be considered",
        "pulmonary hypertension",
        "lvef",
        "catheterization",
        "biomarker",
        "populations",
        "bnp",
        "recommended",
        "echocardiography",
        "ecg",
        "special",
        "nt-probnp",
        "echo",
        "may be considered",
        "electrocardiogram",
        "female"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 4319",
          "page_number": 90,
          "content": "Recommendations | Classa | Levelb\nIn high-risk female CS, pre-pregnancy counselling\nand management during pregnancy and around\ndelivery by a multidisciplinary pregnancy heart\nteam is recommended. | I | C\nA baseline CV evaluation including history,\nphysical examination, ECG, NP, and\nechocardiography is recommended in female CS\nwith a history of CTRCD who are considering\npregnancy. | I | C\nA baseline CV evaluation including history,\nphysical examination, ECG, and echocardiography\nshould be considered in all female CS who\nreceived potentially cardiotoxic cancer therapy\nand are considering pregnancy. | IIa | C\nA CV evaluation including echocardiography is\nrecommended at 12 weeks of pregnancy in female\nCS who are either high-risk or who received\npotentially cardiotoxic cancer therapy and did not\nhave a baseline CV assessment. | I | C\nA second CV evaluation including\nechocardiography should be considered at 20\nweeks of pregnancy in high-risk female CSc who\nreceived potentially cardiotoxic cancer therapy. | IIa | C",
          "bbox": [
            48.0,
            175.5419921875,
            288.0,
            478.5404815673828
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "10. Patient information, communication, and self-management",
      "start_page": 101,
      "end_page": 103,
      "content": "10. Patient information,\ncommunication, and\nself-management\nCollaboration between different healthcare professionals and pa-\ntients is of paramount importance for the most effective manage-\nment of patients with cancer and CVD. Appropriate language and\ncommunication should be used to allow patients to receive clear\nand accurate information about their condition, and play an active\nrole in managing their treatment.11\nThe ﬁrst goal of this process is to raise the patient’s awareness of\nthe possible presence or development of a CVD, either during can-\ncer or after having some oncological therapy. Patients should under-\nstand that cancer and CVD share many CVRF and reducing risk is\nvital for the prevention of cancer, cancer relapse, and the develop-\nment or worsening of a CVD during or after treatment. Patients\nshould be informed—at the end of chemotherapy—that a persona-\nlized follow-up plan and regular CV controls are needed to detect\npotential reversible stages of CV toxicities. Education, counselling,\nand support to promote healthy lifestyle and to treat modiﬁable\nRecommendation Table 50 — Recommendations for\nriskstratiﬁcationandmonitoringforpatientswithcardiac\nimplantable electronic devices undergoing radiotherapy\nRecommendations\nClassa\nLevelb\nRisk stratiﬁcation including planned radiation type\nand energy, dose to CIED, the patient’s device\ntype, and pacing dependence is recommended\nprior to starting treatment.824,825,827,828\nI\nC\nIn patients undergoing RT, a CIED check is\nrecommended in all patients before and after\ncompleting RT, and during RT according to\nindividual risk.824,826\nI\nC\nIn patients with a CIED undergoing RT at high risk\nof arrhythmia and/or device dysfunction, ECG\nmonitoring and/or pulse oximetry are\nrecommended during every RT session.827,829,831\nI\nC\n© ESC 2022\nCIED, cardiac implantable electronic device; ECG, electrocardiogram; RT, radiotherapy.\naClass of recommendation.\nbLevel of evidence.\nInteraction between healthcare professionals and patients with cancer\nInformation\nRaise awareness\nof possible CVD\nwith cancer\nUnderstand shared\nrisk factors for\ncancer and CVD\nAppropriate lifestyle\nmodification\nActive treatment\nof CVRF\nRecognition and\nreport of early CV\nsymptoms and signs\nRegular CV follow-up \n(also if asymptomatic)\nDon’t stop\ncardioprotective therapy\nwithout medical advice\nTimely EoL and\nDNR discussion\nEducation, counselling, and support\nConsider specific psychologic and social conditions\nAid of digital health tools or information leaflets\nAppropriate language\nand communication\nFigure 47 Patient information, communication, and self-management. CV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk fac-\ntors; DNR, do not resuscitate; EoL, end of life.\n4330\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nCVRF should be offered to patients with cancer, in order to reduce\nthe burden of complications during and after anticancer therapy.\nPatients should receive guidance to recognize and to report signs\nand symptoms of CVD, in order to receive prompt and effective treat-\nment, ideally without interfering with their cancer treatment. Patients\nshould also be advised not to stop cardioprotective therapies without\nmedical guidance, even if they recover their cardiac function. To help\nin this complex task, leaﬂets speciﬁcally designed for this context may\nbe used,832,833 eventually with the aid of digital tools (Figure 47).\n11. The role of scientiﬁc societies\nin the promotion and\ndevelopment of cardio-oncology\nin modern medicine\nCardio-oncology is a subspecialty that has seen huge development and\ngrowth in recent years with the formation—in almost all national and\ninternational\nsocieties—of\ncardio-oncology\nworking\ngroups.\nMoreover, cancer and medical associations have also developed an in-\ncreasing interest in cardio-oncology. Important roles of these scientiﬁc\nsocieties are clinical research, education, and advocacy. The ESC-CCO\nstrategic plan and mission include improvement of prevention, diagno-\nsis, treatment, and management of CTR-CVT and enhancement of the\nstandard of care for patients with cancer (Figure 48).\n12. Key messages\nThis is the ﬁrst ESC cardio-oncology Guideline and contains 272 new\nrecommendations. The key messages from this guideline are:\n• A guiding principle of cardio-oncology is integration, and\ncardio-oncology providers must have knowledge of the broad\nscope of cardiology, oncology, and haematology. Communication\nbetween different healthcare professionals is critical to optimize\nthe care of patients with cancer and CVD.\n• Cardio-oncology programmes facilitate cancer treatment by min-\nimizing unnecessary cancer therapy interruptions and CTR-CVT\nThe role of scientific societies in the promotion and\ndevelopment of cardio-oncology\nCardio-\noncology\nAdvocacy\nResearch\nEducation\nEngagement\nBasic and translational\nresearch\nClinical research\nLong-term survivorship\nprogrammes\nAppropriate\nresources\nCommunication\nKnowledge\nOrganization\nCommunity level\nInternational level\nNational level\nRegional level\nPolitical strategies\nagainst cancer and CVD\nCommunity\nHealthcare authorities\nHealthcare professionals\nPatients\nCommunication\nstrategies\nFigure 48 The role of scientiﬁc societies in the promotion and development of cardio-oncology. CVD, cardiovascular disease.\nESC Guidelines\n4331\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "keywords": [
        "guideline",
        "self",
        "cardiovascular risk",
        "recommended",
        "communication",
        "ecg",
        "management",
        "arrhythmia",
        "patient",
        "information",
        "electrocardiogram"
      ],
      "tables": [
        {
          "title": "4330 ESC Guidelines",
          "page_number": 101,
          "content": "Recommendations | Classa | Levelb\nRisk stratification including planned radiation type\nand energy, dose to CIED, the patient’s device\ntype, and pacing dependence is recommended\nprior to starting treatment.824,825,827,828 | I | C\nIn patients undergoing RT, a CIED check is\nrecommended in all patients before and after\ncompleting RT, and during RT according to\nindividual risk.824,826 | I | C\nIn patients with a CIED undergoing RT at high risk\nof arrhythmia and/or device dysfunction, ECG\nmonitoring and/or pulse oximetry are\nrecommended during every RT session.827,829,831 | I | C",
          "bbox": [
            43.0,
            94.0009765625,
            283.0,
            263.0
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "11. The role of scientific societies in the promotion and development of cardio-oncology in modern medicine",
      "start_page": 102,
      "end_page": 103,
      "content": "CVRF should be offered to patients with cancer, in order to reduce\nthe burden of complications during and after anticancer therapy.\nPatients should receive guidance to recognize and to report signs\nand symptoms of CVD, in order to receive prompt and effective treat-\nment, ideally without interfering with their cancer treatment. Patients\nshould also be advised not to stop cardioprotective therapies without\nmedical guidance, even if they recover their cardiac function. To help\nin this complex task, leaﬂets speciﬁcally designed for this context may\nbe used,832,833 eventually with the aid of digital tools (Figure 47).\n11. The role of scientiﬁc societies\nin the promotion and\ndevelopment of cardio-oncology\nin modern medicine\nCardio-oncology is a subspecialty that has seen huge development and\ngrowth in recent years with the formation—in almost all national and\ninternational\nsocieties—of\ncardio-oncology\nworking\ngroups.\nMoreover, cancer and medical associations have also developed an in-\ncreasing interest in cardio-oncology. Important roles of these scientiﬁc\nsocieties are clinical research, education, and advocacy. The ESC-CCO\nstrategic plan and mission include improvement of prevention, diagno-\nsis, treatment, and management of CTR-CVT and enhancement of the\nstandard of care for patients with cancer (Figure 48).\n12. Key messages\nThis is the ﬁrst ESC cardio-oncology Guideline and contains 272 new\nrecommendations. The key messages from this guideline are:\n• A guiding principle of cardio-oncology is integration, and\ncardio-oncology providers must have knowledge of the broad\nscope of cardiology, oncology, and haematology. Communication\nbetween different healthcare professionals is critical to optimize\nthe care of patients with cancer and CVD.\n• Cardio-oncology programmes facilitate cancer treatment by min-\nimizing unnecessary cancer therapy interruptions and CTR-CVT\nThe role of scientific societies in the promotion and\ndevelopment of cardio-oncology\nCardio-\noncology\nAdvocacy\nResearch\nEducation\nEngagement\nBasic and translational\nresearch\nClinical research\nLong-term survivorship\nprogrammes\nAppropriate\nresources\nCommunication\nKnowledge\nOrganization\nCommunity level\nInternational level\nNational level\nRegional level\nPolitical strategies\nagainst cancer and CVD\nCommunity\nHealthcare authorities\nHealthcare professionals\nPatients\nCommunication\nstrategies\nFigure 48 The role of scientiﬁc societies in the promotion and development of cardio-oncology. CVD, cardiovascular disease.\nESC Guidelines\n4331\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "keywords": [
        "oncology",
        "guideline",
        "role",
        "scientific",
        "development",
        "cardio",
        "modern",
        "medicine",
        "promotion",
        "societies"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "12. Key messages",
      "start_page": 102,
      "end_page": 104,
      "content": "CVRF should be offered to patients with cancer, in order to reduce\nthe burden of complications during and after anticancer therapy.\nPatients should receive guidance to recognize and to report signs\nand symptoms of CVD, in order to receive prompt and effective treat-\nment, ideally without interfering with their cancer treatment. Patients\nshould also be advised not to stop cardioprotective therapies without\nmedical guidance, even if they recover their cardiac function. To help\nin this complex task, leaﬂets speciﬁcally designed for this context may\nbe used,832,833 eventually with the aid of digital tools (Figure 47).\n11. The role of scientiﬁc societies\nin the promotion and\ndevelopment of cardio-oncology\nin modern medicine\nCardio-oncology is a subspecialty that has seen huge development and\ngrowth in recent years with the formation—in almost all national and\ninternational\nsocieties—of\ncardio-oncology\nworking\ngroups.\nMoreover, cancer and medical associations have also developed an in-\ncreasing interest in cardio-oncology. Important roles of these scientiﬁc\nsocieties are clinical research, education, and advocacy. The ESC-CCO\nstrategic plan and mission include improvement of prevention, diagno-\nsis, treatment, and management of CTR-CVT and enhancement of the\nstandard of care for patients with cancer (Figure 48).\n12. Key messages\nThis is the ﬁrst ESC cardio-oncology Guideline and contains 272 new\nrecommendations. The key messages from this guideline are:\n• A guiding principle of cardio-oncology is integration, and\ncardio-oncology providers must have knowledge of the broad\nscope of cardiology, oncology, and haematology. Communication\nbetween different healthcare professionals is critical to optimize\nthe care of patients with cancer and CVD.\n• Cardio-oncology programmes facilitate cancer treatment by min-\nimizing unnecessary cancer therapy interruptions and CTR-CVT\nThe role of scientific societies in the promotion and\ndevelopment of cardio-oncology\nCardio-\noncology\nAdvocacy\nResearch\nEducation\nEngagement\nBasic and translational\nresearch\nClinical research\nLong-term survivorship\nprogrammes\nAppropriate\nresources\nCommunication\nKnowledge\nOrganization\nCommunity level\nInternational level\nNational level\nRegional level\nPolitical strategies\nagainst cancer and CVD\nCommunity\nHealthcare authorities\nHealthcare professionals\nPatients\nCommunication\nstrategies\nFigure 48 The role of scientiﬁc societies in the promotion and development of cardio-oncology. CVD, cardiovascular disease.\nESC Guidelines\n4331\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nacross the entire continuum of cancer care. In patients who de-\nvelop CTR-CVT, a MDT discussion is required to balance the\nrisk/beneﬁt of cancer treatment discontinuation.\n• There is a new international deﬁnition of CTR-CVT (Table 3).\n• CV toxicity risk is a dynamic variable. This guideline is structured to\nprovide a personalized approach to care based upon the baseline\nCV toxicity risk. A baseline CV risk assessment is recommended\nfor all patients with cancer scheduled to receive a potentially car-\ndiotoxic anticancer therapy. This enables the oncology team to\nconsider CV risk while making cancer treatment choices, educating\npatients regarding their CV risk, and personalizing CV surveillance\nand follow-up strategy.\n• Primary prevention of CV toxicity from cancer therapy aims to\navoid or minimize the development of CTR-CVT in patients with-\nout CVD.\n• Secondary prevention refers to interventions in patients with pre-\nexisting CVD, including prior or new CTR-CVT. A MDT is recom-\nmended when patients with cancer have complex CVD that may\nimpact on their cancer treatment.\n• Deﬁning and delivering an appropriate prevention and surveillance\nplan for potential CV complications is recommended. Optimal\nmanagement of CVRF and pre-existing CVD is mandatory to facili-\ntate cancer therapy and to improve patients’ prognosis.\n• Detailed monitoring pathways during cancer therapy—including\n3D echocardiography, GLS, and cardiac biomarkers—are pro-\nvided to detect CV toxicity based upon speciﬁc cancer therapies\nand baseline CV toxicity risk.\n• Treatment recommendations for CTRCD during and after cancer\ntherapy depend upon CTRCD severity and symptoms. New guid-\nance on continuing trastuzumab in BC patients who develop\nasymptomatic moderate CTRCD (LVEF 40–49%) while starting\ncardioprotective medication is provided.\n• Use of a structured algorithm to guide decisions regarding anticoa-\ngulation management in patients with cancer presenting with AF\nor VTE encompassing the TBIP assessment is encouraged.\n• After\ncancer\ntreatment\nis\ncompleted,\nthe\nfocus\nof\nthe\ncardio-oncology team shifts to coordination of long-term follow-\nup. This starts with an ‘end-of-treatment’ assessment in the ﬁrst\nyear after treatment, reviewing patients with cancer who have re-\nceived cardiotoxic anticancer therapies to reassess their CV tox-\nicity risk and guide long-term surveillance planning.\n• A new algorithm (Figure 37) is provided to guide weaning off of CV\nmedication in CS.\n• Patients with cancer, CS, and the patient’s family/carers should re-\nceive guidance to promote healthy lifestyle and recognize and re-\nport signs and symptoms of CVD, to receive prompt and effective\ntreatment, without interfering with their cancer treatment.\n• Patients must receive psychological support when needed and\nclear and accurate information about their condition to play an ac-\ntive role in managing their treatment and increase adherence to\ncancer and CV treatments.\n13. Future needs\nThere are a low number of dedicated cardio-oncology services and\nmost patients are reviewed in general cardiology clinics in Europe\nand worldwide. Strategic investments in cardio-oncology care\nnetworks and cardio-oncology services provision are needed to\nmeet the projected increased clinical demand in the near fu-\nture,834 and to facilitate research, training, and educational activ-\nities. A dedicated training core curriculum for a minimum of\n1-year medical training is urgently needed. It may include: (1)\nknowledge of the broad scope of cardiology, oncology, and\nhaematology; (2) CV competencies for CTR-CVT prevention,\nsurveillance, and management of patients with cancer in dedicated\noutpatients’ cardio-oncology clinics; (3) inpatient consultative\nservices; and (4) dedicated time to achieve competences in CV im-\naging, HF, and vascular cardiology.\nCollaboration between healthcare providers, clinical and basic in-\nvestigators, healthcare authorities, regulatory bodies, advocacy\ngroups, and patients’ associations is needed to address future needs\n(see Section 11).\nAs this Guideline was developed, it became clear that there is a sig-\nniﬁcant lack of RCT to guide decision-making, with many recommen-\ndations supported by level of evidence C. This is complicated by the\nfast-moving pace of new oncology treatment developments against a\nbackground of dynamic CV toxicity likelihood. Therefore, large num-\nbers of patients and longer follow-up are required to provide sufﬁ-\ncient statistical power and deﬁnitive answers. In the future, the\nfollowing strategies and areas of research are priorities:\n• New trial designs focusing upon the ‘at-risk’ cancer patient\npopulations.\n• Validating current HFA-ICOS risk assessment tools and surveil-\nlance algorithms.\n• Assessment of new technologies for the detection of early\nCTRCD, broadening the biomarker panel and recognizing the spe-\nciﬁc patterns in early myocardial damage.\n• Reﬁning\nCV\nrisk\nscores\n(e.g.\nEuroSCORE\nII,\nSCORE2,\nSCORE2-OP, CHA2DS2-VASc, HAS-BLED, SYNTAX) for appli-\ncation in cancer populations.\n• Optimal treatment of steroid-resistant ICI CV toxicity and long-\nterm CV effects of ICI therapy.\n• Selection criteria for modern percutaneous structural (TAVI,\nMitraclip, LAA occluder devices) and electrophysiological (abla-\ntion) CV therapies in patients with active cancer.\n• Patient-speciﬁc predictive algorithms for QTc prolongation with\ncancer drugs.\n• Assessment of genetic proﬁles in more speciﬁc CTRCD risk\nprediction.\n• Identiﬁcation of the cancer patient populations with mild or mod-\nerate CTRCD during treatment who can safely wean off long-term\nCV medication.\n• Optimal modalities for screening long-term survivor populations\nfor the complications of anthracycline chemotherapy and medias-\ntinal radiation.\n• Creation of large cardio-oncology registries to collect ‘big data’ on\nlarge patient populations.\n• Application of artiﬁcial intelligence and other new data analytics to\nidentify new patients with cancer at risk and new parameters that\ncan predict risk of CTR-CVT, response to speciﬁc cardioprotec-\ntive interventions, and long-term risk and safety to wean off CV\ntherapies initiated during cancer treatment.\n4332\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "keywords": [
        "messages",
        "lvef",
        "vte",
        "guideline",
        "score2",
        "biomarker",
        "tavi",
        "recommended",
        "echocardiography",
        "genetic",
        "score2-op",
        "secondary prevention",
        "primary prevention"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 4333",
          "page_number": 104,
          "content": "Recommendations |  | Classa | Levelb | \n | Recommendation Table 1 for a general approach to cardiovascular toxicity risk categorization |  |  | \nCV toxicity risk stratification before starting potentially cardiotoxic anticancer therapy is recommended in all patients with\ncancer. |  | I | B | \nCommunicating the results of the CV toxicity risk assessment to the patient and other appropriate healthcare professionals is\nrecommended. |  | I | C | \nIt is recommended that patients categorized as low CV toxicity risk should proceed with anticancer therapy without\ndelay. |  | I | C | \nCardiology referral is recommended in high-risk and very high-risk patients before anticancer therapy. |  | I | C | \nDiscussion of the risk/benefit balance of cardiotoxic anticancer treatment in high- and very high-risk patients in a multidisciplinary\napproach prior to starting treatment is recommended. |  | I | C | \nCardiology referral is recommended for patients with cancer and pre-existing CVD or abnormal findings at baseline CV toxicity risk\nassessment who require potentially cardiotoxic anticancer therapy. |  | I | C | ",
          "bbox": [
            48.0,
            543.5009765625,
            552.2800537109375,
            732.2222222222222
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "13. Future needs",
      "start_page": 103,
      "end_page": 105,
      "content": "across the entire continuum of cancer care. In patients who de-\nvelop CTR-CVT, a MDT discussion is required to balance the\nrisk/beneﬁt of cancer treatment discontinuation.\n• There is a new international deﬁnition of CTR-CVT (Table 3).\n• CV toxicity risk is a dynamic variable. This guideline is structured to\nprovide a personalized approach to care based upon the baseline\nCV toxicity risk. A baseline CV risk assessment is recommended\nfor all patients with cancer scheduled to receive a potentially car-\ndiotoxic anticancer therapy. This enables the oncology team to\nconsider CV risk while making cancer treatment choices, educating\npatients regarding their CV risk, and personalizing CV surveillance\nand follow-up strategy.\n• Primary prevention of CV toxicity from cancer therapy aims to\navoid or minimize the development of CTR-CVT in patients with-\nout CVD.\n• Secondary prevention refers to interventions in patients with pre-\nexisting CVD, including prior or new CTR-CVT. A MDT is recom-\nmended when patients with cancer have complex CVD that may\nimpact on their cancer treatment.\n• Deﬁning and delivering an appropriate prevention and surveillance\nplan for potential CV complications is recommended. Optimal\nmanagement of CVRF and pre-existing CVD is mandatory to facili-\ntate cancer therapy and to improve patients’ prognosis.\n• Detailed monitoring pathways during cancer therapy—including\n3D echocardiography, GLS, and cardiac biomarkers—are pro-\nvided to detect CV toxicity based upon speciﬁc cancer therapies\nand baseline CV toxicity risk.\n• Treatment recommendations for CTRCD during and after cancer\ntherapy depend upon CTRCD severity and symptoms. New guid-\nance on continuing trastuzumab in BC patients who develop\nasymptomatic moderate CTRCD (LVEF 40–49%) while starting\ncardioprotective medication is provided.\n• Use of a structured algorithm to guide decisions regarding anticoa-\ngulation management in patients with cancer presenting with AF\nor VTE encompassing the TBIP assessment is encouraged.\n• After\ncancer\ntreatment\nis\ncompleted,\nthe\nfocus\nof\nthe\ncardio-oncology team shifts to coordination of long-term follow-\nup. This starts with an ‘end-of-treatment’ assessment in the ﬁrst\nyear after treatment, reviewing patients with cancer who have re-\nceived cardiotoxic anticancer therapies to reassess their CV tox-\nicity risk and guide long-term surveillance planning.\n• A new algorithm (Figure 37) is provided to guide weaning off of CV\nmedication in CS.\n• Patients with cancer, CS, and the patient’s family/carers should re-\nceive guidance to promote healthy lifestyle and recognize and re-\nport signs and symptoms of CVD, to receive prompt and effective\ntreatment, without interfering with their cancer treatment.\n• Patients must receive psychological support when needed and\nclear and accurate information about their condition to play an ac-\ntive role in managing their treatment and increase adherence to\ncancer and CV treatments.\n13. Future needs\nThere are a low number of dedicated cardio-oncology services and\nmost patients are reviewed in general cardiology clinics in Europe\nand worldwide. Strategic investments in cardio-oncology care\nnetworks and cardio-oncology services provision are needed to\nmeet the projected increased clinical demand in the near fu-\nture,834 and to facilitate research, training, and educational activ-\nities. A dedicated training core curriculum for a minimum of\n1-year medical training is urgently needed. It may include: (1)\nknowledge of the broad scope of cardiology, oncology, and\nhaematology; (2) CV competencies for CTR-CVT prevention,\nsurveillance, and management of patients with cancer in dedicated\noutpatients’ cardio-oncology clinics; (3) inpatient consultative\nservices; and (4) dedicated time to achieve competences in CV im-\naging, HF, and vascular cardiology.\nCollaboration between healthcare providers, clinical and basic in-\nvestigators, healthcare authorities, regulatory bodies, advocacy\ngroups, and patients’ associations is needed to address future needs\n(see Section 11).\nAs this Guideline was developed, it became clear that there is a sig-\nniﬁcant lack of RCT to guide decision-making, with many recommen-\ndations supported by level of evidence C. This is complicated by the\nfast-moving pace of new oncology treatment developments against a\nbackground of dynamic CV toxicity likelihood. Therefore, large num-\nbers of patients and longer follow-up are required to provide sufﬁ-\ncient statistical power and deﬁnitive answers. In the future, the\nfollowing strategies and areas of research are priorities:\n• New trial designs focusing upon the ‘at-risk’ cancer patient\npopulations.\n• Validating current HFA-ICOS risk assessment tools and surveil-\nlance algorithms.\n• Assessment of new technologies for the detection of early\nCTRCD, broadening the biomarker panel and recognizing the spe-\nciﬁc patterns in early myocardial damage.\n• Reﬁning\nCV\nrisk\nscores\n(e.g.\nEuroSCORE\nII,\nSCORE2,\nSCORE2-OP, CHA2DS2-VASc, HAS-BLED, SYNTAX) for appli-\ncation in cancer populations.\n• Optimal treatment of steroid-resistant ICI CV toxicity and long-\nterm CV effects of ICI therapy.\n• Selection criteria for modern percutaneous structural (TAVI,\nMitraclip, LAA occluder devices) and electrophysiological (abla-\ntion) CV therapies in patients with active cancer.\n• Patient-speciﬁc predictive algorithms for QTc prolongation with\ncancer drugs.\n• Assessment of genetic proﬁles in more speciﬁc CTRCD risk\nprediction.\n• Identiﬁcation of the cancer patient populations with mild or mod-\nerate CTRCD during treatment who can safely wean off long-term\nCV medication.\n• Optimal modalities for screening long-term survivor populations\nfor the complications of anthracycline chemotherapy and medias-\ntinal radiation.\n• Creation of large cardio-oncology registries to collect ‘big data’ on\nlarge patient populations.\n• Application of artiﬁcial intelligence and other new data analytics to\nidentify new patients with cancer at risk and new parameters that\ncan predict risk of CTR-CVT, response to speciﬁc cardioprotec-\ntive interventions, and long-term risk and safety to wean off CV\ntherapies initiated during cancer treatment.\n4332\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n14. Gaps in evidence\nCancer and CVD are the two major public health problems with great\neconomic and social impact. In addition, CTR-CVT are associated with\nanexcessofbothCVandoncologicalmortality,especiallywhenthey limit\npatients’ ability to complete effective treatments. However, the intersec-\ntion of cancer and CVD has only recently gained wider interest and many\nareas with lack of evidence need to be addressed in future research.\nRole of cardio-oncology services and cardio-oncology\ncare networks\n• Robust evidence on the impact of dedicated cardio-oncology pro-\ngrammes and cardio-oncology rehabilitation on the prognosis of\npatients with cancer and survivors.\n• Speciﬁcation of roles of different healthcare professionals (includ-\ning nurses and pharmacists) in cardio-oncology teams.\n• Cardio-oncology care networks to improve the management of\npatients with cancer and to discuss difﬁcult cases.\n• Cardio-oncology team support and involvement in oncology trials\ndesign (including patients’ representatives).\n• Understand how to engage patients with cancer in their own CV\ncare (inclusion of digital tools).\nResearch, education, and training in cardio-oncology\n• Consensus about CV toxicity deﬁnitions used in oncology trials.\n• Deﬁne standards for CV toxicity monitoring in oncology trials to\navoid unexpected CV toxicities when new drugs are approved for\nclinical use.\n• Relevant model systems to allow high-throughput screening of\nnew cancer treatments for CV toxicity.\n• Improved knowledge on CV toxicity mechanisms of new targeted\ncancer therapies and ICI and optimal treatment of CV toxicities.\n• Improved knowledge on the effects of radiation to speciﬁc cardiac\nsubstructures and the interactions between cardiotoxic systemic\ntherapy and RT.\n• Further research into the underlying mechanisms that connect\nCVD and cancer, such as a genetic predisposition to CV toxicity.\n• Personalized medicine and use of big data and artiﬁcial intelligence\ntools.\nCardiovascular toxicity risk stratiﬁcation\n• Development of CV toxicity risk prediction tools including both\ntreatment- and patient-related risk factors.\n• Validated prospective CV toxicity risk scores based on clinical\noutcomes.\n• Further research on the role of genetics in CV toxicity risk\nstratiﬁcation.\n• Validation of CPET parameters for CV outcomes in patients with\ncancer.\nPrevention, diagnosis, and management of CTR-CVT\n• Raise awareness of the beneﬁts of minimizing CV risk in patients\nwith cancer in order to reduce the risk of CTR-CVT.\n• More data on new technologies (biomarkers, advanced echocardi-\nography, CMR, etc.) and genetic proﬁles for the detection of early\nCV toxicity.\n• Prospective studies showing the impact on outcomes and/or qual-\nity of life (and frailty) of early CTR-CVT diagnosis and treatment.\n• Further evidence from prospective RCTs to deﬁne when cardio-\nprotective medications improve patients’ outcomes.\n• Further research on the potential for aerobic exercise to reduce\nCTR-CVT.\n• RCTs of (new) CV therapies in patients with different types of\nCTR-CVT.\nLong-term cancer survivorship programmes\n• Development of optimal CV follow-up programmes after treat-\nment for cancer (research on risk stratiﬁcation, efﬁcacy, and fre-\nquency of screening protocols).\n• Best screening strategies for RT-induced CAD.\n• Further research on CV preventive strategies for long-term CS.\n15. ‘What to do’ and ‘what not to do’ messages from the Guidelines\nRecommendations\nClassa\nLevelb\nRecommendation Table 1 for a general approach to cardiovascular toxicity risk categorization\nCV toxicity risk stratiﬁcation before starting potentially cardiotoxic anticancer therapy is recommended in all patients with\ncancer.\nI\nB\nCommunicating the results of the CV toxicity risk assessment to the patient and other appropriate healthcare professionals is\nrecommended.\nI\nC\nIt is recommended that patients categorized as low CV toxicity risk should proceed with anticancer therapy without\ndelay.\nI\nC\nCardiology referral is recommended in high-risk and very high-risk patients before anticancer therapy.\nI\nC\nDiscussion of the risk/beneﬁt balance of cardiotoxic anticancer treatment in high- and very high-risk patients in a multidisciplinary\napproach prior to starting treatment is recommended.\nI\nC\nCardiology referral is recommended for patients with cancer and pre-existing CVD or abnormal ﬁndings at baseline CV toxicity risk\nassessment who require potentially cardiotoxic anticancer therapy.\nI\nC\nContinued\nESC Guidelines\n4333\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "keywords": [
        "lvef",
        "vte",
        "guideline",
        "score2",
        "biomarker",
        "needs",
        "tavi",
        "future",
        "recommended",
        "echocardiography",
        "genetic",
        "exercise",
        "score2-op",
        "secondary prevention",
        "primary prevention"
      ],
      "tables": [
        {
          "title": "4334 ESC Guidelines",
          "page_number": 105,
          "content": " | Recommendation Table 2 for electrocardiogram baseline assessment |  |  | \nAn ECG is recommended in all patients starting cancer therapy as part of their baseline CV risk assessment. |  | I | C | \nIn patients with an abnormal baseline ECG, referral to a cardiologist is recommended. |  | I | C | \n | Recommendation Table 3 for cardiac biomarker assessment prior to potentially cardiotoxic therapies |  |  | \nBaseline measurement of NP and/or cTn is recommended in all patients with cancer at risk of CTRCD if these biomarkers are going to\nbe measured during treatment to detect CTRCD. |  | I | C | \n | Recommendation Table 4 for cardiac imaging modalities in patients with cancer |  |  | \n | General |  |  | \nEchocardiography is recommended as the first-line modality for the assessment of cardiac function in patients with cancer. |  | I | C | \n3D echocardiography is recommended as the preferred echocardiographic modality to measure LVEF. |  | I | B | \nGLS is recommended in all patients with cancer having echocardiography, if available. |  | I | C | \n | Baseline cardiac imaging prior to potentially cardiotoxic therapies |  |  | \nBaseline comprehensive TTE is recommended in all patients with cancer at high risk and very high risk of CV toxicity before starting\nanticancer therapy. |  | I | C | \n | Recommendation Table 5 for primary prevention of cancer therapy-related cardiovascular toxicity |  |  | \nManagement of CVRF according to the 2021 ESC Guidelines on CVD prevention in clinical practice is recommended before, during, and\nafter cancer therapy. |  | I | C | \n | Recommendation Table 6 for secondary prevention of cancer therapy-related cardiovascular toxicity |  |  | \nManagement of CVD according to applicable ESC Guidelines is recommended before, during, and after cancer therapy. |  | I | C | \n | Recommendation Table 7 for baseline risk assessment and monitoring during anthracycline chemotherapy and in the first 12 months\nafter therapy |  |  | \n | TTE |  |  | \nBaseline echocardiography is recommended in all patients with cancer before anthracycline chemotherapy. |  | I | B | \nIn all adults receiving anthracycline chemotherapy, an echocardiogram is recommended within 12 months after completing treatment. |  | I | B | \nIn high- and very high-risk patients, echocardiography is recommended every two cycles and within 3 months after completing\ntreatment. |  | I | C | \n | Cardiac serum biomarkers |  |  | \nBaseline measurement of NP and cTn is recommended in high- and very high-risk patients prior to anthracycline chemotherapy. |  | I | B | \ncTn and NP monitoring before every cycle during anthracycline chemotherapy and 3 and 12 months after therapy completion is\nrecommended in high- and very high-risk patients. |  | I | B | \n | Recommendation Table 8 for baseline risk assessment and monitoring during HER2-targeted therapies and in the first 12 months\nafter therapy |  |  | \n | TTE |  |  | \nBaseline echocardiography is recommended before HER2-targeted therapies in all patients. |  | I | B | \nIn patients receiving neoadjuvant or adjuvant HER2-targeted therapies, echocardiography is recommended every 3 months and within\n12 months after completing treatment. |  | I | B | \nIn metastatic HER2+ disease, echocardiography is recommended every 3 months during the first year; if the patient remains\nasymptomatic without CV toxicity, then surveillance can be reduced to every 6 months during future treatment. |  | I | C | \n | Cardiac biomarkers |  |  | \nBaseline NP and cTn measurement are recommended in high- and very high-risk patients prior to anti-HER2-targeted therapies. |  | I | C | ",
          "bbox": [
            43.0,
            59.5,
            547.280040922619,
            741.2181905110677
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "14. Gaps in evidence",
      "start_page": 104,
      "end_page": 105,
      "content": "14. Gaps in evidence\nCancer and CVD are the two major public health problems with great\neconomic and social impact. In addition, CTR-CVT are associated with\nanexcessofbothCVandoncologicalmortality,especiallywhenthey limit\npatients’ ability to complete effective treatments. However, the intersec-\ntion of cancer and CVD has only recently gained wider interest and many\nareas with lack of evidence need to be addressed in future research.\nRole of cardio-oncology services and cardio-oncology\ncare networks\n• Robust evidence on the impact of dedicated cardio-oncology pro-\ngrammes and cardio-oncology rehabilitation on the prognosis of\npatients with cancer and survivors.\n• Speciﬁcation of roles of different healthcare professionals (includ-\ning nurses and pharmacists) in cardio-oncology teams.\n• Cardio-oncology care networks to improve the management of\npatients with cancer and to discuss difﬁcult cases.\n• Cardio-oncology team support and involvement in oncology trials\ndesign (including patients’ representatives).\n• Understand how to engage patients with cancer in their own CV\ncare (inclusion of digital tools).\nResearch, education, and training in cardio-oncology\n• Consensus about CV toxicity deﬁnitions used in oncology trials.\n• Deﬁne standards for CV toxicity monitoring in oncology trials to\navoid unexpected CV toxicities when new drugs are approved for\nclinical use.\n• Relevant model systems to allow high-throughput screening of\nnew cancer treatments for CV toxicity.\n• Improved knowledge on CV toxicity mechanisms of new targeted\ncancer therapies and ICI and optimal treatment of CV toxicities.\n• Improved knowledge on the effects of radiation to speciﬁc cardiac\nsubstructures and the interactions between cardiotoxic systemic\ntherapy and RT.\n• Further research into the underlying mechanisms that connect\nCVD and cancer, such as a genetic predisposition to CV toxicity.\n• Personalized medicine and use of big data and artiﬁcial intelligence\ntools.\nCardiovascular toxicity risk stratiﬁcation\n• Development of CV toxicity risk prediction tools including both\ntreatment- and patient-related risk factors.\n• Validated prospective CV toxicity risk scores based on clinical\noutcomes.\n• Further research on the role of genetics in CV toxicity risk\nstratiﬁcation.\n• Validation of CPET parameters for CV outcomes in patients with\ncancer.\nPrevention, diagnosis, and management of CTR-CVT\n• Raise awareness of the beneﬁts of minimizing CV risk in patients\nwith cancer in order to reduce the risk of CTR-CVT.\n• More data on new technologies (biomarkers, advanced echocardi-\nography, CMR, etc.) and genetic proﬁles for the detection of early\nCV toxicity.\n• Prospective studies showing the impact on outcomes and/or qual-\nity of life (and frailty) of early CTR-CVT diagnosis and treatment.\n• Further evidence from prospective RCTs to deﬁne when cardio-\nprotective medications improve patients’ outcomes.\n• Further research on the potential for aerobic exercise to reduce\nCTR-CVT.\n• RCTs of (new) CV therapies in patients with different types of\nCTR-CVT.\nLong-term cancer survivorship programmes\n• Development of optimal CV follow-up programmes after treat-\nment for cancer (research on risk stratiﬁcation, efﬁcacy, and fre-\nquency of screening protocols).\n• Best screening strategies for RT-induced CAD.\n• Further research on CV preventive strategies for long-term CS.\n15. ‘What to do’ and ‘what not to do’ messages from the Guidelines\nRecommendations\nClassa\nLevelb\nRecommendation Table 1 for a general approach to cardiovascular toxicity risk categorization\nCV toxicity risk stratiﬁcation before starting potentially cardiotoxic anticancer therapy is recommended in all patients with\ncancer.\nI\nB\nCommunicating the results of the CV toxicity risk assessment to the patient and other appropriate healthcare professionals is\nrecommended.\nI\nC\nIt is recommended that patients categorized as low CV toxicity risk should proceed with anticancer therapy without\ndelay.\nI\nC\nCardiology referral is recommended in high-risk and very high-risk patients before anticancer therapy.\nI\nC\nDiscussion of the risk/beneﬁt balance of cardiotoxic anticancer treatment in high- and very high-risk patients in a multidisciplinary\napproach prior to starting treatment is recommended.\nI\nC\nCardiology referral is recommended for patients with cancer and pre-existing CVD or abnormal ﬁndings at baseline CV toxicity risk\nassessment who require potentially cardiotoxic anticancer therapy.\nI\nC\nContinued\nESC Guidelines\n4333\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "keywords": [
        "evidence",
        "recommended",
        "genetic",
        "exercise",
        "gaps"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "15. ‘What to do’ and ‘what not to do’ messages from the Guidelines",
      "start_page": 104,
      "end_page": 114,
      "content": "14. Gaps in evidence\nCancer and CVD are the two major public health problems with great\neconomic and social impact. In addition, CTR-CVT are associated with\nanexcessofbothCVandoncologicalmortality,especiallywhenthey limit\npatients’ ability to complete effective treatments. However, the intersec-\ntion of cancer and CVD has only recently gained wider interest and many\nareas with lack of evidence need to be addressed in future research.\nRole of cardio-oncology services and cardio-oncology\ncare networks\n• Robust evidence on the impact of dedicated cardio-oncology pro-\ngrammes and cardio-oncology rehabilitation on the prognosis of\npatients with cancer and survivors.\n• Speciﬁcation of roles of different healthcare professionals (includ-\ning nurses and pharmacists) in cardio-oncology teams.\n• Cardio-oncology care networks to improve the management of\npatients with cancer and to discuss difﬁcult cases.\n• Cardio-oncology team support and involvement in oncology trials\ndesign (including patients’ representatives).\n• Understand how to engage patients with cancer in their own CV\ncare (inclusion of digital tools).\nResearch, education, and training in cardio-oncology\n• Consensus about CV toxicity deﬁnitions used in oncology trials.\n• Deﬁne standards for CV toxicity monitoring in oncology trials to\navoid unexpected CV toxicities when new drugs are approved for\nclinical use.\n• Relevant model systems to allow high-throughput screening of\nnew cancer treatments for CV toxicity.\n• Improved knowledge on CV toxicity mechanisms of new targeted\ncancer therapies and ICI and optimal treatment of CV toxicities.\n• Improved knowledge on the effects of radiation to speciﬁc cardiac\nsubstructures and the interactions between cardiotoxic systemic\ntherapy and RT.\n• Further research into the underlying mechanisms that connect\nCVD and cancer, such as a genetic predisposition to CV toxicity.\n• Personalized medicine and use of big data and artiﬁcial intelligence\ntools.\nCardiovascular toxicity risk stratiﬁcation\n• Development of CV toxicity risk prediction tools including both\ntreatment- and patient-related risk factors.\n• Validated prospective CV toxicity risk scores based on clinical\noutcomes.\n• Further research on the role of genetics in CV toxicity risk\nstratiﬁcation.\n• Validation of CPET parameters for CV outcomes in patients with\ncancer.\nPrevention, diagnosis, and management of CTR-CVT\n• Raise awareness of the beneﬁts of minimizing CV risk in patients\nwith cancer in order to reduce the risk of CTR-CVT.\n• More data on new technologies (biomarkers, advanced echocardi-\nography, CMR, etc.) and genetic proﬁles for the detection of early\nCV toxicity.\n• Prospective studies showing the impact on outcomes and/or qual-\nity of life (and frailty) of early CTR-CVT diagnosis and treatment.\n• Further evidence from prospective RCTs to deﬁne when cardio-\nprotective medications improve patients’ outcomes.\n• Further research on the potential for aerobic exercise to reduce\nCTR-CVT.\n• RCTs of (new) CV therapies in patients with different types of\nCTR-CVT.\nLong-term cancer survivorship programmes\n• Development of optimal CV follow-up programmes after treat-\nment for cancer (research on risk stratiﬁcation, efﬁcacy, and fre-\nquency of screening protocols).\n• Best screening strategies for RT-induced CAD.\n• Further research on CV preventive strategies for long-term CS.\n15. ‘What to do’ and ‘what not to do’ messages from the Guidelines\nRecommendations\nClassa\nLevelb\nRecommendation Table 1 for a general approach to cardiovascular toxicity risk categorization\nCV toxicity risk stratiﬁcation before starting potentially cardiotoxic anticancer therapy is recommended in all patients with\ncancer.\nI\nB\nCommunicating the results of the CV toxicity risk assessment to the patient and other appropriate healthcare professionals is\nrecommended.\nI\nC\nIt is recommended that patients categorized as low CV toxicity risk should proceed with anticancer therapy without\ndelay.\nI\nC\nCardiology referral is recommended in high-risk and very high-risk patients before anticancer therapy.\nI\nC\nDiscussion of the risk/beneﬁt balance of cardiotoxic anticancer treatment in high- and very high-risk patients in a multidisciplinary\napproach prior to starting treatment is recommended.\nI\nC\nCardiology referral is recommended for patients with cancer and pre-existing CVD or abnormal ﬁndings at baseline CV toxicity risk\nassessment who require potentially cardiotoxic anticancer therapy.\nI\nC\nContinued\nESC Guidelines\n4333\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nRecommendation Table 2 for electrocardiogram baseline assessment\nAn ECG is recommended in all patients starting cancer therapy as part of their baseline CV risk assessment.\nI\nC\nIn patients with an abnormal baseline ECG, referral to a cardiologist is recommended.\nI\nC\nRecommendation Table 3 for cardiac biomarker assessment prior to potentially cardiotoxic therapies\nBaseline measurement of NP and/or cTn is recommended in all patients with cancer at risk of CTRCD if these biomarkers are going to\nbe measured during treatment to detect CTRCD.\nI\nC\nRecommendation Table 4 for cardiac imaging modalities in patients with cancer\nGeneral\nEchocardiography is recommended as the ﬁrst-line modality for the assessment of cardiac function in patients with cancer.\nI\nC\n3D echocardiography is recommended as the preferred echocardiographic modality to measure LVEF.\nI\nB\nGLS is recommended in all patients with cancer having echocardiography, if available.\nI\nC\nBaseline cardiac imaging prior to potentially cardiotoxic therapies\nBaseline comprehensive TTE is recommended in all patients with cancer at high risk and very high risk of CV toxicity before starting\nanticancer therapy.\nI\nC\nRecommendation Table 5 for primary prevention of cancer therapy-related cardiovascular toxicity\nManagement of CVRF according to the 2021 ESC Guidelines on CVD prevention in clinical practice is recommended before, during, and\nafter cancer therapy.\nI\nC\nRecommendation Table 6 for secondary prevention of cancer therapy-related cardiovascular toxicity\nManagement of CVD according to applicable ESC Guidelines is recommended before, during, and after cancer therapy.\nI\nC\nRecommendation Table 7 for baseline risk assessment and monitoring during anthracycline chemotherapy and in the ﬁrst 12 months\nafter therapy\nTTE\nBaseline echocardiography is recommended in all patients with cancer before anthracycline chemotherapy.\nI\nB\nIn all adults receiving anthracycline chemotherapy, an echocardiogram is recommended within 12 months after completing treatment.\nI\nB\nIn high- and very high-risk patients, echocardiography is recommended every two cycles and within 3 months after completing\ntreatment.\nI\nC\nCardiac serum biomarkers\nBaseline measurement of NP and cTn is recommended in high- and very high-risk patients prior to anthracycline chemotherapy.\nI\nB\ncTn and NP monitoring before every cycle during anthracycline chemotherapy and 3 and 12 months after therapy completion is\nrecommended in high- and very high-risk patients.\nI\nB\nRecommendation Table 8 for baseline risk assessment and monitoring during HER2-targeted therapies and in the ﬁrst 12 months\nafter therapy\nTTE\nBaseline echocardiography is recommended before HER2-targeted therapies in all patients.\nI\nB\nIn patients receiving neoadjuvant or adjuvant HER2-targeted therapies, echocardiography is recommended every 3 months and within\n12 months after completing treatment.\nI\nB\nIn metastatic HER2+ disease, echocardiography is recommended every 3 months during the ﬁrst year; if the patient remains\nasymptomatic without CV toxicity, then surveillance can be reduced to every 6 months during future treatment.\nI\nC\nCardiac biomarkers\nBaseline NP and cTn measurement are recommended in high- and very high-risk patients prior to anti-HER2-targeted therapies.\nI\nC\nContinued\n4334\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nRecommendation Table 9 for baseline risk assessment and monitoring during ﬂuoropyrimidine therapy\nBaseline CV risk assessment and evaluation including BP measurement, ECG, lipid proﬁle, HbA1c measurement, and SCORE2/SCORE2-\nOP or equivalent is recommended before starting ﬂuoropyrimidines.\nI\nC\nA baseline echocardiogram is recommended in patients with a history of symptomatic CVD before starting ﬂuoropyrimidines.\nI\nC\nRecommendation Table 10 for baseline risk assessment and monitoring during VEGFi\nBP monitoring\nBP measurement is recommended for patients treated with VEGFi, bevacizumab, or ramucirumab at every clinical visit.\nI\nC\nDaily home monitoring of BP for patients treated with VEGFi during the ﬁrst cycle, after each increase of VEGFi dose, and every 2–3\nweeks thereafter is recommended.\nI\nC\nECG monitoring\nIn patients treated with VEGFi at moderate or high risk of QTc prolongation, QTc monitoring is recommended monthly during the ﬁrst\n3 months and every 3–6 months thereafter.\nI\nC\nEchocardiography\nBaseline echocardiography is recommended in high- and very high-risk patients treated with VEGFi or bevacizumab.\nI\nC\nRecommendation Table 11 for baseline risk assessment and monitoring during second- and third-generation BCR-ABL tyrosine\nkinase inhibitors\nBaseline CV risk assessment is recommended in patients who require second- or third-generation BCR-ABL TKI.\nI\nC\nIn patients treated with nilotinib or ponatinib, CV risk assessment is recommended every 3 months during the ﬁrst year and every 6–12\nmonths thereafter.\nI\nC\nBaseline echocardiography is recommended in patients scheduled to receive dasatinib.\nI\nC\nRecommendation Table 12 for baseline risk assessment and monitoring Bruton tyrosine kinase inhibitor therapy\nBP monitoring and management\nBP measurement is recommended for patients treated with BTK inhibitors at every clinical visit.\nI\nB\nEchocardiography\nBaseline echocardiography is recommended in high-risk patients scheduled to receive BTK inhibitors.\nI\nC\nTTE is recommended in all patients who develop AF during BTK inhibitor therapy.\nI\nC\nAF\nOpportunistic screening for AF by pulse-taking or ECG rhythm strip is recommended at every clinical visit during BTK inhibitor therapy.\nI\nC\nRecommendation Table 13 for baseline risk assessment and monitoring during multiple myeloma therapies\nBP monitoring\nBP measurement is recommended for patients treated with PI at every clinical visit.\nI\nC\nCardiac serum biomarkers\nMeasurement of NP is recommended prior to PI in high- and very high-risk patients.\nI\nC\nNP and cTn measurements are recommended at baseline and every 3–6 months in patients with AL-CA.\nI\nB\nTTE\nBaseline echocardiography, including assessment for AL-CA, is recommended in all patients with MM scheduled to receive PI.\nI\nC\nContinued\nESC Guidelines\n4335\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nVTE prophylaxis\nTherapeutic doses of LMWH are recommended in patients with MM with previous VTE.\nI\nB\nProphylactic doses of LMWH are recommended in patients with MM with VTE-related risk factors (excluding previous VTE) at least\nduring the ﬁrst 6 months of therapy.\nI\nA\nRecommendation Table 14 for baseline risk assessment and monitoring during combined RAF and MEK inhibitor therapy\nBP monitoring at each clinical visit and weekly outpatient monitoring during the ﬁrst 3 months of treatment and monthly thereafter is\nrecommended.\nI\nC\nIn patients treated with cobimetinib/vemurafenib, an ECG is recommended at 2 and 4 weeks after initiation of treatment and every 3\nmonths thereafter.\nI\nC\nBaseline echocardiography is recommended in all high- and very high-risk patients scheduled to receive combined RAF and MEK\ninhibitors.\nI\nC\nRecommendation Table 15 for baseline risk assessment and monitoring during immunotherapy\nECG, NP, and cTn measurements are recommended in all patients before starting ICI therapy.\nI\nB\nBaseline echocardiography is recommended in high-risk patients before starting ICI therapy.\nI\nB\nCV assessment is recommended every 6–12 months in high-risk patients who require long-term (.12 months) ICI treatment.\nI\nC\nRecommendation Table 16 for baseline risk assessment and monitoring during androgen deprivation therapy for prostate cancer\nBaseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended in\npatients treated with ADT without pre-existing CVD.\nI\nB\nBaseline and serial ECGs are recommended in patients at risk of QTc prolongation during ADT therapy.\nI\nB\nAnnual CV risk assessment is recommended during ADT.\nI\nB\nRecommendation Table 17 for baseline risk assessment and monitoring during endocrine therapy for breast cancer\nBaseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended in\nBC patients receiving endocrine therapies without pre-existing CVD.\nI\nC\nAnnual CV risk assessment is recommended during endocrine therapy in BC patients with high 10-year risk of (fatal and non-fatal) CV\nevents according to SCORE2/SCORE2-OP.\nI\nC\nRecommendation Table 18 for baseline risk assessment and monitoring during cyclin-dependent kinase 4/6 inhibitor therapy\nQTc monitoring is recommended at baseline and 14 and 28 days in all patients with cancer receiving ribociclib.\nI\nA\nQTc monitoring is recommended in patients treated with ribociclib with any dose increase.\nI\nB\nRecommendation Table 19 for baseline risk assessment and monitoring during ALK and EGFR inhibitors\nBaseline CV risk assessment is recommended in patients before ALK inhibitors and EGFR inhibitors.\nI\nC\nBaseline echocardiography is recommended in all patients with cancer before starting osimertinib.\nI\nB\nRecommendation Table 20 for baseline risk assessment and monitoring in patients receiving chimeric antigen receptor T cell\nand tumour-inﬁltrating lymphocytes therapies\nBaseline ECG, NP, and cTn are recommended in all patients with cancer before starting CAR-T and TIL therapies.\nI\nC\nA baseline echocardiography is recommended in patients with pre-existing CVD before starting CAR-T and TIL therapies.\nI\nC\nMeasurement of NP, cTn, and echocardiography are recommended in patients who develop CRS of ASTCT ≥2.\nI\nC\nContinued\n4336\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nRecommendation Table 21 for baseline risk assessment of patients before radiotherapy to a volume including the heart\nBaseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended.\nI\nB\nRecommendation Table 22 for baseline risk assessment in haematopoietic stem cell transplantation patients\nBaseline and serial CV risk assessment (3 and 12 months, then yearly) including BP measurement, ECG, lipid measurement, and HbA1c is\nrecommended in HSCT patients.\nI\nC\nEchocardiography is recommended in all patients before HSCT.\nI\nC\nRecommendation Table 23 for the management of cardiovascular disease and cancer therapy-related cardiovascular toxicity in\npatients receiving anticancer treatment\nA specialist CV assessment is recommended for optimal diagnostic workup and management of patients with cancer who present with\nnew CV toxicity during and after cancer treatment.\nI\nC\nRecommendation Table 24 for the management of cancer treatment-related cardiac dysfunction during anthracycline\nchemotherapy\nAnthracycline chemotherapy-induced symptomatic CTRCD\nHF therapy is recommended for patients who develop symptomatic CTRCD during anthracycline chemotherapy.\nI\nB\nDiscontinuation of anthracycline chemotherapy is recommended in patients who develop symptomatic severe CTRCD.\nI\nC\nTemporary interruption of anthracycline chemotherapy is recommended in patients who develop symptomatic moderate CTRCD and\na multidisciplinary approach regarding the decision to restart is recommended.\nI\nC\nA multidisciplinary approach regarding interruption vs. continuation of anthracycline chemotherapy is recommended in patients who\ndevelop mild symptomatic CTRCD.\nI\nC\nAnthracycline chemotherapy-induced asymptomatic CTRCD\nTemporary interruption of anthracycline chemotherapy and initiation of HF therapy is recommended in patients who develop\nasymptomatic moderate or severe CTRCD.\nI\nC\nA multidisciplinary approach regarding the decision when to restart is recommended in all patients with moderate or severe\nasymptomatic CTRCD.\nI\nC\nContinuation of anthracycline chemotherapy is recommended in asymptomatic patients who have LVEF ≥50% and who have\ndeveloped a signiﬁcant fall in GLS or a troponin or a NP elevation .ULN.\nI\nC\nRecommendation Table 25 for the management of cancer treatment-related cardiac dysfunction during HER2-targeted therapies\nHER2-targeted therapy-induced symptomatic CTRCD\nHF therapy is recommended for patients who develop symptomatic moderate-to-severe CTRCD with LVEF , 50% during HER2-\ntargeted treatment.\nI\nB\nTemporary interruption of HER2-targeted treatment is recommended in patients who develop moderate or severe symptomatic CTRCD\nand the decision to restart should be based on a multidisciplinary approach after improvement of LV function and symptoms resolved.\nI\nC\nIn patients who develop mild symptomatic CTRCD, HF therapy and a multidisciplinary approach regarding the decision to continue vs.\ninterrupt HER2-targeted therapy are recommended.\nI\nC\nHER2-targeted therapy-induced asymptomatic CTRCD\nTemporary interruption of HER2-targeted therapy and initiation of HF therapy is recommended in patients who develop asymptomatic\nsevere CTRCD.\nI\nC\nA multidisciplinary approach regarding the decision to restart HER2-targeted treatment is recommended in patients with severe\nasymptomatic CTRCD.\nI\nC\nContinuation of HER2-targeted therapy is recommended in patients who develop asymptomatic mild (LVEF ≥50%) CTRCDc with\nmore frequent cardiac monitoring.\nI\nC\nACE-I/ARB and beta-blockers are recommended in patients who develop asymptomatic moderate (LVEF 40–49%) CTRCDc during\nHER2-targeted treatment.\nI\nC\nRecommendation Table 26 for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis\ncTn, ECG, and CV imaging (echocardiography and CMR) are recommended to diagnose ICI-associated myocarditis.\nI\nB\nIn patients with suspected ICI-associated myocarditis, temporary interruption of ICI treatment is recommended until the diagnosis is\nconﬁrmed or refuted.\nI\nC\nContinued\nESC Guidelines\n4337\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nInterruption of ICI treatment is recommended in patients with conﬁrmed ICI-associated myocarditis.\nI\nC\nContinuous ECG monitoring to assess for new AV block and tachyarrhythmias during the acute phase is recommended for all patients\nwith symptomatic ICI-associated myocarditis.\nI\nC\nEarly high-dose corticosteroids are recommended in patients with cancer and conﬁrmed ICI-associated myocarditis.\nI\nC\nContinuation of high-dose corticosteroids is recommended for the treatment of ICI-associated myocarditis until resolution of\nsymptoms, LV systolic dysfunction, conduction abnormalities, and signiﬁcant cTn reduction.\nI\nC\nAdmission to ICU (level 3), treatment with i.v. methylprednisolone, and optimal CV treatment including mechanical support (when\nindicated) is recommended for patients with ICI-associated fulminant myocarditis.\nI\nC\nA multidisciplinary discussion is recommended before restarting ICI treatment in selected patients with previous uncomplicated ICI-\nassociated myocarditis.\nI\nC\nRecommendation Table 27 for the diagnosis and management of Takotsubo syndrome in patients with cancer\nCoronary angiography (invasive or CCTA) is recommended to exclude ACS.\nI\nC\nCMR is recommended to exclude myocarditis and MI.\nI\nB\nQT-prolonging drugs are not recommended during the acute TTS phase.\nIII\nC\nRecommendation Table 28 for the management of acute coronary syndromes in patients receiving anticancer treatment\nAn invasive strategy is recommended in patients with cancer presenting with STEMI or high-risk NSTE-ACS with life expectancy ≥6\nmonths.\nI\nB\nA temporary interruption of cancer therapy is recommended in patients where the cancer therapy is suspected as a contributing cause.\nI\nC\nIn patients with cancer, thrombocytopaenia and ACS, aspirin is not recommended if platelets ,10 000/µL.\nIII\nC\nIn patients with cancer, thrombocytopaenia and ACS, clopidogrel is not recommended if platelets ,30 000/µL and prasugrel or\nticagrelor are not recommended if platelets ,50 000/µL.\nIII\nC\nRecommendation Table 29 for the management of chronic coronary syndromes in patients receiving anticancer treatment\nIndividualized duration of DAPT is recommended in patients with cancer with CCS, following revascularization, based upon thrombotic/\nischaemic and bleeding risk, type and stage of cancer, and current cancer treatment.\nI\nC\nRecommendation Table 30 for the management of valvular heart disease in patients receiving anticancer treatment\nIn patients with cancer and pre-existing severe VHD, management according to the 2021 ESC/EACTS Guidelines for the management\nof VHD is recommended, taking into consideration cancer prognosis and patient preferences.\nI\nC\nIn patients with cancer developing new VHD during cancer therapy, management according to the 2021 ESC/EACTS Guidelines for the\nmanagement of VHD is recommended, taking into consideration cancer prognosis and patient comorbidities.\nI\nC\nRecommendation Table 31 for the management of atrial ﬁbrillation in patients receiving anticancer treatment\nLong-term anticoagulation is recommended for stroke/systemic thromboembolism prevention in patients with cancer with AF and a\nCHA2DS2-VASc score ≥2 (men) or ≥3 (women) as per the 2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation.\nI\nC\nThromboembolic and bleeding risk reassessment is recommended during follow-up in patients with cancer with AF.\nI\nC\nAntiplatelet therapy or prophylactic LMWH are not recommended for stroke or systemic thromboembolism prevention in AF with\ncancer.\nIII\nC\nRecommendation Table 32 for the management of long QTc and ventricular arrhythmias in patients receiving anticancer treatment\nHow to manage QTc prolongation in patients with cancer\nDiscontinuation of QTc-prolonging cancer therapy is recommended in patients who develop TdP or sustained ventricular\ntachyarrhythmias during treatment.\nI\nC\nTemporary interruption of QTc-prolonging cancer therapy is recommended in patients who develop asymptomatic QTcF ≥500 ms\nand an ECG should be repeated every 24 h until resolution of the QTcF prolongation.\nI\nC\nImmediate withdrawal of any offending drug and correction of electrolyte abnormalities and other risk factors is recommended in\npatients with cancer who develop QTcF ≥500 ms.\nI\nC\nWeekly ECG monitoring is recommended in asymptomatic patients with cancer with QTcF 480–500 ms who are treated with a QTc-\nprolonging cancer therapy.\nI\nC\nContinued\n4338\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nA 12-lead ECG is recommended after any dose increase of QTc-prolonging cancer therapy.\nI\nC\nRestarting QTc-prolonging cancer therapy\nA multidisciplinary discussion is recommended before restarting QTc-prolonging drugs in patients who have developed signiﬁcant QTcF\nprolongation, to discuss alternative cancer treatments.\nI\nC\nWeekly ECG monitoring during the ﬁrst 4–6 weeks and then monthly thereafter is recommended in patients with cancer after\nrestarting QTc-prolonging cancer therapy.\nI\nC\nRecommendation Table 33 for the management of arterial hypertension in patients receiving anticancer treatment\nGeneral\nEffective treatment of cancer therapy-induced arterial hypertension to prevent cancer treatment interruption and CV complications is\nrecommended.\nI\nC\nA BP target ,140 mmHg systolic and ,90 mmHg diastolic is recommended during cancer therapy.\nI\nC\nThe competing cancer and CV risk evaluation is recommended if the systolic BP is ≥180 mmHg or diastolic BP ≥110 mmHg, and any\ncancer therapy associated with hypertension should be deferred or temporarily withheld until the BP is controlled to values\n,160 mmHg (systolic) and ,100 mmHg (diastolic).\nI\nC\nCancer therapy-induced arterial hypertension treatment\nACE-I or ARB are the ﬁrst-line antihypertensive drugs recommended for BP management in patients with cancer.\nI\nB\nDihydropyridine CCB are recommended as second-line antihypertensive drugs for patients with cancer with uncontrolled BP.\nI\nC\nCombination therapy with ACE-I or ARB and dihydropyridine CCB is recommended in patients with cancer with systolic\nBP ≥160 mmHg and diastolic BP ≥100 mmHg.\nI\nC\nDiltiazem and verapamil are not recommended to treat arterial hypertension in patients with cancer due to their drug–drug\ninteractions.\nIII\nC\nRecommendation Table 34 for the management of venous thromboembolism in patients receiving anticancer treatment\nApixaban, edoxaban, or rivaroxaban are recommended for the treatment of symptomatic or incidental VTE in patients with cancer\nwithout contraindications.\nI\nA\nLMWH are recommended for the treatment of symptomatic or incidental VTE in patients with cancer with platelet count .50 000/µL.\nI\nA\nCatheter-associated VTE\nDuration of anticoagulation in patients with cancer with a catheter-associated VTE is recommended for a minimum of 3 months and\ncontinuing longer if the catheter remains in situ.\nI\nC\nRecommendation Table 35 for venous thromboembolism prophylaxis during anticancer treatment\nExtended prophylaxis with LMWH for 4 weeks post-operatively is recommended for patients with cancer undergoing major open or\nlaparoscopic abdominal or pelvic surgery with low bleeding risk and high VTE risk.\nI\nB\nProphylactic LMWH for the primary prevention of VTE is indicated in hospitalized patients with cancer or those with prolonged bed\nrest or reduced mobility in the absence of bleeding or other contraindications.\nI\nB\nA discussion with the patient about the relative beneﬁts and harms, cancer prognosis, drug cost, and duration of treatment is\nrecommended prior to prophylactic anticoagulation for the primary prevention of VTE.\nI\nC\nRecommendation Table 36 for management of peripheral artery disease during anticancer treatment\nIn patients who develop new symptomatic PAD, a multidisciplinary approach regarding the decision to continue vs. interrupt\nculprit cancer therapy is recommended.\nI\nC\nRecommendation Table 37 for the management of pulmonary hypertension during anticancer treatment\nRight-heart catheterization and discontinuation of dasatinib is recommended in patients who develop symptomatic or asymptomatic\nincrease in peak TRV . 3.4 m/s.\nI\nC\nIn patients with conﬁrmed dasatinib-induced PAH or new asymptomatic peak TRV . 3.4 m/s, an alternative BCR-ABL inhibitor is\nrecommended after peak TRV recovery to ,2.8 m/s.\nI\nC\nRecommendation Table 38 for the management of pericardial diseases in patients receiving anticancer treatment\nGeneral\nDiagnosis and management of acute pericarditis in patients with cancer based on the 2015 ESC Guidelines for the diagnosis and\nmanagement of pericardial diseases is recommended and a multidisciplinary discussion is needed before interrupting cancer therapy.\nI\nC\nContinued\nESC Guidelines\n4339\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nDiagnosis and management of ICI-associated pericarditis\nMultimodality CV imaging (echocardiography, CMR + CT), ECG and measurement of cardiac biomarkers are recommended to\nconﬁrm the diagnosis, assess the haemodynamic consequences of pericardial disease, and rule out associated myocarditis.\nI\nC\nPrednisolone and colchicine are recommended for patients with ICI-associated pericarditis.\nI\nC\nInterruption of ICI treatment in patients with conﬁrmed ICI-associated pericarditis with moderate-to-severe pericardial effusion is\nrecommended.\nI\nC\nA multidisciplinary discussion is recommended before restarting ICI treatment.\nI\nC\nRecommendation Table 39 for end-of-cancer therapy cardiovascular risk assessment\nEducating and supporting patients with cancer to make appropriate healthy lifestyle choices is recommended.\nI\nC\nEducation is recommended for patients with cancer regarding recognition for early signs and symptoms of CVD.\nI\nC\nCVRF assessment is recommended during the ﬁrst year after cancer therapy and thereafter according to the 2021 ESC Guidelines on\nCVD prevention in clinical practice.\nI\nB\nIn asymptomatic high-risk patients, echocardiography and cardiac serum biomarkers are recommended at 3 and 12 months after\ncompletion of cancer therapy.\nI\nB\nCardiology referral is recommended in patients with cancer with new cardiac symptoms or new asymptomatic abnormalities in\nechocardiography and/or cardiac serum biomarkers at the end of therapy assessment.\nI\nC\nLong-term continuation of cardiac medication is recommended in patients who develop severe CTRCD during cancer therapy.\nI\nC\nCV follow-up and treatment optimization is recommended in patients who developed TKI-mediated hypertension during cancer\ntherapy.\nI\nC\nCV follow-up and treatment optimization is recommended in patients who developed vascular toxicities during cancer therapy.\nI\nC\nECG follow-up is recommended in patients who developed QT lengthening or LQTS during cancer therapy.\nI\nC\nRecommendation Table 40 for cardiovascular surveillance in asymptomatic adults who are childhood and adolescent cancer\nsurvivors\nEducation of adults who are childhood and adolescent CS treated with anthracyclines, mitoxantrone, and/or RT to a volume including\nthe heart and their healthcare providers regarding their increased CV risk is recommended.\nI\nB\nAnnual screening for modiﬁable CVRF is recommended in adults who are childhood and adolescent CS treated with anthracyclines,\nmitoxantrone, and/or RT to a volume including the heart.\nI\nC\nCV assessment is recommended in female childhood and adolescent CS prior to pregnancy or in the ﬁrst trimester.\nI\nC\nRecommendation Table 41 for cardiovascular surveillance in asymptomatic adult cancer survivors\nAnnual CV risk assessment, including ECG and NP, and CVRF management is recommended in CS who were treated with a potentially\ncardiotoxic cancer drug or RT.\nI\nB\nCV toxicity risk restratiﬁcation is recommended 5 years after therapy to organize long-term follow-up.\nI\nC\nRecommendation Table 42 for adult cancer survivors who develop cancer therapy-related cardiac dysfunction late after cardiotoxic\ncancer therapy\nACE-I/ARB and/or beta-blockers are recommended in adult CS with moderate asymptomatic CTRCD.\nI\nC\nRecommendation Table 43 for adult cancer survivors with coronary artery disease\nAsymptomatic radiation-induced CAD detected during surveillance\nNon-invasive stress testing is recommended in asymptomatic CS with new moderate or severe radiation-induced CAD detected on\nCCTA to guide ischaemia-directed management.\nI\nC\nA MDT discussion is recommended for clinical decision-making in patients with radiation-induced CAD and inducible ischaemia or\nsevere left main CAD.\nI\nC\nContinued\n4340\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nSymptomatic CAD\nPre-operative assessment of LIMA and RIMA viability, venous access, and sternal wound healing is recommended in CS with radiation-\ninduced CAD where CABG is considered.\nI\nC\nRecommendation Table 44 for adult cancer survivors with valvular heart disease\nA MDT approach is recommended to discuss and deﬁne the surgical risk in CS with severe VHD.\nI\nC\nRecommendation Table 46 for cardiovascular monitoring in cancer survivors during pregnancy\nIn high-risk female CS, pre-pregnancy counselling and management during pregnancy and around delivery by a multidisciplinary\npregnancy heart team is recommended.\nI\nC\nA baseline CV evaluation including history, physical examination, ECG, NP, and echocardiography is recommended in female CS with a\nhistory of CTRCD who are considering pregnancy.\nI\nC\nA CV evaluation including echocardiography is recommended at 12 weeks of pregnancy in female CS who are either high-risk or who\nreceived potentially cardiotoxic cancer therapy and did not have a baseline CV assessment.\nI\nC\nRecommendation Table 47 for cardiovascular assessment and monitoring of pregnant women with cancer\nManagement by an expert MDT (the pregnancy heart team) in an expert centre is recommended for pregnant women with cancer who\nrequire cardiotoxic cancer therapy.\nI\nC\nCardiac assessment prior to cardiotoxic cancer therapy in pregnant women is recommended and consists of clinical history, physical\nexamination, ECG, and echocardiography.\nI\nC\nRecommendation Table 48 for carcinoid valvular heart diseases\nEchocardiography is recommended for the detection of carcinoid cardiac involvement in all patients with carcinoid syndrome and\nelevated NP levels and/or clinical signs of carcinoid heart disease, and for surveillance every 3 or 6 months depending on the severity of\ncardiac involvement and clinical status.\nI\nB\nA MDT discussion for optimal medial management to prevent carcinoid crisis is recommended before any invasive or surgical cardiac\nprocedure.\nI\nC\nValve replacement surgery is recommended in symptomatic patients with severe carcinoid tricuspid or pulmonary VHD and an\nexpected survival ≥12 months.\nI\nC\nValve replacement or repair surgery is recommended in symptomatic patients with severe carcinoid mitral or aortic VHD and an\nexpected survival ≥12 months.\nI\nC\nRecommendation Table 49 for amyloid light-chain cardiac amyloidosis diagnosis and monitoring\nEchocardiography, NP, and cTn are recommended for the diagnosis of AL-CA in patients with plasma cell dyscrasia.\nI\nB\nCMR is recommended in patients with suspected AL-CA.\nI\nA\nRecommendation Table 50 for risk stratiﬁcation and monitoring for patients with cardiac implantable electronic devices undergoing\nradiotherapy\nRisk stratiﬁcation including planned radiation type and energy, dose to CIED, the patient’s device type, and pacing dependence is\nrecommended prior to starting treatment.\nI\nC\nIn patients undergoing RT, a CIED check is recommended in all patients before and after completing RT, and during RT according to\nindividual risk.\nI\nC\nIn patients with a CIED undergoing RT at high risk of arrhythmia and/or device dysfunction, ECG monitoring and/or pulse oximetry are\nrecommended during every RT session.\nI\nC\n© ESC 2022\n3D, three-dimensional; ACE-I, angiotensin-converting enzyme inhibitors; ACS, acute coronary syndromes; ADT, androgen deprivation therapy; AF, atrial ﬁbrillation; AL-CA, amyloid light-chain\ncardiac amyloidosis; ALK, anaplastic lymphoma kinase;ARB, angiotensin receptorblocker; ASTCT, AmericanSociety for Transplantation and Cellular;AV, atrioventricular; BC, breast cancer; BCR-\nABL, breakpoint cluster region–Abelson oncogene locus; BP, blood pressure; BTK, Bruton tyrosine kinase; CABG, coronary artery bypass graft; CAD, coronary artery disease; CAR-T, chimeric\nantigen receptor T cell; CCB, calcium channel blockers; CCS, chronic coronary syndromes; CCTA, coronary computed tomography angiography; CHA2DS2-VASc, Congestive heart failure,\nHypertension, Age .75 years (2 points), Diabetes mellitus, Stroke (2 points)—Vascular disease, Age 65–74 years, Sex category (female); CIED, cardiac implantable electronic device; CMR,\ncardiac magnetic resonance; CRS, cytokine release syndrome; CT, computed tomography; cTn, cardiac troponin; CTRCD, cancer therapy-related cardiac dysfunction; CS, cancer survivors;\nCV, cardiovascular; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; DAPT, dual antiplatelet therapy; EACTS, European Association for Cardio-Thoracic Surgery; ECG,\nelectrocardiogram; EGFR, epidermal growth factor receptor; ESC, European Society of Cardiology; GLS, global longitudinal strain; HbA1c, glycated haemoglobin; HER2, human epidermal\nreceptor 2; HF, heart failure; HSCT, haematopoietic stem cell transplantation; ICI, immune checkpoint inhibitors; ICU, intensive care unit; i.v., intravenous; LIMA, left internal mammary\nartery; LMWH, low-molecular-weight heparins; LQTS, long QT syndrome; LV, left ventricular; LVEF, left ventricular ejection fraction; MDT, multidisciplinary team; MEK, mitogen-activated\nextracellular signal-regulated kinase; MI, myocardial infarction; MM, multiple myeloma; NP, natriuretic peptides; NSTE-ACS, non-ST-segment elevation acute coronary syndromes; PAD,\nperipheral artery disease; PAH, pulmonary arterial hypertension; PI, proteasome inhibitors; QTc, corrected QT interval; QTcF, corrected QT interval using Fridericia correction; RAF, rapidly\naccelerated ﬁbrosarcoma; RIMA, right internal mammary artery; RT, radiotherapy; SCORE2, Systematic Coronary Risk Estimation 2; SCORE2-OP, Systematic Coronary Risk Estimation 2—\nOlder Persons; STEMI, ST-segment elevation myocardial infarction; TdP, torsade de pointes; TIL, tumour-inﬁltrating lymphocytes; TKI, tyrosine kinase inhibitors; TTE, transthoracic\nechocardiography; TTS, Takotsubo syndrome; TRV, tricuspid regurgitation velocity; ULN, upper limit of normal; VEGFi, vascular endothelial growth factor inhibitors; VHD, valvular heart\ndisease; VTE, venous thromboembolism.\naClass of recommendation.\nbLevel of evidence.\nESC Guidelines\n4341\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n16. Quality indicators for\ncardio-oncology\nQuality indicators (QIs) are tools that may be used to evaluate care\nquality, including structural, process, and outcomes of care.835 They\nmay also serve as a mechanism for enhancing adherence to guideline\nrecommendations, through associated quality improvement initia-\ntives and the benchmarking of care providers.836,837 As such, the\nrole of QIs in improving care and outcomes for CVD is increasingly\nrecognized by healthcare authorities, professional organizations,\npayers, and the public.835\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of CV care and has established methods for the de-\nvelopment of the ESC QIs for the quantiﬁcation of care and\noutcomes for CVD.835 These methods were used to develop QIs\npertinent to cardio-oncology in parallel with the writing of this\nClinical Practice Guideline document and through the collaboration\nwith patient representatives and domain experts. The QIs, alongside\ntheir measurement speciﬁcations and development process will be\npublished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online.\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Liam S. Couch,\nKing’s College London BHF Centre, the Rayne Institute, St\nThomas’\nHospital,\nKing’s\nCollege\nLondon,\nLondon,\nUnited\nKingdom;\nRiccardo\nAsteggiano,\nCardiology,\nLARC\n(Laboratorio Analisi Ricerca Clinica), Turin, Italy, and School of\nMedicine, Insubria University, Varese, Italy; Marianne C. Aznar,\nDivision of Cancer Sciences, Faculty of Biology, Medicine and\nHealth, University of Manchester, Manchester, United Kingdom;\nJutta\nBergler-Klein,\nDepartment\nof\nCardiology,\nMedical\nUniversity\nof\nVienna,\nVienna,\nAustria;\nGiuseppe\nBoriani,\nCardiology Division, Department of Biomedical, Metabolic and\nNeural\nSciences,\nUniversity\nof\nModena\nand\nReggio\nEmilia,\nPoliclinico\ndi\nModena,\nModena,\nItaly;\nDaniela\nCardinale,\nCardioncology Unit, European Institute of Oncology—I.R.C.C.S.,\nMilan,\nItaly;\nRaul\nCordoba,\nDepartment\nof\nHematology,\nFundacion Jimenez Diaz University Hospital, Madrid, Spain, and\nCancer Research Group, Health Research Institute IIS-FJD, Madrid,\nSpain; Bernard Cosyns, Cardiology, Centrum voor Hart en\nVaatziekten\n(CHVZ),\nUniversitair\nZiekenhuis\nBrussel\n(UZB),\nBrussels, Belgium, and In Vivo Molecular and Cellular (ICMI)\nCenter,\nVrij\nUniversiteit\nBrussel,\nBrussels,\nBelgium;\nDavid\nJ. Cutter, Nufﬁeld Department of Population Health, University\nof Oxford, Oxford, United Kingdom, and Oxford Cancer Centre,\nOxford University Hospitals NHS Foundation Trust, Oxford,\nUnited Kingdom; Evandro de Azambuja, Medical Oncology\nDepartment, Institut Jules Bordet, Brussels, Belgium; Rudolf\nA. de Boer, Cardiology, University Medical Center Groningen,\nGroningen,\nNetherlands;\nSusan\nF.\nDent,\nDepartment\nof\nMedicine, Duke Cancer Institute, Durham, NC, United States of\nAmerica; Dimitrios Farmakis, Medical School, University of\nCyprus, Nicosia, Cyprus; Soﬁe A. Gevaert, Cardiology, Ghent\nUniversity Hospital, Ghent, Belgium; Diana A. Gorog, Postgraduate\nMedicine, University of Hertfordshire, Hatﬁeld, United Kingdom, and\nNational Heart and Lung Institute, Imperial College, London, United\nKingdom,\nand\nCardiology\nDepartment,\nEast\nand\nNorth\nHertfordshire NHS Trust, Stevenage, United Kingdom; Joerg\nHerrmann, Department of Cardiovascular Diseases, Mayo Clinic,\nRochester, MN, United States of America; Daniel Lenihan,\nCardio-Oncology, International Cardio-Oncology Society, Tampa, FL,\nUnited States of America, and Cardiology, Saint Francis Healthcare,\nCape Girardeau, MO, United States of America; Javid Moslehi,\nSection\nof\nCardio-Oncology\n&\nImmunology,\nCardiovascular\nResearch Institute, University of California, San Francisco (UCSF),\nSan Francisco, CA, United States of America; Brenda Moura,\nCardiology Department, Armed Forces Hospital, Porto, Portugal,\nand Faculty of Medicine, University of Porto, Porto, Portugal; Sonja\nS. Salinger, Clinic for Cardiovascular Disease, University Clinical\nCenter, Nis, Serbia, and Medical Faculty, University of Nis, Nis,\nSerbia; Richard Stephens (United Kingdom), ESC Patient Forum,\nSophia Antipolis, France; Thomas M. Suter, Department of\nCardiology, Inselspital, Bern University Hospital, University of Bern,\nBern, Switzerland; Sebastian Szmit, Department of Pulmonary\nCirculation, Thromboembolic Diseases and Cardiology, Centre of\nPostgraduate Medical Education, Otwock, Poland, and Institute of\nHematology\nand\nTransfusion\nMedicine,\nTransfusion\nMedicine,\nWarsaw, Poland; Juan Tamargo, Pharmacology and Toxicology,\nUniversidad\nComplutense,\nMadrid,\nSpain;\nPaaladinesh\nThavendiranathan,\nDepartment\nof\nMedicine,\nDivision\nof\nCardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter\nMunk Cardiac Center, Toronto General Hospital, University Health\nNetwork,\nUniversity\nof\nToronto,\nToronto,\nCanada;\nCarlo\nG. Tocchetti, Cardio-Oncology Unit, Department of Translational\nMedical Sciences, Federico II University, Naples, Italy, and Center for\nBasic\nand\nClinical\nImmunology\nResearch\n(CISI),\nFederico\nII\nUniversity, Naples, Italy, and Interdepartmental Center for Clinical\nand Translational Research (CIRCET), Federico II University, Naples,\nItaly; Peter van der Meer, Cardiology, University Medical Center\nGroningen, Groningen, Netherlands; Helena J.H. van der Pal,\nPrincess Máxima Center for Pediatric Oncology, Princess Máxima\nCenter for Pediatric Oncology, Utrecht, Netherlands.\n20. Appendix\nESC Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nDocument\nReviewers:\nPatrizio\nLancellotti\n(CPG\nReview\nCoordinator) (Belgium), Franck Thuny (CPG Review Coordinator)\n(France), Magdy Abdelhamid (Egypt), Victor Aboyans (France),\nBerthe Aleman (Netherlands), Joachim Alexandre (France), Ana\nBarac (United States of America), Michael A. Borger (Germany),\n4342\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "keywords": [
        "hypertension",
        "heart failure",
        "systolic dysfunction",
        "vte",
        "guideline",
        "what",
        "blood pressure",
        "age",
        "recommended",
        "risk estimation",
        "genetic",
        "echocardiography",
        "angiography",
        "coronary artery",
        "sex",
        "hba1c",
        "cvd risk",
        "diabetes",
        "calcium channel",
        "secondary prevention",
        "primary prevention",
        "antihypertensive",
        "arrhythmia",
        "anticoagulation",
        "tricuspid",
        "female",
        "diastolic",
        "lvef",
        "pulmonary hypertension",
        "catheterization"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 4335",
          "page_number": 106,
          "content": " | Recommendation Table 9 for baseline risk assessment and monitoring during fluoropyrimidine therapy |  |  | \nBaseline CV risk assessment and evaluation including BP measurement, ECG, lipid profile, HbA1c measurement, and SCORE2/SCORE2-\nOP or equivalent is recommended before starting fluoropyrimidines. |  | I | C | \nA baseline echocardiogram is recommended in patients with a history of symptomatic CVD before starting fluoropyrimidines. |  | I | C | \n | Recommendation Table 10 for baseline risk assessment and monitoring during VEGFi |  |  | \n | BP monitoring |  |  | \nBP measurement is recommended for patients treated with VEGFi, bevacizumab, or ramucirumab at every clinical visit. |  | I | C | \nDaily home monitoring of BP for patients treated with VEGFi during the first cycle, after each increase of VEGFi dose, and every 2–3\nweeks thereafter is recommended. |  | I | C | \n | ECG monitoring |  |  | \nIn patients treated with VEGFi at moderate or high risk of QTc prolongation, QTc monitoring is recommended monthly during the first\n3 months and every 3–6 months thereafter. |  | I | C | \n | Echocardiography |  |  | \nBaseline echocardiography is recommended in high- and very high-risk patients treated with VEGFi or bevacizumab. |  | I | C | \n | Recommendation Table 11 for baseline risk assessment and monitoring during second- and third-generation BCR-ABL tyrosine\nkinase inhibitors |  |  | \nBaseline CV risk assessment is recommended in patients who require second- or third-generation BCR-ABL TKI. |  | I | C | \nIn patients treated with nilotinib or ponatinib, CV risk assessment is recommended every 3 months during the first year and every 6–12\nmonths thereafter. |  | I | C | \nBaseline echocardiography is recommended in patients scheduled to receive dasatinib. |  | I | C | \n | Recommendation Table 12 for baseline risk assessment and monitoring Bruton tyrosine kinase inhibitor therapy |  |  | \n | BP monitoring and management |  |  | \nBP measurement is recommended for patients treated with BTK inhibitors at every clinical visit. |  | I | B | \n | Echocardiography |  |  | \nBaseline echocardiography is recommended in high-risk patients scheduled to receive BTK inhibitors. |  | I | C | \nTTE is recommended in all patients who develop AF during BTK inhibitor therapy. |  | I | C | \n | AF |  |  | \nOpportunistic screening for AF by pulse-taking or ECG rhythm strip is recommended at every clinical visit during BTK inhibitor therapy. |  | I | C | \n | Recommendation Table 13 for baseline risk assessment and monitoring during multiple myeloma therapies |  |  | \n | BP monitoring |  |  | \nBP measurement is recommended for patients treated with PI at every clinical visit. |  | I | C | \n | Cardiac serum biomarkers |  |  | \nMeasurement of NP is recommended prior to PI in high- and very high-risk patients. |  | I | C | \nNP and cTn measurements are recommended at baseline and every 3–6 months in patients with AL-CA. |  | I | B | \n | TTE |  |  | \nBaseline echocardiography, including assessment for AL-CA, is recommended in all patients with MM scheduled to receive PI. |  | I | C | ",
          "bbox": [
            48.0,
            59.5,
            552.2800633630087,
            720.2181905110677
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "4336 ESC Guidelines",
          "page_number": 107,
          "content": " | VTE prophylaxis |  |  | \nTherapeutic doses of LMWH are recommended in patients with MM with previous VTE. |  | I | B | \nProphylactic doses of LMWH are recommended in patients with MM with VTE-related risk factors (excluding previous VTE) at least\nduring the first 6 months of therapy. |  | I | A | \n | Recommendation Table 14 for baseline risk assessment and monitoring during combined RAF and MEK inhibitor therapy |  |  | \nBP monitoring at each clinical visit and weekly outpatient monitoring during the first 3 months of treatment and monthly thereafter is\nrecommended. |  | I | C | \nIn patients treated with cobimetinib/vemurafenib, an ECG is recommended at 2 and 4 weeks after initiation of treatment and every 3\nmonths thereafter. |  | I | C | \nBaseline echocardiography is recommended in all high- and very high-risk patients scheduled to receive combined RAF and MEK\ninhibitors. |  | I | C | \n | Recommendation Table 15 for baseline risk assessment and monitoring during immunotherapy |  |  | \nECG, NP, and cTn measurements are recommended in all patients before starting ICI therapy. |  | I | B | \nBaseline echocardiography is recommended in high-risk patients before starting ICI therapy. |  | I | B | \nCV assessment is recommended every 6–12 months in high-risk patients who require long-term (.12 months) ICI treatment. |  | I | C | \n | Recommendation Table 16 for baseline risk assessment and monitoring during androgen deprivation therapy for prostate cancer |  |  | \nBaseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended in\npatients treated with ADT without pre-existing CVD. |  | I | B | \nBaseline and serial ECGs are recommended in patients at risk of QTc prolongation during ADT therapy. |  | I | B | \nAnnual CV risk assessment is recommended during ADT. |  | I | B | \n | Recommendation Table 17 for baseline risk assessment and monitoring during endocrine therapy for breast cancer |  |  | \nBaseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended in\nBC patients receiving endocrine therapies without pre-existing CVD. |  | I | C | \nAnnual CV risk assessment is recommended during endocrine therapy in BC patients with high 10-year risk of (fatal and non-fatal) CV\nevents according to SCORE2/SCORE2-OP. |  | I | C | \n | Recommendation Table 18 for baseline risk assessment and monitoring during cyclin-dependent kinase 4/6 inhibitor therapy |  |  | \nQTc monitoring is recommended at baseline and 14 and 28 days in all patients with cancer receiving ribociclib. |  | I | A | \nQTc monitoring is recommended in patients treated with ribociclib with any dose increase. |  | I | B | \n | Recommendation Table 19 for baseline risk assessment and monitoring during ALK and EGFR inhibitors |  |  | \nBaseline CV risk assessment is recommended in patients before ALK inhibitors and EGFR inhibitors. |  | I | C | \nBaseline echocardiography is recommended in all patients with cancer before starting osimertinib. |  | I | B | \n | Recommendation Table 20 for baseline risk assessment and monitoring in patients receiving chimeric antigen receptor T cell\nand tumour-infiltrating lymphocytes therapies |  |  | \nBaseline ECG, NP, and cTn are recommended in all patients with cancer before starting CAR-T and TIL therapies. |  | I | C | \nA baseline echocardiography is recommended in patients with pre-existing CVD before starting CAR-T and TIL therapies. |  | I | C | \nMeasurement of NP, cTn, and echocardiography are recommended in patients who develop CRS of ASTCT ≥2. |  | I | C | ",
          "bbox": [
            43.0,
            59.5,
            547.2800259976774,
            699.2192314995659
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 4337",
          "page_number": 108,
          "content": " | Recommendation Table 21 for baseline risk assessment of patients before radiotherapy to a volume including the heart |  |  | \nBaseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended. |  | I | B | \n | Recommendation Table 22 for baseline risk assessment in haematopoietic stem cell transplantation patients |  |  | \nBaseline and serial CV risk assessment (3 and 12 months, then yearly) including BP measurement, ECG, lipid measurement, and HbA1c is\nrecommended in HSCT patients. |  | I | C | \nEchocardiography is recommended in all patients before HSCT. |  | I | C | \n | Recommendation Table 23 for the management of cardiovascular disease and cancer therapy-related cardiovascular toxicity in\npatients receiving anticancer treatment |  |  | \nA specialist CV assessment is recommended for optimal diagnostic workup and management of patients with cancer who present with\nnew CV toxicity during and after cancer treatment. |  | I | C | \n | Recommendation Table 24 for the management of cancer treatment-related cardiac dysfunction during anthracycline\nchemotherapy |  |  | \n | Anthracycline chemotherapy-induced symptomatic CTRCD |  |  | \nHF therapy is recommended for patients who develop symptomatic CTRCD during anthracycline chemotherapy. |  | I | B | \nDiscontinuation of anthracycline chemotherapy is recommended in patients who develop symptomatic severe CTRCD. |  | I | C | \nTemporary interruption of anthracycline chemotherapy is recommended in patients who develop symptomatic moderate CTRCD and\na multidisciplinary approach regarding the decision to restart is recommended. |  | I | C | \nA multidisciplinary approach regarding interruption vs. continuation of anthracycline chemotherapy is recommended in patients who\ndevelop mild symptomatic CTRCD. |  | I | C | \n | Anthracycline chemotherapy-induced asymptomatic CTRCD |  |  | \nTemporary interruption of anthracycline chemotherapy and initiation of HF therapy is recommended in patients who develop\nasymptomatic moderate or severe CTRCD. |  | I | C | \nA multidisciplinary approach regarding the decision when to restart is recommended in all patients with moderate or severe\nasymptomatic CTRCD. |  | I | C | \nContinuation of anthracycline chemotherapy is recommended in asymptomatic patients who have LVEF ≥50% and who have\ndeveloped a significant fall in GLS or a troponin or a NP elevation .ULN. |  | I | C | \n | Recommendation Table 25 for the management of cancer treatment-related cardiac dysfunction during HER2-targeted therapies |  |  | \n | HER2-targeted therapy-induced symptomatic CTRCD |  |  | \nHF therapy is recommended for patients who develop symptomatic moderate-to-severe CTRCD with LVEF , 50% during HER2-\ntargeted treatment. |  | I | B | \nTemporary interruption of HER2-targeted treatment is recommended in patients who develop moderate or severe symptomatic CTRCD\nand the decision to restart should be based on a multidisciplinary approach after improvement of LV function and symptoms resolved. |  | I | C | \nIn patients who develop mild symptomatic CTRCD, HF therapy and a multidisciplinary approach regarding the decision to continue vs.\ninterrupt HER2-targeted therapy are recommended. |  | I | C | \n | HER2-targeted therapy-induced asymptomatic CTRCD |  |  | \nTemporary interruption of HER2-targeted therapy and initiation of HF therapy is recommended in patients who develop asymptomatic\nsevere CTRCD. |  | I | C | \nA multidisciplinary approach regarding the decision to restart HER2-targeted treatment is recommended in patients with severe\nasymptomatic CTRCD. |  | I | C | \nContinuation of HER2-targeted therapy is recommended in patients who develop asymptomatic mild (LVEF ≥50%) CTRCDc with\nmore frequent cardiac monitoring. |  | I | C | \nACE-I/ARB and beta-blockers are recommended in patients who develop asymptomatic moderate (LVEF 40–49%) CTRCDc during\nHER2-targeted treatment. |  | I | C | \n | Recommendation Table 26 for the diagnosis and management of immune checkpoint inhibitor-associated myocarditis |  |  | \ncTn, ECG, and CV imaging (echocardiography and CMR) are recommended to diagnose ICI-associated myocarditis. |  | I | B | \nIn patients with suspected ICI-associated myocarditis, temporary interruption of ICI treatment is recommended until the diagnosis is\nconfirmed or refuted. |  | I | C | ",
          "bbox": [
            48.0,
            59.5,
            552.2800605969551,
            743.2181939019097
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "4338 ESC Guidelines",
          "page_number": 109,
          "content": "Interruption of ICI treatment is recommended in patients with confirmed ICI-associated myocarditis. |  | I | C | \nContinuous ECG monitoring to assess for new AV block and tachyarrhythmias during the acute phase is recommended for all patients\nwith symptomatic ICI-associated myocarditis. |  | I | C | \nEarly high-dose corticosteroids are recommended in patients with cancer and confirmed ICI-associated myocarditis. |  | I | C | \nContinuation of high-dose corticosteroids is recommended for the treatment of ICI-associated myocarditis until resolution of\nsymptoms, LV systolic dysfunction, conduction abnormalities, and significant cTn reduction. |  | I | C | \nAdmission to ICU (level 3), treatment with i.v. methylprednisolone, and optimal CV treatment including mechanical support (when\nindicated) is recommended for patients with ICI-associated fulminant myocarditis. |  | I | C | \nA multidisciplinary discussion is recommended before restarting ICI treatment in selected patients with previous uncomplicated ICI-\nassociated myocarditis. |  | I | C | \n | Recommendation Table 27 for the diagnosis and management of Takotsubo syndrome in patients with cancer |  |  | \nCoronary angiography (invasive or CCTA) is recommended to exclude ACS. |  | I | C | \nCMR is recommended to exclude myocarditis and MI. |  | I | B | \nQT-prolonging drugs are not recommended during the acute TTS phase. |  | III | C | \n | Recommendation Table 28 for the management of acute coronary syndromes in patients receiving anticancer treatment |  |  | \nAn invasive strategy is recommended in patients with cancer presenting with STEMI or high-risk NSTE-ACS with life expectancy ≥6\nmonths. |  | I | B | \nA temporary interruption of cancer therapy is recommended in patients where the cancer therapy is suspected as a contributing cause. |  | I | C | \nIn patients with cancer, thrombocytopaenia and ACS, aspirin is not recommended if platelets ,10 000/µL. |  | III | C | \nIn patients with cancer, thrombocytopaenia and ACS, clopidogrel is not recommended if platelets ,30 000/µL and prasugrel or\nticagrelor are not recommended if platelets ,50 000/µL. |  | III | C | \n | Recommendation Table 29 for the management of chronic coronary syndromes in patients receiving anticancer treatment |  |  | \nIndividualized duration of DAPT is recommended in patients with cancer with CCS, following revascularization, based upon thrombotic/\nischaemic and bleeding risk, type and stage of cancer, and current cancer treatment. |  | I | C | \n | Recommendation Table 30 for the management of valvular heart disease in patients receiving anticancer treatment |  |  | \nIn patients with cancer and pre-existing severe VHD, management according to the 2021 ESC/EACTS Guidelines for the management\nof VHD is recommended, taking into consideration cancer prognosis and patient preferences. |  | I | C | \nIn patients with cancer developing new VHD during cancer therapy, management according to the 2021 ESC/EACTS Guidelines for the\nmanagement of VHD is recommended, taking into consideration cancer prognosis and patient comorbidities. |  | I | C | \n | Recommendation Table 31 for the management of atrial fibrillation in patients receiving anticancer treatment |  |  | \nLong-term anticoagulation is recommended for stroke/systemic thromboembolism prevention in patients with cancer with AF and a\nCHA DS-VASc score ≥2 (men) or ≥3 (women) as per the 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation.\n2 2 |  | I | C | \nThromboembolic and bleeding risk reassessment is recommended during follow-up in patients with cancer with AF. |  | I | C | \nAntiplatelet therapy or prophylactic LMWH are not recommended for stroke or systemic thromboembolism prevention in AF with\ncancer. |  | III | C | \n | Recommendation Table 32 for the management of long QTc and ventricular arrhythmias in patients receiving anticancer treatment |  |  | \n | How to manage QTc prolongation in patients with cancer |  |  | \nDiscontinuation of QTc-prolonging cancer therapy is recommended in patients who develop TdP or sustained ventricular\ntachyarrhythmias during treatment. |  | I | C | \nTemporary interruption of QTc-prolonging cancer therapy is recommended in patients who develop asymptomatic QTcF ≥500 ms\nand an ECG should be repeated every 24 h until resolution of the QTcF prolongation. |  | I | C | \nImmediate withdrawal of any offending drug and correction of electrolyte abnormalities and other risk factors is recommended in\npatients with cancer who develop QTcF ≥500 ms. |  | I | C | \nWeekly ECG monitoring is recommended in asymptomatic patients with cancer with QTcF 480–500 ms who are treated with a QTc-\nprolonging cancer therapy. |  | I | C | ",
          "bbox": [
            43.0,
            59.5,
            547.2800144504856,
            746.219224717882
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 4339",
          "page_number": 110,
          "content": "A 12-lead ECG is recommended after any dose increase of QTc-prolonging cancer therapy. |  | I | C | \n | Restarting QTc-prolonging cancer therapy |  |  | \nA multidisciplinary discussion is recommended before restarting QTc-prolonging drugs in patients who have developed significant QTcF\nprolongation, to discuss alternative cancer treatments. |  | I | C | \nWeekly ECG monitoring during the first 4–6 weeks and then monthly thereafter is recommended in patients with cancer after\nrestarting QTc-prolonging cancer therapy. |  | I | C | \n | Recommendation Table 33 for the management of arterial hypertension in patients receiving anticancer treatment |  |  | \n | General |  |  | \nEffective treatment of cancer therapy-induced arterial hypertension to prevent cancer treatment interruption and CV complications is\nrecommended. |  | I | C | \nA BP target ,140 mmHg systolic and ,90 mmHg diastolic is recommended during cancer therapy. |  | I | C | \nThe competing cancer and CV risk evaluation is recommended if the systolic BP is ≥180 mmHg or diastolic BP ≥110 mmHg, and any\ncancer therapy associated with hypertension should be deferred or temporarily withheld until the BP is controlled to values\n,160 mmHg (systolic) and ,100 mmHg (diastolic). |  | I | C | \n | Cancer therapy-induced arterial hypertension treatment |  |  | \nACE-I or ARB are the first-line antihypertensive drugs recommended for BP management in patients with cancer. |  | I | B | \nDihydropyridine CCB are recommended as second-line antihypertensive drugs for patients with cancer with uncontrolled BP. |  | I | C | \nCombination therapy with ACE-I or ARB and dihydropyridine CCB is recommended in patients with cancer with systolic\nBP ≥160 mmHg and diastolic BP ≥100 mmHg. |  | I | C | \nDiltiazem and verapamil are not recommended to treat arterial hypertension in patients with cancer due to their drug–drug\ninteractions. |  | III | C | \nRecommendation Table 34 for the management of venous thromboembolism in patients receiving anticancer treatment |  |  |  | \nApixaban, edoxaban, or rivaroxaban are recommended for the treatment of symptomatic or incidental VTE in patients with cancer\nwithout contraindications. |  | I | A | \nLMWH are recommended for the treatment of symptomatic or incidental VTE in patients with cancer with platelet count .50 000/µL. |  | I | A | \n | Catheter-associated VTE |  |  | \nDuration of anticoagulation in patients with cancer with a catheter-associated VTE is recommended for a minimum of 3 months and\ncontinuing longer if the catheter remains in situ. |  | I | C | \n | Recommendation Table 35 for venous thromboembolism prophylaxis during anticancer treatment |  |  | \nExtended prophylaxis with LMWH for 4 weeks post-operatively is recommended for patients with cancer undergoing major open or\nlaparoscopic abdominal or pelvic surgery with low bleeding risk and high VTE risk. |  | I | B | \nProphylactic LMWH for the primary prevention of VTE is indicated in hospitalized patients with cancer or those with prolonged bed\nrest or reduced mobility in the absence of bleeding or other contraindications. |  | I | B | \nA discussion with the patient about the relative benefits and harms, cancer prognosis, drug cost, and duration of treatment is\nrecommended prior to prophylactic anticoagulation for the primary prevention of VTE. |  | I | C | \n | Recommendation Table 36 for management of peripheral artery disease during anticancer treatment |  |  | \nIn patients who develop new symptomatic PAD, a multidisciplinary approach regarding the decision to continue vs. interrupt\nculprit cancer therapy is recommended. |  | I | C | \n | Recommendation Table 37 for the management of pulmonary hypertension during anticancer treatment |  |  | \nRight-heart catheterization and discontinuation of dasatinib is recommended in patients who develop symptomatic or asymptomatic\nincrease in peak TRV . 3.4 m/s. |  | I | C | \nIn patients with confirmed dasatinib-induced PAH or new asymptomatic peak TRV . 3.4 m/s, an alternative BCR-ABL inhibitor is\nrecommended after peak TRV recovery to ,2.8 m/s. |  | I | C | \n | Recommendation Table 38 for the management of pericardial diseases in patients receiving anticancer treatment |  |  | \n | General |  |  | \nDiagnosis and management of acute pericarditis in patients with cancer based on the 2015 ESC Guidelines for the diagnosis and\nmanagement of pericardial diseases is recommended and a multidisciplinary discussion is needed before interrupting cancer therapy. |  | I | C | ",
          "bbox": [
            48.0,
            59.5,
            552.2800650247714,
            735.2184210883247
          ],
          "function_potential": "raw"
        },
        {
          "title": "4340 ESC Guidelines",
          "page_number": 111,
          "content": " | Diagnosis and management of ICI-associated pericarditis |  |  | \nMultimodality CV imaging (echocardiography, CMR + CT), ECG and measurement of cardiac biomarkers are recommended to\nconfirm the diagnosis, assess the haemodynamic consequences of pericardial disease, and rule out associated myocarditis. |  | I | C | \nPrednisolone and colchicine are recommended for patients with ICI-associated pericarditis. |  | I | C | \nInterruption of ICI treatment in patients with confirmed ICI-associated pericarditis with moderate-to-severe pericardial effusion is\nrecommended. |  | I | C | \nA multidisciplinary discussion is recommended before restarting ICI treatment. |  | I | C | \n | Recommendation Table 39 for end-of-cancer therapy cardiovascular risk assessment |  |  | \nEducating and supporting patients with cancer to make appropriate healthy lifestyle choices is recommended. |  | I | C | \nEducation is recommended for patients with cancer regarding recognition for early signs and symptoms of CVD. |  | I | C | \nCVRF assessment is recommended during the first year after cancer therapy and thereafter according to the 2021 ESC Guidelines on\nCVD prevention in clinical practice. |  | I | B | \nIn asymptomatic high-risk patients, echocardiography and cardiac serum biomarkers are recommended at 3 and 12 months after\ncompletion of cancer therapy. |  | I | B | \nCardiology referral is recommended in patients with cancer with new cardiac symptoms or new asymptomatic abnormalities in\nechocardiography and/or cardiac serum biomarkers at the end of therapy assessment. |  | I | C | \nLong-term continuation of cardiac medication is recommended in patients who develop severe CTRCD during cancer therapy. |  | I | C | \nCV follow-up and treatment optimization is recommended in patients who developed TKI-mediated hypertension during cancer\ntherapy. |  | I | C | \nCV follow-up and treatment optimization is recommended in patients who developed vascular toxicities during cancer therapy. |  | I | C | \nECG follow-up is recommended in patients who developed QT lengthening or LQTS during cancer therapy. |  | I | C | \n | Recommendation Table 40 for cardiovascular surveillance in asymptomatic adults who are childhood and adolescent cancer\nsurvivors |  |  | \nEducation of adults who are childhood and adolescent CS treated with anthracyclines, mitoxantrone, and/or RT to a volume including\nthe heart and their healthcare providers regarding their increased CV risk is recommended. |  | I | B | \nAnnual screening for modifiable CVRF is recommended in adults who are childhood and adolescent CS treated with anthracyclines,\nmitoxantrone, and/or RT to a volume including the heart. |  | I | C | \nCV assessment is recommended in female childhood and adolescent CS prior to pregnancy or in the first trimester. |  | I | C | \n | Recommendation Table 41 for cardiovascular surveillance in asymptomatic adult cancer survivors |  |  | \nAnnual CV risk assessment, including ECG and NP, and CVRF management is recommended in CS who were treated with a potentially\ncardiotoxic cancer drug or RT. |  | I | B | \nCV toxicity risk restratification is recommended 5 years after therapy to organize long-term follow-up. |  | I | C | \n | Recommendation Table 42 for adult cancer survivors who develop cancer therapy-related cardiac dysfunction late after cardiotoxic\ncancer therapy |  |  | \nACE-I/ARB and/or beta-blockers are recommended in adult CS with moderate asymptomatic CTRCD. |  | I | C | \n | Recommendation Table 43 for adult cancer survivors with coronary artery disease |  |  | \n | Asymptomatic radiation-induced CAD detected during surveillance |  |  | \nNon-invasive stress testing is recommended in asymptomatic CS with new moderate or severe radiation-induced CAD detected on\nCCTA to guide ischaemia-directed management. |  | I | C | \nA MDT discussion is recommended for clinical decision-making in patients with radiation-induced CAD and inducible ischaemia or\nsevere left main CAD. |  | I | C | ",
          "bbox": [
            43.0,
            59.5,
            547.2800101143973,
            720.219224717882
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 4341",
          "page_number": 112,
          "content": " | Symptomatic CAD |  |  | \nPre-operative assessment of LIMA and RIMA viability, venous access, and sternal wound healing is recommended in CS with radiation-\ninduced CAD where CABG is considered. |  | I | C | \n | Recommendation Table 44 for adult cancer survivors with valvular heart disease |  |  | \nA MDT approach is recommended to discuss and define the surgical risk in CS with severe VHD. |  | I | C | \n | Recommendation Table 46 for cardiovascular monitoring in cancer survivors during pregnancy |  |  | \nIn high-risk female CS, pre-pregnancy counselling and management during pregnancy and around delivery by a multidisciplinary\npregnancy heart team is recommended. |  | I | C | \nA baseline CV evaluation including history, physical examination, ECG, NP, and echocardiography is recommended in female CS with a\nhistory of CTRCD who are considering pregnancy. |  | I | C | \nA CV evaluation including echocardiography is recommended at 12 weeks of pregnancy in female CS who are either high-risk or who\nreceived potentially cardiotoxic cancer therapy and did not have a baseline CV assessment. |  | I | C | \n | Recommendation Table 47 for cardiovascular assessment and monitoring of pregnant women with cancer |  |  | \nManagement by an expert MDT (the pregnancy heart team) in an expert centre is recommended for pregnant women with cancer who\nrequire cardiotoxic cancer therapy. |  | I | C | \nCardiac assessment prior to cardiotoxic cancer therapy in pregnant women is recommended and consists of clinical history, physical\nexamination, ECG, and echocardiography. |  | I | C | \n | Recommendation Table 48 for carcinoid valvular heart diseases |  |  | \nEchocardiography is recommended for the detection of carcinoid cardiac involvement in all patients with carcinoid syndrome and\nelevated NP levels and/or clinical signs of carcinoid heart disease, and for surveillance every 3 or 6 months depending on the severity of\ncardiac involvement and clinical status. |  | I | B | \nA MDT discussion for optimal medial management to prevent carcinoid crisis is recommended before any invasive or surgical cardiac\nprocedure. |  | I | C | \nValve replacement surgery is recommended in symptomatic patients with severe carcinoid tricuspid or pulmonary VHD and an\nexpected survival ≥12 months. |  | I | C | \nValve replacement or repair surgery is recommended in symptomatic patients with severe carcinoid mitral or aortic VHD and an\nexpected survival ≥12 months. |  | I | C | \n | Recommendation Table 49 for amyloid light-chain cardiac amyloidosis diagnosis and monitoring |  |  | \nEchocardiography, NP, and cTn are recommended for the diagnosis of AL-CA in patients with plasma cell dyscrasia. |  | I | B | \nCMR is recommended in patients with suspected AL-CA. |  | I | A | \n | Recommendation Table 50 for risk stratification and monitoring for patients with cardiac implantable electronic devices undergoing\nradiotherapy |  |  | \nRisk stratification including planned radiation type and energy, dose to CIED, the patient’s device type, and pacing dependence is\nrecommended prior to starting treatment. |  | I | C | \nIn patients undergoing RT, a CIED check is recommended in all patients before and after completing RT, and during RT according to\nindividual risk. |  | I | C | \nIn patients with a CIED undergoing RT at high risk of arrhythmia and/or device dysfunction, ECG monitoring and/or pulse oximetry are\nrecommended during every RT session. |  | I | C | ",
          "bbox": [
            48.0,
            59.5,
            552.2800607988911,
            594.4970092773438
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "16. Quality indicators for cardio-oncology",
      "start_page": 113,
      "end_page": 114,
      "content": "16. Quality indicators for\ncardio-oncology\nQuality indicators (QIs) are tools that may be used to evaluate care\nquality, including structural, process, and outcomes of care.835 They\nmay also serve as a mechanism for enhancing adherence to guideline\nrecommendations, through associated quality improvement initia-\ntives and the benchmarking of care providers.836,837 As such, the\nrole of QIs in improving care and outcomes for CVD is increasingly\nrecognized by healthcare authorities, professional organizations,\npayers, and the public.835\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of CV care and has established methods for the de-\nvelopment of the ESC QIs for the quantiﬁcation of care and\noutcomes for CVD.835 These methods were used to develop QIs\npertinent to cardio-oncology in parallel with the writing of this\nClinical Practice Guideline document and through the collaboration\nwith patient representatives and domain experts. The QIs, alongside\ntheir measurement speciﬁcations and development process will be\npublished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online.\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Liam S. Couch,\nKing’s College London BHF Centre, the Rayne Institute, St\nThomas’\nHospital,\nKing’s\nCollege\nLondon,\nLondon,\nUnited\nKingdom;\nRiccardo\nAsteggiano,\nCardiology,\nLARC\n(Laboratorio Analisi Ricerca Clinica), Turin, Italy, and School of\nMedicine, Insubria University, Varese, Italy; Marianne C. Aznar,\nDivision of Cancer Sciences, Faculty of Biology, Medicine and\nHealth, University of Manchester, Manchester, United Kingdom;\nJutta\nBergler-Klein,\nDepartment\nof\nCardiology,\nMedical\nUniversity\nof\nVienna,\nVienna,\nAustria;\nGiuseppe\nBoriani,\nCardiology Division, Department of Biomedical, Metabolic and\nNeural\nSciences,\nUniversity\nof\nModena\nand\nReggio\nEmilia,\nPoliclinico\ndi\nModena,\nModena,\nItaly;\nDaniela\nCardinale,\nCardioncology Unit, European Institute of Oncology—I.R.C.C.S.,\nMilan,\nItaly;\nRaul\nCordoba,\nDepartment\nof\nHematology,\nFundacion Jimenez Diaz University Hospital, Madrid, Spain, and\nCancer Research Group, Health Research Institute IIS-FJD, Madrid,\nSpain; Bernard Cosyns, Cardiology, Centrum voor Hart en\nVaatziekten\n(CHVZ),\nUniversitair\nZiekenhuis\nBrussel\n(UZB),\nBrussels, Belgium, and In Vivo Molecular and Cellular (ICMI)\nCenter,\nVrij\nUniversiteit\nBrussel,\nBrussels,\nBelgium;\nDavid\nJ. Cutter, Nufﬁeld Department of Population Health, University\nof Oxford, Oxford, United Kingdom, and Oxford Cancer Centre,\nOxford University Hospitals NHS Foundation Trust, Oxford,\nUnited Kingdom; Evandro de Azambuja, Medical Oncology\nDepartment, Institut Jules Bordet, Brussels, Belgium; Rudolf\nA. de Boer, Cardiology, University Medical Center Groningen,\nGroningen,\nNetherlands;\nSusan\nF.\nDent,\nDepartment\nof\nMedicine, Duke Cancer Institute, Durham, NC, United States of\nAmerica; Dimitrios Farmakis, Medical School, University of\nCyprus, Nicosia, Cyprus; Soﬁe A. Gevaert, Cardiology, Ghent\nUniversity Hospital, Ghent, Belgium; Diana A. Gorog, Postgraduate\nMedicine, University of Hertfordshire, Hatﬁeld, United Kingdom, and\nNational Heart and Lung Institute, Imperial College, London, United\nKingdom,\nand\nCardiology\nDepartment,\nEast\nand\nNorth\nHertfordshire NHS Trust, Stevenage, United Kingdom; Joerg\nHerrmann, Department of Cardiovascular Diseases, Mayo Clinic,\nRochester, MN, United States of America; Daniel Lenihan,\nCardio-Oncology, International Cardio-Oncology Society, Tampa, FL,\nUnited States of America, and Cardiology, Saint Francis Healthcare,\nCape Girardeau, MO, United States of America; Javid Moslehi,\nSection\nof\nCardio-Oncology\n&\nImmunology,\nCardiovascular\nResearch Institute, University of California, San Francisco (UCSF),\nSan Francisco, CA, United States of America; Brenda Moura,\nCardiology Department, Armed Forces Hospital, Porto, Portugal,\nand Faculty of Medicine, University of Porto, Porto, Portugal; Sonja\nS. Salinger, Clinic for Cardiovascular Disease, University Clinical\nCenter, Nis, Serbia, and Medical Faculty, University of Nis, Nis,\nSerbia; Richard Stephens (United Kingdom), ESC Patient Forum,\nSophia Antipolis, France; Thomas M. Suter, Department of\nCardiology, Inselspital, Bern University Hospital, University of Bern,\nBern, Switzerland; Sebastian Szmit, Department of Pulmonary\nCirculation, Thromboembolic Diseases and Cardiology, Centre of\nPostgraduate Medical Education, Otwock, Poland, and Institute of\nHematology\nand\nTransfusion\nMedicine,\nTransfusion\nMedicine,\nWarsaw, Poland; Juan Tamargo, Pharmacology and Toxicology,\nUniversidad\nComplutense,\nMadrid,\nSpain;\nPaaladinesh\nThavendiranathan,\nDepartment\nof\nMedicine,\nDivision\nof\nCardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter\nMunk Cardiac Center, Toronto General Hospital, University Health\nNetwork,\nUniversity\nof\nToronto,\nToronto,\nCanada;\nCarlo\nG. Tocchetti, Cardio-Oncology Unit, Department of Translational\nMedical Sciences, Federico II University, Naples, Italy, and Center for\nBasic\nand\nClinical\nImmunology\nResearch\n(CISI),\nFederico\nII\nUniversity, Naples, Italy, and Interdepartmental Center for Clinical\nand Translational Research (CIRCET), Federico II University, Naples,\nItaly; Peter van der Meer, Cardiology, University Medical Center\nGroningen, Groningen, Netherlands; Helena J.H. van der Pal,\nPrincess Máxima Center for Pediatric Oncology, Princess Máxima\nCenter for Pediatric Oncology, Utrecht, Netherlands.\n20. Appendix\nESC Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nDocument\nReviewers:\nPatrizio\nLancellotti\n(CPG\nReview\nCoordinator) (Belgium), Franck Thuny (CPG Review Coordinator)\n(France), Magdy Abdelhamid (Egypt), Victor Aboyans (France),\nBerthe Aleman (Netherlands), Joachim Alexandre (France), Ana\nBarac (United States of America), Michael A. Borger (Germany),\n4342\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "keywords": [
        "oncology",
        "guideline",
        "cardio",
        "indicators",
        "quality"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "17. Supplementary data",
      "start_page": 113,
      "end_page": 114,
      "content": "16. Quality indicators for\ncardio-oncology\nQuality indicators (QIs) are tools that may be used to evaluate care\nquality, including structural, process, and outcomes of care.835 They\nmay also serve as a mechanism for enhancing adherence to guideline\nrecommendations, through associated quality improvement initia-\ntives and the benchmarking of care providers.836,837 As such, the\nrole of QIs in improving care and outcomes for CVD is increasingly\nrecognized by healthcare authorities, professional organizations,\npayers, and the public.835\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of CV care and has established methods for the de-\nvelopment of the ESC QIs for the quantiﬁcation of care and\noutcomes for CVD.835 These methods were used to develop QIs\npertinent to cardio-oncology in parallel with the writing of this\nClinical Practice Guideline document and through the collaboration\nwith patient representatives and domain experts. The QIs, alongside\ntheir measurement speciﬁcations and development process will be\npublished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online.\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Liam S. Couch,\nKing’s College London BHF Centre, the Rayne Institute, St\nThomas’\nHospital,\nKing’s\nCollege\nLondon,\nLondon,\nUnited\nKingdom;\nRiccardo\nAsteggiano,\nCardiology,\nLARC\n(Laboratorio Analisi Ricerca Clinica), Turin, Italy, and School of\nMedicine, Insubria University, Varese, Italy; Marianne C. Aznar,\nDivision of Cancer Sciences, Faculty of Biology, Medicine and\nHealth, University of Manchester, Manchester, United Kingdom;\nJutta\nBergler-Klein,\nDepartment\nof\nCardiology,\nMedical\nUniversity\nof\nVienna,\nVienna,\nAustria;\nGiuseppe\nBoriani,\nCardiology Division, Department of Biomedical, Metabolic and\nNeural\nSciences,\nUniversity\nof\nModena\nand\nReggio\nEmilia,\nPoliclinico\ndi\nModena,\nModena,\nItaly;\nDaniela\nCardinale,\nCardioncology Unit, European Institute of Oncology—I.R.C.C.S.,\nMilan,\nItaly;\nRaul\nCordoba,\nDepartment\nof\nHematology,\nFundacion Jimenez Diaz University Hospital, Madrid, Spain, and\nCancer Research Group, Health Research Institute IIS-FJD, Madrid,\nSpain; Bernard Cosyns, Cardiology, Centrum voor Hart en\nVaatziekten\n(CHVZ),\nUniversitair\nZiekenhuis\nBrussel\n(UZB),\nBrussels, Belgium, and In Vivo Molecular and Cellular (ICMI)\nCenter,\nVrij\nUniversiteit\nBrussel,\nBrussels,\nBelgium;\nDavid\nJ. Cutter, Nufﬁeld Department of Population Health, University\nof Oxford, Oxford, United Kingdom, and Oxford Cancer Centre,\nOxford University Hospitals NHS Foundation Trust, Oxford,\nUnited Kingdom; Evandro de Azambuja, Medical Oncology\nDepartment, Institut Jules Bordet, Brussels, Belgium; Rudolf\nA. de Boer, Cardiology, University Medical Center Groningen,\nGroningen,\nNetherlands;\nSusan\nF.\nDent,\nDepartment\nof\nMedicine, Duke Cancer Institute, Durham, NC, United States of\nAmerica; Dimitrios Farmakis, Medical School, University of\nCyprus, Nicosia, Cyprus; Soﬁe A. Gevaert, Cardiology, Ghent\nUniversity Hospital, Ghent, Belgium; Diana A. Gorog, Postgraduate\nMedicine, University of Hertfordshire, Hatﬁeld, United Kingdom, and\nNational Heart and Lung Institute, Imperial College, London, United\nKingdom,\nand\nCardiology\nDepartment,\nEast\nand\nNorth\nHertfordshire NHS Trust, Stevenage, United Kingdom; Joerg\nHerrmann, Department of Cardiovascular Diseases, Mayo Clinic,\nRochester, MN, United States of America; Daniel Lenihan,\nCardio-Oncology, International Cardio-Oncology Society, Tampa, FL,\nUnited States of America, and Cardiology, Saint Francis Healthcare,\nCape Girardeau, MO, United States of America; Javid Moslehi,\nSection\nof\nCardio-Oncology\n&\nImmunology,\nCardiovascular\nResearch Institute, University of California, San Francisco (UCSF),\nSan Francisco, CA, United States of America; Brenda Moura,\nCardiology Department, Armed Forces Hospital, Porto, Portugal,\nand Faculty of Medicine, University of Porto, Porto, Portugal; Sonja\nS. Salinger, Clinic for Cardiovascular Disease, University Clinical\nCenter, Nis, Serbia, and Medical Faculty, University of Nis, Nis,\nSerbia; Richard Stephens (United Kingdom), ESC Patient Forum,\nSophia Antipolis, France; Thomas M. Suter, Department of\nCardiology, Inselspital, Bern University Hospital, University of Bern,\nBern, Switzerland; Sebastian Szmit, Department of Pulmonary\nCirculation, Thromboembolic Diseases and Cardiology, Centre of\nPostgraduate Medical Education, Otwock, Poland, and Institute of\nHematology\nand\nTransfusion\nMedicine,\nTransfusion\nMedicine,\nWarsaw, Poland; Juan Tamargo, Pharmacology and Toxicology,\nUniversidad\nComplutense,\nMadrid,\nSpain;\nPaaladinesh\nThavendiranathan,\nDepartment\nof\nMedicine,\nDivision\nof\nCardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter\nMunk Cardiac Center, Toronto General Hospital, University Health\nNetwork,\nUniversity\nof\nToronto,\nToronto,\nCanada;\nCarlo\nG. Tocchetti, Cardio-Oncology Unit, Department of Translational\nMedical Sciences, Federico II University, Naples, Italy, and Center for\nBasic\nand\nClinical\nImmunology\nResearch\n(CISI),\nFederico\nII\nUniversity, Naples, Italy, and Interdepartmental Center for Clinical\nand Translational Research (CIRCET), Federico II University, Naples,\nItaly; Peter van der Meer, Cardiology, University Medical Center\nGroningen, Groningen, Netherlands; Helena J.H. van der Pal,\nPrincess Máxima Center for Pediatric Oncology, Princess Máxima\nCenter for Pediatric Oncology, Utrecht, Netherlands.\n20. Appendix\nESC Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nDocument\nReviewers:\nPatrizio\nLancellotti\n(CPG\nReview\nCoordinator) (Belgium), Franck Thuny (CPG Review Coordinator)\n(France), Magdy Abdelhamid (Egypt), Victor Aboyans (France),\nBerthe Aleman (Netherlands), Joachim Alexandre (France), Ana\nBarac (United States of America), Michael A. Borger (Germany),\n4342\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "keywords": [
        "data",
        "supplementary",
        "guideline"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "18. Data availability statement",
      "start_page": 113,
      "end_page": 114,
      "content": "16. Quality indicators for\ncardio-oncology\nQuality indicators (QIs) are tools that may be used to evaluate care\nquality, including structural, process, and outcomes of care.835 They\nmay also serve as a mechanism for enhancing adherence to guideline\nrecommendations, through associated quality improvement initia-\ntives and the benchmarking of care providers.836,837 As such, the\nrole of QIs in improving care and outcomes for CVD is increasingly\nrecognized by healthcare authorities, professional organizations,\npayers, and the public.835\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of CV care and has established methods for the de-\nvelopment of the ESC QIs for the quantiﬁcation of care and\noutcomes for CVD.835 These methods were used to develop QIs\npertinent to cardio-oncology in parallel with the writing of this\nClinical Practice Guideline document and through the collaboration\nwith patient representatives and domain experts. The QIs, alongside\ntheir measurement speciﬁcations and development process will be\npublished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online.\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Liam S. Couch,\nKing’s College London BHF Centre, the Rayne Institute, St\nThomas’\nHospital,\nKing’s\nCollege\nLondon,\nLondon,\nUnited\nKingdom;\nRiccardo\nAsteggiano,\nCardiology,\nLARC\n(Laboratorio Analisi Ricerca Clinica), Turin, Italy, and School of\nMedicine, Insubria University, Varese, Italy; Marianne C. Aznar,\nDivision of Cancer Sciences, Faculty of Biology, Medicine and\nHealth, University of Manchester, Manchester, United Kingdom;\nJutta\nBergler-Klein,\nDepartment\nof\nCardiology,\nMedical\nUniversity\nof\nVienna,\nVienna,\nAustria;\nGiuseppe\nBoriani,\nCardiology Division, Department of Biomedical, Metabolic and\nNeural\nSciences,\nUniversity\nof\nModena\nand\nReggio\nEmilia,\nPoliclinico\ndi\nModena,\nModena,\nItaly;\nDaniela\nCardinale,\nCardioncology Unit, European Institute of Oncology—I.R.C.C.S.,\nMilan,\nItaly;\nRaul\nCordoba,\nDepartment\nof\nHematology,\nFundacion Jimenez Diaz University Hospital, Madrid, Spain, and\nCancer Research Group, Health Research Institute IIS-FJD, Madrid,\nSpain; Bernard Cosyns, Cardiology, Centrum voor Hart en\nVaatziekten\n(CHVZ),\nUniversitair\nZiekenhuis\nBrussel\n(UZB),\nBrussels, Belgium, and In Vivo Molecular and Cellular (ICMI)\nCenter,\nVrij\nUniversiteit\nBrussel,\nBrussels,\nBelgium;\nDavid\nJ. Cutter, Nufﬁeld Department of Population Health, University\nof Oxford, Oxford, United Kingdom, and Oxford Cancer Centre,\nOxford University Hospitals NHS Foundation Trust, Oxford,\nUnited Kingdom; Evandro de Azambuja, Medical Oncology\nDepartment, Institut Jules Bordet, Brussels, Belgium; Rudolf\nA. de Boer, Cardiology, University Medical Center Groningen,\nGroningen,\nNetherlands;\nSusan\nF.\nDent,\nDepartment\nof\nMedicine, Duke Cancer Institute, Durham, NC, United States of\nAmerica; Dimitrios Farmakis, Medical School, University of\nCyprus, Nicosia, Cyprus; Soﬁe A. Gevaert, Cardiology, Ghent\nUniversity Hospital, Ghent, Belgium; Diana A. Gorog, Postgraduate\nMedicine, University of Hertfordshire, Hatﬁeld, United Kingdom, and\nNational Heart and Lung Institute, Imperial College, London, United\nKingdom,\nand\nCardiology\nDepartment,\nEast\nand\nNorth\nHertfordshire NHS Trust, Stevenage, United Kingdom; Joerg\nHerrmann, Department of Cardiovascular Diseases, Mayo Clinic,\nRochester, MN, United States of America; Daniel Lenihan,\nCardio-Oncology, International Cardio-Oncology Society, Tampa, FL,\nUnited States of America, and Cardiology, Saint Francis Healthcare,\nCape Girardeau, MO, United States of America; Javid Moslehi,\nSection\nof\nCardio-Oncology\n&\nImmunology,\nCardiovascular\nResearch Institute, University of California, San Francisco (UCSF),\nSan Francisco, CA, United States of America; Brenda Moura,\nCardiology Department, Armed Forces Hospital, Porto, Portugal,\nand Faculty of Medicine, University of Porto, Porto, Portugal; Sonja\nS. Salinger, Clinic for Cardiovascular Disease, University Clinical\nCenter, Nis, Serbia, and Medical Faculty, University of Nis, Nis,\nSerbia; Richard Stephens (United Kingdom), ESC Patient Forum,\nSophia Antipolis, France; Thomas M. Suter, Department of\nCardiology, Inselspital, Bern University Hospital, University of Bern,\nBern, Switzerland; Sebastian Szmit, Department of Pulmonary\nCirculation, Thromboembolic Diseases and Cardiology, Centre of\nPostgraduate Medical Education, Otwock, Poland, and Institute of\nHematology\nand\nTransfusion\nMedicine,\nTransfusion\nMedicine,\nWarsaw, Poland; Juan Tamargo, Pharmacology and Toxicology,\nUniversidad\nComplutense,\nMadrid,\nSpain;\nPaaladinesh\nThavendiranathan,\nDepartment\nof\nMedicine,\nDivision\nof\nCardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter\nMunk Cardiac Center, Toronto General Hospital, University Health\nNetwork,\nUniversity\nof\nToronto,\nToronto,\nCanada;\nCarlo\nG. Tocchetti, Cardio-Oncology Unit, Department of Translational\nMedical Sciences, Federico II University, Naples, Italy, and Center for\nBasic\nand\nClinical\nImmunology\nResearch\n(CISI),\nFederico\nII\nUniversity, Naples, Italy, and Interdepartmental Center for Clinical\nand Translational Research (CIRCET), Federico II University, Naples,\nItaly; Peter van der Meer, Cardiology, University Medical Center\nGroningen, Groningen, Netherlands; Helena J.H. van der Pal,\nPrincess Máxima Center for Pediatric Oncology, Princess Máxima\nCenter for Pediatric Oncology, Utrecht, Netherlands.\n20. Appendix\nESC Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nDocument\nReviewers:\nPatrizio\nLancellotti\n(CPG\nReview\nCoordinator) (Belgium), Franck Thuny (CPG Review Coordinator)\n(France), Magdy Abdelhamid (Egypt), Victor Aboyans (France),\nBerthe Aleman (Netherlands), Joachim Alexandre (France), Ana\nBarac (United States of America), Michael A. Borger (Germany),\n4342\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "keywords": [
        "data",
        "statement",
        "availability",
        "guideline"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "19. Author information",
      "start_page": 113,
      "end_page": 133,
      "content": "16. Quality indicators for\ncardio-oncology\nQuality indicators (QIs) are tools that may be used to evaluate care\nquality, including structural, process, and outcomes of care.835 They\nmay also serve as a mechanism for enhancing adherence to guideline\nrecommendations, through associated quality improvement initia-\ntives and the benchmarking of care providers.836,837 As such, the\nrole of QIs in improving care and outcomes for CVD is increasingly\nrecognized by healthcare authorities, professional organizations,\npayers, and the public.835\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of CV care and has established methods for the de-\nvelopment of the ESC QIs for the quantiﬁcation of care and\noutcomes for CVD.835 These methods were used to develop QIs\npertinent to cardio-oncology in parallel with the writing of this\nClinical Practice Guideline document and through the collaboration\nwith patient representatives and domain experts. The QIs, alongside\ntheir measurement speciﬁcations and development process will be\npublished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online.\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Liam S. Couch,\nKing’s College London BHF Centre, the Rayne Institute, St\nThomas’\nHospital,\nKing’s\nCollege\nLondon,\nLondon,\nUnited\nKingdom;\nRiccardo\nAsteggiano,\nCardiology,\nLARC\n(Laboratorio Analisi Ricerca Clinica), Turin, Italy, and School of\nMedicine, Insubria University, Varese, Italy; Marianne C. Aznar,\nDivision of Cancer Sciences, Faculty of Biology, Medicine and\nHealth, University of Manchester, Manchester, United Kingdom;\nJutta\nBergler-Klein,\nDepartment\nof\nCardiology,\nMedical\nUniversity\nof\nVienna,\nVienna,\nAustria;\nGiuseppe\nBoriani,\nCardiology Division, Department of Biomedical, Metabolic and\nNeural\nSciences,\nUniversity\nof\nModena\nand\nReggio\nEmilia,\nPoliclinico\ndi\nModena,\nModena,\nItaly;\nDaniela\nCardinale,\nCardioncology Unit, European Institute of Oncology—I.R.C.C.S.,\nMilan,\nItaly;\nRaul\nCordoba,\nDepartment\nof\nHematology,\nFundacion Jimenez Diaz University Hospital, Madrid, Spain, and\nCancer Research Group, Health Research Institute IIS-FJD, Madrid,\nSpain; Bernard Cosyns, Cardiology, Centrum voor Hart en\nVaatziekten\n(CHVZ),\nUniversitair\nZiekenhuis\nBrussel\n(UZB),\nBrussels, Belgium, and In Vivo Molecular and Cellular (ICMI)\nCenter,\nVrij\nUniversiteit\nBrussel,\nBrussels,\nBelgium;\nDavid\nJ. Cutter, Nufﬁeld Department of Population Health, University\nof Oxford, Oxford, United Kingdom, and Oxford Cancer Centre,\nOxford University Hospitals NHS Foundation Trust, Oxford,\nUnited Kingdom; Evandro de Azambuja, Medical Oncology\nDepartment, Institut Jules Bordet, Brussels, Belgium; Rudolf\nA. de Boer, Cardiology, University Medical Center Groningen,\nGroningen,\nNetherlands;\nSusan\nF.\nDent,\nDepartment\nof\nMedicine, Duke Cancer Institute, Durham, NC, United States of\nAmerica; Dimitrios Farmakis, Medical School, University of\nCyprus, Nicosia, Cyprus; Soﬁe A. Gevaert, Cardiology, Ghent\nUniversity Hospital, Ghent, Belgium; Diana A. Gorog, Postgraduate\nMedicine, University of Hertfordshire, Hatﬁeld, United Kingdom, and\nNational Heart and Lung Institute, Imperial College, London, United\nKingdom,\nand\nCardiology\nDepartment,\nEast\nand\nNorth\nHertfordshire NHS Trust, Stevenage, United Kingdom; Joerg\nHerrmann, Department of Cardiovascular Diseases, Mayo Clinic,\nRochester, MN, United States of America; Daniel Lenihan,\nCardio-Oncology, International Cardio-Oncology Society, Tampa, FL,\nUnited States of America, and Cardiology, Saint Francis Healthcare,\nCape Girardeau, MO, United States of America; Javid Moslehi,\nSection\nof\nCardio-Oncology\n&\nImmunology,\nCardiovascular\nResearch Institute, University of California, San Francisco (UCSF),\nSan Francisco, CA, United States of America; Brenda Moura,\nCardiology Department, Armed Forces Hospital, Porto, Portugal,\nand Faculty of Medicine, University of Porto, Porto, Portugal; Sonja\nS. Salinger, Clinic for Cardiovascular Disease, University Clinical\nCenter, Nis, Serbia, and Medical Faculty, University of Nis, Nis,\nSerbia; Richard Stephens (United Kingdom), ESC Patient Forum,\nSophia Antipolis, France; Thomas M. Suter, Department of\nCardiology, Inselspital, Bern University Hospital, University of Bern,\nBern, Switzerland; Sebastian Szmit, Department of Pulmonary\nCirculation, Thromboembolic Diseases and Cardiology, Centre of\nPostgraduate Medical Education, Otwock, Poland, and Institute of\nHematology\nand\nTransfusion\nMedicine,\nTransfusion\nMedicine,\nWarsaw, Poland; Juan Tamargo, Pharmacology and Toxicology,\nUniversidad\nComplutense,\nMadrid,\nSpain;\nPaaladinesh\nThavendiranathan,\nDepartment\nof\nMedicine,\nDivision\nof\nCardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter\nMunk Cardiac Center, Toronto General Hospital, University Health\nNetwork,\nUniversity\nof\nToronto,\nToronto,\nCanada;\nCarlo\nG. Tocchetti, Cardio-Oncology Unit, Department of Translational\nMedical Sciences, Federico II University, Naples, Italy, and Center for\nBasic\nand\nClinical\nImmunology\nResearch\n(CISI),\nFederico\nII\nUniversity, Naples, Italy, and Interdepartmental Center for Clinical\nand Translational Research (CIRCET), Federico II University, Naples,\nItaly; Peter van der Meer, Cardiology, University Medical Center\nGroningen, Groningen, Netherlands; Helena J.H. van der Pal,\nPrincess Máxima Center for Pediatric Oncology, Princess Máxima\nCenter for Pediatric Oncology, Utrecht, Netherlands.\n20. Appendix\nESC Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nDocument\nReviewers:\nPatrizio\nLancellotti\n(CPG\nReview\nCoordinator) (Belgium), Franck Thuny (CPG Review Coordinator)\n(France), Magdy Abdelhamid (Egypt), Victor Aboyans (France),\nBerthe Aleman (Netherlands), Joachim Alexandre (France), Ana\nBarac (United States of America), Michael A. Borger (Germany),\n4342\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nRuben Casado-Arroyo (Belgium), Jennifer Cautela (France), Jolanta\nČelutkienė (Lithuania), Maja Cikes (Croatia), Alain Cohen-Solal\n(France), Kreena Dhiman (United Kingdom), Stéphane Ederhy\n(France), Thor Edvardsen (Norway), Laurent Fauchier (France),\nMichael Fradley (United States of America), Julia Grapsa (United\nKingdom), Sigrun Halvorsen (Norway), Michael Heuser (Germany),\nMarc Humbert (France), Tiny Jaarsma (Sweden), Thomas Kahan\n(Sweden), Aleksandra Konradi (Russian Federation), Konstantinos\nC. Koskinas (Switzerland), Dipak Kotecha (United Kingdom),\nBonnie Ky (United States of America), Ulf Landmesser (Germany),\nBasil S. Lewis (Israel), Ales Linhart (Czech Republic), Gregory\nY.\nH.\nLip\n(United\nKingdom),\nMaja-Lisa\nLøchen\n(Norway),\nKatarzyna Malaczynska-Rajpold (United Kingdom), Marco Metra\n(Italy),\nRichard\nMindham\n(United\nKingdom),\nMarie\nMoonen\n(Belgium), Tomas G. Neilan (United States of America), Jens\nCosedis Nielsen (Denmark), Anna-Sonia Petronio (Italy), Eva\nPrescott (Denmark), Amina Rakisheva (Kazakhstan), Joe-Elie Salem\n(France), Gianluigi Savarese (Sweden), Marta Sitges (Spain), Jurrien\nten\nBerg\n(Netherlands),\nRhian\nM.\nTouyz\n(Canada/United\nKingdom),\nAgnieszka\nTycinska\n(Poland),\nMatthias\nWilhelm\n(Switzerland), Jose Luis Zamorano (Spain)\nESC National Cardiac Societies actively involved in the review\nprocess of the 2022 ESC Guidelines on cardio-oncology: Algeria:\nAlgerian Society of Cardiology, Nadia Laredj; Armenia: Armenian\nCardiologists Association, Parounak Zelveian; Austria: Austrian\nSociety of Cardiology, Peter P. Rainer; Azerbaijan: Azerbaijan\nSociety of Cardiology, Fuad Samadov; Belarus: Belorussian\nScientiﬁc\nSociety\nof\nCardiologists,\nUladzimir\nAndrushchuk;\nBelgium: Belgian Society of Cardiology, Bernhard L. Gerber;\nBosnia and Herzegovina: Association of Cardiologists of\nBosnia and Herzegovina, Mirsad Selimović; Bulgaria: Bulgarian\nSociety of Cardiology, Elena Kinova; Croatia: Croatian Cardiac\nSociety, Jure Samardzic; Cyprus: Cyprus Society of Cardiology,\nEvagoras Economides; Czechia: Czech Society of Cardiology,\nRadek Pudil; Denmark: Danish Society of Cardiology, Kirsten\nM.\nNielsen;\nEgypt:\nEgyptian\nSociety\nof\nCardiology,\nTarek\nA. Kafafy; Estonia: Estonian Society of Cardiology, Riina Vettus;\nFinland: Finnish Cardiac Society, Suvi Tuohinen; France: French\nSociety of Cardiology, Stéphane Ederhy; Georgia: Georgian\nSociety of Cardiology, Zurab Pagava; Germany: German Cardiac\nSociety, Tienush Rassaf; Greece: Hellenic Society of Cardiology,\nAlexandros Briasoulis; Hungary: Hungarian Society of Cardiology,\nDániel Czuriga; Iceland: Icelandic Society of Cardiology, Karl\nK. Andersen; Ireland: Irish Cardiac Society, Yvonne Smyth;\nIsrael: Israel Heart Society, Zaza Iakobishvili; Italy: Italian\nFederation of Cardiology, Iris Parrini; Kazakhstan: Association of\nCardiologists\nof\nKazakhstan,\nAmina\nRakisheva;\nKosovo\n(Republic of): Kosovo Society of Cardiology, Edita Pllana Pruthi;\nKyrgyzstan: Kyrgyz Society of Cardiology, Erkin Mirrakhimov;\nLatvia: Latvian Society of Cardiology, Oskars Kalejs; Lebanon:\nLebanese Society of Cardiology, Hadi Skouri; Libya: Libyan\nCardiac Society, Hisham Benlamin; Lithuania: Lithuanian Society\nof Cardiology, Diana Žaliaduonytė; Luxembourg: Luxembourg\nSociety of Cardiology, Alessandra Iovino; Malta: Maltese Cardiac\nSociety, Alice M. Moore; Moldova (Republic of): Moldavian\nSociety of Cardiology, Daniela Bursacovschi; Morocco: Moroccan\nSociety of Cardiology, Aatif Benyass; Netherlands: Netherlands\nSociety of Cardiology, Olivier Manintveld; North Macedonia:\nNorth\nMacedonian\nSociety\nof Cardiology,\nMarijan Bosevski;\nNorway:\nNorwegian\nSociety\nof\nCardiology,\nGeeta\nGulati;\nPoland: Polish Cardiac Society, Przemysław Leszek; Portugal:\nPortuguese Society of Cardiology, Manuela Fiuza; Romania:\nRomanian Society of Cardiology, Ruxandra Jurcut; Russian\nFederation: Russian Society of Cardiology, Yury Vasyuk; San\nMarino: San Marino Society of Cardiology, Marina Foscoli;\nSerbia: Cardiology Society of Serbia, Dragan Simic; Slovakia:\nSlovak\nSociety\nof\nCardiology,\nMiroslav\nSlanina;\nSlovenia:\nSlovenian Society of Cardiology, Luka Lipar; Spain: Spanish\nSociety of Cardiology, Ana Martin-Garcia; Sweden: Swedish\nSociety of Cardiology, Laila Hübbert; Switzerland: Swiss Society\nof Cardiology, Reto Kurmann; Syrian Arab Republic: Syrian\nCardiovascular Association, Ahmad Alayed; Tunisia: Tunisian\nSociety of Cardiology and Cardio-Vascular Surgery, Leila Abid;\nTurkey: Turkish Society of Cardiology, Cafer Zorkun; Ukraine:\nUkrainian Association of Cardiology, Elena Nesukay; United\nKingdom of Great Britain and Northern Ireland: British\nCardiovascular\nSociety,\nCharlotte\nManisty,\nUzbekistan:\nAssociation of Cardiologists of Uzbekistan, Nigora Srojidinova.\nESC Clinical Practice Guidelines (CPG) Committee: Colin\nBaigent (Chairperson) (United Kingdom), Magdy Abdelhamid\n(Egypt),\nVictor\nAboyans\n(France),\nSotiris\nAntoniou\n(United\nKingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy),\nAndreas\nBaumbach\n(United\nKingdom),\nMichael\nA.\nBorger\n(Germany), Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia),\nJean-Philippe Collet (France), Volkmar Falk (Germany), Laurent\nFauchier\n(France),\nChris\nP.\nGale\n(United\nKingdom),\nSigrun\nHalvorsen\n(Norway),\nBernard\nIung\n(France),\nTiny\nJaarsma\n(Sweden), Aleksandra Konradi (Russian Federation), Konstantinos\nC. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf\nLandmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech\nRepublic), Maja-Lisa Løchen (Norway), Richard Mindham (United\nKingdom), Jens Cosedis Nielsen (Denmark), Steffen E. Petersen\n(United Kingdom), Eva Prescott (Denmark), Amina Rakisheva\n(Kazakhstan), Marta Sitges (Spain), Rhian M. Touyz (Canada/United\nKingdom).\n21. References\n1. Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Deﬁning\ncardiovascular toxicities of cancer therapies: an International Cardio-Oncology\nSociety (IC-OS) consensus statement. Eur Heart J 2022;43:280–299.\n2. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation\nand management of patients with heart disease and cancer: Cardio-oncology. Mayo\nClin Proc 2014;89:1287–1306.\n3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global\ncancer statistics 2020: GLOBOCAN estimates of incidence and mortality world-\nwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–249.\n4. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R,\nGalderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascu-\nlar toxicity developed under the auspices of the ESC Committee for Practice\nGuidelines. Eur Heart J 2016;37:2768–2801.\n5. Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van Der Meer P,\net al. Cardio-oncology services: rationale, organization, and implementation. Eur\nHeart J 2019;40:1756–1763.\n6. Michel G, Mulder RL, van der Pal HJH, Skinner R, Bárdi E, Brown MC, et al.\nEvidence-based recommendations for the organization of long-term follow-up\nESC Guidelines\n4343\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\ncare for childhood and adolescent cancer survivors: a report from the\nPanCareSurFup Guidelines Working Group. J Cancer Surviv 2019;13:759–772.\n7. Armenian SH, Hudson MM, Mulder RL, Chen MH, Constine LS, Dwyer M, et al.\nRecommendations for cardiomyopathy surveillance for survivors of childhood can-\ncer: a report from the International Late Effects of Childhood Cancer Guideline\nHarmonization Group. Lancet Oncol 2015;16:e123–e136.\n8. van Kalsbeek RJ, Mulder RLRL, Skinner R, Kremer LCMCM. The concept of cancer\nsurvivorship and models for long-term follow-up. Front Horm Res 2021;54:1–15.\n9. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and ar-\nrhythmia. Nat Rev Cardiol 2020;17:474–502.\n10. Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol 2020;17:\n503–522.\n11. Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, et al.\nCardio-oncology rehabilitation to manage cardiovascular outcomes in cancer pa-\ntients and survivors: a scientiﬁc statement from the American Heart Association.\nCirculation 2019;139:e997–e1012.\n12. Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al.\nBaseline cardiovascular risk assessment in cancer patients scheduled to receive car-\ndiotoxic cancer therapies: a position statement and new risk assessment tools from\nthe Cardio-Oncology Study Group of the Heart Failure Association of the\nEuropean Society. Eur J Heart Fail 2020;22:1945–1960.\n13. Battisti NML, Andres MS, Lee KA, Ramalingam S, Nash T, Mappouridou S, et al.\nIncidence of cardiotoxicity and validation of the Heart Failure Association–\nInternational Cardio-Oncology Society risk stratiﬁcation tool in patients treated\nwith trastuzumab for HER2-positive early breast cancer. Breast Cancer Res Treat\n2021;188:149–163.\n14. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021\nESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.\nEur Heart J 2021;42:3599–3726.\n15. Jaffe AS, Vasile VC, Milone M, Saenger AK, Olson KN, Apple FS. Diseased skeletal\nmuscle: a noncardiac source of increased circulating concentrations of cardiac\ntroponin T. J Am Coll Cardiol 2011;58:1819–1824.\n16. Schmid J, Liesinger L, Birner-Gruenberger R, Stojakovic T, Scharnagl H, Dieplinger\nB, et al. Elevated cardiac troponin T in patients with skeletal myopathies. J Am Coll\nCardiol 2018;71:1540–1549.\n17. Delombaerde D, Vervloet D, Franssen C, Croes L, Gremonprez F, Prenen H, et al.\nClinical implications of isolated troponinemia following immune checkpoint inhibi-\ntor therapy. ESMO Open 2021;6:100216.\n18. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U,\net al. Cardiovascular magnetic resonance in nonischemic myocardial inﬂammation:\nexpert recommendations. J Am Coll Cardiol 2018;72:3158–3176.\n19. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021\nESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J\n2021;42:3227–3337.\n20. Vandenberk B, Vandael E, Robyns T, Vandenberghe J, Garweg C, Foulon V, et al.\nWhich QT correction formulae to use for QT monitoring? J Am Heart Assoc\n2016;5:e003264.\n21. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al.\nPrevention and monitoring of cardiac dysfunction in survivors of adult cancers:\nAmerican Society of Clinical Oncology clinical practice guideline. J Clin Oncol\n2017;35:893–911.\n22. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management\nof cardiac disease in cancer patients throughout oncological treatment: ESMO con-\nsensus recommendations. Ann Oncol 2020;31:171–190.\n23. Rossello X, Dorresteijn JAN, Janssen A, Lambrinou E, Scherrenberg M,\nBonnefoy-Cudraz E, et al. Risk prediction tools in cardiovascular disease preven-\ntion: a report from the ESC Prevention of CVD Programme led by the\nEuropean Association of Preventive Cardiology (EAPC) in collaboration with the\nAcute Cardiovascular Care Association (ACCA) and the Association of\nCardiovascular Nursing and Allied Professions (ACNAP). Eur J Cardiovasc Nurs\n2019;18:534–544.\n24. Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE, Ewer MS, et al. Seven-year\nfollow-up assessment of cardiac function in NSABP B-31, a randomized trial com-\nparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP\nplus trastuzumab as adjuvant therapy for patients with node-positive, human epi-\ndermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30:\n3792–3799.\n25. Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and car-\ndiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart\nAssoc 2014;3:e000472.\n26. Rushton M, Johnson C, Dent S. Trastuzumab-induced cardiotoxicity: testing a clin-\nical risk score in a real-world cardio-oncology population. Curr Oncol 2017;24:\n176–180.\n27. Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D, et al. The de-\nvelopment of a predictive model to estimate cardiotoxic risk for patients with\nmetastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat 2008;\n107:443–450.\n28. Abdel-Qadir H, Thavendiranathan P, Austin PC, Lee DS, Amir E, Tu J V, et al.\nDevelopment and validation of a multivariable prediction model for major adverse\ncardiovascular events after early stage breast cancer: a population-based cohort\nstudy. Eur Heart J 2019;40:3913–3920.\n29. Kang Y, Assuncao BL, Denduluri S, McCurdy S, Luger S, Lefebvre B, et al.\nSymptomatic heart failure in acute leukemia patients treated with anthracyclines.\nJACC CardioOncology 2019;1:208–217.\n30. Martín García A, Mitroi C, Mazón Ramos P, García Sanz R, Virizuela JA, Arenas M,\net al. Stratiﬁcation and management of cardiovascular risk in cancer patients. A con-\nsensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC,\nand AECC. Rev Española Cardiol (English Ed) 2021;74:438–448.\n31. Caro-Codón J, López-Fernández T, Álvarez-Ortega C, Zamora Auñón P,\nRodríguez IR, Gómez Prieto P, et al. Cardiovascular risk factors during cancer treat-\nment. Prevalence and prognostic relevance: insights from the CARDIOTOX regis-\ntry. Eur J Prev Cardiol 2022;29(6):859–868.\n32. Feijen EAM, Leisenring WM, Stratton KL, Ness KK, Van Der Pal HJH, Van Dalen EC,\net al. Derivation of anthracycline and anthraquinone equivalence ratios to doxo-\nrubicin for late-onset cardiotoxicity. JAMA Oncol 2019;5:864–871.\n33. Pareek N, Cevallos J, Moliner P, Shah M, Tan LL, Chambers V, et al. Activity and\noutcomes of a cardio-oncology service in the United Kingdom—a ﬁve-year experi-\nence. Eur J Heart Fail 2018;20:1721–1731.\n34. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular\ndisease and cancer. Circulation 2016;133:1104–1114.\n35. Caocci G, Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, et al. Arterial occlu-\nsive events in chronic myeloid leukemia patients treated with ponatinib in the real-\nlife practice are predicted by the Systematic Coronary Risk Evaluation (SCORE)\nchart. Hematol Oncol 2019;37:296–302.\n36. Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, et al. Clonal hematopoiesis:\ncrossroads of aging, cardiovascular disease, and cancer: JACC review topic of the\nweek. J Am Coll Cardiol 2019;74:567–577.\n37. Garcia-Pavia P, Kim Y, Restrepo-Cordoba MA, Lunde IG, Wakimoto H, Smith AM,\net al. Genetic variants associated with cancer therapy-induced cardiomyopathy.\nCirculation 2019;140:31–41.\n38. Bhatia S. Genetics of anthracycline cardiomyopathy in cancer survivors. JACC\nCardioOncology 2020;2:539–552.\n39. Katzke VA, Kaaks R, Kühn T. Lifestyle and cancer risk. Cancer J 2015;21:104–110.\n40. Shariﬁ-Rad J, Rodrigues CF, Sharopov F, Docea AO, Karaca AC, Shariﬁ-Rad M, et al.\nDiet, lifestyle and cardiovascular diseases: linking pathophysiology to cardioprotec-\ntive effects of natural bioactive compounds. Int J Environ Res Public Health 2020;17:\n2326.\n41. Turner MC, Andersen ZJ, Baccarelli A, Diver WR, Gapstur SM, Pope CA, et al.\nOutdoor air pollution and cancer: an overview of the current evidence and public\nhealth recommendations. CA Cancer J Clin 2020;70 :460–479.\n42. Lind PM, Lind L. Are persistent organic pollutants linked to lipid abnormalities, ath-\nerosclerosis and cardiovascular disease? A review. J Lipid Atheroscler 2020;9:\n334–348.\n43. Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, et al. The\ncancer patient and cardiology. Eur J Heart Fail 2020;22:2290–2309.\n44. Fradley MG, Moslehi J. QT prolongation and oncology drug development. Card\nElectrophysiol Clin 2015;7:341–355.\n45. Porta-Sánchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, et al.\nIncidence, diagnosis, and management of QT prolongation induced by cancer ther-\napies: a systematic review. J Am Heart Assoc 2017;6:e007724.\n46. Curigliano G, Spitaleri G, Fingert HJ, de Braud F, Sessa C, Loh E, et al. Drug-induced\nQTc interval prolongation: a proposal towards an efﬁcient and safe anticancer drug\ndevelopment. Eur J Cancer 2008;44:494–500.\n47. Viganego F, Singh R, Fradley MG. Arrhythmias and other electrophysiology issues in\ncancer patients receiving chemotherapy or radiation. Curr Cardiol Rep 2016;18:52.\n48. Curigliano G, Spitaleri G, De Braud F, Cardinale D, Cipolla C, Civelli M, et al. QTc\nprolongation assessment in anticancer drug development: clinical and methodo-\nlogical issues. Ecancermedicalscience 2009;3:130.\n49. Salem J-E, Nguyen LS, Moslehi JJ, Ederhy S, Lebrun-Vignes B, Roden DM, et al.\nAnticancer drug-induced life-threatening ventricular arrhythmias: a World Health\nOrganization pharmacovigilance study. Eur Heart J 2021;42:3915–3928.\n50. Lentz R, Feinglass J, Ma S, Akhter N. Risk factors for the development of atrial ﬁb-\nrillation on ibrutinib treatment. Leuk Lymphoma 2019;60:1447–1453.\n51. Mato AR, Clasen S, Pickens P, Gashonia L, Rhodes J, Svoboda J, et al. Left atrial ab-\nnormality (LAA) as a predictor of ibrutinib-associated atrial ﬁbrillation in patients\nwith chronic lymphocytic leukemia. Cancer Biol Ther 2018;19:1–2.\n52. Singla A, Hogan WJ, Ansell SM, Buadi FK, Dingli D, Dispenzieri A, et al. Incidence of\nsupraventricular arrhythmias during autologous peripheral blood stem cell trans-\nplantation. Biol Blood Marrow Transplant 2013;19:1233–1237.\n4344\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n53. Pudil R, Mueller C, Čelutkienė J, Henriksen PA, Lenihan D, Dent S, et al. Role of\nserum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a pos-\nition statement from the Cardio-Oncology Study Group of the Heart Failure\nAssociation and the Cardio-Oncology Council of the European Society of\nCardiology. Eur J Heart Fail 2020;22:1966–1983.\n54. Čelutkienė J, Pudil R, López-Fernández T, Grapsa J, Nihoyannopoulos P,\nBergler-Klein J, et al. Role of cardiovascular imaging in cancer patients receiving car-\ndiotoxic therapies: a position statement on behalf of the Heart Failure Association\n(HFA), the European Association of Cardiovascular Imaging (EACVI) and the\nCardio-Oncology Council of the European Society of Cardiology (ESC). Eur J\nHeart Fail 2020;22:1504–1524.\n55. Michel L, Mincu RI, Mahabadi AA, Settelmeier S, Al-Rashid F, Rassaf T, et al.\nTroponins and brain natriuretic peptides for the prediction of cardiotoxicity in can-\ncer patients: a meta-analysis. Eur J Heart Fail 2020;22:350–361.\n56. Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, et al. Changes in\ncardiac biomarkers during doxorubicin treatment of pediatric patients with high-\nrisk acute lymphoblastic leukemia: associations with long-term echocardiographic\noutcomes. J Clin Oncol 2012;30:1042–1049.\n57. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, et al. The effect\nof dexrazoxane on myocardial injury in doxorubicin-treated children with acute\nlymphoblastic leukemia. N Engl J Med 2004;351:145–153.\n58. Xue K, Gu JJ, Zhang Q, Liu X, Wang J, Li XQ, et al. Cardiotoxicity as indicated by\nLVEF and troponin T sensitivity following two anthracycline-based regimens in\nlymphoma: results from a randomized prospective clinical trial. Oncotarget 2016;\n7:32519–32531.\n59. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al.\nPrognostic value of troponin I in cardiac risk stratiﬁcation of cancer patients under-\ngoing high-dose chemotherapy. Circulation 2004;109:2749–2754.\n60. Putt M, Hahn VS, Januzzi JL, Sawaya H, Sebag IA, Plana JC, et al. Longitudinal changes\nin multiple biomarkers are associated with cardiotoxicity in breast cancer patients\ntreated with doxorubicin, taxanes, and trastuzumab. Clin Chem 2015;61:\n1164–1172.\n61. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al.\nTrastuzumab-induced cardiotoxicity: clinical and prognostic implications of tropo-\nnin I evaluation. J Clin Oncol 2010;28:3910–3916.\n62. Zardavas D, Suter TM, Van Veldhuisen DJ, Steinseifer J, Noe J, Lauer S, et al. Role of\ntroponins I and T and N-terminal prohormone of brain natriuretic peptide in mon-\nitoring cardiac safety of patients with early-stage human epidermal growth factor\nreceptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study\ncardiac marker substudy. J Clin Oncol 2017;35:878–884.\n63. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, et al.\nHeart Failure Association of the European Society of Cardiology practical guidance\non the use of natriuretic peptide concentrations. Eur J Heart Fail 2019;21:715–731.\n64. Feola M, Garrone O, Occelli M, Francini A, Biggi A, Visconti G, et al. Cardiotoxicity\nafter anthracycline chemotherapy in breast carcinoma: effects on left ventricular\nejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 2011;148:\n194–198.\n65. Demissei BG, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C, et al.\nChanges in cardiovascular biomarkers with breast cancer therapy and associations\nwith cardiac dysfunction. J Am Heart Assoc 2020;9:e014708.\n66. Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, et al. Prospective study of\ncardiac events during proteasome inhibitor therapy for relapsed multiple myeloma.\nJ Clin Oncol 2019;37:1946–1955.\n67. Pavo N, Raderer M, Hülsmann M, Neuhold S, Adlbrecht C, Strunk G, et al.\nCardiovascular biomarkers in patients with cancer and their association with all-\ncause mortality. Heart 2015;101:1874–1880.\n68. López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR,\nFarmakis D, et al. Classiﬁcation, prevalence, and outcomes of anticancer\ntherapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J 2020;41:\n1720–1729.\n69. Ky B, Putt M, Sawaya H, French B, Januzzi JL, Sebag IA, et al. Early increases in mul-\ntiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer\ntreated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014;63:\n809–816.\n70. Gioffré S, Chiesa M, Cardinale DM, Ricci V, Vavassori C, Cipolla CM, et al.\nCirculating microRNAs as potential predictors of anthracycline-induced troponin\nelevation in breast cancer patients: diverging effects of doxorubicin and epirubicin.\nJ Clin Med 2020;9:1418.\n71. Beer LA, Kossenkov AV, Liu Q, Luning Prak E, Domchek S, Speicher DW, et al.\nBaseline\nimmunoglobulin\ne\nlevels\nas\na\nmarker\nof\ndoxorubicin-\nand\ntrastuzumab-associated cardiac dysfunction. Circ Res 2016;119:1135–1144.\n72. Plana JC, Thavendiranathan P, Bucciarelli-Ducci C, Lancellotti P. Multi-modality im-\naging in the assessment of cardiovascular toxicity in the cancer patient. JACC\nCardiovasc Imaging 2018;11:1173–1186.\n73. Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G, et al.\nStandardization of adult transthoracic echocardiography reporting in agreement\nwith recent chamber quantiﬁcation, diastolic function, and heart valve disease re-\ncommendations: an expert consensus document of the European Association of\nCardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017;18:1301–1310.\n74. De Azambuja E, Procter MJ, Van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O,\nSteinseifer J, et al. Trastuzumab-associated cardiac events at 8 years of median\nfollow-up in the herceptin adjuvant trial (BIG 1-01). J Clin Oncol 2014;32:\n2159–2165.\n75. Santoro C, Arpino G, Esposito R, Lembo M, Paciolla I, Cardalesi C, et al. 2D and 3D\nstrain for detection of subclinical anthracycline cardiotoxicity in breast cancer pa-\ntients: A balance with feasibility. Eur Heart J Cardiovasc Imaging 2017;18:930–936.\n76. Zhang KW, Finkelman BS, Gulati G, Narayan HK, Upshaw J, Narayan V, et al.\nAbnormalities in 3-dimensional left ventricular mechanics with anthracycline\nchemotherapy are associated with systolic and diastolic dysfunction. JACC\nCardiovasc Imaging 2018;11:1059–1068.\n77. Lang RM, Badano LP, Mor-Avi V, Aﬁlalo J, Armstrong A, Ernande L, et al.\nRecommendations for cardiac chamber quantiﬁcation by echocardiography in\nadults: an update from the American Society of Echocardiography and the\nEuropean Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging\n2015;16:233–270.\n78. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH.\nReproducibility of echocardiographic techniques for sequential assessment of left\nventricular ejection fraction and volumes: application to patients undergoing cancer\nchemotherapy. J Am Coll Cardiol 2013;61:77–84.\n79. Dorosz JL, Lezotte DC, Weitzenkamp DA, Allen LA, Salcedo EE. Performance of\n3-dimensional echocardiography in measuring left ventricular volumes and ejection\nfraction: a systematic review and meta-analysis. J Am Coll Cardiol 2012;59:\n1799–1808.\n80. Hoffmann R, Barletta G, Von Bardeleben S, Vanoverschelde JL, Kasprzak J, Greis C,\net al. Analysis of left ventricular volumes and function: a multicenter comparison of\ncardiac magnetic resonance imaging, cine ventriculography, and unenhanced and\ncontrast-enhanced two-dimensional and three-dimensional echocardiography. J\nAm Soc Echocardiogr 2014;27:292–301.\n81. Jenkins C, Moir S, Chan J, Rakhit D, Haluska B, Marwick TH. Left ventricular volume\nmeasurement with echocardiography: a comparison of left ventricular opaciﬁca-\ntion, three-dimensional echocardiography, or both with magnetic resonance im-\naging. Eur Heart J 2009;30:98–106.\n82. Porter TR, Mulvagh SL, Abdelmoneim SS, Becher H, Belcik JT, Bierig M, et al. Clinical\napplications of ultrasonic enhancing agents in echocardiography: 2018 American\nSociety of Echocardiography Guidelines Update. J Am Soc Echocardiogr 2018;31:\n241–274.\n83. Houbois CP, Nolan M, Somerset E, Shalmon T, Esmaeilzadeh M, Lamacie MM, et al.\nSerial cardiovascular magnetic resonance strain measurements to identify cardio-\ntoxicity in breast cancer: comparison with echocardiography. JACC Cardiovasc\nImaging 2021;14:962–974.\n84. Dobbin SJH, Mangion K, Berry C, Roditi G, Basak S, Sourbron S, et al. Cardiotoxicity\nand myocardial hypoperfusion associated with anti-vascular endothelial growth fac-\ntor therapies: prospective cardiac magnetic resonance imaging in patients with can-\ncer. Eur J Heart Fail 2020;22:1276–1277.\n85. Mousavi N, Tan TC, Ali M, Halpern EF, Wang L, Scherrer-Crosbie M.\nEchocardiographic parameters of left ventricular size and function as predictors\nof symptomatic heart failure in patients with a left ventricular ejection fraction of\n50–59% treated with anthracyclines. Eur Heart J Cardiovasc Imaging 2015;16:\n977–984.\n86. Čelutkienė J, Plymen CM, Flachskampf FA, de Boer RA, Grapsa J, Manka R, et al.\nInnovative imaging methods in heart failure: a shifting paradigm in cardiac assess-\nment. Position statement on behalf of the Heart Failure Association of the\nEuropean Society of Cardiology. Eur J Heart Fail 2018;20:1615–1633.\n87. Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a\nsystematic review and meta-analysis of global longitudinal strain and ejection frac-\ntion. Heart 2014;100:1673–1680.\n88. Baron T, Berglund L, Hedin EM, Flachskampf FA. Test–retest reliability of new and\nconventional echocardiographic parameters of left ventricular systolic function. Clin\nRes Cardiol 2019;108:355–365.\n89. Lambert J, Lamacie M, Thampinathan B, Altaha MA, Esmaeilzadeh M, Nolan M, et al.\nVariability in echocardiography and MRI for detection of cancer therapy cardiotoxi-\ncity. Heart 2020;106:817–823.\n90. Thavendiranathan P, Negishi T, Coté MA, Penicka M, Massey R, Cho GY, et al.\nSingle versus standard multiview assessment of global longitudinal strain for the\ndiagnosis of cardiotoxicity during cancer therapy. JACC Cardiovasc Imaging 2018;\n11:1109–1118.\n91. Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH. Use of speckle\nstrain to assess left ventricular responses to cardiotoxic chemotherapy and cardi-\noprotection. Eur Heart J Cardiovasc Imaging 2014;15:324–331.\nESC Guidelines\n4345\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n92. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myo-\ncardial strain imaging by echocardiography for the early detection of cardiotoxicity\nin patients during and after cancer chemotherapy: a systematic review. J Am Coll\nCardiol 2014;63:2751–2768.\n93. Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D,\net al. Assessment of prognostic value of left ventricular global longitudinal strain for\nearly prediction of chemotherapy-induced cardiotoxicity: a systematic review and\nmeta-analysis. JAMA Cardiol 2019;4:1007–1018.\n94. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert\nconsensus for multimodality imaging evaluation of adult patients during and after\ncancer therapy: a report from the American Society of Echocardiography and\nthe European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc\nImaging 2014;15:1063–1093.\n95. Farsalinos KE, Daraban AM, Ünlü S, Thomas JD, Badano LP, Voigt JU. Head-to-head\ncomparison of global longitudinal strain measurements among nine different ven-\ndors: the EACVI/ASE inter-vendor comparison study. J Am Soc Echocardiogr\n2015;28:1171–1181.e2.\n96. Narayan HK, French B, Khan AM, Plappert T, Hyman D, Bajulaiye A, et al.\nNoninvasive measures of ventricular–arterial coupling and circumferential strain\npredict cancer therapeutics–related cardiac dysfunction. JACC Cardiovasc Imaging\n2016;9:1131–1141.\n97. Nagiub M, Nixon JV, Kontos MC. Ability of nonstrain diastolic parameters to pre-\ndict doxorubicin-induced cardiomyopathy: a systematic review with meta-analysis.\nCardiol Rev 2018;26:29–34.\n98. Upshaw JN, Finkelman B, Hubbard RA, Smith AM, Narayan HK, Arndt L, et al.\nComprehensive assessment of changes in left ventricular diastolic function with\ncontemporary breast cancer therapy. JACC Cardiovasc Imaging 2020;13:198–210.\n99. Phillips WJ, Johnson C, Law A, Turek M, Small AR, Dent S, et al. Comparison of\nFramingham risk score and chest-CT identiﬁed coronary artery calciﬁcation in\nbreast cancer patients to predict cardiovascular events. Int J Cardiol 2019;289:\n138–143.\n100. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al.\n2019 ESC Guidelines for the diagnosis and management of chronic coronary syn-\ndromes: The Task Force for the diagnosis and management of chronic coronary\nsyndromes of the European Society of Cardiology (ESC). Eur Heart J 2020;41:\n407–477.\n101. Lopez-Mattei JC, Yang EH, Ferencik M, Baldassarre LA, Dent S, Budoff MJ. Cardiac\ncomputed tomography in cardio-oncology: JACC: CardioOncology primer. Cardio\nOncol 2021;3:635–649.\n102. Thavendiranathan P, Negishi T, Somerset E, Negishi K, Penicka M, Lemieux J, et al.\nStrain-guided management of potentially cardiotoxic cancer therapy. J Am Coll\nCardiol 2021;77:392–401.\n103. Esmaeilzadeh M, Fresno CMU, Somerset E, Shalmon T, Amir E, Fan CPS, et al. A\ncombined echocardiography approach for the diagnosis of cancer therapy-related\ncardiac dysfunction in women with early-stage breast cancer. JAMA Cardiol 2022;7:\n330–340.\n104. Drafts BC, Twomley KM, D’Agostino R, Lawrence J, Avis N, Ellis LR, et al. Low to\nmoderate dose anthracycline-based chemotherapy is associated with early non-\ninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc\nImaging 2013;6:877–885.\n105. Giusca S, Korosoglou G, Montenbruck M, Geršak B, Schwarz AK, Esch S, et al.\nMultiparametric early detection and prediction of cardiotoxicity using myocardial\nstrain, T1 and T2 mapping, and biochemical markers: a longitudinal cardiac resonance\nimaging study during 2 years of follow-up. Circ Cardiovasc Imaging 2021;14:e012459.\n106. Dhir V, Yan AT, Nisenbaum R, Sloninko J, Connelly KA, Barfett J, et al. Assessment\nof left ventricular function by CMR versus MUGA scans in breast cancer patients\nreceiving trastuzumab: a prospective observational study. Int J Cardiovasc Imaging\n2019;35:2085–2093.\n107. Walker J, Bhullar N, Fallah-Rad N, Lytwyn M, Golian M, Fang T, et al. Role of three-\ndimensional echocardiography in breast cancer: comparison with two-dimensional\nechocardiography, multiple-gated acquisition scans, and cardiac magnetic reson-\nance imaging. J Clin Oncol 2010;28:3429–3436.\n108. Huang H, Nijjar PS, Misialek JR, Blaes A, Derrico NP, Kazmirczak F, et al. Accuracy\nof left ventricular ejection fraction by contemporary multiple gated acquisition\nscanning in patients with cancer: comparison with cardiovascular magnetic reson-\nance. J Cardiovasc Magn Reson 2017;19:34.\n109. Hoppeler H, Weibel ER. Limits for oxygen and substrate transport in mammals. J\nExp Biol 1998;201:1051–1064.\n110. Kaminsky LA, Imboden MT, Arena R, Myers J. Reference standards for cardio-\nrespiratory ﬁtness measured with cardiopulmonary exercise testing using cycle er-\ngometry: data from the Fitness Registry and the Importance of Exercise National\nDatabase (FRIEND) registry. Mayo Clin Proc 2017;92:228–233.\n111. Imboden MT, Harber MP, Whaley MH, Finch WH, Bishop DL, Kaminsky LA.\nCardiorespiratory ﬁtness and mortality in healthy men and women. J Am Coll\nCardiol 2018;72:2283–2292.\n112. Jetté M, Sidney K, Blümchen G. Metabolic equivalents (METS) in exercise testing,\nexercise prescription, and evaluation of functional capacity. Clin Cardiol 1990;13:\n555–565.\n113. Ross R, Blair SN, Arena R, Church TS, Després JP, Franklin BA, et al. Importance of\nassessing cardiorespiratory ﬁtness in clinical practice: a case for ﬁtness as a clinical\nvital sign: a scientiﬁc statement from the American Heart Association. Circulation\n2016;134:e653–e699.\n114. Schmid D, Leitzmann MF. Cardiorespiratory ﬁtness as predictor of cancer mortal-\nity: a systematic review and meta-analysis. Ann Oncol 2015;26:272–278.\n115. Gupta S, Rohatgi A, Ayers CR, Willis BL, Haskell WL, Khera A, et al.\nCardiorespiratory ﬁtness and classiﬁcation of risk of cardiovascular disease mortal-\nity. Circulation 2011;123:1377–1383.\n116. Holtermann A, Marott JL, Gyntelberg F, Søgaard K, Mortensen OS, Prescott E, et al.\nSelf-reported cardiorespiratory ﬁtness: prediction and classiﬁcation of risk of car-\ndiovascular disease mortality and longevity—a prospective investigation in the\nCopenhagen City Heart Study. J Am Heart Assoc 2015;4:e001495.\n117. Stamatakis E, Hamer M, O’Donovan G, Batty GD, Kivimaki M. A non-exercise test-\ning method for estimating cardiorespiratory ﬁtness: associations with all-cause and\ncardiovascular mortality in a pooled analysis of eight population-based cohorts. Eur\nHeart J 2013;34:750–758.\n118. Wickramasinghe CD, Ayers CR, Das S, De Lemos JA, Willis BL, Berry JD.\nPrediction of 30-year risk for cardiovascular mortality by ﬁtness and risk factor le-\nvels: the Cooper Center Longitudinal Study. Circ Cardiovasc Qual Outcomes 2014;7:\n597–602.\n119. Fardman A, Banschick GD, Rabia R, Percik R, Fourey D, Segev S, et al.\nCardiorespiratory ﬁtness and survival following cancer diagnosis. Eur J Prev\nCardiol 2021;28:1242–1249.\n120. Groarke JD, Payne DL, Claggett B, Mehra MR, Gong J, Caron J, et al. Association of\npost-diagnosis cardiorespiratory ﬁtness with cause-speciﬁc mortality in cancer. Eur\nHeart J Qual Care Clin Outcomes 2020;6:315–322.\n121. Jones LM, Stoner L, Brown C, Baldi JC, McLaren B. Cardiorespiratory ﬁtness pre-\ndicts cardiovascular health in breast cancer survivors, independent of body com-\nposition, age and time post-treatment completion. Breast Cancer 2019;26:\n729–737.\n122. Ha D, Mazzone PJ, Ries AL, Malhotra A, Fuster M. The utility of exercise testing in\npatients with lung cancer. J Thorac Oncol 2016;11:1397–1410.\n123. West MA, Lythgoe D, Barben CP, Noble L, Kemp GJ, Jack S, et al. Cardiopulmonary\nexercise variables are associated with postoperative morbidity after major colonic\nsurgery: a prospective blinded observational study. Br J Anaesth 2014;112:665–671.\n124. West MA, Parry MG, Lythgoe D, Barben CP, Kemp GJ, Grocott MPW, et al.\nCardiopulmonary exercise testing for the prediction of morbidity risk after rectal\ncancer surgery. Br J Surg 2014;101:1166–1172.\n125. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC\nguidelines on cardiovascular assessment and management of patients undergoing non-\ncardiac surgery. Eur Heart J 2022;43:3826–3924.\n126. Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, et al. A coding vari-\nant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in child-\nhood cancer. Nat Genet 2015;47:1079–1084.\n127. Blanco JG, Sun CL, Landier W, Chen L, Esparza-Duran D, Leisenring W, et al.\nAnthracycline-related cardiomyopathy after childhood cancer: role of polymorph-\nisms in carbonyl reductase genes—a report from the Children’s Oncology Group. J\nClin Oncol 2012;30:1415–1421.\n128. Wojnowski L, Kulle B, Schirmer M, Schlüter G, Schmidt A, Rosenberger A, et al.\nNAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are as-\nsociated\nwith\ndoxorubicin-induced\ncardiotoxicity.\nCirculation\n2005;112:\n3754–3762.\n129. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant\nmyocarditis with combination immune checkpoint blockade. N Engl J Med 2016;\n375:1749–1755.\n130. European Society of Cardiology. ESC CardioMed. 3rd ed. Oxford: Oxford\nUniversity Press; 2018.\n131. Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med\n2016;375:1457–1467.\n132. Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler-Klein J, Cohen-Solal A, et al.\nCancer diagnosis in patients with heart failure: epidemiology, clinical implications\nand gaps in knowledge. Eur J Heart Fail 2018;20:879–887.\n133. D’Ascenzi F, Anselmi F, Fiorentini C, Mannucci R, Bonifazi M, Mondillo S. The ben-\neﬁts of exercise in cancer patients and the criteria for exercise prescription in\ncardio-oncology. Eur J Prev Cardiol 2021;28:725–735.\n134. Ogunmoroti O, Allen NB, Cushman M, Michos ED, Rundek T, Rana JS, et al.\nAssociation between life’s simple 7 and noncardiovascular disease: the multi-ethnic\nstudy of atherosclerosis. J Am Heart Assoc 2016;5:e003954.\n135. Michos ED, Marshall CH. Healthy lifestyle beneﬁts both cancer and cardiovascular\ndisease: more bang for the buck. JACC CardioOncology 2021;3:675–677.\n4346\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n136. Murray J, Bennett H, Bezak E, Perry R. The role of exercise in the prevention of\ncancer therapy-related cardiac dysfunction in breast cancer patients undergoing\nchemotherapy: systematic review. Eur J Prev Cardiol 2022;29:463–472.\n137. Scott JM, Nilsen TS, Gupta D, Jones LW. Exercise therapy and cardiovascular tox-\nicity in cancer. Circulation 2018;137:1176–1191.\n138. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/\nESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;\n39:3021–3104.\n139. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC\nGuidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in col-\nlaboration with the EASD. Eur Heart J 2020;41:255–323.\n140. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019\nESC/EAS Guidelines for the management of dyslipidaemias: lipid modiﬁcation to re-\nduce cardiovascular risk. Eur Heart J 2020;41:111–188.\n141. Beavers CJ, Rodgers JE, Bagnola AJ, Beckie TM, Campia U, Di Palo KE, et al.\nCardio-oncology drug interactions: a scientiﬁc statement from the American\nHeart Association. Circulation 2022;145:e811–e838.\n142. Ferdinandy P, Baczkó I, Bencsik P, Giricz Z, Görbe A, Pacher P, et al. Deﬁnition of\nhidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical\nimplications. Eur Heart J 2019;40:1771–1777.\n143. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardio-\ntoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer\n2013;49:2900–2909.\n144. Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart\nfailure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.\nJ Am Coll Cardiol 2012;60:2504–2512.\n145. Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, De Caralt TM, et al.\nEnalapril and carvedilol for preventing chemotherapy-induced left ventricular sys-\ntolic dysfunction in patients with malignant hemopathies: the OVERCOME trial\n(preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients\nsubmitted\nto\nintensive\nChemOtherapy\nfor\nthe\ntreatment\nof\nMalignant\nhEmopathies). J Am Coll Cardiol 2013;61:2355–2362.\n146. Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, das Dores Cruz F,\nGonçalves Brandão SM, Rigaud VOC, et al. Carvedilol for prevention of\nchemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol 2018;71:\n2281–2290.\n147. Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, et al.\nAnthracycline-induced cardiotoxicity: a multicenter randomised trial comparing\ntwo\nstrategies\nfor\nguiding\nprevention\nwith\nenalapril:\nThe\nInternational\nCardioOncology Society-one trial. Eur J Cancer 2018;94:126–137.\n148. Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, et al. Protective effects of\nspironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail\n2015;17:81–89.\n149. Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S, et al. Efﬁciency of ator-\nvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll\nCardiol 2011;58:988–989.\n150. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al.\nPrevention of cardiac dysfunction during adjuvant breast cancer therapy\n(PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical\ntrial of candesartan and metoprolol. Eur Heart J 2016;37:1671–1680.\n151. Gulati G, Heck SL, Røsjø H, Ree AH, Hoffmann P, Hagve TA, et al. Neurohormonal\nblockade and circulating cardiovascular biomarkers during anthracycline therapy in\nbreast cancer patients: results from the PRADA (Prevention of Cardiac\nDysfunction During Adjuvant Breast Cancer Therapy) study. J Am Heart Assoc\n2017;6:e006513.\n152. Guglin M, Krischer J, Tamura R, Fink A, Bello-Matricaria L, McCaskill-Stevens W,\net al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardi-\notoxicity in patients with breast cancer. J Am Coll Cardiol 2019;73:2859–2868.\n153. Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al.\nMultidisciplinary approach to novel therapies in cardio-oncology research\n(MANTICORE\n101-Breast):\na\nrandomized\ntrial\nfor\nthe\nprevention\nof\ntrastuzumab-associated cardiotoxicity. J Clin Oncol 2017;35:870–877.\n154. Boekhout AH, Gietema JA, Kerklaan BM, VanWerkhoven ED, Altena R, Honkoop\nA, et al. Angiotensin II receptor inhibition with candesartan to prevent\ntrastuzumab-related cardiotoxic effects in patients with early breast cancer a ran-\ndomized clinical trial. JAMA Oncol 2016;2:1030–1037.\n155. Caspani F, Tralongo AC, Campiotti L, Asteggiano R, Guasti L, Squizzato A.\nPrevention of anthracycline-induced cardiotoxicity: a systematic review and\nmeta-analysis. Intern Emerg Med 2021;16:477–486.\n156. Huang S, Zhao Q, Yang ZG, Diao KY, He Y, Shi K, et al. Protective role of beta-\nblockers in chemotherapy-induced cardiotoxicity—a systematic review and\nmeta-analysis of carvedilol. Heart Fail Rev 2019;24:325–333.\n157. Vaduganathan M, Hirji SA, Qamar A, Bajaj N, Gupta A, Zaha VG, et al. Efﬁcacy of\nneurohormonal therapies in preventing cardiotoxicity in patients with cancer\nundergoing chemotherapy. JACC CardioOncology 2019;1:54–65.\n158. Macedo AVS, Hajjar LA, Lyon AR, Nascimento BR, Putzu A, Rossi L, et al. Efﬁcacy of\ndexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. JACC\nCardioOncology 2019;1:68–79.\n159. Li X, Li Y, Zhang T, Xiong X, Liu N, Pang B, et al. Role of cardioprotective agents on\nchemotherapy-induced\nheart\nfailure:\na\nsystematic\nreview\nand\nnetwork\nmeta-analysis of randomized controlled trials. Pharmacol Res 2020;151:104577.\n160. Fang K, Zhang Y, Liu W, He C. Effects of angiotensin-converting enzyme inhibitor/\nangiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: a\nmeta-analysis of randomized controlled trials. Heart Fail Rev 2021;26:101–109.\n161. Shapira J, Gotfried M, Lishner M, Ravid M. Reduced cardiotoxicity of doxorubicin by\na 6-hour infusion regimen. A prospective randomized evaluation. Cancer 1990;65:\n870–873.\n162. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH,\net al. American Society of Clinical Oncology 2008 clinical practice guideline update:\nuse of chemotherapy and radiation therapy protectants. J Clin Oncol 2009;27:\n127–145.\n163. European Medicines Agency. Savene: EPAR—Product Information (Internet) 2008\n(updated 2019).\n164. Vejpongsa P, Yeh ETH. Prevention of anthracycline-induced cardiotoxicity: chal-\nlenges and opportunities. J Am Coll Cardiol 2014;64:938–945.\n165. Yamaguchi N, Fujii T, Aoi S, Kozuch PS, Hortobagyi GN, Blum RH. Comparison of\ncardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in\nbreast cancer: a Bayesian network meta-analysis. Eur J Cancer 2015;51:2314–2320.\n166. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Delayed ad-\nministration of dexrazoxane provides cardioprotection for patients with advanced\nbreast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997;15:\n1333–1340.\n167. van Dalen EC, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective inter-\nventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev\n2011;2011:CD003917.\n168. Waterhouse DN, Tardi PG, Mayer LD, Bally MB. A comparison of liposomal for-\nmulations of doxorubicin with drug administered in free form: changing toxicity\nproﬁles. Drug Saf 2001;24:903–920.\n169. Verellen D, De Ridder M, Linthout N, Tournel K, Soete G, Storme G. Innovations in\nimage-guided radiotherapy. Nat Rev Cancer 2007;7:949–960.\n170. De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-Johnson F.\nRadiotherapy toxicity. Nat Rev Dis Prim 2019;5:13.\n171. Meattini I, Poortmans PM, Aznar MC, Becherini C, Bonzano E, Cardinale D, et al.\nAssociation of breast cancer irradiation with cardiac toxic effects: a narrative re-\nview. JAMA Oncol 2021;7:924–932.\n172. Banﬁll K, Giuliani M, Aznar M, Franks K, McWilliam A, Schmitt M, et al. Cardiac tox-\nicity of thoracic radiotherapy: existing evidence and future directions. J Thorac Oncol\n2021;16:216–227.\n173. Mitchell JD, Cehic DA, Morgia M, Bergrom C, Toohey J, Guerrero PA, et al.\nCardiovascular manifestations from therapeutic radiation: a multidisciplinary ex-\npert consensus statement from the International Cardio-Oncology Society. JACC\nCardioOncology 2021;3:360–380.\n174. Kirwan CC, Coles CE, Bliss J, Kirwan C, Kilburn L, Fox L, et al. It’s PRIMETIME.\nPostoperative avoidance of radiotherapy: biomarker selection of women at very\nlow risk of local recurrence. Clin Oncol 2016;28:594–596.\n175. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al.\nPrevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients\nby angiotensin-converting enzyme inhibition. Circulation 2006;114:2474–2481.\n176. Abdel-Qadir H, Bobrowski D, Zhou L, Austin PC, Calvillo-Argüelles O, Amir E,\net al. Statin exposure and risk of heart failure after anthracycline-or trastuzumab-\nbased chemotherapy for early breast cancer: a propensity score⍰matched cohort\nstudy. J Am Heart Assoc 2021;10:e018393.\n177. Calvillo-Argüelles O, Abdel-Qadir H, Michalowska M, Billia F, Suntheralingam S,\nAmir E, et al. Cardioprotective effect of statins in patients with HER2-positive\nbreast cancer receiving trastuzumab therapy. Can J Cardiol 2019;35:153–159.\n178. Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the\nrisk for incident heart failure in patients with breast cancer receiving anthracycline\nchemotherapy: an observational clinical cohort study. J Am Coll Cardiol 2012;60:\n2384–2390.\n179. Chotenimitkhun R, D’Agostino R, Lawrence JA, Hamilton CA, Jordan JH, Vasu S,\net al. Chronic statin administration may attenuate early anthracycline-associated\ndeclines in left ventricular ejection function. Can J Cardiol 2015;31:302–307.\n180. Obasi M, Abovich A, Vo JB, Gao Y, Papatheodorou SI, Nohria A, et al. Statins to\nmitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastu-\nzumab: a systematic review and meta-analysis. Cancer Causes Control 2021;32:\n1395–1405.\n181. Kim J, Nishimura Y, Kewcharoen J, Yess J. Statin use can attenuate the decline in left\nventricular ejection fraction and the incidence of cardiomyopathy in cardiotoxic\nchemotherapy recipients: a systematic review and meta-analysis. J Clin Med 2021;\n10:3731.\nESC Guidelines\n4347\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n182. Sanﬁlippo KM, Keller J, Gage BF, Luo S, Wang TF, Moskowitz G, et al. Statins are\nassociated with reduced mortality in multiple myeloma. J Clin Oncol 2016;34:\n4008–4014.\n183. Afzal A, Fiala MA, Gage BF, Wildes TM, Sanﬁlippo K. Statins reduce mortality in\nmultiple myeloma: a population-based US study. Clin Lymphoma Myeloma Leuk\n2020;20:e937–e943.\n184. Nabati M, Janbabai G, Esmailian J, Yazdani J. Effect of rosuvastatin in preventing\nchemotherapy-induced cardiotoxicity in women with breast cancer: a randomized,\nsingle-blind, placebo-controlled trial. J Cardiovasc Pharmacol Ther 2019;24:233–241.\n185. Shahid I, Yamani N, Ali A, Kumar P, Figueredo V, Unzek S, et al. Meta-analysis evalu-\nating the use of statins to attenuate cardiotoxicity in cancer patients receiving an-\nthracyclines and trastuzumab-based chemotherapy. Am J Cardiol 2021;156:\n142–145.\n186. Nabati M, Janbabai G, Baghyari S, Esmaili K, Yazdani J. Cardioprotective effects of\ncarvedilol in inhibiting doxorubicin-induced cardiotoxicity. J Cardiovasc Pharmacol\n2017;69:279–285.\n187. Warrington L, Absolom K, Conner M, Kellar I, Clayton B, Ayres M, et al. Electronic\nsystems for patients to report and manage side effects of cancer treatment: system-\natic review. J Med Internet Res 2019;21:e10875.\n188. López-Fernández T, Martín García A, Santaballa Beltrán A, Montero Luis Á, García\nSanz R, Mazón Ramos P, et al. Cardio-onco-hematology in clinical practice. Position\npaper and recommendations. Rev Española Cardiol (English Ed) 2017;70:474–486.\n189. Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, et al. Prospective evaluation of\nthe cardiac safety of HER2-targeted therapies in patients with HER2-positive breast\ncancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res\nTreat 2019;175:595–603.\n190. Fornaro A, Olivotto I, Rigacci L, Ciaccheri M, Tomberli B, Ferrantini C, et al.\nComparison of long-term outcome in anthracycline-related versus idiopathic di-\nlated cardiomyopathy: a single centre experience. Eur J Heart Fail 2018;20:898–906.\n191. Chow SL, Maisel AS, Anand I, Bozkurt B, De Boer RA, Felker GM, et al. Role of bio-\nmarkers for the prevention, assessment, and management of heart failure: a scien-\ntiﬁc statement from the American Heart Association. Circulation 2017;135:\ne1054–e1091. Erratum in: Circulation 2017;136:e345.\n192. De Boer RA, Daniels LB, Maisel AS, Januzzi JL. State of the art: newer biomarkers in\nheart failure. Eur J Heart Fail 2015;17:559–569.\n193. Piek A, Du W, de Boer RA, Silljé HHW. Novel heart failure biomarkers: why do we\nfail to exploit their potential? Crit Rev Clin Lab Sci 2018;55:246–263.\n194. Du W, Piek A, Marloes Schouten E, van de Kolk CWA, Mueller C, Mebazaa A, et al.\nPlasma levels of heart failure biomarkers are primarily a reﬂection of extracardiac\nproduction. Theranostics 2018;8:4155–4169.\n195. Suthahar N, Lau ES, Blaha MJ, Paniagua SM, Larson MG, Psaty BM, et al. Sex-speciﬁc\nassociations of cardiovascular risk factors and biomarkers with incident heart fail-\nure. J Am Coll Cardiol 2020;76:1455–1465.\n196. Bracun V, Aboumsallem JP, van der Meer P, de Boer RA. Cardiac biomarkers in pa-\ntients with cancer: considerations, clinical implications, and future avenues. Curr\nOncol Rep 2020;22:67.\n197. Ananthan K, Lyon AR. The role of biomarkers in cardio-oncology. J Cardiovasc\nTransl Res 2020;13:431–450.\n198. López-Fernández T, Thavendiranathan P. Emerging cardiac imaging modalities for\nthe early detection of cardiotoxicity due to anticancer therapies. Rev Española\nCardiol (English Ed) 2017;70:487–495.\n199. Eschenhagen T, Force T, Ewer MS, De Keulenaer GW, Suter TM, Anker SD, et al.\nCardiovascular side effects of cancer therapies: a position statement from the\nHeart Failure Association of the European Society of Cardiology. Eur J Heart Fail\n2011;13:1–10.\n200. Keramida K, Farmakis D, López Fernández T, Lancellotti P. Focused echocardiog-\nraphy in cardio-oncology. Echocardiography 2020;37:1149–1158.\n201. Liu JE, Barac A, Thavendiranathan P, Scherrer-Crosbie M. Strain imaging in\ncardio-oncology. JACC CardioOncology 2020;2:677–689.\n202. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and\nincremental value of deformation indices for prediction of trastuzumab-induced\ncardiotoxicity. J Am Soc Echocardiogr 2013;26:493–498.\n203. Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Aakhus S, Miyazaki S, et al.\nCardioprotection using strain-guided management of potentially cardiotoxic can-\ncer therapy: 1 year results of the SUCCOUR trial. Eur Heart J 2020;41:\nehaa946.3282.\n204. Vallabhaneni S, Zhang KW, Alvarez JA, Joshua C, Henning DM, Woodard PK, et al.\nRole of cardiovascular magnetic resonance in early detection and treatment of car-\ndiac dysfunction in oncology patients. Int J Cardiovasc Imaging 2021;37:3003–3017.\n205. Lapinskas T, Hireche-Chikaoui H, Zieschang V, Erley J, Stehning C, Gebker R, et al.\nEffect of comprehensive initial training on the variability of left ventricular measures\nusing fast-SENC cardiac magnetic resonance imaging. Sci Rep 2019;9:12223.\n206. Korosoglou G, Giusca S, Montenbruck M, Patel AR, Lapinskas T, Götze C, et al. Fast\nstrain-encoded cardiac magnetic resonance for diagnostic classiﬁcation and risk\nstratiﬁcation of heart failure patients. JACC Cardiovasc Imaging 2021;14:1177–1188.\n207. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/\nAHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management\nof heart failure: a report of the American College of Cardiology/American Heart\nAssociation Task Force on Clinical Practice Guidelines and the Heart Failure\nSociety of America. Circulation 2017;136:e137–e161.\n208. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early\ndetection of anthracycline cardiotoxicity and improvement with heart failure ther-\napy. Circulation 2015;131:1981–1988.\n209. Wang L, Tan TC, Halpern EF, Neilan TG, Francis SA, Picard MH, et al. Major cardiac\nevents and the value of echocardiographic evaluation in patients receiving\nanthracycline-based chemotherapy. Am J Cardiol 2015;116:442–446.\n210. Abu-Khalaf MM, Safonov A, Stratton J, Wang S, Hatzis C, Park E, et al. Examining the\ncost-effectiveness of baseline left ventricular function assessment among breast\ncancer patients undergoing anthracycline-based therapy. Breast Cancer Res Treat\n2019;176:261–270.\n211. Lenihan DJ, Stevens PL, Massey M, Plana JC, Araujo DM, Fanale MA, et al. The utility\nof point-of-care biomarkers to detect cardiotoxicity during anthracycline chemo-\ntherapy: a feasibility study. J Card Fail 2016;22:433–438.\n212. Meessen JMTA, Cardinale D, Ciceri F, Sandri MT, Civelli M, Bottazzi B, et al.\nCirculating biomarkers and cardiac function over 3 years after chemotherapy\nwith anthracyclines: the ICOS-ONE trial. ESC Heart Fail 2020;7:1452–1466.\n213. Jones M, O’Gorman P, Kelly C, Mahon N, Fitzgibbon MC. High-sensitive cardiac\ntroponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac\ninjury. Ann Clin Biochem 2017;54:149–157.\n214. Brandão M, Pondé NF, Poggio F, Kotecki N, Salis M, Lambertini M, et al.\nCombination therapies for the treatment of HER2-positive breast cancer: current\nand future prospects. Expert Rev Anticancer Ther 2018;18:629–649.\n215. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell\nBiol 2001;2:127–137.\n216. Belmonte F, Das S, Sysa-Shah P, Sivakumaran V, Stanley B, Guo X, et al. ErbB2 over-\nexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxy-\ngen species, and protects against doxorubicin cardiotoxicity. Am J Physiol Heart Circ\nPhysiol 2015;309:H1271–H1280.\n217. Martel S, Maurer C, Lambertini M, Pondé N, De Azambuja E. Breast cancer\ntreatment-induced cardiotoxicity. Expert Opin Drug Saf 2017;16:1021–1038.\n218. de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M, et al. A\npooled analysis of the cardiac events in the trastuzumab adjuvant trials. Breast\nCancer Res Treat 2020;179:161–171.\n219. Eiger D, Pondé NF, Agbor-Tarh D, Moreno-Aspitia A, Piccart M, Hilbers FS, et al.\nLong-term cardiac outcomes of patients with HER2-positive breast cancer treated\nin the adjuvant lapatinib and/or trastuzumab treatment optimization trial. Br J\nCancer 2020;122:1453–1460.\n220. Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D, et al. Assessment\nof cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophos-\nphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in\nnode-positive, HER2-overexpressing breast cancer. J Clin Oncol 2005;23:\n7811–7819.\n221. Martin M, Press M, Ph D, Mackey J, Glaspy J, Chan A, et al. Adjuvant trastuzumab in\nHER2-positive breast cancer. NEJM 2011;365:1273–1283.\n222. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al.\n2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive\nbreast cancer: a randomised controlled trial. Lancet 2007;369:29–36.\n223. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I,\net al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.\nN Engl J Med 2005;353:1659–1672.\n224. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al.\nTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast can-\ncer. N Engl J Med 2005;353:1673–1684.\n225. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de\nAzambuja E, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy\nin HER2-positive early breast cancer: ﬁnal analysis of the HERceptin Adjuvant\n(HERA) trial. Lancet 2017;389:1195–1205.\n226. Tan TC, Bouras S, Sawaya H, Sebag IA, Cohen V, Picard MH, et al. Time trends of\nleft ventricular ejection fraction and myocardial deformation indices in a cohort of\nwomen with breast cancer treated with anthracyclines, taxanes, and trastuzumab. J\nAm Soc Echocardiogr 2015;28:509–514.\n227. Ben Kridis W, Sghaier S, Charfeddine S, Toumi N, Daoud J, Kammoun S, et al. A\nprospective study about trastuzumab-induced cardiotoxicity in HER2-positive\nbreast cancer. Am J Clin Oncol Cancer Clin Trials 2020;43:510–516.\n228. Yang ZY, Wang W, Wang X, Qin ZQ. Cardiotoxicity of epidermal growth factor\nreceptor 2-targeted drugs for breast cancer. Front Pharmacol 2021;12:741451.\n229. Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden\nC, et al. 2013 ESC guidelines on the management of stable coronary artery disease:\nthe Task Force on the management of stable coronary artery disease of the\nEuropean Society of Cardiology. Eur Heart J 2013;34:2949–3003.\n4348\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n230. Padegimas A, Carver JR. How to\ndiagnose and manage patients with\nﬂuoropyrimidine-induced\nchest\npain:\na\nsingle\ncenter\napproach.\nJACC\nCardioOncology 2020;2:650–654.\n231. Kwakman JJM, Simkens LHJ, Mol L, Kok WEM, Koopman M, Punt CJA. Incidence of\ncapecitabine-related cardiotoxicity in different treatment schedules of metastatic\ncolorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch\nColorectal Cancer Group. Eur J Cancer 2017;76:93–99.\n232. Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can\ninduce acute coronary syndrome similar to 5-ﬂuorouracil. Ann Oncol 2002;13:\n797–801.\n233. Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the patho-\nphysiology of 5-ﬂuorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol 2014;\n15:47.\n234. Edvardsen T, Asch FM, Davidson B, Delgado V, DeMaria A, Dilsizian V, et al.\nNon-invasive imaging in coronary syndromes: recommendations of the European\nAssociation\nof\nCardiovascular\nImaging\nand\nthe\nAmerican\nSociety\nof\nEchocardiography, in collaboration with the American Society of Nuclear\nCardiology, Society of Cardiovascular Comuted Tomography, and Society for\nCardiovascular Magnetic Resonance. Eur Heart J Cardiovasc Imaging 2022;23:\ne6–e33.\n235. Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, et al. 5-ﬂuorouracil\nand cardiotoxicity: a review. Ther Adv Med Oncol 2018;10:1758835918780140.\n236. Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with no-\nvel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends\nCardiovasc Med 2013;23:104–113.\n237. Choueiri TK, Schutz FAB, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thrombo-\nembolic events with sunitinib and sorafenib: a systematic review and meta-analysis\nof clinical trials. J Clin Oncol 2010;28:2280–2285.\n238. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibi-\ntors: With a special focus on cardiac repolarisation (QT interval). Drug Saf 2013;\n36:295–316.\n239. Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E. Cardiovascular tox-\nicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and\nmeta-analysis. Cancer Treat Rev 2017;53:120–127.\n240. Desai A, Noor A, Joshi S, Kim AS. Takotsubo cardiomyopathy in cancer patients.\nCardio-Oncology 2019;5:7.\n241. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the\ntreatment of cancer on the cardiovascular system: focus on hypertension.\nCirculation 2011;124:1687–1691.\n242. Shah CP, Moreb JS. Cardiotoxicity due to targeted anticancer agents: a growing\nchallenge. Ther Adv Cardiovasc Dis 2019;13:1753944719843435.\n243. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiv-\ning sunitinib. N Engl J Med 2008;358:95–97.\n244. Hamnvik OPR, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, et al. Clinical\nrisk factors for the development of hypertension in patients treated with inhibitors\nof the VEGF signaling pathway. Cancer 2015;121:311–319.\n245. Ghatalia P, Morgan CJ, Je Y, Nguyen PL, Trinh QD, Choueiri TK, et al. Congestive\nheart failure with vascular endothelial growth factor receptor tyrosine kinase inhi-\nbitors. Crit Rev Oncol Hematol 2015;94:228–237.\n246. Nhola LF, Abdelmoneim SS, Villarraga HR, Kohli M, Grothey A, Bordun KA, et al.\nEchocardiographic assessment for the detection of cardiotoxicity due to vascular\nendothelial growth factor inhibitor therapy in metastatic renal cell and colorectal\ncancers. J Am Soc Echocardiogr 2019;32:267–276.\n247. Uraizee I, Cheng S, Moslehi J. Reversible cardiomyopathy associated with sunitinib\nand sorafenib. N Engl J Med 2011;365:1649–1650.\n248. Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, et al. Mechanisms\nof VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and\nvascular disease. Hypertension 2018;71:E1–E8.\n249. Zang J, Wu S, Tang L, Xu X, Bai J, Ding C, et al. Incidence and risk of QTc interval\nprolongation among cancer patients treated with vandetanib: a systematic review\nand meta-analysis. PLoS One 2012;7:e30353.\n250. Ghatalia P, Je Y, Kaymakcalan MD, Sonpavde G, Choueiri TK. QTc interval pro-\nlongation with vascular endothelial growth factor receptor tyrosine kinase inhibi-\ntors. Br J Cancer 2015;112:296–305.\n251. Alexandre J, Salem JE, Moslehi J, Sassier M, Ropert C, Cautela J, et al. Identiﬁcation of\nanticancer drugs associated with atrial ﬁbrillation: analysis of the WHO pharmacov-\nigilance database. Eur Heart J Cardiovasc Pharmacother 2021;7:312–320.\n252. EMA. Medicines | European Medicines Agency. Eur Med Agency Sci Med Heal n.d.\n253. FDA. Drugs@FDA: FDA-Approved Drugs. FDA US Food Drug Adm n.d.\n254. Steingart RM, Bakris GL, Chen HX, Chen MH, Force T, Ivy SP, et al. Management of\ncardiac toxicity in patients receiving vascular endothelial growth factor signaling\npathway inhibitors. Am Heart J 2012;163:156–163.\n255. Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, et al. Initial as-\nsessment, surveillance, and management of blood pressure in patients receiving\nvascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst\n2010;102:596–604.\n256. Barber MC, Mauro MJ, Moslehi J. Cardiovascular care of patients with chronic mye-\nloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. Hematology 2017;\n2017:110–114.\n257. Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity\nin chronic myeloid leukemia. J Clin Oncol 2015;33:4210–4218.\n258. Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular\nand metabolic implications of novel targeted cancer therapies: focus on kinase in-\nhibitors. J Am Coll Cardiol 2015;66:1160–1178.\n259. Buza V, Rajagopalan B, Curtis AB. Cancer treatment-induced arrhythmias: focus on\nchemotherapy and targeted therapies. Circ Arrhythmia Electrophysiol 2017;10:\ne005443.\n260. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, et al.\nVascular toxicities of cancer therapies: the old and the new—an evolving avenue.\nCirculation 2016;133:1272–1289.\n261. Cirmi S, El Abd A, Letinier L, Navarra M, Salvo F. Cardiovascular toxicity of tyrosine\nkinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse\nevent reporting system database (FAERS). Cancers (Basel) 2020;12:826.\n262. Gribben JG, Bosch F, Cymbalista F, Geisler CH, Ghia P, Hillmen P, et al. Optimising\noutcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy:\nEuropean recommendations for clinical practice. Br J Haematol 2018;180:666–679.\n263. Shanafelt TD, Parikh SA, Noseworthy PA, Goede V, Chaffee KG, Bahlo J, et al.\nAtrial ﬁbrillation in patients with chronic lymphocytic leukemia (CLL). Leuk\nLymphoma 2017;58:1630–1639.\n264. Dickerson T, Wiczer T, Waller A, Philippon J, Porter K, Haddad D, et al.\nHypertension and incident cardiovascular events following ibrutinib initiation.\nBlood 2019;134:1919–1928.\n265. Brown JR, Moslehi J, O’Brien S, Ghia P, Hillmen P, Cymbalista F, et al.\nCharacterization of atrial ﬁbrillation adverse events reported in ibrutinib rando-\nmized controlled registration trials. Haematologica 2017;102:1796–1805.\n266. López-Fernández, T, Canales M, Farmakis D, García-Sanz R, Bosch F, Loscertales J,\net al. Ibrutinib-associated atrial ﬁbrillation: a practical approach. Ann Hematol Oncol\n2018;5:1203.\n267. Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB,\net al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol 2019;74:\n1667–1678.\n268. Abdel-Qadir H, Sabrie N, Leong D, Pang A, Austin PC, Prica A, et al. Cardiovascular\nrisk associated with ibrutinib use in chronic lymphocytic leukemia: a population-\nbased cohort study. J Clin Oncol 2021;39:3453–3462.\n269. Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al.\nAcalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia:\nresults of the ﬁrst randomized phase III trial. J Clin Oncol 2021;39:3441–3452.\n270. Common Terminology Criteria for Adverse Events (CTCAE) v6.0. National Cancer Institute,\n2022. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.\n271. Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, et al.\nCardiovascular adverse events in patients with chronic lymphocytic leukemia receiv-\ning acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica 2022;\n107:1335–1346.\n272. Svennberg E, Tjong F, Goette A, Akoum N, Di Biaise L, Bordachar P, et al. How to use\ndigital devices to detect and manage arrhythmias: an EHRA practical guide. Europace.\n2022;24:979–1005.\n273. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al.\n2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation devel-\noped in collaboration with the European Association for Cardio-Thoracic Surgery\n(EACTS). Eur Heart J 2021;42:373–498.\n274. McMullen JR, Boey EJ, Ooi JYY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases\nthe risk of atrial ﬁbrillation, potentially through inhibition of cardiac PI3K-Akt signal-\ning. Blood 2014;124:3829–3830.\n275. Lee HJ, Chihara D, Wang M, Mouhayar E, Kim P. Ibrutinib-related atrial ﬁbrillation in\npatients with mantle cell lymphoma. Leuk Lymphoma 2016;57:2914–2916.\n276. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratiﬁcation and\nmanagement. Am J Hematol 2020;95:548–567.\n277. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued\nimprovement in survival in multiple myeloma: changes in early mortality and out-\ncomes in older patients. Leukemia 2014;28:1122–1128.\n278. Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction—Alzheimer’s dis-\nease of the heart? N Engl J Med 2013;368:455–464.\n279. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, et al.\nCarﬁlzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N\nEngl J Med 2015;372:142–152.\n280. Chari A, Keith Stewart A, Russell SD, Moreau P, Herrmann J, Banchs J, et al. Analysis\nof carﬁlzomib cardiovascular safety proﬁle across relapsed and/or refractory mul-\ntiple myeloma clinical trials. Blood Adv 2018;2:1633–1644.\nESC Guidelines\n4349\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n281. Waxman AJ, Clasen S, Hwang WT, Garfall A, Vogl DT, Carver J, et al.\nCarﬁlzomib-associated cardiovascular adverse events: a systematic review and\nmeta-analysis. JAMA Oncol 2018;4:e174519.\n282. Mauri L, Elmariah S, Yeh RW, Cutlip DE, Steg PG, Windecker S, et al. Causes of late\nmortality with dual antiplatelet therapy after coronary stents. Eur Heart J 2016;37:\n378–385.\n283. Gavazzoni M, Lombardi CM, Vizzardi E, Gorga E, Sciatti E, Rossi L, et al. Irreversible\nproteasome inhibition with carﬁlzomib as ﬁrst line therapy in patients with newly\ndiagnosed multiple myeloma: early in vivo cardiovascular effects. Eur J Pharmacol\n2018;838:85–90.\n284. Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, et al. Integrated safety\nproﬁle of single-agent carﬁlzomib: experience from 526 patients enrolled in 4 phase\nII clinical studies. Haematologica 2013;98:1753–1761.\n285. RidolﬁRL, Bulkley BH, Hutchins GM. The conduction system in cardiac amyloidosis.\nClinical and pathologic features of 23 patients. Am J Med 1977;62:677–686.\n286. Fakhri B, Fiala MA, Shah N, Vij R, Wildes TM. Measuring cardiopulmonary compli-\ncations\nof\ncarﬁlzomib\ntreatment\nand\nassociated\nrisk\nfactors\nusing\nthe\nSEER-Medicare database. Cancer 2020;126:808–813.\n287. Feng DL, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, et al.\nIntracardiac thrombosis and embolism in patients with cardiac amyloidosis.\nCirculation 2007;116:2420–2426.\n288. Mancuso S, Carlisi M, Sarocchi M, Napolitano M, Siragusa S. Cardio-oncology in\nmultiple myeloma: is it time for a speciﬁc focus? Leuk Lymphoma 2018;59:\n1764–1766.\n289. Danhof S, Schreder M, Rasche L, Striﬂer S, Einsele H, Knop S. ‘Real-life’ experience\nof preapproval carﬁlzomib-based therapy in myeloma—analysis of cardiac toxicity\nand predisposing factors. Eur J Haematol 2016;97:25–32.\n290. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and\ntreatment of cardiac amyloidosis. A position statement of the European Society of\nCardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail\n2021;23:512–526.\n291. Feng DL, Syed IS, Martinez M, Oh JK, Jaffe AS, Grogan M, et al. Intracardiac throm-\nbosis and anticoagulation therapy in cardiac amyloidosis. Circulation 2009;119:\n2490–2497.\n292. Sonneveld P, Asselbergs E, Zweegman S, Van Der Holt B, Kersten MJ, Vellenga E,\net al. Phase 2 study of carﬁlzomib, thalidomide, and dexamethasone as induction/\nconsolidation therapy for newly diagnosed multiple myeloma. Blood 2015;125:\n449–456.\n293. Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, et al. Phase 2\ndose-expansion study (PX-171-006) of carﬁlzomib, lenalidomide, and low-dose\ndexamethasone in relapsed or progressive multiple myeloma. Blood 2013;122:\n3122–3128.\n294. Fradley MG, Groarke JD, Laubach J, Alsina M, Lenihan DJ, Cornell RF, et al.\nRecurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor\nand immunomodulatory therapy for the treatment of multiple myeloma. Br J\nHaematol 2018;180:271–275.\n295. Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME, et al. Cardiovascular\nand thrombotic complications of novel multiple myeloma therapies: a review. JAMA\nOncol 2017;3:980–988.\n296. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B,\net al. Prevention of thalidomide- and lenalidomide-associated thrombosis in mye-\nloma. Leukemia 2008;22:414–423.\n297. Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, Mirelis JG, Baksi AJ, Moon JC,\net al. High prevalence of intracardiac thrombi in cardiac amyloidosis. J Am Coll\nCardiol 2019;73:1733–1734.\n298. Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American\nSociety of Hematology 2021 guidelines for management of venous thromboembol-\nism: prevention and treatment in patients with cancer. Blood Adv 2021;5:927–974.\n299. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous\nthromboembolism prophylaxis and treatment in patients with cancer: ASCO clin-\nical practice guideline update. J Clin Oncol 2020;38:496–520.\n300. Piedra K, Peterson T, Tan C, Orozco J, Hultcrantz M, Hassoun H, et al. Comparison\nof venous thromboembolism incidence in newly diagnosed multiple myeloma pa-\ntients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carﬁlzomib,\nlenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophy-\nlaxis. Br J Haematol 2022;196:105–109.\n301. Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Harrell S, et al.\nPrimary prevention of venous thromboembolism with apixaban for multiple mye-\nloma patients receiving immunomodulatory agents. Br J Haematol 2020;190:\n555–561.\n302. Swan D, Rocci A, Bradbury C, Thachil J. Venous thromboembolism in multiple\nmyeloma—choice of prophylaxis, role of direct oral anticoagulants and special con-\nsiderations. Br J Haematol 2018;183:538–556.\n303. Lendvai N, Tsakos I, Devlin SM, Schaffer WL, Hassoun H, Lesokhin AM, et al.\nPredictive biomarkers and practical considerations in the management of\ncarﬁlzomib-associated cardiotoxicity. Leuk Lymphoma 2018;59:1981–1985.\n304. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, et al. Aspirin,\nwarfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma\ntreated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol\n2011;29:986–993.\n305. Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, et al.\nAspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed mul-\ntiple myeloma treated with lenalidomide. Blood 2012;119:933–939.\n306. Chalayer E, Bourmaud A, Tinquaut F, Chauvin F, Tardy B. Cost-effectiveness ana-\nlysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in pa-\ntients newly diagnosed with multiple myeloma. Thromb Res 2016;145:119–125.\n307. Zoppellaro G, Veronese N, Granziera S, Gobbi L, Stubbs B, Cohen AT. Primary\nthromboembolic prevention in multiple myeloma patients: an exploratory\nmeta-analysis on aspirin use. Semin Hematol 2018;55:182–184.\n308. Mincu RI, Mahabadi AA, Michel L, Mrotzek SM, Schadendorf D, Rassaf T, et al.\nCardiovascular adverse events associated with BRAF and MEK inhibitors: a system-\natic review and meta-analysis. JAMA Netw Open 2019;2:e198890.\n309. Glen C, Tan YY, Waterston A, Evans TRJ, Jones RJ, Petrie MC, et al. Mechanistic and\nclinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC:\nCardioOncology state-of-the-art review. Cardio Oncol 2022;4:1–18.\n310. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved\nsurvival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;\n367:107–114.\n311. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D,\net al. Improved overall survival in melanoma with combined dabrafenib and trame-\ntinib. N Engl J Med 2015;372:30–39.\n312. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J, et al.\nDabrafenib\nand\ntrametinib\nversus\ndabrafenib\nand\nplacebo\nfor\nVal600\nBRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised con-\ntrolled trial. Lancet 2015;386:444–451.\n313. Bronte E, Bronte G, Novo G, Rinaldi G, Bronte F, Passiglia F, et al. Cardiotoxicity\nmechanisms\nof\nthe\ncombination\nof\nBRAF-inhibitors\nand\nMEK-inhibitors.\nPharmacol Ther 2018;192:65–73.\n314. Gogas HJ, Flaherty KT, Dummer R, Ascierto PA, Arance A, Mandala M, et al.\nAdverse events associated with encorafenib plus binimetinib in the COLUMBUS\nstudy: incidence, course and management. Eur J Cancer 2019;119:97–106.\n315. Banks M, Crowell K, Proctor A, Jensen BC. Cardiovascular effects of the MEK in-\nhibitor, trametinib: a case report, literature review, and consideration of mechan-\nism. Cardiovasc Toxicol 2017;17:487–493.\n316. Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular\ntoxicities associated with immune checkpoint inhibitors. Cardiovasc Res 2019;115:\n854–868.\n317. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated\nwith immune checkpoint blockade. N Engl J Med 2018;378:158–168.\n318. Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association\nbetween immune checkpoint inhibitors with cardiovascular events and athero-\nsclerotic plaque. Circulation 2020;142:2299–2311.\n319. Rubio-Infante N, Ramírez-Flores YA, Castillo EC, Lozano O, García-Rivas G,\nTorre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor\ntherapy: a meta-analysis. Eur J Heart Fail 2021;23:1739–1747.\n320. Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al.\nCardiovascular toxicities associated with immune checkpoint inhibitors: an obser-\nvational, retrospective, pharmacovigilance study. Lancet Oncol 2018;19:1579–1589.\n321. Dolladille C, Ederhy S, Allouche S, Dupas Q, Gervais R, Madelaine J, et al. Late car-\ndiac adverse events in patients with cancer treated with immune checkpoint inhi-\nbitors. J Immunother Cancer 2020;8:e000261.\n322. D’Souza M, Nielsen D, Svane IM, Iversen K, Rasmussen PV, Madelaire C, et al. The\nrisk of cardiac events in patients receiving immune checkpoint inhibitors: a nation-\nwide Danish study. Eur Heart J 2021;42:1621–1631.\n323. Dolladille C, Akroun J, Morice P-M, Dompmartin A, Ezine E, Sassier M, et al.\nCardiovascular immunotoxicities associated with immune checkpoint inhibitors:\na safety meta-analysis. Eur Heart J 2021;42:4964–4977.\n324. Zamami Y, Niimura T, Okada N, Koyama T, Fukushima K, Izawa-Ishizawa Y, et al.\nFactors associated with immune checkpoint inhibitor–related myocarditis. JAMA\nOncol 2019;5:1635–1637.\n325. Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The evolving immunother-\napy landscape and the epidemiology, diagnosis, and management of cardiotoxicity:\nJACC: CardioOncology primer. JACC CardioOncology 2021;3:35–47.\n326. Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors\nand cardiovascular toxicity. Lancet Oncol 2018;19:e447–e458.\n327. Schiffer WB, Deych E, Lenihan DJ, Zhang KW. Coronary and aortic calciﬁcation are\nassociated with cardiovascular events on immune checkpoint inhibitor therapy. Int J\nCardiol 2021;322:177–182.\n4350\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n328. Naing A, Infante J, Goel S, Burris H, Black C, Marshall S, et al. Anti-PD-1 monoclonal\nantibody MEDI0680 in a phase I study of patients with advanced solid malignancies. J\nImmunother Cancer 2019;7:225.\n329. Allenbach Y, Anquetil\nC, Manouchehri\nA, Benveniste O, Lambotte\nO,\nLebrun-Vignes B, et al. Immune checkpoint inhibitor-induced myositis, the earliest\nand most lethal complication among rheumatic and musculoskeletal toxicities.\nAutoimmun Rev 2020;19:102586.\n330. Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, et al.\nImmune checkpoint inhibitor–associated myositis: expanding the spectrum of car-\ndiac complications of the immunotherapy revolution. Circulation 2018;138:\n743–745.\n331. Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al.\nMyocarditis in the setting of cancer therapeutics: proposed case deﬁnitions for\nemerging clinical syndromes in cardio-oncology. Circulation 2019;140:80–91.\n332. Lehmann LH, Cautela J, Palaskas N, Baik AH, Meijers WC, Allenbach Y, et al. Clinical\nstrategy for the diagnosis and treatment of immune checkpoint inhibitor-associated\nmyocarditis: a narrative review. JAMA Cardiol 2021;6:1329–1337.\n333. Rini B, Moslehi JJ, Bonaca M, Schmidinger M, Albiges L, Choueiri TK, et al.\nProspective cardiovascular surveillance of immune checkpoint inhibitor-based\ncombination therapy in patients with advanced renal cell cancer: data from the\nphase 3 JAVELIN Renal 101 trial. J Clin Oncol 2022;40:1929–1938.\n334. Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, et al.\nGlobal longitudinal strain and cardiac events in patients with immune checkpoint\ninhibitor-related myocarditis. J Am Coll Cardiol 2020;75:467–478.\n335. Kondapalli L, Bottinor W, Lenneman C. By releasing the brakes with immunother-\napy, are we accelerating atherosclerosis? Circulation 2020;142:2312–2315.\n336. Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-\nterm implications of toxicity. Nat Rev Clin Oncol 2022;19:254–267.\n337. Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, et al. Androgen deprivation therapy\nfor prostate cancer is associated with cardiovascular morbidity and mortality: a\nmeta-analysis of population-based observational studies. PLoS One 2014;9:\ne107516.\n338. Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, et al.\nCardiovascular effects of androgen deprivation therapy for the treatment of pros-\ntate cancer: ABCDE Steps to reduce cardiovascular disease in patients with pros-\ntate cancer. Circulation 2016;133:537–541.\n339. Okwuosa TM, Morgans A, Rhee J-W, Reding KW, Maliski S, Plana J-C, et al. Impact\nof hormonal therapies for treatment of hormone-dependent cancers (breast and\nprostate) on the cardiovascular system: effects and modiﬁcations: a scientiﬁc state-\nment from the American Heart Association. Circ Genomic Precis Med 2021;14:\ne000082.\n340. Barber M, Nguyen L, Wassermann J, Spano J, Funck-Brentano C, Salem J. Cardiac\narrhythmia considerations of hormone cancer therapies. Cardiovasc Res 2019;115:\n878–894.\n341. Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral\nrelugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J\nMed 2020;382:2187–2196.\n342. Abufaraj M, Iwata T, Kimura S, Haddad A, Al-Ani H, Abusubaih L, et al. Differential\nimpact of gonadotropin-releasing hormone antagonist versus agonist on clinical\nsafety and oncologic outcomes on patients with metastatic prostate cancer: a\nmeta-analysis of randomized controlled trials. Eur Urol 2021;79:44–53.\n343. Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sørensen PS, et al.\nCardiovascular safety of degarelix versus leuprolide in patients with prostate can-\ncer: the primary results of the PRONOUNCE randomized trial. Circulation 2021;\n144:1295–1307.\n344. Wilk M, Waśko-Grabowska A, Skoneczna I, Szmit S. Angiotensin system inhibitors\nmay improve outcomes of patients with castration-resistant prostate cancer during\nabiraterone acetate treatment—a cardio-oncology study. Front Oncol 2021;11:\n664741.\n345. Salem JE, Waintraub X, Courtillot C, Shaffer CM, Gandjbakhch E, Maupain C, et al.\nHypogonadism as a reversible cause of Torsades de Pointes in men. Circulation\n2018;138:110–113.\n346. Salem JE, Alexandre J, Bachelot A, Funck-Brentano C. Inﬂuence of steroid hor-\nmones on ventricular repolarization. Pharmacol Ther 2016;167:38–47.\n347. Salem JE, Yang T, Moslehi JJ, Waintraub X, Gandjbakhch E, Bachelot A, et al.\nAndrogenic effects on ventricular repolarization a translational study from the\ninternational pharmacovigilance database to iPSC-cardiomyocytes. Circulation\n2019;140:1070–1080.\n348. Hasegawa K, Ito H, Kaseno K, Miyazaki S, Shiomi Y, Tama N, et al. Impact of medical\ncastration on malignant arrhythmias in patients with prostate cancer. J Am Heart\nAssoc 2021;10:e017267.\n349. Fradley MG, Beckie TM, Brown SA, Cheng RK, Dent SF, Nohria A, et al.\nRecognition, prevention, and management of arrhythmias and autonomic disorders\nin cardio-oncology: a scientiﬁc statement from the American Heart Association.\nCirculation 2021;144:E41–E55.\n350. Olsson H, Petri N, Erichsen L, Malmberg A, Grundemar L. Effect of degarelix, a\ngonadotropin-releasing hormone receptor antagonist for the treatment of pros-\ntate cancer, on cardiac repolarisation in a randomised, placebo and active compara-\ntor controlled thorough QT/QTc trial in healthy men. Clin Drug Investig 2017;37:\n873–879.\n351. Baum M, Buzdar AU, Cuzick J, Forbes J, Houghton J, Klijn JGM, et al. Anastrozole\nalone or in combination with tamoxifen versus tamoxifen alone for adjuvant treat-\nment of postmenopausal women with early breast cancer: ﬁrst results of the ATAC\nrandomised trial. Lancet 2002;359:2131–2139.\n352. ARIMIDEX® (anastrozole). Highlights of Prescribing Information. Wilmington, DE:\nAstraZeneca Pharmaceuticals LP, 2014.\n353. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B,\nKeshaviah A, Coates AS, Mouridsen H, Mauriac L, et al. A comparison of letrozole\nand tamoxifen in postmenopausal women with early breast cancer. N Engl J Med\n2005;353:2747–2757.\n354. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine\ntherapy in postmenopausal breast cancer patients: a systematic review and\nmeta-analysis. J Natl Cancer Inst 2011;103:1299–1309.\n355. Goldvaser H, Barnes TA, Seruga B, Cescon DW, Ocaña A, Ribnikar D, et al.\nToxicity of extended adjuvant therapy with aromatase inhibitors in early breast\ncancer: a systematic review and meta-analysis. J Natl Cancer Inst 2018;110:31–39.\n356. Curigliano G, Azambuja E, Lenihan D, Calabrò MG, Cardinale D, Cipolla CM.\nPrevention, monitoring, and management of cardiac dysfunction in patients with\nmetastatic breast cancer. Oncologist 2019;24:e1034–e1043.\n357. KISQALI (ribociclib). Highlights of Prescribing Information. East Hanover, NJ: Novartis\nPharmaceuticals Corporation, 2018.\n358. IBRANCE (palbociclib). Highlights of Prescribing Information. New York, NY: Pﬁzer,\n2018.\n359. VERZENIO (abemaciclib). Highlights of Prescribing Information. Indianapolis, IN: Eli\nLilly and Company, 2018.\n360. Santoni M, Occhipinti G, Romagnoli E, Miccini F, Scoccia L, Giulietti M, et al.\nDifferent cardiotoxicity of palbociclib and ribociclib in breast cancer: gene expres-\nsion and pharmacological data analyses, biological basis, and therapeutic implica-\ntions. BioDrugs 2019;33:613–620.\n361. Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S,\net al. Ribociclib as ﬁrst-line therapy for HR-positive, advanced breast cancer. N\nEngl J Med 2016;375:1738–1748.\n362. Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus\nendocrine therapy for premenopausal women with hormone-receptor-positive,\nadvanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet\nOncol 2018;19:904–915.\n363. Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, et al. Palbociclib and letro-\nzole in advanced breast cancer. N Engl J Med 2016;375:1925–1936.\n364. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant\nplus\npalbociclib\nversus\nfulvestrant\nplus\nplacebo\nfor\ntreatment\nof\nhormone-receptor-positive, HER2–negative metastatic breast cancer that pro-\ngressed on previous endocrine therapy (PALOMA-3): ﬁnal analysis of the multicen-\ntre, double-blind, phas. Lancet Oncol 2016;17:425–439.\n365. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III\nrandomized study of ribociclib and fulvestrant in hormone receptor-positive, hu-\nman epidermal growth factor receptor 2-negative advanced breast cancer:\nMONALEESA-3. J Clin Oncol 2018;36:2465–2472.\n366. Durairaj C, Ruiz-Garcia A, Gauthier ER, Huang X, Lu DR, Hoffman JT, et al.\nPalbociclib has no clinically relevant effect on the QTc interval in patients with ad-\nvanced breast cancer. Anticancer Drugs 2018;29:271–280.\n367. Im S-A, Lu Y-S, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival\nwith ribociclib plus endocrine therapy in breast cancer. N Engl J Med 2019;381:\n307–316.\n368. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im S-A, et al. Overall\nsurvival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med\n2020;382:514–524.\n369. Tamargo J, Caballero R, Delpón E. Cancer chemotherapy and cardiac arrhythmias:\na review. Drug Saf 2015;38:129–152.\n370. Wang L, Wang W. Safety and efﬁcacy of anaplastic lymphoma kinase tyrosine ki-\nnase inhibitors in non-small cell lung cancer (Review). Oncol Rep 2021;45:13–28.\n371. Rao VU, Reeves DJ, Chugh AR, O’Quinn R, Fradley MG, Raghavendra M, et al.\nClinical approach to cardiovascular toxicity of oral antineoplastic agents: JACC\nstate-of-the-art review. J Am Coll Cardiol 2021;77:2693–2716.\n372. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First-line lorlatinib or\ncrizotinib in advanced ALK-positive lung cancer. N Engl J Med 2020;383:\n2018–2029.\n373. Thein KZ, Swarup S, Ball S, Quirch M, Vorakunthada Y, Htwe KK, et al. Incidence of\ncardiac toxicities in patients with advanced non-small cell lung cancer treated with\nosimertinib: a combined analysis of two phase III randomized controlled trials. Ann\nOncol 2018;29:viii500.\nESC Guidelines\n4351\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n374. Anand K, Ensor J, Trachtenberg B, Bernicker EH. Osimertinib-induced cardiotoxi-\ncity: a retrospective review of the FDA Adverse Events Reporting System (FAERS).\nJACC CardioOncology 2019;1:172–178.\n375. Kunimasa K, Kamada R, Oka T, Oboshi M, Kimura M, Inoue T, et al. Cardiac adverse\nevents in EGFR-mutated non-small cell lung cancer treated with osimertinib. JACC\nCardioOncology 2020;2:1–10.\n376. Ewer MS, Tekumalla SH, Walding A, Atuah KN. Cardiac safety of osimertinib: a re-\nview of data. J Clin Oncol 2021;39:328–337.\n377. Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell\ntherapy. Biol Blood Marrow Transplant 2019;25:e123–e127.\n378. Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, et al.\nCardiovascular events among adults treated with chimeric antigen receptor\nT-cells (CAR-T). J Am Coll Cardiol 2019;74:3099–3108.\n379. Goldman A, Maor E, Bomze D, Liu JE, Herrmann J, Fein J, et al. Adverse cardiovas-\ncular and pulmonary events associated with chimeric antigen receptor T-cell ther-\napy. J Am Coll Cardiol 2021;78:1800–1813.\n380. Fradley MG, Damrongwatanasuk R, Chandrasekhar S, Alomar M, Kip KE, Sarnaik\nAA. Cardiovascular toxicity and mortality associated with adoptive cell therapy\nand tumor-inﬁltrating lymphocytes for advanced stage melanoma. J Immunother\n2021;44:86–89.\n381. Ghosh AK, Chen DH, Guha A, Mackenzie S, Walker JM, Roddie C. CAR T cell\ntherapy-related cardiovascular outcomes and management: systemic disease or\ndirect cardiotoxicity? JACC CardioOncology 2020;2:97–109.\n382. Lefebvre B, Kang Y, Smith AM, Frey NV, Carver JR, Scherrer-Crosbie M.\nCardiovascular effects of CAR T cell therapy: a restrospective study. JACC\nCardioOncology 2020;2:193–203.\n383. Salem JE, Ederhy S, Lebrun-Vignes B, Moslehi JJ. Cardiac events associated with chi-\nmeric antigen receptor T-cells (CAR-T): a VigiBase perspective. J Am Coll Cardiol\n2020;75:2521–2523.\n384. Ganatra S, Redd R, Hayek SS, Parikh R, Azam T, Yanik GA, et al. Chimeric antigen\nreceptor T-cell therapy-associated cardiomyopathy in patients with refractory or\nrelapsed non-Hodgkin lymphoma. Circulation 2020;142:1687–1690.\n385. Lee JB, Vasic D, Kang H, Fang KKL, Zhang L. State-of-art of cellular therapy for acute\nleukemia. Int J Mol Sci 2021;22:4590.\n386. Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al.\nSociety for Immunotherapy of Cancer (SITC) clinical practice guideline on immune\ncheckpoint inhibitor-related adverse events. J Immunother Cancer 2021;9:e002435.\n387. Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, et al.\nDiagnosis, grading and management of toxicities from immunotherapies in children,\nadolescents and young adults with cancer. Nat Rev Clin Oncol 2021;18:435–453.\n388. Maus M V, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, et al. Society\nfor Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector\ncell-related adverse events. J Immunother Cancer 2020;8:e001511.\n389. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al.\nRisk of ischemic heart disease in women after radiotherapy for breast cancer. N\nEngl J Med 2013;368:987–998.\n390. Van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CPM, Krol ADG, Hauptmann\nM, et al. Radiation dose-response relationship for risk of coronary heart disease in\nsurvivors of Hodgkin lymphoma. J Clin Oncol 2016;34:235–243.\n391. Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, Van Nimwegen FA, Krol ADG,\net al. Risk for valvular heart disease after treatment for Hodgkin lymphoma. J Natl\nCancer Inst 2015;107:djv008.\n392. Bergom C, Bradley JA, Ng AK, Samson P, Robinson C, Lopez-Mattei J, et al. Past,\npresent, and future of radiation-induced cardiotoxicity: reﬁnements in targeting,\nsurveillance, and risk stratiﬁcation. JACC CardioOncology 2021;3:343–359.\n393. Belzile-Dugas E, Eisenberg MJ. Radiation-induced cardiovascular disease: review of\nan underrecognized pathology. J Am Heart Assoc 2021;10:e021686.\n394. Carlson LE, Watt GP, Tonorezos ES, Chow EJ, Yu AF, Woods M, et al. Coronary\nartery disease in young women after radiation therapy for breast cancer. JACC\nCardioOncology 2021;3:381–392.\n395. Jacob S, Camilleri J, Derreumaux S, Walker V, Lairez O, Lapeyre M, et al. Is mean\nheart dose a relevant surrogate parameter of left ventricle and coronary arteries\nexposure during breast cancer radiotherapy: a dosimetric evaluation based on\nindividually-determined radiation dose (BACCARAT study). Radiat Oncol 2019;\n14:29.\n396. Hoppe BS, Bates JE, Mendenhall NP, Morris CG, Louis D, Ho MW, et al. The mean-\ningless meaning of mean heart dose in mediastinal lymphoma in the modern radi-\nation therapy era. Pract Radiat Oncol 2020;10:e147–e154.\n397. Maraldo M V, Giusti F, Vogelius IR, Lundemann M, Van der Kaaij MAE, Ramadan S,\net al. Cardiovascular disease after treatment for Hodgkin’s lymphoma: an analysis of\nnine collaborative EORTC-LYSA trials. Lancet Haematol 2015;2:e492–e502.\n398. Atkins KM, Bitterman DS, Chaunzwa TL, Kozono DE, Baldini EH, Aerts HJWL, et al.\nMean heart dose is an inadequate surrogate for left anterior descending coronary\nartery dose and the risk of major adverse cardiac events in lung cancer radiation\ntherapy. Int J Radiat Oncol 2021;110:1473–1479.\n399. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al.\nCardiac outcomes in a cohort of adult survivors of childhood and adolescent can-\ncer: retrospective analysis of the childhood cancer survivor study cohort. BMJ 2009;\n339:b4606.\n400. Van Nimwegen FA, Schaapveld M, Janus CPM, Krol ADG, Petersen EJ, Raemaekers\nJMM, et al. Cardiovascular disease after Hodgkin lymphoma treatment 40-year dis-\nease risk. JAMA Intern Med 2015;175:1007–1017.\n401. Jacobse JN, Duane FK, Boekel NB, Schaapveld M, Hauptmann M, Hooning MJ, et al.\nRadiation dose-response for risk of myocardial infarction in breast cancer survi-\nvors. Int J Radiat Oncol Biol Phys 2019;103:595–604.\n402. Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, et al. Positron emission\ntomography-guided treatment in early-stage favorable Hodgkin lymphoma: ﬁnal re-\nsults of the international, randomized phase III HD16 trial by the German Hodgkin\nStudy Group. J Clin Oncol 2019;37:2835–2845.\n403. Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Results of\na trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med\n2015;372:1598–1607.\n404. Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving sur-\ngery with or without irradiation in women aged 65 years or older with early breast\ncancer (PRIME II): a randomised controlled trial. Lancet Oncol 2015;16:266–273.\n405. Song AJ, Manukian G, Taylor AK, Anne PR, Simone NL. Concerns for active breath-\ning control (ABC) with breast cancer in the era of COVID-19: maximizing infection\ncontrol while minimizing heart dose. Adv Radiat Oncol 2020;5:573–574.\n406. Petersen PM, Aznar MC, Berthelsen AK, Loft A, Schut DA, Maraldo M, et al.\nProspective phase II trial of image-guided radiotherapy in Hodgkin lymphoma:\nbeneﬁt of deep inspiration breath-hold. Acta Oncol (Madr) 2015;54:60–66.\n407. Persson GF, Scherman Rydhög J, Josipovic M, Maraldo M V, Nygård L, Costa J, et al.\nDeep inspiration breath-hold volumetric modulated arc radiotherapy decreases\ndose to mediastinal structures in locally advanced lung cancer. Acta Oncol (Madr)\n2016;55:1053–1056.\n408. Dabaja BS, Hoppe BS, Plastaras JP, Newhauser W, Rosolova K, Flampouri S, et al.\nProton therapy for adults with mediastinal lymphomas: the International\nLymphoma Radiation Oncology Group guidelines. Blood 2018;132:1635–1646.\nErratum in: Blood 2019;133:1384–1385.\n409. Rotz SJ, Ryan TD, Hayek SS. Cardiovascular disease and its management in children\nand adults undergoing hematopoietic stem cell transplantation. J Thromb\nThrombolysis 2021;51:854–869.\n410. Oliveira GH, Al-Kindi SG, Guha A, Dey AK, Rhea IB, DeLima MJ. Cardiovascular risk\nassessment and management of patients undergoing hematopoietic cell transplant-\nation. Bone Marrow Transplant 2021;56:544–551.\n411. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al.\nHematopoietic cell transplantation (HCT)-speciﬁc comorbidity index: a new tool\nfor risk assessment before allogeneic HCT. Blood 2005;106:2912–2919.\n412. Tichelli A, Bucher C, Rovó A, Stussi G, Stern M, Paulussen M, et al. Premature car-\ndiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood\n2007;110:3463–3471.\n413. Alblooshi R, Kanfar S, Lord B, Atenafu EG, Michelis FV, Pasic I, et al. Clinical preva-\nlence and outcome of cardiovascular events in the ﬁrst 100 days postallogeneic\nhematopoietic stem cell transplant. Eur J Haematol 2021;106:32–39.\n414. Duléry R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E, et al. Early cardiac tox-\nicity associated with post-transplant cyclophosphamide in allogeneic stem cell\ntransplantation. JACC CardioOncology 2021;3:250–259.\n415. López-Fernández T, Vadillo IS, de la Guía AL, Barbier KH. Cardiovascular issues in\nhematopoietic stem cell transplantation (HSCT). Curr Treat Options Oncol 2021;22:\n51.\n416. Ohmoto A, Fuji S. Cardiac complications associated with hematopoietic stem-cell\ntransplantation. Bone Marrow Transplant 2021;56:2637–2643.\n417. Takatsuka H, Nakajima T, Nomura K, Okikawa Y, Wakae T, Toda A, et al. Prognosis\nvalue of atrial natriuretic peptide and brain natriuretic peptide for heart failure in\npatients undergoing allogeneic bone marrow transplantation. Hematology 2006;\n11:351–354.\n418. Snowden JA, Hill GR, Hunt P, Carnoutsos S, Spearing RL, Espiner E, et al.\nAssessment of cardiotoxicity during haemopoietic stem cell transplantation with\nplasma brain natriuretic peptide. Bone Marrow Transplant 2000;26:309–313.\n419. Alvarez-Cardona JA, Zhang KW, Mitchell JD, Zaha VG, Fisch MJ, Lenihan DJ.\nCardiac\nbiomarkers\nduring\ncancer\ntherapy:\npractical\napplications\nfor\ncardio-oncology. JACC CardioOncology 2020;2:791–794.\n420. Mohammed J, Smith SR, Burns L, Basak G, Aljurf M, Savani BN, et al. Role of physical\ntherapy before and after hematopoietic stem cell transplantation: white paper re-\nport. Biol Blood Marrow Transplant 2019;25:e191–e198.\n421. Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, et al.\nCardiovascular risk factors and morbidity in long-term survivors of testicular can-\ncer: a 20-year follow-up study. J Clin Oncol 2010;28:4649–4657.\n4352\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n422. Herrmann J. Cardiovascular toxicity with cisplatin in patients with testicular cancer:\nlooking for something heavier than heavy metal. JACC CardioOncology 2020;2:\n456–459.\n423. Cerchione C, Peleteiro Raíndo A, Mosquera Orgueira A, Mosquera Torre A, Bao\nPérez L, Marconi G, et al. Safety of FLT3 inhibitors in patients with acute myeloid\nleukemia. Expert Rev Hematol 2021;14:851–865.\n424. Dong H, Yao L, Wang M, Wang M, Li X, Sun X, et al. Can ACEI/ARB prevent the\ncardiotoxicity caused by chemotherapy in early-stage breast cancer?—A\nmeta-analysis of randomized controlled trials. Transl Cancer Res 2020;11:\n7034–7043.\n425. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al.\nAnthracycline-induced cardiomyopathy: clinical relevance and response to pharma-\ncologic therapy. J Am Coll Cardiol 2010;55:213–220.\n426. Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab der-\nuxtecan in previously treated HER2-positive breast cancer. N Engl J Med 2020;382:\n610–621.\n427. Hussain Y, Drill E, Dang CT, Liu JE, Steingart RM, Yu AF. Cardiac outcomes of tras-\ntuzumab therapy in patients with HER2-positive breast cancer and reduced left\nventricular ejection fraction. Breast Cancer Res Treat 2019;175:239–246.\n428. Leong DP, Cosman T, Alhussein MM, Kumar Tyagi N, Karampatos S, Barron CC,\net al. Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial.\nJACC CardioOncology 2019;1:1–10.\n429. Omland T, Heck SL, Gulati G. The role of cardioprotection in cancer therapy car-\ndiotoxicity: JACC: CardioOncology state-of-the-art review. Cardio Oncol 2022;4:\n19–37.\n430. Russell SD, Blackwell KL, Lawrence J, Pippen JE, Roe MT, Wood F, et al.\nIndependent adjudication of symptomatic heart failure with the use of doxorubicin\nand cyclophosphamide followed by trastuzumab adjuvant therapy: A combined re-\nview of cardiac data from the National Surgical Adjuvant Breast and Bowel Project\nB-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin\nOncol 2010;28:3416–3421.\n431. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al.\nReversibility of trastuzumab-related cardiotoxicity: new insights based on clinical\ncourse and response to medical treatment. J Clin Oncol 2005;23:7820–7826.\n432. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term\ncardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson\nCancer Center experience. J Clin Oncol 2006;24:4107–4115.\n433. Khoury K, Lynce F, Barac A, Geng X, Dang C, Yu AF, et al. Long-term follow-up\nassessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of\nHER2-targeted therapies in patients with breast cancer and compromised heart\nfunction. Breast Cancer Res Treat 2021;185:863–868.\n434. Mahmood SS, Fradley MG, Cohen J V, Nohria A, Reynolds KL, Heinzerling LM, et al.\nMyocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol\n2018;71:1755–1764.\n435. Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek S, Asnani A, et al.\nElectrocardiographic manifestations of immune checkpoint inhibitor myocarditis.\nCirculation 2021;144:1521–1523. Erratum in: Circulation 2021;144:e490.\n436. Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, et al.\nMajor adverse cardiovascular events and the timing and dose of corticosteroids\nin immune checkpoint inhibitor-associated myocarditis. Circulation 2020;141:\n2031–2034.\n437. Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Sufﬁotti M, Moslehi JJ, et al.\n68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myo-\ncarditis. J Immunother Cancer 2021;9:e003594.\n438. Finke D, Heckmann MB, Herpel E, Katus HA, Haberkorn U, Leuschner F, et al. Early\ndetection of checkpoint inhibitor-associated myocarditis using 68Ga-FAPI PET/CT.\nFront Cardiovasc Med 2021;8:614997.\n439. Chen Y, Jia Y, Liu Q, Shen Y, Zhu H, Dong X, et al. Myocarditis related to immune\ncheckpoint inhibitors treatment: two case reports and literature review. Ann Palliat\nMed 2021;10:8512–8517.\n440. Palaskas NL, Segura A, Lelenwa L, Siddiqui BA, Subudhi SK, Lopez-Mattei J, et al.\nImmune checkpoint inhibitor myocarditis: elucidating the spectrum of disease\nthrough endomyocardial biopsy. Eur J Heart Fail 2021;23:1725–1735.\n441. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstrom-Lundqvist C, et al.\n2019 ESC Guidelines for the management of patients with supraventricular tachy-\ncardia. Eur Heart J 2020;41:655–720.\n442. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022\nESC Guidelines for the management of patients with ventricular arrhythmias and\nthe prevention of sudden cardiac death. Eur Heart J 2022;43:3997–4126.\n443. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al.\n2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur\nHeart J 2021;42:3427–3520.\n444. Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015\nESC Guidelines for the diagnosis and management of pericardial diseases: the Task\nForce for the Diagnosis and Management of Pericardial Diseases of the European\nSociety of Cardiology (ESC) Endorsed by: The European Association for\nCardio-Thoracic Surgery (EACTS). Eur Heart J 2015;36:2921–2964.\n445. Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, et al.\nManagement of acute myocarditis and chronic inﬂammatory cardiomyopathy: an\nexpert consensus document. Circ Heart Fail 2020;13:e007405.\n446. Thuny F, Alexandre J, Salem JE, Mirabel M, Dolladille C, Cohen-Solal A, et al.\nManagement of immune checkpoint inhibitor–induced myocarditis: the French\nWorking Group’s Plea for a pragmatic approach. JACC CardioOncology 2021;3:\n157–161.\n447. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-\nblind, placebo-controlled, pilot trial of inﬂiximab, a chimeric monoclonal antibody\nto tumor necrosis factor-α, in patients with moderate-to-severe heart failure:\nResults of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH)\ntrial. Circulation 2003;107:3133–3140.\n448. Cautela J, Zeriouh S, Gaubert M, Bonello L, Laine M, Peyrol M, et al. Intensiﬁed im-\nmunosuppressive therapy in patients with immune checkpoint inhibitor-induced\nmyocarditis. J Immunother Cancer 2020;8:e001887.\n449. Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, et al. Immune\ncheckpoint inhibitor rechallenge after immune-related adverse events in patients\nwith cancer. JAMA Oncol 2020;6:865–871.\n450. Roth ME, Muluneh B, Jensen BC, Madamanchi C, Lee CB. Left ventricular dysfunc-\ntion after treatment with ipilimumab for metastatic melanoma. Am J Ther 2016;23:\ne1925–e1928.\n451. Weinstock C, Khozin S, Suzman D, Zhang L, Tang S, Wahby S, et al. U.S. Food and\nDrug Administration approval summary: atezolizumab for metastatic non–small\ncell lung cancer. Clin Cancer Res 2017;23:4534–4539.\n452. Ball S, Ghosh RK, Wongsaengsak S, Bandyopadhyay D, Ghosh GC, Aronow WS,\net al. Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic\nof the week. J Am Coll Cardiol 2019;74:1714–1727.\n453. Thavendiranathan P, Zhang L, Zafar A, Drobni ZD, Mahmood SS, Cabral M, et al.\nMyocardial T1 and T2 mapping by magnetic resonance in patients with immune\ncheckpoint inhibitor–associated myocarditis. J Am Coll Cardiol 2021;77:1503–1516.\n454. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al.\nManagement of immune-related adverse events in patients treated with immune\ncheckpoint inhibitor therapy: American Society of Clinical Oncology clinical prac-\ntice guideline. J Clin Oncol 2018;36:1714–1768.\n455. Guha A, Addison D, Jain P, Gutierrez JM, Ghosh A, Roddie C, et al. Cardiovascular\nevents associated with chimeric antigen receptor T cell therapy: cross-sectional\nFDA adverse events reporting system analysis: cardiovascular events with CAR-T\ntherapy. Biol Blood Marrow Transplant 2020;26:2211–2216.\n456. Kupari M, Volin L, Suokas A, Hekali P, Ruutu T. Cardiac involvement in bone mar-\nrow transplantation: serial changes in left ventricular size, mass and performance. J\nIntern Med 1990;227:259–266.\n457. Tonorezos ES, Stillwell EE, Calloway JJ, Glew T, Wessler JD, Rebolledo BJ, et al.\nArrhythmias in the setting of hematopoietic cell transplants. Bone Marrow\nTransplant 2015;50:1212–1216.\n458. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020\nESC Guidelines for the management of acute coronary syndromes in patients pre-\nsenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289–1367.\n459. Abo S, Ritchie D, Denehy L, Panek-Hudson Y, Irving L, Granger CL. A hospital and\nhome-based exercise program to address functional decline in people following\nallogeneic stem cell transplantation. Support Care Cancer 2018;26:1727–1736.\n460. Squires RW, Shultz AM, Herrmann J. Exercise training and cardiovascular health in\ncancer patients. Curr Oncol Rep 2018;20:27.\n461. Keen C, Skilbeck J, Ross H, Smith L, Collins K, Dixey J, et al. Is it feasible to conduct a\nrandomised controlled trial of pretransplant exercise (prehabilitation) for patients\nwith multiple myeloma awaiting autologous haematopoietic stem cell transplant-\nation? Protocol for the PREeMPT study. BMJ Open 2018;8:e021333.\n462. Desai R, Desai A, Abbas SA, Patel U, Bansod S, Damarlapally N, et al. National\nprevalence, trends and outcomes of takotsubo syndrome in hospitalizations with\nprior history of mediastinal/intrathoracic cancer and radiation therapy. Int J\nCardiol 2020;309:14–18.\n463. Sattler K, El-Battrawy I, Lang S, Zhou X, Schramm K, Tülümen E, et al. Prevalence of\ncancer in Takotsubo cardiomyopathy: short and long-term outcome. Int J Cardiol\n2017;238:159–165.\n464. Omerovic E, Citro R, Bossone E, Redfors B, Backs J, Bruns B, et al. Pathophysiology\nof Takotsubo syndrome—a joint scientiﬁc statement from the HFA TTS and\nMyocardial Function Working Group of the ESC—Part 2: vascular pathophysi-\nology, gender and sex hormones, genetics, chronic cardiovascular problems and\nclinical implications. Eur J Heart Fail 2022;24:274–286.\n465. Omerovic E, Citro R, Bossone E, Redfors B, Backs J, Bruns B, et al. Pathophysiology\nof Takotsubo syndrome—a joint scientiﬁc statement from the HFA TTS Study\nGroup and Myocardial Function Working Group of the ESC—Part 1: overview\nand the central role for catecholamines and sympathetic nervous system. Eur J\nHeart Fail 2022;24:257–273.\nESC Guidelines\n4353\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n466. Couch LS, Fiedler J, Chick G, Clayton R, Dries E, Wienecke LM, et al. Circulating\nmicroRNAs predispose to Takotsubo syndrome following high-dose adrenaline\nexposure. Cardiovasc Res 2022;118:1758–1770.\n467. Ghadri J-R, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International\nexpert consensus document on Takotsubo syndrome (part II): diagnostic workup,\noutcome, and management. Eur Heart J 2018;39:2047–2062.\n468. Ghadri J-R, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International\nexpert consensus document on Takotsubo syndrome (part I): clinical characteris-\ntics, diagnostic criteria, and pathophysiology. Eur Heart J 2018;39:2032–2046.\n469. Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, et al.\nCurrent state of knowledge on Takotsubo syndrome: a Position Statement from\nthe Taskforce on Takotsubo Syndrome of the Heart Failure Association of the\nEuropean Society of Cardiology. Eur J Heart Fail 2016;18:8–27.\n470. Demers M, Krause DS, Schatzberg D, Martinod K, Voorhees JR, Fuchs TA, et al.\nCancers predispose neutrophils to release extracellular DNA traps that contribute\nto cancer-associated thrombosis. Proc Natl Acad Sci U S A 2012;109:13076–13081.\n471. Mrotzek SM, Lena A, Hadzibegovic S, Ludwig R, Al-Rashid F, Mahabadi AA, et al.\nAssessment of coronary artery disease during hospitalization for cancer treatment.\nClin Res Cardiol 2021;110:200–210.\n472. Nykl R, Fischer O, Vykoupil K, Taborsky M. A unique reason for coronary spasm\ncausing temporary ST elevation myocardial infarction (inferior STEMI)—systemic\ninﬂammatory response syndrome after use of pembrolizumab. Arch Med Sci\nAtheroscler Dis 2017;2:100–102.\n473. Ferreira M, Pichon E, Carmier D, Bouquet E, Pageot C, Bejan-Angoulvant T, et al.\nCoronary toxicities of anti-PD-1 and anti-PD-L1 immunotherapies: a case report\nand review of the literature and international registries. Target Oncol 2018;13:\n509–515.\n474. Iannaccone M, D’Ascenzo F, Vadalà P, Wilton SB, Noussan P, Colombo F, et al.\nPrevalence and outcome of patients with cancer and acute coronary syndrome\nundergoing percutaneous coronary intervention: a BleeMACS substudy. Eur\nHeart Journal Acute Cardiovasc Care 2018;7:631–638.\n475. Bharadwaj A, Potts J, Mohamed MO, Parwani P, Swamy P, Lopez-Mattei JC, et al.\nAcute myocardial infarction treatments and outcomes in 6.5 million patients\nwith a current or historical diagnosis of cancer in the USA. Eur Heart J 2020;41:\n2183–2193.\n476. Velders MA, Boden H, Hofma SH, Osanto S, Van Der Hoeven BL, Heestermans\nAACM, et al. Outcome after ST elevation myocardial infarction in patients with\ncancer treated with primary percutaneous coronary intervention. Am J Cardiol\n2013;112:1867–1872.\n477. Ueki Y, Vögeli B, Karagiannis A, Zanchin T, Zanchin C, Rhyner D, et al. Ischemia and\nbleeding in cancer patients undergoing percutaneous coronary intervention. JACC\nCardioOncology 2019;1:145–155.\n478. Potts JE, Iliescu CA, Lopez Mattei JC, Martinez SC, Holmvang L, Ludman P, et al.\nPercutaneous coronary intervention in cancer patients: a report of the prevalence\nand outcomes in the United States. Eur Heart J 2019;40:1790–1800.\n479. Guddati AK, Joy PS, Kumar G. Analysis of outcomes of percutaneous coronary\nintervention in metastatic cancer patients with acute coronary syndrome over a\n10-year period. J Cancer Res Clin Oncol 2016;142:471–479.\n480. Pothineni NV, Shah NN, Rochlani Y, Saad M, Kovelamudi S, Marmagkiolis K, et al.\nTemporal trends and outcomes of acute myocardial infarction in patients with can-\ncer. Ann Transl Med 2017;5:482.\n481. Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and out-\ncomes of acute coronary syndrome in the cancer population. Clin Cardiol 2012;35:\n443–450.\n482. Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, et al.\nEvaluation and management of cancer patients presenting with acute cardiovascu-\nlar disease: a Consensus Document of the Acute CardioVascular Care (ACVC) as-\nsociation and the ESC council of Cardio-Oncology—Part 1: acute coronary\nsyndromes and acute pericardial diseases. Eur Heart J Acute Cardiovasc Care 2021;\n10:947–959.\n483. Mohamed MO, Van Spall HGC, Kontopantelis E, Alkhouli M, Barac A, Elgendy IY,\net al. Effect of primary percutaneous coronary intervention on in-hospital out-\ncomes among active cancer patients presenting with ST-elevation myocardial in-\nfarction: a propensity score matching analysis. Eur Heart J Acute Cardiovasc Care\n2021;10:829–839.\n484. Iliescu CA, Grines CL, Herrmann J, Yang EH, Cilingiroglu M, Charitakis K, et al. SCAI\nExpert consensus statement: Evaluation, management, and special considerations\nof cardio-oncology patients in the cardiac catheterization laboratory (endorsed\nby the Cardiological Society of India, and Sociedad Latino Americana de\nCardiologıa Intervencionista). Catheter Cardiovasc Interv 2016;87:E202–E223.\n485. Iliescu CA, Cilingiroglu M, Giza DE, Rosales O, Lebeau J, Guerrero-Mantilla I, et al.\n‘Bringing on the light’ in a complex clinical scenario: optical coherence tomog-\nraphy–guided discontinuation of antiplatelet therapy in cancer patients with coron-\nary artery disease (PROTECT-OCT registry). Am Heart J 2017;194:83–91.\n486. Iliescu C, Balanescu DV, Donisan T, Giza DE, Muñoz Gonzalez ED, Cilingiroglu M,\net al. Safety of diagnostic and therapeutic cardiac catheterization in cancer patients\nwith acute coronary syndrome and chronic thrombocytopenia. Am J Cardiol 2018;\n122:1465–1470.\n487. Cianci G, Morelli MF, Cannita K, Morese R, Ricevuto E, Di Rocco ZC, et al.\nProphylactic options in patients with 5-ﬂuorouracil-associated cardiotoxicity. Br J\nCancer 2003;88:1507–1509.\n488. Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine-induced chest pain\nrelieved by diltiazem. Am J Cardiol 2012;110:1623–1626.\n489. Akpek G, Hartshorn KL. Failure of oral nitrate and calcium channel blocker therapy\nto prevent 5-ﬂuorouracil-related myocardial ischemia: a case report. Cancer\nChemother Pharmacol 1999;43:157–161.\n490. Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular com-\nplications of cancer therapy: best practices in diagnosis, prevention, and manage-\nment: part 2. J Am Coll Cardiol 2017;70:2552–2565.\n491. Campia U, Moslehi JJ, Amiri-Kordestani L, Barac A, Beckman JA, Chism DD, et al.\nCardio-oncology: vascular and metabolic perspectives: a scientiﬁc statement from\nthe American Heart Association. Circulation 2019;139:e579–e602.\n492. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence,\npathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231–2247.\n493. Lenneman CG, Sawyer DB. Cardio-oncology: an update on cardiotoxicity of\ncancer-related treatment. Circ Res 2016;118:1008–1020.\n494. Novo G, Di Lisi D, Bronte E, MacAione F, Accurso V, Badalamenti G, et al.\nCardiovascular toxicity in cancer patients treated with tyrosine kinase inhibitors:\na real-world single-center experience. Oncology 2020;98:445–451.\n495. Bharadwaj AS, Swamy PM, Mamas MA. Outcomes of percutaneous coronary inter-\nventions in cancer patients. Expert Rev Cardiovasc Ther 2020;18:25–32.\n496. Kwok CS, Wong CW, Kontopantelis E, Barac A, Brown SA, Velagapudi P, et al.\nPercutaneous coronary intervention in patients with cancer and readmissions with-\nin 90 days for acute myocardial infarction and bleeding in the USA. Eur Heart J 2021;\n42:1019–1034.\n497. van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ,\net al. Predictors of coronary stent thrombosis. The Dutch Stent Thrombosis\nRegistry. J Am Coll Cardiol 2009;53:1399–1409.\n498. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al.\nDeﬁning high bleeding risk in patients undergoing percutaneous coronary interven-\ntion. Circulation 2019;140:240–261.\n499. Stewart MH, Jahangir E, Polin NM. Valvular heart disease in cancer patients: eti-\nology, diagnosis, and management. Curr Treat Options Cardiovasc Med 2017;19:53.\n500. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid,\nsubclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated\nwith radiation therapy. J Am Med Assoc 2003;290:2831–2837.\n501. Salz T, Zabor EC, de Nully Brown P, Dalton SO, Raghunathan NJ, Matasar MJ, et al.\nPreexisting cardiovascular risk and subsequent heart failure among non-Hodgkin\nlymphoma survivors. J Clin Oncol 2017;35:3837–3843.\n502. Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, et al.\nTrastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk fac-\ntors. Ann Oncol 2012;23:897–902.\n503. Sato A, Yoshihisa A, Miyata-Tatsumi M, Oikawa M, Kobayashi A, Ishida T, et al.\nValvular heart disease as a possible predictor of trastuzumab-induced cardiotoxi-\ncity in patients with breast cancer. Mol Clin Oncol 2019;10:37–42.\n504. Watanabe Y, Kozuma K, Hioki H, Kawashima H, Nara Y, Kataoka A, et al.\nComparison of results of transcatheter aortic valve implantation in patients with\nversus without active cancer. Am J Cardiol 2016;118:572–577.\n505. Nagata H, Kanzaki R, Kanou T, Ose N, Funaki S, Shintani Y, et al. Two cases of lob-\nectomy for lung cancer after transcatheter aortic valve implantation. Surg Case\nReports 2018;4:139.\n506. Landes U, Iakobishvili Z, Vronsky D, Zusman O, Barsheshet A, Jaffe R, et al.\nTranscatheter aortic valve replacement in oncology patients with severe aortic\nstenosis. JACC Cardiovasc Interv 2019;12:78–86.\n507. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021\nESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J\n2022;43:561–632.\n508. López-Fernández T, Martín-García A, Roldán Rabadán I, Mitroi C, Mazón Ramos P,\nDíez-Villanueva P, et al. Atrial ﬁbrillation in active cancer patients: expert position\npaper and recommendations. Rev Española Cardiol (English Ed) 2019;72:749–759.\n509. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial ﬁbrillation in\ncancer. J Am Coll Cardiol 2014;63:945–953.\n510. Yun JP, Choi EK, Do Han K, Park SH, Jung JH, Park SH, et al. Risk of atrial ﬁbrillation\naccording\nto\ncancer\ntype:\na\nnationwide\npopulation-based\nstudy.\nJACC\nCardioOncology 2021;3:221–232.\n511. Guha A, Fradley MG, Dent SF, Weintraub NL, Lustberg MB, Alonso A, et al.\nIncidence, risk factors, and mortality of atrial ﬁbrillation in breast cancer: a\nSEER-Medicare analysis. Eur Heart J 2021;43:300–312.\n4354\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n512. Hu YF, Liu CJ, Chang PMH, Tsao HM, Lin YJ, Chang SL, et al. Incident thrombo-\nembolism and heart failure associated with new-onset atrial ﬁbrillation in cancer pa-\ntients. Int J Cardiol 2013;165:355–357.\n513. Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP.\nAnticoagulation strategies in patients with cancer: JACC review topic of the\nweek. J Am Coll Cardiol 2019;73:1336–1349.\n514. Malavasi VL, Fantecchi E, Gianolio L, Pesce F, Longo G, Marietta M, et al. Atrial ﬁb-\nrillation in patients with active malignancy and use of anticoagulants: under-\nprescription but no adverse impact on all-cause mortality. Eur J Intern Med 2019;\n59:27–33.\n515. Al-Kindi SG, Oliveira GH. Prevalence of preexisting cardiovascular disease in pa-\ntients with different types of cancer the unmet need for onco-cardiology. Mayo\nClin Proc 2016;91:81–83.\n516. Alexandre J, Moslehi JJ, Bersell KR, Funck-Brentano C, Roden DM, Salem JE.\nAnticancer drug-induced cardiac rhythm disorders: current knowledge and basic\nunderlying mechanisms. Pharmacol Ther 2018;189:89–103.\n517. Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, et al. Practical man-\nagement of ibrutinib in the real life: focus on atrial ﬁbrillation and bleeding. Hematol\nOncol 2018;36:624–632.\n518. Tang CPS, Lip GYH, McCormack T, Lyon AR, Hillmen P, Iyengar S, et al.\nManagement of cardiovascular complications of Bruton tyrosine kinase inhibitors.\nBr J Haematol 2022;196:70–78.\n519. Pastori D, Marang A, Bisson A, Menichelli D, Herbert J, Lip GYH, et al.\nThromboembolism, mortality, and bleeding in 2,435,541 atrial ﬁbrillation patients\nwith and without cancer: a nationwide cohort study. Cancer 2021;127:2122–2129.\n520. Potpara TS, Lip GYH, Blomstrom-Lundqvist C, Boriani G, Van Gelder IC,\nHeidbuchel H, et al. The 4S-AF scheme (Stroke Risk; Symptoms; Severity of\nBurden; Substrate): a novel approach to in-depth characterization (rather than clas-\nsiﬁcation) of atrial ﬁbrillation. Thromb Haemost 2021;121:270–278.\n521. Boriani G, Bonini N, Albini A, Venturelli A, Imberti JF, Vitolo M. Cardioversion of\nrecent-onset atrial ﬁbrillation: current evidence, practical considerations, and con-\ntroversies in a complex clinical scenario. Kardiol Pol 2020;78:1088–1098.\n522. Kanmanthareddy A, Vallakati A, Reddy Yeruva M, Dixit S, Di Biase L, Mansour M,\net al. Pulmonary vein isolation for atrial ﬁbrillation in the postpneumonectomy\npopulation: a feasibility, safety, and outcomes study. J Cardiovasc Electrophysiol\n2015;26:385–389.\n523. Lip GYH, Banerjee A, Boriani G, En Chiang C, Fargo R, Freedman B, et al.\nAntithrombotic therapy for atrial ﬁbrillation: CHEST guideline and expert panel re-\nport. Chest 2018;154:1121–1201.\n524. Proietti M, Lane DA, Boriani G, Lip GYH. Stroke prevention, evaluation of bleeding\nrisk, and anticoagulant treatment management in atrial ﬁbrillation contemporary\ninternational guidelines. Can J Cardiol 2019;35:619–633.\n525. Boriani G, Lee G, Parrini I, Lopez-Fernandez T, Lyon AR, Suter T, et al.\nAnticoagulation in patients with atrial ﬁbrillation and active cancer: an international\nsurvey on patient management. Eur J Prev Cardiol 2021;28:611–621.\n526. D’Souza M, Carlson N, Fosbøl E, Lamberts M, Smedegaard L, Nielsen D, et al.\nCHA2DS2-VASC score and risk of thromboembolism and bleeding in patients\nwith atrial ﬁbrillation and recent cancer. Eur J Prev Cardiol 2018;25:651–658.\n527. Farmakis D. Anticoagulation for atrial ﬁbrillation in active cancer: what the cardiol-\nogists think. Eur J Prev Cardiol 2021;28:608–610.\n528. Cohen A, Donal E, Delgado V, Pepi M, Tsang T, Gerber B, et al. EACVI recommen-\ndations on cardiovascular imaging for the detection of embolic sources: endorsed\nby the Canadian Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2021;\n22:E24–E57.\n529. Schulman S, Anger SU, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Deﬁnition of\nmajor bleeding in clinical investigations of antihemostatic medicinal products in sur-\ngical patients. J Thromb Haemost 2010;8:202–204.\n530. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European\nHeart Rhythm Association practical guide on the use of non-vitamin K antagonist\noral anticoagulants in patients with atrial ﬁbrillation. Europace 2021;23:1612–1676.\n531. Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, et al.\nEfﬁcacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial ﬁb-\nrillation and a history of cancer: Observations from ROCKET AF. Eur Heart J Qual\nCare Clin Outcomes 2019;5:145–152.\n532. Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, et al. Efﬁcacy\nand safety of apixaban versus warfarin in patients with atrial ﬁbrillation and a history\nof cancer: insights from the ARISTOTLE trial. Am J Med 2017;130:1440–1448.e1.\n533. Fanola CL, Ruff CT, Murphy SA, Jin J, Duggal A, Babilonia NA, et al. Efﬁcacy and\nsafety of edoxaban in patients with active malignancy and atrial ﬁbrillation: analysis\nof the engage AF-TIMI 48 trial. J Am Heart Assoc 2018;7:e008987.\n534. Sawant AC, Kumar A, McCray W, Tetewsky S, Parone L, Sridhara S, et al. Superior\nsafety of direct oral anticoagulants compared to warfarin in patients with atrial ﬁb-\nrillation and underlying cancer: a national Veterans Affairs database study. J Geriatr\nCardiol 2019;16:706–709.\n535. Shah S, Norby FL, Datta YH, Lutsey PL, MacLehose RF, Chen LY, et al. Comparative\neffectiveness of direct oral anticoagulants and warfarin in patients with cancer and\natrial ﬁbrillation. Blood Adv 2018;2:200–209.\n536. Mariani MV, Magnocavallo M, Straito M, Piro A, Severino P, Iannucci G, et al. Direct\noral anticoagulants versus vitamin K antagonists in patients with atrial ﬁbrillation\nand cancer a meta-analysis. J Thromb Thrombolysis 2021;51:419–429.\n537. Deitelzweig S, Keshishian AV, Zhang Y, Kang A, Dhamane AD, Luo X, et al.\nEffectiveness and safety of oral anticoagulants among nonvalvular atrial ﬁbrillation\npatients with active cancer. JACC CardioOncology 2021;3:411–424.\n538. Lin YS, Kuan FC, Chao TF, Wu M, Chen SW, Chen MC, et al. Mortality associated\nwith the use of non-vitamin K antagonist oral anticoagulants in cancer patients: da-\nbigatran versus rivaroxaban. Cancer Med 2021;10:7079–7088.\n539. Isogai T, Saad AM, Abushouk AI, Shekhar S, Kuroda S, Gad MM, et al. Procedural\nand short-term outcomes of percutaneous left atrial appendage closure in patients\nwith cancer. Am J Cardiol 2021;141:154–157.\n540. Boriani G, Fauchier L, Aguinaga L, Beattie JM, Blomstrom Lundqvist C, Cohen A,\net al. European Heart Rhythm Association (EHRA) consensus document on man-\nagement of arrhythmias and cardiac electronic devices in the critically ill and post-\nsurgery patient, endorsed by Heart Rhythm Society (HRS), Asia Paciﬁc Heart\nRhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa\n(CASSA), and Latin American Heart Rhythm Society (LAHRS). Europace 2019;\n21:7–8.\n541. Butt JH, Olesen JB, Havers-Borgersen E, Gundlund A, Andersson C, Gislason GH,\net al. Risk of thromboembolism associated with atrial ﬁbrillation following noncar-\ndiac surgery. J Am Coll Cardiol 2018;72:2027–2036.\n542. Enriquez A, Biagi J, Redfearn D, Boles U, Kamel D, Ali FS, et al. Increased incidence\nof ventricular arrhythmias in patients with advanced cancer and implantable\ncardioverter-deﬁbrillators. JACC Clin Electrophysiol 2017;3:50–56.\n543. Roden DM. Predicting drug-induced QT prolongation and torsades de pointes. J\nPhysiol 2016;594:2459–2468.\n544. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al.\n2017 AHA/ACC/HRS guideline for management of patients with ventricular ar-\nrhythmias and the prevention of sudden cardiac death: Executive summary: a re-\nport of the American College of Cardiology/American Heart Association Task\nForce on Clinical Practice Guidelines and the Heart Rhythm Society. Heart\nRhythm 2018;15:e190–e252.\n545. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long\nQT syndrome. An update. Circulation 1993;88:782–784.\n546. Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Leclerc J, et al.\nDrug-induced arrhythmias: a scientiﬁc statement from the American Heart\nAssociation. Circulation 2020;142:E214–E233.\n547. AZCERT. CredibleMeds.org n.d.\n548. Coppola C, Rienzo A, Piscopo G, Barbieri A, Arra C, Maurea N. Management of\nQT prolongation induced by anti-cancer drugs: target therapy and old agents.\nDifferent algorithms for different drugs. Cancer Treat Rev 2018;63:135–143.\n549. European Medicines Agency. ICH guideline E14/S7B on clinical and nonclinical\nevaluation of QT/QTc interval prolongation and proarrhythmic potential—ques-\ntions & answers. Sci Med Heal 2020:EMA/CHMP/ICH/415588/2020.\n550. Atallah-Yunes SA, Kadado AJ, Kaufman GP, Hernandez-Montfort J. Immune check-\npoint inhibitor therapy and myocarditis: a systematic review of reported cases. J\nCancer Res Clin Oncol 2019;145:1527–1557.\n551. Cirne F, Zhou S, Kappel C, El-Kadi A, Barron CC, Ellis PM, et al. ALK inhibitor-\ninduced bradycardia: a systematic review and meta-analysis. Lung Cancer 2021;\n161:9–17.\n552. Hassen LJ, Lenihan DJ, Baliga RR. Hypertension in the cardio-oncology clinic. Heart\nFail Clin 2019;15:487–495.\n553. Szmit S, Jurczak W, Zaucha JM, Drozd-Sokołowska J, Spychałowicz W, Joks M, et al.\nPre-existing arterial hypertension as a risk factor for early left ventricular systolic\ndysfunction following (R)-CHOP chemotherapy in patients with lymphoma. J Am\nSoc Hypertens 2014;8:791–799.\n554. Di Lorenzo G, Autorino R, Bruni G, Cartentì G, Ricevuto E, Tudini M, et al.\nCardiovascular toxicity following sunitinib therapy in metastatic renal cell carcin-\noma: a multicenter analysis. Ann Oncol 2009;20:1535–1542.\n555. Penttilä P, Rautiola J, Poussa T, Peltola K, Bono P. Angiotensin inhibitors as treat-\nment of sunitinib/pazopanib-induced hypertension in metastatic renal cell carcin-\noma. Clin Genitourin Cancer 2017;15:384–390.e3.\n556. Izzedine H, Derosa L, Le Teuff G, Albiges L, Escudier B. Hypertension and angioten-\nsin system inhibitors: impact on outcome in sunitinib-treated patients for metastat-\nic renal cell carcinoma. Ann Oncol 2015;26:1128–1133.\n557. McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OPR, Sabbisetti VS,\net al. Angiotensin system inhibitors and survival outcomes in patients with meta-\nstatic renal cell carcinoma. Clin Cancer Res 2015;21:2471–2479.\n558. Khorana\nAA,\nFrancis\nCW,\nCulakova\nE,\nKuderer\nNM,\nLyman\nGH.\nThromboembolism is a leading cause of death in cancer patients receiving out-\npatient chemotherapy. J Thromb Haemost 2007;5:632–634.\nESC Guidelines\n4355\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n559. Puurunen MK, Gona PN, Larson MG, Murabito JM, Magnani JW, O’Donnell CJ.\nEpidemiology of venous thromboembolism in the Framingham Heart Study.\nThromb Res 2016;145:27–33.\n560. Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thrombo-\nembolism in patients with cancer—a cohort study using linked United Kingdom da-\ntabases. Eur J Cancer 2013;49:1404–1413.\n561. Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden\nof disease and beneﬁts of thromboprophylaxis. Cancer 2011;117:1334–1349.\n562. Abdulla A, Davis WM, Ratnaweera N, Szefer E, Ballantyne Scott B, Lee AYY. A\nmeta-analysis of case fatality rates of recurrent venous thromboembolism and ma-\njor bleeding in patients with cancer. Thromb Haemost 2020;120:702–713.\n563. Mulder FI, Carrier M, van Doormaal F, Robin P, Otten HM, Salaun PY, et al. Risk\nscores for occult cancer in patients with unprovoked venous thromboembolism:\nresults from an individual patient data meta-analysis. J Thromb Haemost 2020;18:\n2622–2628.\n564. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the pa-\ntient with cancer. J Clin Oncol 2009;27:4839–4847.\n565. Li X, Hu Y, Lin P, Zhang J, Tang Y, Yi Q, et al. Comparison of different clinical prog-\nnostic scores in patients with pulmonary embolism and active cancer. Thromb\nHaemost 2021;121:834–844.\n566. Konstantinides SV, Meyer G, Bueno H, Galié N, Gibbs JSR, Ageno W, et al. 2019\nESC Guidelines for the diagnosis and management of acute pulmonary embolism\ndeveloped in collaboration with the European Respiratory Society (ERS). Eur\nHeart J 2020;41:543–603.\n567. Mazzolai L, Ageno W, Alatri A, Bauersachs R, Becattini C, Brodmann M, et al. Second\nconsensus document on diagnosis and management of acute deep vein thrombosis:\nupdated document elaborated by the ESC Working Group on aorta and peripheral\nvascular diseases and the ESC Working Group on pulmonary circulation and right\nventricular function. Eur J Prev Cardiol 2022;29:1248–1263\n568. Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MS V, et al. Risk of arterial\nthromboembolism in patients with cancer. J Am Coll Cardiol 2017;70:926–938.\n569. Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. J\nCardiol 2018;72:89–93.\n570. Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, et al.\nScreening adult survivors of childhood cancer for cardiomyopathy: comparison\nof echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012;\n30:2876–2884.\n571. Hooks M, Okasha O, Velangi PS, Nijjar PS, Farzaneh-Far A, Shenoy C. Left ventricu-\nlar thrombus on cardiovascular magnetic resonance imaging in non-ischaemic car-\ndiomyopathy. Eur Heart J Cardiovasc Imaging 2020. doi:10.1093/ehjci/jeaa244.\nOnline ahead of print 7 October 2020.\n572. Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al.\nLow-molecular-weight heparin versus a coumarin for the prevention of recurrent\nvenous thromboembolism in patients with cancer. N Engl J Med 2003;349:146–153.\n573. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, et al. Long-term\nlow-molecular-weight heparin versus usual care in proximal-vein thrombosis pa-\ntients with cancer. Am J Med 2006;119:1062–1072.\n574. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J. Secondary preven-\ntion of venous thromboembolic events in patients with active cancer: enoxaparin\nalone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl\nThromb 2006;12:389–396.\n575. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al.\nComparison of low-molecular-weight heparin and warfarin for the secondary pre-\nvention of venous thromboembolism in patients with cancer: a randomized con-\ntrolled study. Arch Intern Med 2002;162:1729–1735.\n576. Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al.\nTinzaparin vs warfarin for treatment of acute venous thromboembolism in patients\nwith active cancer: a randomized clinical trial. JAMA J Am Med Assoc 2015;314:\n677–686.\n577. Lee YJ, Park JK, Uhm JS, Kim JY, Pak HN, Lee MH, et al. Bleeding risk and major ad-\nverse events in patients with cancer on oral anticoagulation therapy. Int J Cardiol\n2016;203:372–378.\n578. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al.\nEdoxaban for the treatment of cancer-associated venous thromboembolism. N\nEngl J Med 2018;378:615–624.\n579. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison\nof an oral factor Xa inhibitor with low molecular weight heparin in patients with\ncancer\nwith\nvenous\nthromboembolism:\nresults\nof\na\nrandomized\ntrial\n(SELECT-D). J Clin Oncol 2018;36:2017–2023.\n580. McBane II RD, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A,\net al. Apixaban and dalteparin in active malignancy-associated venous thrombo-\nembolism: the ADAM VTE trial. J Thromb Haemost 2020;18:411–421.\n581. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman M V, Connors JM, et al.\nApixaban for the treatment of venous thromboembolism associated with cancer.\nN Engl J Med 2020;382:1599–1607.\n582. Ay C, Beyer-Westendorf J, Pabinger I. Treatment of cancer-associated venous\nthromboembolism in the age of direct oral anticoagulants. Ann Oncol 2019;30:\n897–907.\n583. Ageno W, Vedovati MC, Cohen A, Huisman M, Bauersachs R, Gussoni G, et al.\nBleeding with apixaban and dalteparin in patients with cancer-associated venous\nthromboembolism: results from the Caravaggio study. Thromb Haemost 2021;\n121:616–624.\n584. Cohen A, Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P, et al.\nEffectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin\namong venous thromboembolism patients with active cancer: a US claims data ana-\nlysis. Thromb Haemost 2021;121:383–395.\n585. Giustozzi M, Agnelli G, Del Toro-Cervera J, Klok FA, Rosovsky RP, Martin AC, et al.\nDirect oral anticoagulants for the treatment of acute venous thromboembolism as-\nsociated with cancer: a systematic review and meta-analysis. Thromb Haemost 2020;\n120:1128–1136.\n586. Sabatino J, De Rosa S, Polimeni A, Sorrentino S, IndolﬁC. Direct oral anticoagulants\nin patients with active cancer: a systematic review and meta-analysis. JACC\nCardioOncology 2020;2:428–440.\n587. Kraaijpoel N, Carrier M. How I treat cancer-associated venous thromboembolism.\nBlood 2019;133:291–298.\n588. Den Exter PL, Hooijer J, Dekkers OM, Huisman M V. Risk of recurrent venous\nthromboembolism and mortality in patients with cancer incidentally diagnosed\nwith pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol\n2011;29:2405–2409.\n589. Jara-Palomares\nL,\nSolier-Lopez\nA,\nElias-Hernandez\nT,\nAsensio-Cruz\nM,\nBlasco-Esquivias I, Marin-Barrera L, et al. Tinzaparin in cancer associated throm-\nbosis beyond 6 months: TiCAT study. Thromb Res 2017;157:90–96.\n590. Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman M V, et al.\nTreatment of venous thromboembolism in cancer patients with dalteparin for up\nto 12 months: the DALTECAN Study. J Thromb Haemost 2015;13:1028–1035.\n591. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, et al. 2020\nACC/AHA guideline for the management of patients with valvular heart disease: a\nreport of the American College of Cardiology/American Heart Association Joint\nCommittee on Clinical Practice Guidelines. J Am Coll Cardiol 2021;77:e25–e197.\n592. Riondino S, Ferroni P, Del Monte G, Formica V, Guadagni F, Roselli M. Venous\nthromboembolism in cancer patients on simultaneous and palliative care. Cancers\n(Basel) 2020;12:1167.\n593. Xin Z, Liu F, Du Y, Mao F, Wang X, Xu P, et al. Primary prophylaxis for venous\nthromboembolism in ambulatory cancer patients: a systematic review and network\nmeta-analysis. Ann Cardiothorac Surg 2020;9:2970–2981.\n594. Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, et al. 2019 internation-\nal clinical practice guidelines for the treatment and prophylaxis of venous thrombo-\nembolism in patients with cancer. Lancet Oncol 2019;20:e566–e581.\n595. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al.\nDuration of prophylaxis against venous thromboembolism with enoxaparin after\nsurgery for cancer. N Engl J Med 2002;346:975–980.\n596. Khorana A, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and\nvalidation of a predictive model for chemotherapy-associated thrombosis. Blood\n2008;111:4902–4907.\n597. Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El\nShemmari S, et al. A predictive score for thrombosis associated with breast, colo-\nrectal, lung, or ovarian cancer: the prospective COMPASS–cancer-associated\nthrombosis study. Oncologist 2017;22:1222–1231.\n598. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, et al.\nNadroparin for the prevention of thromboembolic events in ambulatory patients\nwith metastatic or locally advanced solid cancer receiving chemotherapy: a rando-\nmised, placebo-controlled, double-blind study. Lancet Oncol 2009;10:943–949.\n599. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, et al.\nSemuloparin for thromboprophylaxis in patients receiving chemotherapy for can-\ncer. N Engl J Med 2012;366:601–609.\n600. Di Nisio M, Porreca E, Candeloro M, De Tursi M, Russi I, Rutjes AWSS. Primary\nprophylaxis for venous thromboembolism in ambulatory cancer patients receiving\nchemotherapy. Cochrane Database Syst Rev 2016;12:CD008500.\n601. Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al.\nApixaban to prevent venous thromboembolism in patients with cancer. N Engl J\nMed 2019;380:711–719.\n602. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al. Rivaroxaban\nfor thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med\n2019;380:720–728.\n603. Angelini DE, Radivoyevitch T, McCrae KR, Khorana AA. Bleeding incidence and risk\nfactors among cancer patients treated with anticoagulation. Am J Hematol 2019;94:\n780–785.\n604. Menapace LA, McCrae KR, Khorana AA. Predictors of recurrent venous thrombo-\nembolism and bleeding on anticoagulation. Thromb Res 2016;140:S93–S98.\n4356\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n605. Roule V, Verdier L, Blanchart K, Ardouin P, Lemaitre A, Bignon M, et al. Systematic\nreview and meta-analysis of the prognostic impact of cancer among patients with\nacute coronary syndrome and/or percutaneous coronary intervention. BMC\nCardiovasc Disord 2020;20:38.\n606. Freedberg DE, Kim LS, Yang YX. The risks and beneﬁts of long-term use of proton\npump inhibitors: expert review and best practice advice from the American\nGastroenterological Association. Gastroenterology 2017;152:706–715.\n607. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC\nfocused update on dual antiplatelet therapy in coronary artery disease developed\nin collaboration with EACTS. Eur Heart J 2018;39:213–260.\n608. Baran DA, Grines CL, Bailey S, Burkhoff D, Hall SA, Henry TD, et al. SCAI clinical\nexpert consensus statement on the classiﬁcation of cardiogenic shock: This docu-\nment was endorsed by the American College of Cardiology (ACC), the American\nHeart Association (AHA), the Society of Critical Care Medicine (SCCM), and the\nSociety of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv\n2019;94:29–37.\n609. Schiffer CA, Bohlke K, Anderson KC. Platelet transfusion for patients with cancer:\nAmerican Society of Clinical Oncology Clinical Practice Guideline Update\nSummary. J Oncol Pract 2018;14:129–133.\n610. Al-Samkari H, Connors JM. Managing the competing risks of thrombosis, bleeding,\nand anticoagulation in patients with malignancy. Blood Adv 2019;3:3770–3779.\n611. Parr SK, Liang J, Schadler KL, Gilchrist SC, Steele CC, Ade CJ. Anticancer\ntherapy-related increases in arterial stiffness: a systematic review and meta-analysis.\nJ Am Heart Assoc 2020;9:e015598.\n612. Gambichler T, Strutzmann S, Tannapfel A, Susok L. Paraneoplastic acral vascular\nsyndrome in a patient with metastatic melanoma under immune checkpoint block-\nade. BMC Cancer 2017;17:327.\n613. Aichberger\nKJ,\nHerndlhofer\nS,\nSchernthaner\nGH,\nSchillinger\nM,\nMitterbauer-Hohendanner G, Sillaber C, et al. Progressive peripheral arterial occlu-\nsive disease and other vascular events during nilotinib therapy in CML. Am J Hematol\n2011;86:533–539.\n614. Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, et al.\nImpact of dose intensity of ponatinib on selected adverse events: multivariate ana-\nlyses from a pooled population of clinical trial patients. Leuk Res 2016;48:84–91.\n615. Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, Le Coutre P. Vascular\nsafety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 2015;\n125:901–906.\n616. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary\narterial hypertension in patients treated by dasatinib. Circulation 2012;125:\n2128–2137.\n617. Ranchoux B, Günther S, Quarck R, Chaumais MC, Dorfmüller P, Antigny F, et al.\nChemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J\nPathol 2015;185:356–371.\n618. Jevnikar M, Montani D, Savale L, Seferian A, Jutant EM, Boucly A, et al. Chronic\nthromboembolic pulmonary hypertension and totally implantable central venous\naccess systems. Eur Respir J 2021;57:2002208.\n619. Price LC, Seckl MJ, Dorfmüller P, Wort SJ. Tumoral pulmonary hypertension. Eur\nRespir Rev 2019;28:180065.\n620. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022\nESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.\nEur Heart J 2022;43:3618–3731.\n621. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib ver-\nsus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J\nMed 2010;362:2260–2270.\n622. Imazio M, Colopi M, De Ferrari GM. Pericardial diseases in patients with cancer:\nContemporary prevalence, management and outcomes. Heart 2020;106:569–574.\n623. Kim SR, Kim EK, Cho J, Chang SA, Park SJ, Lee SC, et al. Effect of anti-inﬂammatory\ndrugs on clinical outcomes in patients with malignant pericardial effusion. J Am Coll\nCardiol 2020;76:1551–1561.\n624. Gong J, Drobni ZD, Zafar A, Quinaglia T, Hartmann S, Gilman HK, et al. Pericardial\ndisease in patients treated with immune checkpoint inhibitors. J Immunother Cancer\n2021;9:e002771.\n625. Inno A, Maurea N, Metro G, Carbone A, Russo A, Gori S. Immune checkpoint\ninhibitors-associated pericardial disease: a systematic review of case reports.\nCancer Immunol Immunother 2021;70:3041–3053.\n626. Sánchez-Enrique C, Nuñez-Gil IJ, Viana-Tejedor A, De Agustín A, Vivas D,\nPalacios-Rubio J, et al. Cause and long-term outcome of cardiac tamponade. Am J\nCardiol 2016;117:664–669.\n627. Saab J, Hoda RS, Narula N, Hoda SA, Geraghty BE, Nasar A, et al. Diagnostic yield of\ncytopathology in evaluating pericardial effusions: clinicopathologic analysis of 419\nspecimens. Cancer Cytopathol 2017;125:128–137.\n628. Patel N, Raﬁque AM, Eshaghian S, Mendoza F, Biner S, Cercek B, et al. Retrospective\ncomparison of outcomes, diagnostic value, and complications of percutaneous pro-\nlonged drainage versus surgical pericardiotomy of pericardial effusion associated\nwith malignancy. Am J Cardiol 2013;112:1235–1239.\n629. Palaskas N, Morgan J, Daigle T, Banchs J, Durand JB, Hong D, et al. Targeted cancer\ntherapies with pericardial effusions requiring pericardiocentesis focusing on im-\nmune checkpoint inhibitors. Am J Cardiol 2019;123:1351–1357.\n630. Shaheen S, Mirshahidi H, Nagaraj G, Hsueh CT. Conservative management of\nnivolumab-induced pericardial effusion: a case report and review of literature.\nExp Hematol Oncol 2018;7:11.\n631. Dixon SB, Howell CR, Lu L, Plana JC, Joshi VM, Luepker R V, et al. Cardiac biomar-\nkers and association with subsequent cardiomyopathy and mortality among adult\nsurvivors of childhood cancer: a report from the St. Jude Lifetime Cohort.\nCancer 2021;127:458–466.\n632. Hershman DL, Till C, Shen S, Wright JD, Ramsey SD, Barlow WE, et al. Association\nof cardiovascular risk factors with cardiac events and survival outcomes among pa-\ntients with breast cancer enrolled in SWOG clinical trials. J Clin Oncol 2018;36:\n2710–2717.\n633. Nolan MT, Marwick TH, Plana JC, Li Z, Ness KK, Joshi VM, et al. Effect of traditional\nheart failure risk factors on myocardial dysfunction in adult survivors of childhood\ncancer. JACC Cardiovasc Imaging 2018;11:1202–1203.\n634. Cho H, Lee S, Sim SH, Park IH, Lee KS, Kwak MH, et al. Cumulative incidence of\nchemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast\ncancer patients. Breast Cancer Res Treat 2020;182:333–343.\n635. Smarz K, Jaxa-Chamiec T, Chwyczko T, Główczyńska R, Jegier A, Niedoszytko P,\net al. Cardiopulmonary exercise testing in adult cardiology: expert opinion of the\nWorking Group of Cardiac Rehabilitation and Exercise Physiology of the Polish\nCardiac Society. Kardiol Pol 2019;77:730–756.\n636. Scott JM, Zabor EC, Schwitzer E, Koelwyn GJ, Adams SC, Nilsen TS, et al. Efﬁcacy of\nexercise therapy on cardiorespiratory ﬁtness in patients with cancer: a systematic\nreview and meta-analysis. J Clin Oncol 2018;36:2297–2304.\n637. Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J, Jones LW. A framework for\nprescription in exercise-oncology research. J Cachexia Sarcopenia Muscle 2015;6:\n115–124.\n638. Wallen MP, Hennessy D, Brown S, Evans L, Rawstorn JC, Wong Shee A, et al.\nHigh-intensity interval training improves cardiorespiratory ﬁtness in cancer patients\nand survivors: a meta-analysis. Eur J Cancer Care (Engl) 2020;29:e13267.\n639. Lee K, Tripathy D, Demark-Wahnefried W, Courneya KS, Sami N, Bernstein L,\net al. Effect of aerobic and resistance exercise intervention on cardiovascular dis-\nease risk in women with early-stage breast cancer: a randomized clinical trial.\nJAMA Oncol 2019;5:710–714.\n640. Adams SC, Delorey DS, Davenport MH, Fairey AS, North S, Courneya KS. Effects\nof high-intensity interval training on fatigue and quality of life in testicular cancer\nsurvivors. Br J Cancer 2018;118:1313–1321.\n641. Mijwel S, Jervaeus A, Bolam KA, Norrbom J, Bergh J, Rundqvist H, et al.\nHigh-intensity exercise during chemotherapy induces beneﬁcial effects 12 months\ninto breast cancer survivorship. J Cancer Surviv 2019;13:244–256.\n642. Marriott CFS, Petrella AFM, Marriott ECS, Boa Sorte Silva NC, Petrella RJ.\nHigh-intensity interval training in older adults: a scoping review. Sport Med - Open\n2021;7:49.\n643. Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J, et al.\nCardiovascular health of patients with cancer and cancer survivors: a roadmap\nto the next level. J Am Coll Cardiol 2015;65:2739–2746.\n644. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al.\nCardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;\n370:2011–2019.\n645. Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, et al. Heart\nfailure associated with sunitinib malate: a multitargeted receptor tyrosine kinase in-\nhibitor. Cancer 2008;112:2500–2508.\n646. Kim PY, Irizarry-Caro JA, Ramesh T, Iliescu C, Lopez-Mattei JC. How to diagnose\nand manage QT prolongation in cancer patients. JACC CardioOncology 2021;3:\n145–149.\n647. Gatta G, Botta L, Rossi S, Aareleid T, Bielska-Lasota M, Clavel J, et al. Childhood\ncancer survival in Europe 1999–2007: results of EUROCARE-5—a population-\nbased study. Lancet Oncol 2014;15:35–47.\n648. Geenen MM, Cardous-Ubbink MC, Kremer LCM, Van Den Bos C, Van Der Pal\nHJH, Heinen RC, et al. Medical assessment of adverse health outcomes in long-term\nsurvivors of childhood cancer. J Am Med Assoc 2007;297:2705–2715.\n649. Armenian SH, Armstrong GT, Aune G, Chow EJ, Ehrhardt MJ, Ky B, et al.\nCardiovascular disease in survivors of childhood cancer: insights into epidemiology,\npathophysiology, and prevention. J Clin Oncol 2018;36:2135–2144.\n650. Fidler MM, Reulen RC, Henson K, Kelly J, Cutter D, Levitt GA, et al.\nPopulation-based long-term cardiac-speciﬁc mortality among 34 489 ﬁve-year sur-\nvivors of childhood cancer in Great Britain. Circulation 2017;135:951–963.\n651. Kremer LCM, van Dalen EC, Offringa M, Voûte PA. Frequency and risk factors of\nanthracycline-induced clinical heart failure in children: a systematic review. Ann\nOncol 2002;13:503–512.\nESC Guidelines\n4357\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n652. Bates JE, Howell RM, Liu Q, Yasui Y, Mulrooney DA, Dhakal S, et al.\nTherapy-related cardiac risk in childhood cancer survivors: an analysis of the child-\nhood cancer survivor study. J Clin Oncol 2019;37:1090–1101.\n653. van Dalen EC, Mulder RL, Suh E, Ehrhardt MJ, Aune GJ, Bardi E, et al. Coronary ar-\ntery disease surveillance among childhood, adolescent and young adult cancer sur-\nvivors: a systematic review and recommendations from the International Late\nEffects of Childhood Cancer Guideline Harmonization Group. Eur J Cancer 2021;\n156:127–137.\n654. Leerink JM, van der Pal HJH, Kremer LCM, Feijen EAM, Meregalli PG, Pourier MS,\net al. Reﬁning the 10-year prediction of left ventricular systolic dysfunction in long-\nterm survivors of childhood cancer. JACC CardioOncology 2021;3:62–72.\n655. Armstrong GT, Oefﬁnger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W, et al.\nModiﬁable risk factors and major cardiac events among adult survivors of childhood\ncancer. J Clin Oncol 2013;31:3673–3680.\n656. Armenian SH, Sun CL, Vase T, Ness KK, Blum E, Francisco L, et al. Cardiovascular\nrisk factors in hematopoietic cell transplantation survivors: role in development of\nsubsequent cardiovascular disease. Blood 2012;120:4505–4512.\n657. Carpenter K, Scavotto M, McGovern A, Ma C, Kenney LB, Mack JW, et al. Early par-\nental knowledge of late effect risks in children with cancer. Pediatr Blood Cancer\n2022;69:e29473.\n658. Herrmann J. From trends to transformation: where cardio-oncology is to make a\ndifference. Eur Heart J 2019;40:3898–3900.\n659. Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Triﬁletti DM, Jiang C, et al. A\npopulation-based study of cardiovascular disease mortality risk in US cancer pa-\ntients. Eur Heart J 2019;40:3889–3897.\n660. Stoltzfus KC, Zhang Y, Sturgeon K, Sinoway LI, Triﬁletti DM, Chinchilli VM, et al.\nFatal heart disease among cancer patients. Nat Commun 2020;11:2011.\n661. Banke A, Fosbøl EL, Møller JE, Gislason GH, Andersen M, Bernsdorf M, et al.\nLong-term effect of epirubicin on incidence of heart failure in women with breast\ncancer: insight from a randomized clinical trial. Eur J Heart Fail 2018;20:1447–1453.\n662. Jacobse JN, Steggink LC, Sonke GS, Schaapveld M, Hummel YM, Steenbruggen TG,\net al. Myocardial dysfunction in long-term breast cancer survivors treated at ages\n40–50 years. Eur J Heart Fail 2020;22:338–346.\n663. Boyne DJ, Mickle AT, Brenner DR, Friedenreich CM, Cheung WY, Tang KL, et al.\nLong-term risk of cardiovascular mortality in lymphoma survivors: a systematic re-\nview and meta-analysis. Cancer Med 2018;7:4801–4813.\n664. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease\nand lung cancer after radiotherapy for early breast cancer: prospective cohort\nstudy of about 300 000 women in US SEER cancer registries. Lancet Oncol 2005;\n6:557–565.\n665. de Vries S, Schaapveld M, Janus CPM, Daniëls LA, Petersen EJ, van der Maazen\nRWM, et al. Long-term cause-speciﬁc mortality in Hodgkin lymphoma patients. J\nNatl Cancer Inst 2021;113:760–769.\n666. Armenian SH, Yang D, Teh JB, Atencio LC, Gonzales A, Wong FL, et al. Prediction\nof cardiovascular disease among hematopoietic cell transplantation survivors. Blood\nAdv 2018;2:1756–1764.\n667. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, De Azambuja E, Procter M, Suter\nTM, et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast\ncancer (HERA): An open-label, randomised controlled trial. Lancet 2013;382:\n1021–1028.\n668. Advani PP, Ballman KV, Dockter TJ, Colon-Otero G, Perez EA. Long-term cardiac\nsafety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial. J Clin Oncol\n2016;34:581–587.\n669. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart\nfailure in older women treated with adjuvant anthracycline chemotherapy for\nbreast cancer. J Clin Oncol 2007;25:3808–3815.\n670. Lancellotti P, Nkomo VT, Badano LP, Bergler J, Bogaert J, Davin L, et al. Expert\nConsensus for multi-modality imaging evaluation of cardiovascular complications\nof radiotherapy in adults: a report from the European Association of\nCardiovascular Imaging and the American Society of Echocardiography. J Am Soc\nEchocardiogr 2013;26:1013–1032.\n671. Tromp J, Boerman LM, Sama IE, Maass SWMC, Maduro JH, Hummel YM, et al.\nLong-term survivors of early breast cancer treated with chemotherapy are charac-\nterized by a pro-inﬂammatory biomarker proﬁle compared to matched controls.\nEur J Heart Fail 2020;22:1239–1246.\n672. Cao Z, Xu C, Yang H, Li S, Wang Y. The role of healthy lifestyle in cancer incidence\nand temporal transitions to cardiometabolic disease. JACC CardioOncology 2021;3:\n663–674.\n673. Limat S, Daguindau E, Cahn JY, Nerich V, Brion A, Perrin S, et al. Incidence and risk-\nfactors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive\nnon-Hodgkin’s lymphoma. J Clin Pharm Ther 2014;39:168–174.\n674. Hershman DL, McBride RB, Eisenberger A, Wei YT, Grann VR, Jacobson JS.\nDoxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse\nB-cell non-Hodgkin’s lymphoma. J Clin Oncol 2008;26:3159–3165.\n675. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of\nenalapril on mortality and the development of heart failure in asymptomatic pa-\ntients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:\n685–691.\n676. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of\ncaptopril on mortality and morbidity in patients with left ventricular dysfunction\nafter myocardial infarction. N Engl J Med 1992;327:669–677.\n677. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients\nwith left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet\n2001;357:1385–1390.\n678. Abdel-Qadir H, Tai F, Croxford R, Austin PC, Amir E, Calvillo-Argüelles O, et al.\nCharacteristics and outcomes of women developing heart failure after early stage\nbreast cancer chemotherapy: a population-based matched cohort study. Circ Heart\nFail 2021;14:e008110.\n679. Curigliano G, Cardinale D, Suter T, Plataniotis G, De Azambuja E, Sandri MT, et al.\nCardiovascular toxicity induced by chemotherapy, targeted agents and radiother-\napy: ESMO clinical practice guidelines. Ann Oncol 2012;23:vii155–66.\n680. Adams MJ, Hardenbergh PH, Constine LS, Lipshultz SE. Radiation-associated car-\ndiovascular disease. Crit Rev Oncol Hematol 2003;45:55–75.\n681. Taylor C, Duane FK, Dodwell D, Gray R, Wang Z, Wang Y, et al. Estimating the\nrisks of breast cancer radiotherapy: evidence from modern radiation doses to\nthe lungs and heart and from previous randomized trials. J Clin Oncol 2017;35:\n1641–1649.\n682. Reed GW, Masri A, Grifﬁn BP, Kapadia SR, Ellis SG, Desai MY. Long-term mortality\nin patients with radiation-associated coronary artery disease treated with percu-\ntaneous coronary intervention. Circ Cardiovasc Interv 2016;9:e003483.\n683. Liang JJ, Sio TT, Slusser JP, Lennon RJ, Miller RC, Sandhu G, et al. Outcomes after\npercutaneous coronary intervention with stents in patients treated with thoracic\nexternal beam radiation for cancer. JACC Cardiovasc Interv 2014;7:1412–1420.\n684. Cuomo JR, Javaheri SP, Sharma GK, Kapoor D, Berman AE, Weintraub NL. How to\nprevent and manage radiation-induced coronary artery disease. Heart 2018;104:\n1647–1653.\n685. Feldman DR, Schaffer WL, Steingart RM. Late cardiovascular toxicity following\nchemotherapy for germ cell tumors. JNCCN J Natl Compr Cancer Netw 2012;10:\n537–544.\n686. Sudhakar R. Response to treatment and outcomes of acute coronary syndrome in\nthe cancer population. Clin Cardiol 2012;35:646.\n687. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related\nmortality. N Engl J Med 2013;368:574–577.\n688. Han X-J, Li J-Q, Khannanova Z, Li Y. Optimal management of coronary artery dis-\nease in cancer patients. Chronic Dis Transl Med 2019;5:221–233.\n689. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al.\n(2018 ESC/EACTS Guidelines on myocardial revascularization). Kardiol Pol 2018;\n76:1585–1664.\n690. Wu W, Masri A, Popovic ZB, Smedira NG, Lytle BW, Marwick TH, et al. Long-term\nsurvival of patients with radiation heart disease undergoing cardiac surgery: a co-\nhort study. Circulation 2013;127:1476–1484.\n691. Gujral DM, Lloyd G, Bhattacharyya S. Radiation-induced valvular heart disease.\nHeart 2016;102:269–276.\n692. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/\nEACTS Guidelines for the management of valvular heart disease. Eur Heart J\n2017;38:2739–2791.\n693. Lind A, Totzeck M, Mahabadi AA, Jánosi RA, El Gabry M, Ruhparwar A, et al. Impact\nof cancer in patients undergoing transcatheter aortic valve replacement: a single-\ncenter study. JACC CardioOncology 2020;2:735–743.\n694. Yazdchi F, Hirji SA, Nohria A, Percy E, Harloff M, Malarczyk A, et al. Transcatheter\ncompared with surgical aortic valve replacement in patients with previous chest-\ndirected radiation therapy. JACC CardioOncology 2021;3:397–407.\n695. Guha A, Dey AK, Omer S, Abraham WT, Attizzani G, Jneid H, et al. Contemporary\ntrends and outcomes of percutaneous and surgical mitral valve replacement or re-\npair in patients with cancer. Am J Cardiol 2020;125:1355–1360.\n696. Elbadawi A, Albaeni A, Elgendy IY, Ogunbayo GO, Jimenez E, Cornwell L, et al.\nTranscatheter versus surgical aortic valve replacement in patients with prior medi-\nastinal radiation. JACC Cardiovasc Interv 2020;13:2658–2666.\n697. Zafar MR, Mustafa SF, Miller TW, Alkhawlani T, Sharma UC. Outcomes after trans-\ncatheter aortic valve replacement in cancer survivors with prior chest radiation\ntherapy: a systematic review and meta-analysis. Cardio-Oncology 2020;6:8.\n698. Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F,\nEisenwort G, et al. Nilotinib-induced vasculopathy: identiﬁcation of vascular endo-\nthelial cells as a primary target site. Leukemia 2017;31:2388–2397.\n699. Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ. Secondary\nRaynaud’s phenomenon and other late vascular complications following chemo-\ntherapy for testicular cancer. Eur J Cancer 1995;31A:2229–2238.\n700. Stelwagen J, Lubberts S, Steggink LC, Steursma G, Kruyt LM, Donkerbroek JW,\net al. Vascular aging in long-term survivors of testicular cancer more than 20 years\n4358\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\nafter treatment with cisplatin-based chemotherapy. Br J Cancer 2020;123:\n1599–1607.\n701. Andreassi MG, Piccaluga E, Gargani L, Sabatino L, Borghini A, Faita F, et al.\nSubclinical carotid atherosclerosis and early vascular aging from long-term low-\ndose ionizing radiation exposure: a genetic, telomere, and vascular ultrasound study\nin cardiac catheterization laboratory staff. JACC Cardiovasc Interv 2015;8:616–627.\n702. Carmody BJ, Arora S, Avena R, Curry KM, Simpkins J, Cosby K, et al. Accelerated\ncarotid artery disease after high-dose head and neck radiotherapy: is there a role\nfor routine carotid duplex surveillance? J Vasc Surg 1999;30:1045–1051.\n703. Carpenter DJ, Mowery YM, Broadwater G, Rodrigues A, Wisdom AJ, Dorth JA,\net al. The risk of carotid stenosis in head and neck cancer patients after radiation\ntherapy. Oral Oncol 2018;80:9–15.\n704. Szpakowski N, Desai MY. Radiation-associated pericardial disease. Curr Cardiol Rep\n2019;21:97.\n705. Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: is the epide-\nmiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys\n2007;67:10–18.\n706. Ning MS, Tang L, Gomez DR, Xu T, Luo Y, Huo J, et al. Incidence and predictors of\npericardial effusion after chemoradiation therapy for locally advanced non-small\ncell lung cancer. Int J Radiat Oncol Biol Phys 2017;99:70–79.\n707. Wei X, Liu HH, Tucker SL, Wang S, Mohan R, Cox JD, et al. Risk factors for peri-\ncardial effusion in inoperable esophageal cancer patients treated with deﬁnitive\nchemoradiation therapy. Int J Radiat Oncol Biol Phys 2008;70:707–714.\n708. Gagliardi G, Constine LS, Moiseenko V, Correa C, Pierce LJ, Allen AM, et al.\nRadiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010;76:\nS77–S85.\n709. Chiabrando JG, Bonaventura A, Vecchié A, Wohlford GF, Mauro AG, Jordan JH,\net al. Management of acute and recurrent pericarditis: JACC state-of-the-art re-\nview. J Am Coll Cardiol 2020;75:76–92.\n710. Donnellan\nE,\nPhelan\nD,\nMccarthy\nCP,\nCollier\nP,\nDesai\nM,\nGrifﬁn\nB.\nRadiation-induced heart disease: a practical guide to diagnosis and management.\nCleve Clin J Med 2016;83:914–922.\n711. Crestanello JA, McGregor CGA, Danielson GK, Daly RC, Dearani JA, Orszulak TA,\net al. Mitral and tricuspid valve repair in patients with previous mediastinal radiation\ntherapy. Ann Thorac Surg 2004;78:826–831.\n712. Heidenreich PA, Kapoor JR. Radiation induced heart disease. Heart 2009;95:\n252–258.\n713. Walsh D, Nelson KA. Autonomic nervous system dysfunction in advanced cancer.\nSupport Care Cancer 2002;10:523–528.\n714. Noor B, Akhavan S, Leuchter M, Yang EH, Ajijola OA. Quantitative assessment of\ncardiovascular autonomic impairment in cancer survivors: a single center case ser-\nies. Cardio-Oncology 2020;6:11.\n715. Gibson TM, Li Z, Green DM, Armstrong GT, Mulrooney DA, Srivastava DK, et al.\nBlood pressure status in adult survivors of childhood cancer: a report from the\nSt. Jude Lifetime Cohort Study. Cancer Epidemiol Biomarkers Prev 2017;26:\n1705–1713.\n716. Friedman DN, Tonorezos ES, Cohen P. Diabetes and metabolic syndrome in sur-\nvivors of childhood cancer. Horm Res Paediatr 2019;91:118–127.\n717. Pekmezi DW, Demark-Wahnefried W. Updated evidence in support of diet and\nexercise interventions in cancer survivors. Acta Oncol (Madr) 2011;50:167–178.\n718. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient man-\nagement. J Clin Oncol 2002;20:1128–1143.\n719. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast\ncancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010;123:\n627–635.\n720. Meyerhardt JA, Ma J, Courneya KS. Energetics in colorectal and prostate cancer. J\nClin Oncol 2010;28:4066–4073.\n721. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, et al. Prospective\nstudy of adiposity and weight change in relation to prostate cancer incidence and\nmortality. Cancer 2007;109:675–684.\n722. Siegel EM, Ulrich CM, Poole EM, Holmes RS, Jacobsen PB, Shibata D. The effects of\nobesity and obesity-related conditions on colorectal cancer prognosis. Cancer\nControl 2010;17:52–57.\n723. Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival\nafter breast cancer diagnosis. J Clin Oncol 2005;23:1370–1378.\n724. Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, et al. Impact\nof body mass index and weight change after treatment on cancer recurrence and\nsurvival in patients with stage III colon cancer: Findings from Cancer and Leukemia\nGroup B 89803. J Clin Oncol 2008;26:4109–4115.\n725. Kroenke CH, Fung TT, Hu FB, Holmes MD. Dietary patterns and survival after\nbreast cancer diagnosis. J Clin Oncol 2005;23:9295–9303.\n726. Kwan ML, Weltzien E, Kushi LH, Castillo A, Slattery ML, Caan BJ. Dietary patterns\nand breast cancer recurrence and survival among women with early-stage breast\ncancer. J Clin Oncol 2009;27:919–926.\n727. Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Hu FB, Mayer RJ, et al. Association\nof dietary patterns with cancer recurrence and survival in patients with stage III co-\nlon cancer. J Am Med Assoc 2007;298:754–764.\n728. Yang J, Li C, Shen Y, Zhou H, Shao Y, Zhu W, et al. Impact of statin use on cancer-\nspeciﬁc mortality and recurrence: a meta-analysis of 60 observational studies.\nMedicine 2020;99:e19596.\n729. Kim J, Choi EA, Han YE, Woo Lee J, Seul Kim Y, Kim Y, et al. Association between\nstatin use and all-cause mortality in cancer survivors, based on the Korean health\ninsurance service between 2002 and 2015. Nutr Metab Cardiovasc Dis 2020;30:\n434–440.\n730. Ren QW, Yu SY, Teng THK, Li X, Cheung KS, Wu MZ, et al. Statin associated lower\ncancer risk and related mortality in patients with heart failure. Eur Heart J 2021;42:\n3049–3059.\n731. Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and\naerobic exercise program reverses muscle loss in men undergoing androgen sup-\npression therapy for prostate cancer without bone metastases: a randomized con-\ntrolled trial. J Clin Oncol 2010;28:340–347.\n732. Speck RM, Courneya KS, Mâsse LC, Duval S, Schmitz KH. An update of controlled\nphysical activity trials in cancer survivors: a systematic review and meta-analysis. J\nCancer Surviv 2010;4:87–100.\n733. Campia U, Barac A. Exercise and aerobic ﬁtness to reduce cancer-related cardio-\nvascular toxicity. Curr Treat Options Cardiovasc Med 2016;18:44.\n734. Jones LW, Liu Q, Armstrong GT, Ness KK, Yasui Y, Devine K, et al. Exercise and\nrisk of major cardiovascular events in adult survivors of childhood Hodgkin lymph-\noma: a report from the childhood cancer survivor study. J Clin Oncol 2014;32:\n3643–3650.\n735. Scott JM, Li N, Liu Q, Yasui Y, Leisenring W, Nathan PC, et al. Association of exercise\nwith mortality in adult survivors of childhood cancer. JAMA Oncol 2018;4:1352–1358.\n736. Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz\nAL, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J\nClin 2012;62:242–274.\n737. CDC. Cancer Data and Statistics | Survival Information from the National Cancer\nInstitute and Centers for Disease Control and Prevention. 2013.\n738. Thompson KA, Hildebrandt MAT, Ater JL. Cardiac outcomes with pregnancy\nafter cardiotoxic therapy for childhood cancer. J Am Coll Cardiol 2017;69:\n594–595.\n739. Nolan M, Oikonomou EK, Silversides CK, Hines MR, Thompson KA, Campbell BA,\net al. Impact of cancer therapy-related cardiac dysfunction on risk of heart failure in\npregnancy. JACC CardioOncology 2020;2:153–162.\n740. Chait-Rubinek L, Mariani JA, Goroncy N, Herschtal A, Wheeler GC, Dwyer MK,\net al. A retrospective evaluation of risk of peripartum cardiac dysfunction in survi-\nvors of childhood, adolescent and young adult malignancies. Cancers (Basel) 2019;\n11:1046.\n741. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C,\nCífková R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardio-\nvascular diseases during pregnancy. Eur Heart J 2018;39:3165–3241.\n742. Mehta LS, Warnes CA, Bradley E, Burton T, Economy K, Mehran R, et al.\nCardiovascular considerations in caring for pregnant patients: a scientiﬁc statement\nfrom the American Heart Association. Circulation 2020;141:e884–e903.\n743. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, eds. WHO Classiﬁcation of\nTumours of the Lung, Pleura, Thymus and Heart, 4th ed. 2015. ISBN 978-92-832-2436-5\n744. Burke A, Tavora F. The 2015 WHO Classiﬁcation of tumors of the heart and peri-\ncardium. J Thorac Oncol 2016;11:441–452.\n745. Cresti A, Chiavarelli M, Glauber M, Tanganelli P, Scalese M, Cesareo F, et al.\nIncidence rate of primary cardiac tumors: a 14-year population study. J\nCardiovasc Med 2016;17:37–43.\n746. Maleszewski JJ, Bois MC, Bois JP, Young PM, Stulak JM, Klarich KW. Neoplasia and\nthe heart: pathological review of effects with clinical and radiological correlation. J\nAm Coll Cardiol 2018;72:202–227.\n747. Tyebally S, Chen S, Bhattacharyya S, Mughrabi S, Hussain Z, Manisty C, et al. Cardiac\ntumors: JACC CardioOncology state-of-the-art review. JACC CardioOncology 2020;2:\n293–311.\n748. Kirkpatrick JN, Wong T, Bednarz JE, Spencer KT, Sugeng L, Ward RP, et al.\nDifferential diagnosis of cardiac masses using contrast echocardiographic perfusion\nimaging. J Am Coll Cardiol 2004;43:1412–1419.\n749. Thiene G, Rizzo S, Marra MP, Valente M, Basso C. Masses and cardiac tumours: clas-\nsiﬁcation and diagnosis. ESC CardioMED, 2018. DOI:10.1093/med/9780198784906.\n003.0386\n750. Zaragosa-Macias E, Chen MA, Gill EA. Real time three-dimensional echocardiog-\nraphy evaluation of intracardiac masses. Echocardiography 2012;29:207–219.\n751. Beroukhim RS, Prakash A, Valsangiacomo Buechel ER, Cava JR, Dorfman AL, Festa\nP, et al. Characterization of cardiac tumors in children by cardiovascular magnetic\nresonance imaging: a multicenter experience. J Am Coll Cardiol 2011;58:1044–1054.\nESC Guidelines\n4359\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n752. Rahbar K, Seifarth H, Schäfers M, Stegger L, Hoffmeier A, Spieker T, et al.\nDifferentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT. J\nNucl Med 2012;53:856–863.\n753. Kassop D, Donovan MS, Cheezum MK, Nguyen BT, Gambill NB, Blankstein R, et al.\nCardiac masses on cardiac CT: a review. Curr Cardiovasc Imaging Rep 2014;7:9281.\n754. D’Angelo EC, Paolisso P, Vitale G, Foà A, Bergamaschi L, Magnani I, et al. Diagnostic\naccuracy of cardiac computed tomography and 18F-ﬂuorodeoxyglucose with posi-\ntron emission tomography in cardiac masses. JACC Cardiovasc Imaging 2020;13:\n2400–2411.\n755. Butany J, Nair V, Naseemuddin A, Nair GM, Catton C, Yau T. Cardiac tumours:\ndiagnosis and management. Lancet Oncol 2005;6:219–228.\n756. Szmit S, Zagrodzka M, Kurzyna M, Opolski G, Szczylik C. Sunitinib malate, a recep-\ntor tyrosine kinase inhibitor, is effective in the treatment of restrictive heart failure\ndue to heart metastases from renal cell carcinoma. Cardiology 2009;114:67–71.\n757. Peccatori FA, Azim JA, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer,\npregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment\nand follow-up. Ann Oncol 2013;24:vi160–70.\n758. Cubillo A, Morales S, Goñi E, Matute F, Muñoz JL, Pérez-Díaz D, et al.\nMultidisciplinary consensus on cancer management during pregnancy. Clin Transl\nOncol 2021;23:1054–1066.\n759. Silverstein J, Post AL, Chien AJ, Olin R, Tsai KK, Ngo Z, et al. Multidisciplinary man-\nagement of cancer during pregnancy. JCO Oncol Pract 2020;16:545–557.\n760. Amant F, Berveiller P, Boere IA, Cardonick E, Fruscio R, Fumagalli M, et al.\nGynecologic cancers in pregnancy: guidelines based on a third international consen-\nsus meeting. Ann Oncol 2019;30:1601–1612.\n761. Dunleavy K, McLintock C. How I treat lymphoma in pregnancy. Blood 2020;136:\n2118–2124.\n762. Ducas RA, Elliott JE, Melnyk SF, Premecz S, Dasilva M, Cleverley K, et al.\nCardiovascular magnetic resonance in pregnancy: insights from the Cardiac\nHemodynamic Imaging and Remodeling in Pregnancy (CHIRP) study. J Cardiovasc\nMagn Reson 2014;16:1.\n763. Savu O, Jurcuţ R, Giuşcǎ\nS, Van Mieghem T, Gussi I, Popescu BA, et al.\nMorphological and functional adaptation of the maternal heart during pregnancy.\nCirc Cardiovasc Imaging 2012;5:289–297.\n764. Narayanan M, Elkayam U, Naqvi TZ. Echocardiography in pregnancy: part 2. Curr\nCardiol Rep 2016;18:90.\n765. Furenäs E, Eriksson P, Wennerholm UB, Dellborg M. Pregnancy in a healthy popu-\nlation: dynamics of NTproBNP and hs-cTroponin T. Open Heart 2020;7:e001293.\n766. Tanous D, Siu SC, Mason J, Greutmann M, Wald RM, Parker JD, et al. B-type natri-\nuretic peptide in pregnant women with heart disease. J Am Coll Cardiol 2010;56:\n1247–1253.\n767. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III. Trends in\nthe incidence of venous thromboembolism during pregnancy or postpartum: a\n30-year population-based study. Ann Intern Med 2005;143:697–706.\n768. Sultan AA, West J, Tata LJ, Fleming KM, Nelson-Piercy C, Grainge MJ. Risk of ﬁrst\nvenous thromboembolism in pregnant women in hospital: population based cohort\nstudy from England. BMJ 2013;347:f6099.\n769. Sultan AA, West J, Tata LJ, Fleming KM, Nelson-Piercy C, Grainge MJ. Risk of ﬁrst\nvenous thromboembolism in and around pregnancy: a population-based cohort\nstudy. Br J Haematol 2012;156:366–373.\n770. Hase EA, de Barros VIPVL, Igai AMK, Francisco RPV, Zugaib M. Risk assessment of\nvenous thromboembolism and thromboprophylaxis in pregnant women hospita-\nlized with cancer: preliminary results from a risk score. Clinics (Sao Paulo) 2018;\n73:e368.\n771. Fox DJ, Khattar RS. Carcinoid heart disease: presentation, diagnosis, and manage-\nment. Heart 2004;90:1224–1228.\n772. Davar J, Connolly HM, Caplin ME, Pavel M, Zacks J, Bhattacharyya S, et al.\nDiagnosing and managing carcinoid heart disease in patients with neuroendocrine\ntumors: an expert statement. J Am Coll Cardiol 2017;69:1288–1304.\n773. Dobson R, Burgess MI, Pritchard DM, Cuthbertson DJ. The clinical presentation\nand management of carcinoid heart disease. Int J Cardiol 2014;173:29–32.\n774. Lichtenauer M, Pichler T, Eder S, Mirna M, Magnes T, Wernly B, et al. Carcinoid\nheart disease involving the left heart: a case report and biomarker analysis. ESC\nHeart Fail 2019;6:222–227.\n775. Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, et al. Frequency of carcinoid\nsyndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet\nOncol 2017;18:525–534.\n776. Bhattacharyya S, Davar J, Dreyfus G, Caplin ME. Carcinoid heart disease. Circulation\n2007;116:2860–2865.\n777. Zuetenhorst JM, Korse CM, Bonfrer JMG, Bakker RH, Taal BG. Role of natriuretic\npeptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J\nCancer 2004;90:2073–2079.\n778. Dobson R, Burgess MI, Banks M, Pritchard DM, Vora J, Valle JW, et al. The associ-\nation of a panel of biomarkers with the presence and severity of carcinoid heart\ndisease: a cross-sectional study. PLoS One 2013;8:e73679.\n779. Korse CM, Taal BG, De Groot CA, Bakker RH, Bonfrer JMG. Chromogranin-A and\nN-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diag-\nnostics in patients with neuroendocrine tumor. J Clin Oncol 2009;27:4293–4299.\n780. Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J. Usefulness of N-terminal\npro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart dis-\nease. Am J Cardiol 2008;102:938–942.\n781. Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, et al.\nTelotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid\nsyndrome. J Clin Oncol 2017;35:14–23.\n782. Dumoulein M, Verslype C, Van Cutsem E, Meuris B, Herijgers P, Flameng W, et al.\nCarcinoid heart disease: case and literature review. Acta Cardiol 2010;65:261–264.\n783. Nguyen A, Schaff HV, Abel MD, Luis SA, Lahr BD, Halfdanarson TR, et al. Improving\noutcome of valve replacement for carcinoid heart disease. J Thorac Cardiovasc Surg\n2019;158:99–107.e2.\n784. Mabvuure N, Cumberworth A, Hindocha S. In patients with carcinoid syndrome\nundergoing valve replacement: will a biological valve have acceptable durability?\nInteract Cardiovasc Thorac Surg 2012;15:467–471.\n785. Connolly HM, Schaff HV, Abel MD, Rubin J, Askew JW, Li Z, et al. Early and late\noutcomes of surgical treatment in carcinoid heart disease. J Am Coll Cardiol 2015;\n66:2189–2196.\n786. Sunjic I, Shin D, Sunjic KM, Popat JV, Tran T, Chae SH, et al. Incidence of atrioven-\ntricular block after valve replacement in carcinoid heart disease. Cardiol Res 2020;\n11:56–60.\n787. Kuntze T, Owais T, Secknus MA, Kaemmerer D, Baum R, Girdauskas E. Results of\ncontemporary valve surgery in patients with carcinoid heart disease. J Heart Valve\nDis 2016;25:356–363.\n788. Luthra S, Olevano C, Richens T, Tsang GM. Percutaneous transcatheter\nvalve-in-valve pulmonary and tricuspid replacement in carcinoid heart disease.\nJACC Case Reports 2020;2:533–536.\n789. Zacks JS, Lavine R. Avoiding a repeat sternotomy in recurrent carcinoid heart dis-\nease. JACC Case Reports 2020;2:537–538.\n790. Bhattacharyya S, Toumpanakis C, Burke M, Taylor AM, Caplin ME, Davar J. Features\nof carcinoid heart disease identiﬁed by 2- and 3-dimensional echocardiography and\ncardiac MRI. Circ Cardiovasc Imaging 2010;3:103–111.\n791. Pellikka PA, Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC, et al.\nCarcinoid heart disease: clinical and echocardiographic spectrum in 74 patients.\nCirculation 1993;87:1188–1196.\n792. Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Blood 2020;\n136:2620–2627.\n793. Witteles RM, Liedtke M. AL amyloidosis for the cardiologist and oncologist: epi-\ndemiology, diagnosis, and management. JACC CardioOncology 2019;1:117–130.\n794. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update\nfor treating physicians. Blood 2013;121:5124–5130.\n795. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common\nquestions encountered in the diagnosis and management of cardiac amyloidosis.\nCirculation 2017;135:1357–1377.\n796. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice\nGuidelines in Oncology. Systemic Light Chain Amyloidosis Version 1. Natl Compr\nCancer Netw 2021. https://www.nccn.org/.\n797. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised\nprognostic staging system for light chain amyloidosis incorporating cardiac biomar-\nkers and serum free light chain measurements. J Clin Oncol 2012;30:989–995.\n798. Zhang KW, Miao J, Mitchell JD, Alvarez-Cardona J, Tomasek K, Su YR, et al. Plasma\nhepatocyte growth factor for diagnosis and prognosis in light chain and transthyr-\netin cardiac amyloidosis. JACC CardioOncology 2020;2:56–66.\n799. Mohan M, Buros A, Mathur P, Gokden N, Singh M, Susanibar S, et al. Clinical char-\nacteristics and prognostic factors in multiple myeloma patients with light chain de-\nposition disease. Am J Hematol 2017;92:739–745.\n800. Grogan M, DIspenzieri A, Gertz MA. Light-chain cardiac amyloidosis: strategies to\npromote early diagnosis and cardiac response. Heart 2017;103:1065–1072.\n801. Jurcuţ R, Onciul S, Adam R, Stan C, Coriu D, Rapezzi C, et al. Multimodality imaging\nin cardiac amyloidosis: a primer for cardiologists. Eur Heart J Cardiovasc Imaging\n2020;21:833–844.\n802. Lee Chuy K, Drill E, Yang JC, Landau H, Hassoun H, Nahhas O, et al. Incremental\nvalue of global longitudinal strain for predicting survival in patients with advanced\nAL amyloidosis. JACC CardioOncology 2020;2:223–231.\n803. Brownrigg J, Lorenzini M, Lumley M, Elliott P. Diagnostic performance of imaging\ninvestigations in detecting and differentiating cardiac amyloidosis: a systematic re-\nview and meta-analysis. ESC Heart Fail 2019;6:1041–1051.\n804. Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, Petrie A, Rezk T, et al.\nNoncontrast magnetic resonance for the diagnosis of cardiac amyloidosis. JACC\nCardiovasc Imaging 2020;13:69–80.\n805. Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al.\nConsensus guidelines for the conduct and reporting of clinical trials in systemic\nlight-chain amyloidosis. Leukemia 2012;26:2317–2325.\n4360\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026\n\n\n806. Eckhert E, Witteles R, Kaufman G, Lafayette R, Arai S, Schrier S, et al. Grading car-\ndiac response in AL amyloidosis: implications for relapse and survival. Br J Haematol\n2019;186:144–146.\n807. Vaxman I, Gertz M. Recent advances in the diagnosis, risk stratiﬁcation, and man-\nagement of systemic light-chain amyloidosis. Acta Haematol 2019;141:93–106.\n808. Giancaterino S, Urey MA, Darden D, Hsu JC. Management of arrhythmias in cardiac\namyloidosis. JACC Clin Electrophysiol 2020;6:351–361.\n809. El-Am EA, Dispenzieri A, Melduni RM, Ammash NM, White RD, Hodge DO, et al.\nDirect current cardioversion of atrial arrhythmias in adults with cardiac amyloid-\nosis. J Am Coll Cardiol 2019;73:589–597.\n810. Tahir UA, Doros G, Kim JS, Connors LH, Seldin DC, Sam F. Predictors of mortality\nin light chain cardiac amyloidosis with heart failure. Sci Rep 2019;9:8552.\n811. Khanna S, Lo P, Cho K, Subbiah R. Ventricular arrhythmias in cardiac amyloidosis: a\nreview of current literature. Clin Med Insights Cardiol 2020;14:1179546820963055.\n812. Kastritis E, Leleu X, Arnulf B, Zamagni E, Cibeira MT, Kwok F, et al. Bortezomib,\nmelphalan, and dexamethasone for light-chain amyloidosis. J Clin Oncol 2020;38:\n3252–3260.\n813. Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, et al.\nDaratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis:\nsafety run-in results of ANDROMEDA. Blood 2020;136:71–80.\n814. Huang X, Ren G, Chen W, Guo J, Zhao L, Zeng C, et al. The role of induction ther-\napy before autologous stem cell transplantation in low disease burden AL amyloid-\nosis patients. Amyloid 2021;28:75–83.\n815. Barrett CD, Dobos K, Liedtke M, Tuzovic M, Haddad F, Kobayashi Y, et al. A chan-\nging landscape of mortality for systemic light chain amyloidosis. JACC Heart Fail\n2019;7:958–966.\n816. Zhang KW, Stockerl-Goldstein KE, Lenihan DJ. Emerging therapeutics for the\ntreatment of light chain and transthyretin amyloidosis. JACC Basic Transl Sci 2019;\n4:438–448.\n817. Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al.\nDaratumumab-based treatment for immunoglobulin light-chain amyloidosis. N\nEngl J Med 2021;385:46–58.\n818. Wechalekar AD, Whelan C. Encouraging impact of doxycycline on early mortality\nin cardiac light chain (AL) amyloidosis. Blood Cancer J 2017;7:e546.\n819. Shen K, Fu W, Wu Y, Dong Y, Huang Z, Wei Y, et al. Doxycycline combined with\nbortezomib–cyclophosphamide–dexamethasone chemotherapy for newly diag-\nnosed cardiac light-chain amyloidosis: a multicenter randomized controlled trial.\nCirculation 2021;145:8–17.\n820. Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, et al.\nLongitudinal systolic strain, cardiac function improvement, and survival following\ntreatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging\n2017;18:1057–1064.\n821. Palladini G, Foli A, Milani P, Russo P, Albertini R, Lavatelli F, et al. Best use of cardiac\nbiomarkers in patients with AL amyloidosis and renal failure. Am J Hematol 2012;87:\n465–471.\n822. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum\ncardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for\nprimary systemic amyloidosis. J Clin Oncol 2004;22:3751–3757.\n823. Zaremba T, Jakobsen AR, SØgaard M, ThØgersen AM, Johansen MB, Madsen LæB,\net al. Risk of device malfunction in cancer patients with implantable cardiac device\nundergoing\nradiotherapy:\na\npopulation-based\ncohort\nstudy.\nPacing\nClin\nElectrophysiol 2015;38:343–356.\n824. Miften M, Mihailidis D, Kry SF, Reft C, Esquivel C, Farr J, et al. Management of radio-\ntherapy patients with implanted cardiac pacemakers and deﬁbrillators: a report of\nthe AAPM TG-203. Med Phys 2019;46:e757–e788.\n825. Hurkmans CW, Knegjens JL, Oei BS, Maas AJJ, Uiterwaal GJ, van der Borden AJ,\net al. Management of radiation oncology patients with a pacemaker or ICD: a\nnew comprehensive practical guideline in The Netherlands. Radiat Oncol 2012;7:\n198.\n826. Indik JH, Gimbel JR, Abe H, Alkmim-Teixeira R, Birgersdotter-Green U, Clarke GD,\net al. 2017 HRS expert consensus statement on magnetic resonance imaging and\nradiation exposure in patients with cardiovascular implantable electronic devices.\nHeart Rhythm 2017;14:e97–e153.\n827. Zaremba T, Jakobsen AR, Søgaard M, Thøgersen AM, Riahi S. Radiotherapy in pa-\ntients with pacemakers and implantable cardioverter deﬁbrillators: a literature re-\nview. Europace 2016;18:479–491.\n828. Grant JD, Jensen GL, Tang C, Pollard JM, Kry SF, Krishnan S, et al.\nRadiotherapy-induced malfunction in contemporary cardiovascular implantable\nelectronic devices: clinical incidence and predictors. JAMA Oncol 2015;1:624–632.\n829. Zecchin M, Severgnini M, Fiorentino A, Malavasi VL, Menegotti L, Alongi F, et al.\nManagement of patients with cardiac implantable electronic devices (CIED) under-\ngoing radiotherapy: a consensus document from Associazione Italiana Aritmologia\ne Cardiostimolazione (AIAC), Associazione Italiana Radioterapia Oncologica\n(AIRO), Associazione Italiana Fisica Medica (AIFM). Int J Cardiol 2018;255:175–183.\n830. Gomez DR, Poenisch F, Pinnix CC, Sheu T, Chang JY, Memon N, et al. Malfunctions\nof implantable cardiac devices in patients receiving proton beam therapy: incidence\nand predictors. Int J Radiat Oncol Biol Phys 2013;87:570–575.\n831. Sharifzadehgan A, Laurans M, Thuillot M, Huertas A, Baudinaud P, Narayanan K,\net al. Radiotherapy in patients with a cardiac implantable electronic device. Am J\nCardiol 2020;128:196–201.\n832. Stienen JJC, Ottevanger PB, Wennekes L, Dekker HM, van der Maazen RWM,\nMandigers CMPW, et al. Development and evaluation of an educational E-tool\nto help patients with non-Hodgkin’s lymphoma manage their personal care path-\nway. JMIR Res Protoc 2015;4:e6.\n833. Murphy P, Levine A, Lerma T, Young S, Hwang J, Goldsby R. A portable survivor-\nship care plan: a tool that helps educate and improve knowledge in childhood can-\ncer survivors. Support Care Cancer 2021;29:169–177.\n834. Asteggiano R, Aboyans V, Lee G, Salinger S, Richter D. Cardiology care delivered to\ncancer patients. Eur Heart J 2020;41:205–206.\n835. Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, et al. European Society\nof Cardiology methodology for the development of quality indicators for the quan-\ntiﬁcation of cardiovascular care and outcomes. Eur Heart J Qual Care Clin Outcomes\n2022;8:4–13.\n836. Minchin M, Roland M, Richardson J, Rowark S, Guthrie B. Quality of care in the\nUnited Kingdom after removal of ﬁnancial incentives. N Engl J Med 2018;379:\n948–957.\n837. Song Z, Ji Y, Safran DG, Chernew ME. Health care spending, utilization, and quality\n8 years into global payment. N Engl J Med 2019;381:252–263.\nESC Guidelines\n4361\nDownloaded from https://academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 14 January 2026",
      "keywords": [
        "hypertension",
        "heart failure",
        "systolic dysfunction",
        "plaque",
        "vte",
        "guideline",
        "framingham",
        "diet",
        "author",
        "blood pressure",
        "age",
        "cardiomyopathy",
        "genetic",
        "echocardiography",
        "coronary artery",
        "stenosis",
        "mri",
        "sex",
        "risk factor",
        "atherosclerosis",
        "diabetes",
        "calcium channel",
        "carotid",
        "primary prevention",
        "arrhythmia",
        "anticoagulation",
        "information",
        "tricuspid",
        "pulmonary embolism",
        "diastolic"
      ],
      "tables": []
    }
  ]
}